0000927653-17-000011.txt : 20170727 0000927653-17-000011.hdr.sgml : 20170727 20170727160526 ACCESSION NUMBER: 0000927653-17-000011 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 70 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170727 DATE AS OF CHANGE: 20170727 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MCKESSON CORP CENTRAL INDEX KEY: 0000927653 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 943207296 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-13252 FILM NUMBER: 17986286 BUSINESS ADDRESS: STREET 1: ONE POST ST STREET 2: MCKESSON PLAZA CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 4159838300 MAIL ADDRESS: STREET 1: ONE POST ST CITY: SAN FRANCISCO STATE: CA ZIP: 94104 FORMER COMPANY: FORMER CONFORMED NAME: MCKESSON HBOC INC DATE OF NAME CHANGE: 19990115 FORMER COMPANY: FORMER CONFORMED NAME: MCKESSON CORP DATE OF NAME CHANGE: 19950209 FORMER COMPANY: FORMER CONFORMED NAME: SP VENTURES INC DATE OF NAME CHANGE: 19940728 10-Q 1 mck_10qx06302017.htm 10-Q Document
Table of Contents                 


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-Q
 
(Mark One)
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2017
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from             to            
Commission File Number: 1-13252
 
McKESSON CORPORATION
(Exact name of registrant as specified in its charter)
 
Delaware
 
94-3207296
(State or other jurisdiction
of incorporation or organization)
 
(I.R.S. Employer
Identification No.)
 
 
 
One Post Street, San Francisco, California
 
94104
(Address of principal executive offices)
 
(Zip Code)
(415) 983-8300
(Registrant’s telephone number, including area code)
 
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
 
x
  
Accelerated filer
 
o
Non-accelerated filer
 
o (Do not check if a smaller reporting company)
  
Smaller reporting company
 
o
 
 
 
 
Emerging growth company
 
o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  o    No  x
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
Class
 
Outstanding as of
June 30, 2017
Common stock, $0.01 par value
 
210,260,531 shares


Table of Contents                 


TABLE OF CONTENTS
 
 
Item
Page
 
 
 
 
 
 
 
 
1.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.
 
 
 
3.
 
 
 
4.
 
 
 
 
 
 
 
 
1.
 
 
 
1A.
 
 
 
2.
 
 
 
3.
 
 
 
4.
 
 
 
5.
 
 
 
6.
 
 
 
 



McKESSON CORPORATION

PART I—FINANCIAL INFORMATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In millions, except per share amounts)
(Unaudited)
 
 
Quarter Ended June 30,
 
2017

2016
Revenues
$
51,051

 
$
49,733

Cost of Sales
(48,491
)
 
(46,826
)
Gross Profit
2,560

 
2,907

Operating Expenses
(1,964
)
 
(1,935
)
Gain on Healthcare Technology Net Asset Exchange
37

 

Total Operating Expenses
(1,927
)
 
(1,935
)
Operating Income
633

 
972

Other Income, Net
13

 
19

Loss from Equity Method Investment in Change Healthcare
(120
)
 

Interest Expense
(68
)
 
(79
)
Income from Continuing Operations Before Income Taxes
458

 
912

Income Tax Expense
(95
)
 
(239
)
Income from Continuing Operations
363


673

Income (Loss) from Discontinued Operations, Net of Tax
2


(113
)
Net Income
365


560

Net Income Attributable to Noncontrolling Interests
(56
)
 
(18
)
Net Income Attributable to McKesson Corporation
$
309

 
$
542

 
 
 
 
Earnings (Loss) Per Common Share Attributable to McKesson Corporation



Diluted
 

 
Continuing operations
$
1.44


$
2.88

Discontinued operations
0.01


(0.50
)
Total
$
1.45


$
2.38

Basic
 
 
 
Continuing operations
$
1.46


$
2.91

Discontinued operations


(0.50
)
Total
$
1.46


$
2.41

 
 
 
 
Dividends Declared Per Common Share
$
0.28

 
$
0.28

 
 
 
 
Weighted Average Common Shares
 
 
 
Diluted
213

 
228

Basic
211

 
225




See Financial Notes

3

McKESSON CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In millions)
(Unaudited)
 
 
Quarter Ended June 30,
 
2017

2016
Net Income
$
365

 
$
560

 
 
 
 
Other Comprehensive Income (Loss), Net of Tax
 
 
 
Foreign currency translation adjustments arising during the period
382

 
(255
)
 
 
 
 
Unrealized losses on net investment hedges arising during the period
(70
)
 

 
 
 
 
Unrealized gains on cash flow hedges arising during the period
14

 

 
 
 
 
Retirement-related benefit plans
(5
)
 
11

Other Comprehensive Income (Loss), Net of Tax
321

 
(244
)
 
 
 
 
Comprehensive Income (Loss)
686

 
316

Comprehensive Loss (Income) Attributable to Noncontrolling Interests
(172
)
 
48

Comprehensive Income (Loss) Attributable to McKesson Corporation
$
514

 
$
364








See Financial Notes

4

McKESSON CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS
(In millions, except per share amounts)
(Unaudited)
 
June 30,
2017
 
March 31,
2017
ASSETS
 
 
 
Current Assets
 
 
 
Cash and cash equivalents
$
2,339

 
$
2,783

Receivables, net
19,132

 
18,215

Inventories, net
15,498

 
15,278

Prepaid expenses and other
728

 
672

Total Current Assets
37,697

 
36,948

Property, Plant and Equipment, Net
2,349

 
2,292

Goodwill
11,750

 
10,586

Intangible Assets, Net
4,238

 
3,665

Equity Method Investment in Change Healthcare
3,855

 
4,063

Other Noncurrent Assets
1,927

 
3,415

Total Assets
$
61,816

 
$
60,969

 
 
 
 
LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND EQUITY
 
 
 
Current Liabilities
 
 
 
Drafts and accounts payable
$
32,015

 
$
31,022

Short-term borrowings
3

 
183

Deferred revenue
279

 
346

Current portion of long-term debt
525

 
1,057

Other accrued liabilities
2,977

 
3,004

Total Current Liabilities
35,799

 
35,612

 
 
 
 
Long-Term Debt
7,424

 
7,305

Long-Term Deferred Tax Liabilities
3,752

 
3,678

Other Noncurrent Liabilities
1,938

 
1,774

Redeemable Noncontrolling Interests
1,390

 
1,327

McKesson Corporation Stockholders’ Equity
 
 
 
Preferred stock, $0.01 par value, 100 shares authorized, no shares issued or outstanding

 

Common stock, $0.01 par value, 800 shares authorized at June 30, 2017 and March 31, 2017, 274 and 273 shares issued at June 30, 2017 and March 31, 2017
3

 
3

Additional Paid-in Capital
6,080

 
6,028

Retained Earnings
13,442

 
13,189

Accumulated Other Comprehensive Loss
(1,936
)
 
(2,141
)
Other
(4
)
 
(2
)
Treasury Shares, at Cost, 64 and 62 at June 30, 2017 and March 31, 2017
(6,282
)
 
(5,982
)
Total McKesson Corporation Stockholders’ Equity
11,303

 
11,095

Noncontrolling Interests
210

 
178

Total Equity
11,513

 
11,273

Total Liabilities, Redeemable Noncontrolling Interests and Equity
$
61,816

 
$
60,969


See Financial Notes

5

McKESSON CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In millions)
(Unaudited)
 
Quarter Ended June 30,
 
2017
 
2016
Operating Activities
 
 
 
Net income
$
365

 
$
560

Adjustments to reconcile to net cash provided by operating activities:
 
 
 
Depreciation and amortization
227

 
242

Loss from equity method investment in Change Healthcare
120

 

Deferred taxes
85

 
31

Charges associated with last-in-first-out inventory method
26

 
47

Loss (gain) from sale of businesses
(1
)
 
113

Other non-cash items
8

 
29

Changes in operating assets and liabilities, net of acquisitions:
 
 
 
Receivables
(363
)
 
(300
)
Inventories
(59
)
 
(121
)
Drafts and accounts payable
463

 
1,549

Deferred revenue
(73
)
 
(113
)
Taxes
(18
)
 
95

Other
(39
)
 
(273
)
Net cash provided by operating activities
741

 
1,859

 
 
 
 
Investing Activities
 
 
 
Payments for property, plant and equipment
(75
)
 
(76
)
Capitalized software expenditures
(43
)
 
(38
)
Acquisitions, net of cash and cash equivalents acquired
(1,485
)
 
(1,819
)
Proceeds from/(payments for) sale of businesses, net
3

 
(101
)
Restricted cash for acquisitions
1,469

 
935

Other
2

 
(55
)
Net cash used in investing activities
(129
)
 
(1,154
)
 
 
 
 
Financing Activities
 
 
 
Proceeds from short-term borrowings
2,282

 
7

Repayments of short-term borrowings
(2,463
)
 
(14
)
Repayments of long-term debt
(541
)
 
(1
)
Common stock transactions:
 
 
 
Issuances
27

 
36

Share repurchases, including shares surrendered for tax withholding
(300
)
 
(58
)
Dividends paid
(62
)
 
(66
)
Other
(74
)
 
14

Net cash used in financing activities
(1,131
)
 
(82
)
Effect of exchange rate changes on cash and cash equivalents
75

 
(12
)
Net increase (decrease) in cash and cash equivalents
(444
)
 
611

Cash and cash equivalents at beginning of period
2,783

 
4,048

Cash and cash equivalents at end of period
$
2,339

 
$
4,659


See Financial Notes

6

McKESSON CORPORATION
FINANCIAL NOTES
(UNAUDITED)


1.
Significant Accounting Policies
Basis of Presentation: The condensed consolidated financial statements of McKesson Corporation (“McKesson,” the “Company,” or “we” and other similar pronouns) include the financial statements of all wholly-owned subsidiaries and majority‑owned or controlled companies. For those consolidated subsidiaries where our ownership is less than 100%, the portion of the net income or loss allocable to the noncontrolling interests is reported as “Net Income Attributable to Noncontrolling Interests” on the condensed consolidated statements of operations. All significant intercompany balances and transactions have been eliminated in consolidation including the intercompany portion of transactions with equity method investees.
We consider ourselves to control an entity if we are the majority owner of and have voting control over such entity. We also assess control through means other than voting rights (“variable interest entities” or “VIEs”) and determine which business entity is the primary beneficiary of the VIE. We consolidate VIEs when it is determined that we are the primary beneficiary of the VIE. Investments in business entities in which we do not have control, but have the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method. Refer to Financial Note 2, “Healthcare Technology Net Asset Exchange” for further information on our equity method investment in Change Healthcare, LLC.
The condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) and, therefore, do not include all information and disclosures normally included in the annual consolidated financial statements.
To prepare the financial statements in conformity with GAAP, management must make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of these financial statements and income and expenses during the reporting period. Actual amounts may differ from these estimated amounts. In our opinion, the accompanying unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair presentation of our financial position, results of operations and cash flows for the interim periods presented.
The results of operations for the quarter ended June 30, 2017 are not necessarily indicative of the results that may be expected for the entire year. These interim financial statements should be read in conjunction with the annual audited financial statements, accounting policies and financial notes included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2017 previously filed with the SEC on May 22, 2017 (“2017 Annual Report”).
The Company’s fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year shall mean the Company’s fiscal year.
Recently Adopted Accounting Pronouncements
Investments: In the first quarter of 2018, we adopted amended guidance for the equity method of accounting. The amended guidance simplifies the transition to the equity method of accounting. This standard eliminates the requirement that when an existing cost method investment qualifies for use of the equity method, an investor must restate its historical financial statements, as if the equity method had been used during all previous periods. Additionally, at the point an investment qualifies for the equity method, any unrealized gain or loss in accumulated other comprehensive income (loss) will be recognized through earnings. The adoption of this amended guidance did not have a material effect on our condensed consolidated financial statements.
Derivatives and Hedging: In the first quarter of 2018, we adopted amended guidance for derivative instrument novations. The amendments clarify that a novation, a change in the counterparty, to a derivative instrument that has been designated as a hedging instrument does not, in and of itself, require dedesignation of that hedging relationship provided all other hedge accounting criteria continue to be met. The adoption of this amended guidance did not have an effect on our condensed consolidated financial statements.
Consolidation: In the first quarter of 2018, we adopted amended guidance for VIEs. The amended guidance requires a single decision maker of a VIE to consider indirect economic interests in the entity held through related parties that are under common control on a proportionate basis when determining whether it is the primary beneficiary of that VIE.  This amendment does not change the existing characteristics of a primary beneficiary. The adoption of this amended guidance did not have a material effect on our condensed consolidated financial statements.


7

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

Inventory: In the first quarter of 2018, we adopted amended guidance for the subsequent measurement of inventory. The amended guidance requires entities to measure inventory at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The requirement would replace the current lower of cost or market evaluation. Accounting guidance is unchanged for inventory measured using last-in, first-out (“LIFO”) or the retail method. The adoption of this amended guidance did not have a material effect on our condensed consolidated financial statements.
Recently Issued Accounting Pronouncements Not Yet Adopted
Share-Based Payments: In May 2017, amended guidance was issued for employee share-based payment awards. This amendment provides guidance on which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. Under the amended guidance, we are required to account for the effects of a modification if the fair value, the vesting conditions or the classification (as an equity instrument or a liability instrument) of the modified award change from that of the original award immediately before the modification. The amended guidance is effective for us on a prospective basis commencing in the first quarter of 2019.  Early adoption is permitted.  We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.
Premium Amortization of Purchased Callable Debt Securities: In March 2017, amended guidance was issued to shorten the amortization period for certain callable debt securities held at a premium.  The amended guidance requires the premium of callable debt securities to be amortized to the earliest call date but does not require an accounting change for securities held at a discount as they would still be amortized to maturity.  The amended guidance is effective for us on a modified retrospective basis commencing in the first quarter of 2020.  Early adoption is permitted.  We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.
Compensation - Retirement Benefits: In March 2017, amended guidance was issued which requires us to report the service cost component of defined benefit pension plans and other postretirement plans in the same line item as other compensation costs arising from services rendered by the pertinent employees during the period. Other components of net benefit cost are required to be presented in the statements of operations separately from the service cost component. This amended guidance is effective for us in the first quarter of 2019 on a retrospective basis. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.
Derecognition of Nonfinancial Assets: In February 2017, amended guidance was issued that defines the term “in substance nonfinancial asset” as a financial asset promised to a counterparty in a contract if substantially all of the fair value of the asset that is promised is concentrated in nonfinancial assets. The scope of this amendment includes nonfinancial assets transferred within a legal entity including a parent entity’s transfer of nonfinancial assets by transferring ownership interests in consolidated subsidiaries. The amendment excludes all businesses and nonprofit activities from its scope and therefore all entities, with limited exceptions, are required to account for the derecognition of a business or nonprofit activity in accordance with the consolidation guidance once this amended guidance becomes effective. We are required to apply this amended guidance at the same time we apply the amended revenue guidance in the first quarter of 2019. It allows for either full retrospective adoption or modified retrospective adoption.  Early adoption is permitted.  We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.
Goodwill Impairment Testing: In January 2017, amended guidance was issued to simplify goodwill impairment testing by eliminating the second step of the impairment test. Under the second step, the implied fair value of goodwill is calculated in a hypothetical analysis by subtracting the fair value of all assets and liabilities of the reporting unit, including any unrecognized intangible assets, from the fair value of the reporting unit calculated in the first step of the impairment test. If the carrying value of goodwill for the reporting unit exceeds the implied fair value of goodwill, an impairment charge is recorded for that excess. The amended guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, if any. The amended guidance is effective for us on a prospective basis commencing in the first quarter of 2021. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.


8

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

Business Combinations: In January 2017, amended guidance was issued to clarify the definition of a business to assist entities in evaluating whether transactions should be accounted for as acquisitions of assets or businesses. The amended guidance provides a practical screen to determine when an integrated set of assets and activities (collectively referred to as a “set”) is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. If the screen is not met, the amended guidance requires that to be considered a business, a set must include an input and a substantive process that together significantly contribute to the ability to create output. The amended guidance is effective for us commencing in the first quarter of 2019 on a prospective basis. Early adoption is permitted in certain circumstances.  We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.
Restricted Cash: In November 2016, amended guidance was issued that requires restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total cash amounts shown on the statement of cash flows. Transfers between cash and cash equivalents and restricted cash or restricted cash equivalents are not reported as cash flow activities in the statement of cash flows.  The amended guidance is effective for us commencing in the first quarter of 2019 on a retrospective basis. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.
Income Taxes - Intra-Entity Transfers of Assets Other Than Inventory: In October 2016, amended guidance was issued to require entities to recognize income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The amended guidance is effective for us commencing in the first quarter of 2019 on a modified retrospective basis. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.
Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments: In August 2016, amended guidance was issued to provide clarification on cash flow classification related to eight specific issues including contingent consideration payments made after a business combination and distributions received from equity method investees.  The amended guidance is effective for us commencing in the first quarter of 2019 on a retrospective basis. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.
Financial Instruments - Credit Losses: In June 2016, amended guidance was issued, which will change the impairment model for most financial assets and require additional disclosures. The amended guidance requires financial assets that are measured at amortized cost, be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of financial assets. The amended guidance also requires us to consider historical experience, current conditions, and reasonable and supportable forecasts that affect the collectibility of the reported amount in estimating credit losses. The amended guidance becomes effective for us commencing in the first quarter of 2021 and will be applied through a cumulative-effect adjustment to the beginning retained earnings in the year of adoption. Early adoption is permitted.  We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.
Leases: In February 2016, amended guidance was issued for lease arrangements. The amended standard will require lessees to recognize assets and liabilities on the balance sheet for all leases with terms longer than 12 months and provide enhanced disclosures on key information of leasing arrangements.  The amended guidance is effective for us commencing in the first quarter of 2020, on a modified retrospective basis.  Early adoption is permitted.  We plan to adopt the new standard on the effective date and are currently evaluating the impact of this amended guidance on our consolidated financial statements. We anticipate that the adoption of the amended lease guidance will materially affect our condensed consolidated balance sheet and will require certain changes to our systems and processes.
Financial Instruments: In January 2016, amended guidance was issued that requires equity investments to be measured at fair value with changes in fair value recognized in net income and enhanced disclosures about those investments. This guidance also simplifies the impairment assessments of equity investments without readily determinable fair value. The investments that are accounted for under the equity method of accounting or result in consolidation of the investee are excluded from the scope of this amended guidance. The amended guidance will become effective for us commencing in the first quarter of 2019 and will be adopted through a cumulative-effect adjustment. Early adoption is not permitted except for certain provisions.  We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.


9

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

Revenue Recognition: In May 2014, amended guidance was issued for recognizing revenue from contracts with customers.  The amended guidance eliminates industry specific guidance and applies to all companies.  Revenues will be recognized when an entity satisfies a performance obligation by transferring control of a promised good or service to a customer in an amount that reflects the consideration to which the entity expects to be entitled for that good or service.  Revenue from a contract that contains multiple performance obligations is allocated to each performance obligation generally on a relative standalone selling price basis.  The amended guidance also requires additional quantitative and qualitative disclosures.  In March, April and May 2016, amended guidance was further issued including clarifying guidance on principal versus agent considerations, ability to choose an accounting policy election to account for shipping and handling activities that occur after the customer has obtained control of a good as an activity to fulfill the promise to transfer the good, and provided certain scope improvements and practical expedients.  The amended standard is effective for us commencing in the first quarter of 2019 and allows for either full retrospective adoption or modified retrospective adoption.  Early adoption is permitted.
While we continue to evaluate the effect of the amended standard, we have conducted a preliminary assessment for our Distribution Solutions segment and do not expect adoption of the amended standard to have a material impact on our consolidated financial statements.  The majority of our Distribution Solutions segment’s revenue is generated from sales of pharmaceutical products, which will continue to be recognized when control of the goods is transferred to the customer. We generally anticipate having substantially similar performance obligations under the amended guidance as compared with deliverables and units of account currently being recognized. We intend to make policy elections within the amended standard that are consistent with our current accounting. Our preliminary assessment does not include certain businesses for which we are exploring strategic alternatives and we continue to evaluate the potential impact of the recent acquisitions. This preliminary assessment is subject to change prior to adoption. Additionally, we anticipate adopting this amended standard on a modified retrospective basis in our first quarter of 2019.
2.    Healthcare Technology Net Asset Exchange
On June 28, 2016, we entered into a contribution agreement (“Contribution Agreement”) with Change Healthcare Holdings, Inc. (“Change”), a Delaware corporation, and others including shareholders of Change to form a joint venture, Change Healthcare, LLC (“Change Healthcare”), a Delaware limited liability company. On March 1, 2017, the transaction closed upon satisfaction of all closing conditions pursuant to the Contribution Agreement. Under the terms of the Contribution Agreement, we contributed the majority of our McKesson Technology Solutions businesses (“Core MTS Business”) to the newly formed joint venture, Change Healthcare. We retained our RelayHealth Pharmacy (“RHP”) and Enterprise Information Solutions (“EIS”) businesses. Change contributed substantially all of its businesses to the joint venture excluding its pharmacy switch and prescription routing business. In exchange for the contribution, we own 70% of the joint venture with the remaining equity ownership held by Change shareholders. The joint venture is jointly governed by us and Change shareholders. Change Healthcare is a healthcare technology company which provides software and analytics, network solutions and technology-enabled services that will deliver wide-ranging financial, operational and clinical benefits to payers, providers and consumers.
McKesson and Change shareholders have agreed to take steps to launch an initial public offering of an entity which holds equity in Change Healthcare, subject to market conditions. Sometime thereafter, we expect to exit our investment in Change Healthcare through a distribution to McKesson shareholders.

Gain from Healthcare Technology Net Asset Exchange
We accounted for this transaction as a sale of the Core MTS Business and a subsequent purchase of a 70% interest in the newly formed joint venture. Accordingly, in the fourth quarter of 2017, we deconsolidated the Core MTS Business and recorded a pre-tax gain of $3,947 million (after-tax gain of $3,018 million) within operating expenses in our consolidated statements of operations. This transaction did not meet the criteria to be reported as a discontinued operation since it did not constitute a significant strategic business shift for the Company. During the first quarter of 2018, we recorded a pre-tax gain of approximately $37 million (after-tax gain of $22 million) under the caption, “Gain on Healthcare Technology Net Asset Exchange,” upon the finalization of net working capital and other adjustments. At June 30, 2017, we had a receivable of $126 million from Change Healthcare representing the final settlement of the net working capital and other adjustments.


10

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

Equity Method Investment in Change Healthcare
Our investment in the joint venture is accounted for using the equity method of accounting. We disclose intervening events at the joint venture in the lag period that could materially affect our consolidated financial statements, if applicable. There were no material intervening events at the joint venture during June 2017. During the first quarter of 2018, we recorded our proportionate share of loss from Change Healthcare of $120 million, which included transaction and integration expenses incurred by the joint venture and amortization expenses associated with equity method intangible assets. This amount was recorded under the caption, “Loss from Equity Method Investment in Change Healthcare,” in our condensed consolidated statement of operations.
At June 30, 2017, the carrying value of our investment was $3,855 million, which exceeded our proportionate share of the joint venture’s book value of net assets by approximately $4,768 million, primarily reflecting equity method intangible assets and goodwill and other fair value adjustments.
Summarized financial information (unaudited) of Change Healthcare is as follows:
(In millions)
Quarter Ended June 30, 2017
Revenues
$
865

Loss from Continuing Operations
(84
)
Net Loss
(84
)
Our proportionate share of Change Healthcares net loss as reported was $59 million ($84 million at our 70% ownership).  Adjustments from their carrying value to our initial fair value basis of accounting resulted in a total reported net loss of $120 million for McKesson.  The amortization of fair value adjustments included incremental intangible amortization and removal of profit associated with the recognition of deferred revenue, as well as basis differences in long-term debt.
Agreements with Change Healthcare and Related Party Transactions
At the closing of the transaction, McKesson, Change Healthcare and certain Change shareholders also entered into various ancillary agreements, including transition services agreements (“TSA”), a transaction and advisory fee agreement (“Advisory Agreement”), a tax receivable agreement (“TRA”) and certain other commercial agreements.
Pursuant to the TRA, McKesson may be required to make certain payments or may be entitled to receive certain payments related to the cash tax savings attributable to the utilization of certain tax attributes, including certain amortizable tax basis in software contributed by McKesson to Change Healthcare. At June 30, 2017 and March 31, 2017, we had a $136 million noncurrent liability payable to Change Healthcare shareholders associated with the TRA. The amount is based on certain estimates and could become payable in periods after a disposition of our investment in Change Healthcare. No such payments were required to be made or received during the first quarter of 2018.
Pursuant to the TSA, McKesson provides various transitional services to the joint venture to support certain operations including information technology, accounting and other administrative services. The total fees charged by us for such transition services were $37 million for the first quarter of 2018. Transition services fees are included within operating expenses in our condensed consolidated statements of operations.
Pursuant to the Advisory Agreement, the joint venture pays McKesson and Change shareholders an agreed upon amount for each fiscal year on a quarterly basis. The foregoing advisory and transaction fees are non-refundable and allocated to McKesson and Change shareholders based on their respective equity ownership percentages. In the first quarter of 2018, we did not earn material advisory fees and transaction fees.
Revenues recorded and expenses incurred under commercial arrangements with Change Healthcare were not material during the first quarter of 2018. At June 30, 2017 and March 31, 2017, receivables from and payables to the joint venture were not material.


11

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

3.
Business Combinations
CoverMyMeds LLC (“CMM”)
On April 3, 2017, we completed our acquisition of CMM, a privately-owned company headquartered in Columbus, Ohio. CMM provides electronic prior authorization solutions to pharmacies, providers, payers, and pharmaceutical manufacturers. The net purchase consideration of $1.3 billion was funded from cash on hand. The cash consideration was initially paid into an escrow account prior to our 2017 fiscal year end, and was included in “Other Noncurrent Assets” within our consolidated balance sheet at March 31, 2017. Pursuant to the agreement, McKesson may pay up to an additional $0.2 billion of contingent consideration based on CMM’s financial performance for 2018 and 2019. We recorded a liability for this remaining contingent consideration at its estimated fair value of $113 million as of the acquisition date on our condensed consolidated balance sheet.  The contingent consideration was estimated using a Monte Carlo simulation, which utilizes Level 3 inputs under the fair value measurement and disclosure guidance, including estimated financial forecasts. The contingent liability is re-measured at fair value at each reporting date until the liability is extinguished with changes in fair value being recorded to our statements of operations.  There was no material change in the contingent liability’s fair value during the first quarter of 2018. The initial fair value of this contingent consideration is a non-cash investing activity. The financial results of CMM are included in our North America pharmaceutical distribution and services business within our Distribution Solutions segment since the acquisition date.
The provisional fair value of assets acquired and liabilities assumed as of the acquisition date, excluding goodwill and intangibles, were $54 million and $8 million. Approximately $854 million of the preliminary purchase price allocation has been assigned to goodwill, which reflects the expected future benefits of certain synergies and intangible assets that do not qualify for separate recognition. The amount of goodwill is fully deductible for tax purposes. Included in the preliminary purchase price allocation are acquired identifiable intangibles of $502 million primarily representing customer relationships with a weighted average life of 17 years. Amounts recognized as of the acquisition date are provisional and subject to change within the measurement period as our fair value assessments are finalized.
Rexall Health
On December 28, 2016, we completed our acquisition of Rexall Health which operates approximately 470 retail pharmacies in Canada, particularly in Ontario and Western Canada. The net cash purchase consideration of $2.9 billion Canadian dollars (or, approximately $2.1 billion) was funded from cash on hand. As part of the transaction, McKesson agreed to divest 27 local stores that the Competition Bureau of Canada (the “Bureau”) identified during its review of the transaction. We expect to complete the sale of these local market divestitures during the first half of 2018. The financial results of Rexall Health are included in our North America pharmaceutical distribution and services business within our Distribution Solutions segment since the acquisition date.
During the first quarter of 2018, we recorded certain measurement period adjustments to the provisional fair value of assets acquired and liabilities assumed as of the acquisition date (primarily an increase of $17 million to intangibles). The amounts as of the acquisition date are provisional and subject to change within the measurement period as our fair value assessments are finalized.
Total adjusted provisional fair value of assets acquired and liabilities assumed as of the acquisition date, excluding goodwill and intangibles, were $674 million and $212 million. Approximately $950 million of the adjusted preliminary purchase price allocation has been assigned to goodwill, which primarily reflects the expected future benefits of certain synergies and intangible assets that do not qualify for separate recognition. Included in the adjusted preliminary purchase price allocation are acquired identifiable intangibles of $872 million, net of intangibles classified as held for sale, primarily representing trade names with a weighted average life of 19 years and customer relationships with a weighted average life of 19 years. At June 30, 2017, assets of those stores to be divested were approximately $193 million and were included under the captions, “Prepaid expenses and other” in the accompanying condensed consolidated balance sheet. There were no material liabilities associated with those stores at June 30, 2017.
The fair value of acquired intangibles from these acquisitions was primarily determined by applying the income approach, using several significant unobservable inputs for projected cash flows and a discount rate. These inputs are considered Level 3 inputs.


12

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

2017 Acquisitions

In the first quarter of 2017, we completed our acquisitions of Vantage Oncology Holdings, LLC (“Vantage”), Biologics, Inc., UDG Healthcare Plc (“UDG”) and other businesses for net cash payments of $1.8 billion.
Other Acquisitions

During the last two years, we also completed other acquisitions within both of our operating segments. Financial results for our business acquisitions have been included in our consolidated financial statements since their respective acquisition dates. Purchase prices for our business acquisitions have been allocated based on estimated fair values at the date of acquisition.
Goodwill recognized for our business acquisitions is generally not expected to be deductible for tax purposes. However, if we acquire the assets of a company, the goodwill may be deductible for tax purposes.
4.
Discontinued Operations
In the fourth quarter of 2016, we entered into an agreement to sell our Brazilian pharmaceutical distribution business to a third party from our Distribution Solutions segment. In the first quarter of 2017, we completed the sale of this business and recognized an after-tax loss of $113 million within discontinued operations primarily for the settlement of certain indemnification matters as well as the release of the cumulative translation losses. We made a payment of approximately $100 million related to the sale of this business in the first quarter of 2017. The results of this business have been classified as discontinued operations since 2015.
The results of discontinued operations for the first quarters of 2018 and 2017 were not material except for the loss recognized upon the disposition of our Brazilian business in 2017. As of June 30, 2017 and March 31, 2017, the carrying amounts of total assets and liabilities of discontinued operations were not material.
5.
Restructuring
In the fourth quarter of 2016, we committed to a restructuring plan to lower our operating costs (the “Cost Alignment Plan”). The Cost Alignment Plan primarily consists of a reduction in workforce, and business process initiatives that will be substantially implemented prior to the end of 2019. Business process initiatives primarily include plans to reduce operating costs of our distribution and pharmacy operations, administrative support functions, and technology platforms, as well as the disposal and abandonment of certain non-core businesses. As a result of the Cost Alignment Plan, we expect to record total pre-tax charges of approximately $250 million to $270 million, of which $246 million of pre-tax charges were recorded to date. Estimated remaining charges primarily consist of exit-related costs and accelerated depreciation and amortization, which are largely attributed to our Distribution Solutions segment.

During the first quarter of 2017, we recorded a pre-tax charge of $9 million as part of the Cost Alignment Plan. There were no material restructuring charges recorded during the first quarter of 2018. During the first quarters of 2018 and 2017, we made $14 million and $45 million of cash payments, primarily related to severance. The reserve balances as of June 30, 2017 and March 31, 2017 include $64 million and $71 million recorded in other accrued liabilities, and $35 million recorded in other noncurrent liabilities in our condensed consolidated balance sheet.
6.
Income Taxes
During the first quarters of 2018 and 2017, income tax expense related to continuing operations was $95 million and $239 million and included net discrete tax expense of $3 million and net discrete tax benefit of $35 million. Our discrete tax benefits for the first quarter of 2017 included $37 million related to the adoption of the amended accounting guidance on employee share-based compensation. Our reported income tax rates for the first quarters of 2018 and 2017 were 20.7% and 26.2%. Fluctuations in our reported income tax rates are primarily due to changes within our business mix, including varying proportions of income attributable to foreign countries that have lower income tax rates, discrete items and the impact of the intercompany sale of software.


13

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

As of June 30, 2017, we had $516 million of unrecognized tax benefits, of which $371 million would reduce income tax expense and the effective tax rate, if recognized. During the next twelve months, it is reasonably possible that audit resolutions could potentially reduce our unrecognized tax benefits by up to $60 million. However, this amount may change as we continue to have ongoing negotiations with various taxing authorities throughout the year.
We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. During the first quarter of 2017, we reached an agreement with the Internal Revenue Service (“IRS”) to settle all outstanding issues relating to the fiscal years 2007 through 2009. This settlement did not have a material impact on our provision for income taxes. We are subject to audit by the IRS for fiscal years 2010 through the current fiscal year. We are generally subject to audit by taxing authorities in various U.S. states and in foreign jurisdictions for fiscal years 2006 through the current fiscal year.
7.
Redeemable Noncontrolling Interests and Noncontrolling Interests
Redeemable Noncontrolling Interests

Our redeemable noncontrolling interests relate to our consolidated subsidiary, Celesio AG (“Celesio”). The domination and profit and loss transfer agreement (the “Domination Agreement”) was entered into between McKesson and Celesio in connection with our 2014 acquisition of Celesio and became effective in December 2014. Under the Domination Agreement, the noncontrolling shareholders of Celesio have a right to put (“Put Right”) their Celesio shares at €22.99 per share increased annually for interest in the amount of 5 percentage points above a base rate published by the German Bundesbank semiannually, less any compensation amount or guaranteed dividend already paid by McKesson in respect of the relevant time period (“Put Amount”). The exercise of the Put Right will reduce the balance of redeemable noncontrolling interests. During the first quarter of 2018, we paid $50 million to purchase 1.9 million shares of Celesio through the exercises of the Put Right by the noncontrolling shareholders, which decreased the carrying value of redeemable noncontrolling interests by $53 million. The balance of redeemable noncontrolling interests is reported at the greater of its carrying value or its maximum redemption value at each reporting date. The redemption value is the Put Amount adjusted for exchange rate fluctuations each period. At June 30, 2017 and March 31, 2017, the carrying value of redeemable noncontrolling interests of $1.39 billion and $1.33 billion exceeded the maximum redemption value of $1.24 billion and $1.21 billion. At June 30, 2017 and March 31, 2017, we owned approximately 77% and 76% of Celesio’s outstanding common shares.

Under the Domination Agreement, the noncontrolling shareholders of Celesio received a one-time guaranteed dividend of €0.83 per Celesio share for the 2014 calendar year and are also entitled to receive an annual recurring compensation amount of €0.83 per Celesio share since January 2015. As a result, during the first quarters of 2018 and 2017, we recorded a total attribution of net income to the noncontrolling shareholders of Celesio of $9 million and $11 million. All amounts were recorded in our condensed consolidated statement of operations within the caption, “Net Income Attributable to Noncontrolling Interests,” and the corresponding liability balance was recorded within other accrued liabilities on our condensed consolidated balance sheet.
During fiscal 2014, subsequent to the effectiveness of the Domination Agreement, certain noncontrolling shareholders of Celesio initiated appraisal proceedings (“Appraisal Proceedings”) with the Stuttgart Regional Court to challenge the adequacy of the compensation amount, the guaranteed dividend and/or the Put Amount. As long as any Appraisal Proceedings are pending, the compensation amount, guaranteed dividend and/or Put Amount will be paid as specified currently in the Domination Agreement.
Noncontrolling Interests
Our noncontrolling interests represent third-party equity interests in our consolidated entities, primarily Vantage and ClarusONE Sourcing Services LLP, were $210 million and $178 million at June 30, 2017 and March 31, 2017. During the first quarters of 2018 and 2017, we allocated a total of $47 million and $7 million of net income to noncontrolling interests.



14

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

Changes in redeemable noncontrolling interests and noncontrolling interests for the first quarter of 2018 were as follows:
(In millions)
Noncontrolling Interests
Redeemable
Noncontrolling
Interests
Balance, March 31, 2017
$
178

$
1,327

Net income attributable to noncontrolling interests
47

9

Other comprehensive income

116

Reclassification of recurring compensation to other accrued liabilities

(9
)
Payments to noncontrolling interests
(18
)

Exercises of Put Right

(53
)
Other
3


Balance, June 30, 2017
$
210

$
1,390


Changes in redeemable noncontrolling interests and noncontrolling interests for the first quarter of 2017 were as follows:
(In millions)
Noncontrolling Interests
Redeemable
Noncontrolling
Interests
Balance, March 31, 2016
$
84

$
1,406

Net income attributable to noncontrolling interests
7

11

Other comprehensive loss

(66
)
Reclassification of recurring compensation to other accrued liabilities

(11
)
Purchase of noncontrolling interests
152


Other
(1
)

Balance, June 30, 2016
$
242

$
1,340


The effect of changes in our ownership interests with noncontrolling interests on our equity of $3 million was recorded as a net increase to McKesson’s stockholders’ paid-in capital during the first quarter of 2018. Net income attributable to McKesson and transfers from noncontrolling interests amounted to $312 million during the first quarter of 2018.
8.
Earnings Per Common Share
Basic earnings per common share are computed by dividing net income by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share are computed similar to basic earnings per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.


15

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

The computations for basic and diluted earnings per common share are as follows:
  
Quarter Ended June 30,
(In millions, except per share amounts)
2017
 
2016
Income from continuing operations
$
363

 
$
673

Net income attributable to noncontrolling interests
(56
)
 
(18
)
Income from continuing operations attributable to McKesson
307

 
655

Income (loss) from discontinued operations, net of tax
2

 
(113
)
Net income attributable to McKesson
$
309

 
$
542

 
 
 
 
Weighted average common shares outstanding:
 
 
 
Basic
211

 
225

Effect of dilutive securities:
 
 
 
Options to purchase common stock
1

 
1

Restricted stock units
1

 
2

Diluted
213

 
228

 
 
 
 
Earnings (loss) per common share attributable to McKesson: (1)
 
 
 
Diluted
 
 
 
Continuing operations
$
1.44

 
$
2.88

Discontinued operations
0.01

 
(0.50
)
Total
$
1.45

 
$
2.38

Basic
 
 
 
Continuing operations
$
1.46

 
$
2.91

Discontinued operations

 
(0.50
)
Total
$
1.46

 
$
2.41

(1)
Certain computations may reflect rounding adjustments.
Potentially dilutive securities include outstanding stock options, restricted stock units, and performance-based and other restricted stock units. Approximately 2 million potentially dilutive securities were excluded from the computations of diluted net earnings per common share for each of the quarters ended June 30, 2017 and 2016, as they were anti-dilutive.
9.
Goodwill and Intangible Assets, Net
Changes in the carrying amount of goodwill were as follows:
(In millions)
Distribution
Solutions
 
Technology
Solutions
 
Total
Balance, March 31, 2017
$
10,132

 
$
454

 
$
10,586

Goodwill acquired
940

 

 
940

Acquisition accounting, transfers and other adjustments (1)
324

 
(330
)
 
(6
)
Foreign currency translation adjustments, net
230

 

 
230

Balance, June 30, 2017
$
11,626

 
$
124

 
$
11,750

(1)
Effective April 1, 2017, our RHP business was transitioned from the Technology Solutions segment to the Distribution Solutions segment.
As of June 30, 2017 and March 31, 2017, accumulated goodwill impairment losses were $290 million primarily in our Technology Solutions segment.


16

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

Information regarding intangible assets is as follows:
 
June 30, 2017
 
March 31, 2017
(Dollars in millions)
Weighted
Average
Remaining
Amortization
Period
(years)
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Carrying
Amount
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships
12
 
$
3,411

 
$
(1,392
)
 
$
2,019

 
$
2,893

 
$
(1,295
)
 
$
1,598

Service agreements
13
 
1,023

 
(332
)
 
691

 
1,009

 
(316
)
 
693

Pharmacy licenses
25
 
772

 
(164
)
 
608

 
741

 
(150
)
 
591

Trademarks and trade names
15
 
870

 
(136
)
 
734

 
845

 
(124
)
 
721

Technology
5
 
151

 
(71
)
 
80

 
69

 
(64
)
 
5

Other
5
 
261

 
(155
)
 
106

 
201

 
(144
)
 
57

Total
 
 
$
6,488


$
(2,250
)
 
$
4,238

 
$
5,758

 
$
(2,093
)
 
$
3,665

Amortization expense of intangible assets was $121 million and $115 million for the quarters ended June 30, 2017 and 2016. Estimated annual amortization expense of these assets is as follows: $328 million, $420 million, $405 million, $393 million and $361 million for the remainder of 2018 and each of the succeeding years through 2022 and $2,331 million thereafter. All intangible assets were subject to amortization as of June 30, 2017 and March 31, 2017.
10.
Debt and Financing Activities
Long-Term Debt
Our long-term debt includes both U.S. dollar and foreign currency (primarily Euro and British pound sterling) denominated borrowings. At June 30, 2017 and March 31, 2017, $7,949 million and $8,362 million of total long-term debt were outstanding, of which $525 million and $1,057 million were included under the caption “Current portion of long-term debt” within the condensed consolidated balance sheets.
During the first quarter of 2018, we repaid our €500 million bond that matured on April 26, 2017.
Revolving Credit Facilities
We have a syndicated $3.5 billion five-year senior unsecured revolving credit facility (the “Global Facility”), which has a $3.15 billion aggregate sublimit of availability in Canadian dollars, British pound sterling and Euros. Borrowings under the Global Facility bear interest based upon the London Interbank Offered Rate, Canadian Dealer Offered Rate for credit extensions denominated in Canadian Dollars, a prime rate, or alternative overnight rates as applicable, plus agreed margins. The Global Facility contains a financial covenant which obligates the Company to maintain a debt to capital ratio of no greater than 65% and other customary investment grade covenants. If we do not comply with these covenants, our ability to use the Global Facility may be suspended and repayment of any outstanding balances under the Global Facility may be required. At June 30, 2017, we were in compliance with all covenants. There were no borrowings outstanding under this facility during the first quarter of 2018, and as of June 30, 2017.
We also maintain bilateral credit lines primarily denominated in Euros with a total committed and uncommitted balance of $244 million. Borrowings and repayments were not material during the first quarters of 2018 and 2017. As of June 30, 2017 and March 31, 2017, amounts outstanding under these credit lines were not material.
Commercial Paper
We maintain a commercial paper program to support our working capital requirements and for other general corporate purposes. Under the program, the Company can issue up to $3.5 billion in outstanding notes. As of June 30, 2017, there were no borrowings outstanding under the commercial paper program. As of March 31, 2017, we had $183 million commercial paper notes outstanding with a weighted average interest rate of 1.20%.


17

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

11.
Pension Benefits
The net periodic expense for our defined pension benefit plans was $6 million for the first quarters of 2018 and 2017.

Cash contributions to these plans were $3 million and $4 million for the first quarters of 2018 and 2017. The projected unit credit method is utilized in measuring net periodic pension expense over the employees’ service life for the pension plans. Unrecognized actuarial losses exceeding 10% of the greater of the projected benefit obligation or the market value of assets are amortized straight-line over the average remaining future service periods and expected life expectancy.
12.
Hedging Activities
In the normal course of business, we are exposed to interest rate and foreign exchange rate fluctuations. At times, we limit these risks through the use of derivatives such as interest rate swaps, cross currency swaps and foreign currency forward contracts. In accordance with our policy, derivatives are only used for hedging purposes. We do not use derivatives for trading or speculative purposes.
Foreign currency exchange risk
We conduct our business worldwide in U.S. dollars and the functional currencies of our foreign subsidiaries, including Euro, British pound sterling and Canadian dollars. Changes in foreign currency exchange rates could have a material adverse impact on our financial results that are reported in U.S. dollars. We are also exposed to foreign currency exchange rate risk related to our foreign subsidiaries, including intercompany loans denominated in non-functional currencies. We have certain foreign currency exchange rate risk programs that use foreign currency forward contracts and cross currency swaps. These forward contracts and cross currency swaps are generally used to offset the potential income statement effects from intercompany loans denominated in non-functional currencies. These programs reduce but do not eliminate foreign exchange rate risk.
Net Investment Hedges and Derivatives Designated as Hedges
We have €1.2 billion Euro-denominated notes and £450 million British pound sterling-denominated notes which hedge portions of our net investments in non-U.S. subsidiaries against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar (“Net Investment Hedges”). For all notes that are designated as net investment hedges and meet effectiveness requirements, the changes in carrying value of the notes attributable to the change in spot rates are recorded in accumulated other comprehensive income (loss) within the condensed consolidated balance sheet where they offset foreign currency translation gains and losses recorded on our net investments.  To the extent foreign currency denominated notes designated as net investment hedges are ineffective, changes in value are recorded in earnings.  Losses from net investment hedges recorded in other comprehensive income were $114 million during the first quarter of 2018. We did not have any ineffective portion of the net investment hedges as of June 30, 2017 and March 31, 2017.
At June 30, 2017 and March 31, 2017, we had forward contracts to hedge the U.S. dollar against cash flows denominated in Canadian dollars with total gross notional values of $243 million, which were designated as cash flow hedges. These contracts will mature between March 2018 and March 2020.
From time to time, we enter into cross currency swaps to hedge intercompany loans denominated in non-functional currencies. For our cross currency swap transactions, we agree with another party to exchange, at specified intervals, one currency for another currency at a fixed exchange rate, generally set at inception, calculated by reference to agreed upon notional amounts. These cross currency swaps are designed to reduce the income statement effects arising from fluctuations in foreign exchange rates and have been designated as cash flow hedges.
At June 30, 2017 and March 31, 2017, we had cross currency swaps with total gross notional amounts of approximately $3,223 million and $2,663 million, which are designated as cash flow hedges. These swaps will mature between February 2018 and January 2024.


18

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

For forward contracts and cross currency swaps that are designated as cash flow hedges, the effective portion of changes in the fair value of the hedges is recorded into accumulated other comprehensive income (loss) and reclassified into earnings in the same period in which the hedged transaction affects earnings. Changes in fair values representing hedge ineffectiveness are recognized in current earnings. Gains or losses on these hedges recorded in other comprehensive income and earnings were not material in the first quarters of 2018 and 2017.
Derivatives Not Designated as Hedges
At June 30, 2017 and March 31, 2017, we had forward contracts to primarily hedge the U.S. dollar against cash flows denominated in Canadian dollars with total gross notional value of $177 million and $173 million. These contracts will mature through August 2017 and none of these contracts were designated for hedge accounting. Losses from these contracts were not material for the first quarters of 2018 and 2017.
We also have a number of forward contracts to hedge the Euro against cash flows denominated primarily in British pound sterling and other European currencies. At June 30, 2017 and March 31, 2017, the total gross notional amounts of these contracts were $167 million and $62 million.
These contracts will mature through December 2017 and none of these contracts were designated for hedge accounting. Changes in the fair values of contracts not designated as hedges are recorded directly into earnings. Gains from these contracts were recorded within operating expenses and were not material for the first quarters of 2018 and 2017. The gains or losses from these contracts are largely offset by changes in the value of the underlying intercompany foreign currency loans.
Information regarding the fair value of derivatives on a gross basis is as follows:
 
Balance Sheet
Caption
June 30, 2017
 
March 31, 2017
 
Fair Value of
Derivative
U.S. Dollar Notional
 
Fair Value of
Derivative
U.S. Dollar Notional
(In millions)
Asset
Liability
 
Asset
Liability
Derivatives designated for hedge accounting
 
 
 
 
 
 
 
 
Foreign exchange contracts (current)
Prepaid expenses and other
$
16

$

$
81

 
$
17

$

$
81

Foreign exchange contracts (non-current)
Other Noncurrent Assets
30


162

 
32


162

Cross currency swaps (current)
Prepaid expenses and other
11


174

 
17


174

Cross currency swaps (non-current)
Other Noncurrent Assets/Liabilities

26

3,049

 
90


2,489

Total
 
$
57

$
26

 
 
$
156

$

 
Derivatives not designated for hedge accounting
 
 
 
 
 
 
 
 
Foreign exchange contracts (current)
Prepaid expenses and other
$
1

$

$
139

 
$
1

$

$
198

Foreign exchange contracts (current)
Other accrued liabilities

4

205

 


37

Total
 
$
1

$
4

 
 
$
1

$

 
Refer to Financial Note 13, "Fair Value Measurements," for more information on these recurring fair value measurements.


19

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

13.
Fair Value Measurements
At June 30, 2017 and March 31, 2017, the carrying amounts of cash, certain cash equivalents, restricted cash, marketable securities, receivables, drafts and accounts payable, short-term borrowings and other current liabilities approximated their estimated fair values because of the short maturity of these financial instruments.
The fair value of our commercial paper was determined using quoted prices in active markets for identical liabilities, which are considered to be Level 1 inputs.
Assets Measured at Fair Value on a Recurring Basis

Our long-term debt is carried at amortized cost. The carrying amounts and estimated fair values of these liabilities were $7.9 billion and $8.4 billion at June 30, 2017, and $8.4 billion and $8.7 billion at March 31, 2017. The estimated fair value of our long-term debt was determined using quoted market prices in a less active market and other observable inputs from available market information, which are considered to be Level 2 inputs, and may not be representative of actual values that could have been realized or that will be realized in the future.
Included in cash and cash equivalents at June 30, 2017 and March 31, 2017 were mainly investments in money market funds of $443 million and $478 million, which are reported at fair value. The fair value of the money market funds was determined by using quoted prices for identical investments in active markets, which are considered to be Level 1 inputs under the fair value measurements and disclosure guidance. The carrying value of all other cash equivalents approximates their fair value due to their relatively short-term nature.
Fair values of our forward foreign currency derivatives were determined using quoted market prices of similar instruments in an active market and other observable inputs from available market information.  Fair values of our foreign currency swaps were determined using the quoted foreign currency exchange rates and other observable inputs from available market information. These inputs are considered Level 2 under the fair value measurements and disclosure guidance, and may not be representative of actual values that could have been realized or that will be realized in the future. Refer to Financial Note 12, "Hedging Activities," for more information on our forward foreign currency derivatives including foreign currency forward contracts and swaps.
There were no transfers between Level 1, Level 2 or Level 3 of the fair value hierarchy during the quarters ended June 30, 2017 and 2016.
Liabilities Measured at Fair Value on a Nonrecurring Basis

At June 30, 2017, we measured the contingent consideration liability related to our acquisition of CMM at fair value on a nonrecurring basis. Refer to Financial Note 3, “Business Combinations”. There were no assets measured at fair value on a nonrecurring basis at June 30, 2017.
14.
Commitments and Contingent Liabilities
In addition to commitments and obligations in the ordinary course of business, we are subject to various claims, including claims with customers and vendors, pending and potential legal actions for damages, investigations relating to governmental laws and regulations and other matters arising out of the normal conduct of our business. As described below, many of these proceedings are at preliminary stages and many seek an indeterminate amount of damages.
When a loss is considered probable and reasonably estimable, we record a liability in the amount of our best estimate for the ultimate loss. However, the likelihood of a loss with respect to a particular contingency is often difficult to predict and determining a meaningful estimate of the loss or a range of loss may not be practicable based on the information available and the potential effect of future events and decisions by third parties that will determine the ultimate resolution of the contingency. Moreover, it is not uncommon for such matters to be resolved over many years, during which time relevant developments and new information must be reevaluated at least quarterly to determine both the likelihood of potential loss and whether it is possible to reasonably estimate a range of possible loss. When a loss is probable but a reasonable estimate cannot be made, disclosure of the proceeding is provided.


20

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. We review all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or range of loss can be made. As discussed above, development of a meaningful estimate of loss or a range of potential loss is complex when the outcome is directly dependent on negotiations with or decisions by third parties, such as regulatory agencies, the court system and other interested parties. Such factors bear directly on whether it is possible to reasonably estimate a range of potential loss and boundaries of high and low estimates.
Significant developments in previously reported proceedings and in other litigation and claims, since the filing of our 2017 Annual Report are set out below. We are party to the legal proceedings described below. Unless otherwise stated, we are currently unable to estimate a range of reasonably possible losses for the unresolved proceedings described below. Should any one or a combination of more than one of these proceedings be successful, or should we determine to settle any or a combination of these matters, we may be required to pay substantial sums, become subject to the entry of an injunction or be forced to change the manner in which we operate our business, which could have a material adverse impact on our financial position or results of operations.
Litigation, Government Subpoenas and Investigations
As previously disclosed, following removal of the action captioned State of West Virginia ex rel. Morrisey v. McKesson Corporation to the United States District Court for the Southern District of West Virginia, the court remanded the matter back to state court. On July 7, 2017, the Company again removed the matter to the United States District Court for the Southern District of West Virginia (Civil Action No. 2:16-cv-03555.)
Since May 24, 2017, the Company has been served with seven complaints filed in state courts in West Virginia alleging claims related to the distribution of controlled substances to pharmacies in West Virginia. These lawsuits are Mayor Reba Honaker, on behalf of the City of Welch v. West Virginia Board of Pharmacy, et al., Cabell County, West Virginia Circuit Court, Civil Action 17-C-18, removed to the United States District Court for the Southern District of West Virginia, Civil Action 1:17-cv-03364; County Commission of Lincoln County v. West Virginia Board of Pharmacy, et al., Lincoln County, West Virginia Circuit Court, Civil Action 17-C-46, removed to the United States District Court for the Southern District of West Virginia, Civil Action 2:17-cv-03366; Mayor Vivian Livinggood on behalf of the Town of Gilbert v. West Virginia Board of Pharmacy, et al., Mingo County, West Virginia Circuit Court, Civil Action 17-C-94, removed to the United States District Court for the Southern District of West Virginia, Civil Action 2:17-cv-03369; Mayor Charles Sparks on behalf of the Town of Kermit v. West Virginia Board of Pharmacy, et al., Mingo County, West Virginia Circuit Court, Civil Action 17-C-13, removed to the United States District Court for the Southern District of West Virginia, Civil Action 2:17-cv-03372; Mayor Robert Carlton on behalf of the City of Williamson v. West Virginia Board of Pharmacy, et al., Mingo County, West Virginia Circuit Court, Civil Action 17-C-99, removed to the United States District Court for the Southern District of West Virginia, Civil Action 2:17-cv-03532; The County Commission of Mercer County v. West Virginia Board of Pharmacy, et al., Mercer County, West Virginia Circuit Court, Civil Action 17-C-236; and Mayor Raaimie Barker on behalf of the Town of Chapmanville v. West Virginia Board of Pharmacy, et al., Logan County, West Virginia Circuit Court, Civil Action 17-C-168. The Company has filed motions to dismiss in all cases in which responses were due.
In response to the previously disclosed case captioned Cherokee Nation v. McKesson Corporation, et al., on June 8, 2017, the Company and the other defendants in this action filed suit in the United States District Court for the Northern District of Oklahoma, McKesson Corporation, et al. v. Todd Hembree, Attorney General of the Cherokee Nation, et al., No. 4:17-cv-00323, seeking a declaratory judgment that the Cherokee Nation District Court has no jurisdiction over the claims asserted by the Cherokee Nation. On that same day, the Company and the other plaintiffs in the federal action filed a motion for a preliminary injunction enjoining the defendants from taking any action in the case pending in the tribal court.
On May 25, 2017, a lawsuit was filed in Stockton County, California Superior Court against various pharmaceutical manufacturers and the Company by the County of San Joaquin, City of Stockton and Montezuma Fire Protection District. City of Stockton, et al. v. Purdue Pharma LP, et al., Case No. STK-CV-UBT-2017-5325.The suit seeks damages for the funds spent by plaintiffs on municipal services due to alleged excessive sales of opioids. The causes of action against the Company are unjust enrichment and parens patriaie claims. On July 17, 2017, this case was removed to the United States District Court for the Eastern District of California (Case No. 2:17-at-00719.)


21

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

Two municipalities in Ohio, the City of Dayton and the City of Lorain, have individually filed suit against various pharmaceutical manufacturers and three wholesalers, including the Company, as well as four individual physicians. City of Dayton v. Purdue Pharma LP, et al., Montgomery County, Ohio Court of Common Pleas, No. 2017 CV 02647, filed on June 5, 2017; and City of Lorain v. Purdue Pharma LP, et al., Lorain County, Ohio Court of Common Pleas, No. 17 CV 192705, filed on June 29, 2017. In each case, the plaintiff claims that all of the defendants engaged in unfair and deceptive acts or practices involving the marketing and sales of opioids, and created a public nuisance. Each plaintiff also contends that the distributor defendants failed to take any action to prevent or reduce the distribution of opioids. The suits contain causes of action for violation of the Ohio Consumer Sales Practices Act; deceptive trade practices; public nuisance; fraud, unjust enrichment; and negligence. On July 7, 2017, the City of Dayton case was removed to the United States District Court for the Southern District of Ohio (Case No. 3:17-cv-229).
On June 12, 2017, the County of Nassau, New York filed suit against various pharmaceutical manufacturers and three wholesalers, including the Company, as well as four individual physicians. The County of Nassau v. Purdue Pharma LP, et al., Supreme Court of the State of New York, County of Nassau, Index No. 605477/2017. The plaintiff claims that all of the defendants engaged in unfair and deceptive acts or practices involving the marketing and sales of opioids, and created a public nuisance. Each plaintiff also contends that the distributor defendants failed to take any action to prevent or reduce the distribution of opioids. The suit contains causes of action for deceptive acts and practices under New York General Business Law § 349; false advertising under New York General Business Law § 350; public nuisance; violation of New York Social Services Law § 145-B; fraud, unjust enrichment; and negligence.
On May 19, 2017, the plaintiff in the previously disclosed case captioned Silverman v. McKesson Corporation, filed a voluntary withdrawal of this action.
From time to time, the Company receives subpoenas or requests for information from various government agencies. The Company generally responds to such subpoenas and requests in a cooperative, thorough and timely manner. These responses sometimes require time and effort and can result in considerable costs being incurred by the Company. For example, the Company has received a request for information from the U.S. Attorney’s Office for the Eastern District of Pennsylvania relating to the use of a Company pharmacy management software system to process partially-filled prescriptions. The Company is currently responding to this request. Such subpoenas and requests also can lead to the assertion of claims or the commencement of civil or criminal legal proceedings against the Company and other members of the health care industry, as well as to settlements.
15.
Stockholders’ Equity
Each share of the Company’s outstanding common stock is permitted one vote on proposals presented to stockholders and is entitled to share equally in any dividends declared by the Company’s Board of Directors (the “Board”).
The Company currently pays quarterly cash dividend of $0.28 per common share. On July 26, 2017, the Company’s quarterly dividend was raised from $0.28 to $0.34 per common share for dividends declared on or after such date by the Board. The Company anticipates that it will continue to pay quarterly cash dividends in the future.  However, the payment and amount of future dividends remain within the discretion of the Board and will depend upon the Company's future earnings, financial condition, capital requirements and other factors.
Share Repurchase Plans

Stock repurchases may be made from time-to-time in open market transactions, privately negotiated transactions, through accelerated share repurchase (“ASR”) programs, or by any combination of such methods. The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including our stock price, corporate and regulatory requirements, restrictions under our debt obligations and other market and economic conditions.
In March 2017, we entered into an ASR program with a third-party financial institution to repurchase $250 million of the Company’s common stock. We received 1.4 million shares in March 2017 and 0.3 million additional shares in April 2017. In June 2017, we also entered into another ASR program with a third-party financial institution to repurchase $250 million of the Company’s common stock. During the first quarter of 2018, we received 1.2 million shares as the initial share settlement under this 2018 ASR program and may receive additional shares at the termination of the ASR. The total authorization outstanding for repurchases of the Company’s common stock was $2.5 billion at June 30, 2017.


22

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

Other Comprehensive Income (Loss)
Information regarding other comprehensive income (loss) including redeemable noncontrolling interests, net of tax, by component is as follows:
 
Quarter Ended June 30,
 (In millions)
2017
 
2016
Foreign currency translation adjustments (1)
 
 
 
Foreign currency translation adjustments arising during period, net of income tax benefit of nil and $12 (2) (3)
$
382

 
$
(275
)
Reclassified to income statement, net of income tax expense of nil and nil (4)

 
20

 
382

 
(255
)
Unrealized gains (losses) on net investment hedges (5)
 
 
 
Unrealized gains (losses) on net investment hedges arising during period, net of income tax benefit of $44 and nil
(70
)
 

Reclassified to income statement, net of income tax expense of nil and nil

 

 
(70
)
 

Unrealized gains on cash flow hedges
 
 
 
Unrealized gains on cash flow hedges arising during period, net of income tax expense of nil and nil
14

 

 
 
 
 
Changes in retirement-related benefit plans (6)
 
 
 
Net actuarial loss and prior service cost arising during the period, net of income tax benefit of nil and nil

 

Amortization of actuarial loss and prior service costs, net of income tax expense of nil and $1 (7)
1

 
3

Foreign currency translation adjustments and other, net of income tax expense of nil and nil
(6
)
 
8

 
(5
)
 
11

 
 
 
 
Other comprehensive income (loss), net of tax
$
321

 
$
(244
)
(1)
Foreign currency translation adjustments primarily result from the conversion of non-U.S. dollar financial statements of our foreign subsidiary, Celesio, into the Company’s reporting currency, U.S. dollars, during the first quarters of 2018 and 2017.
(2)
The net foreign currency translation gains during the first quarter of 2018 were primarily due to the strengthening of the Euro and British pound sterling against the U.S. dollar from April 1, 2017 to June 30, 2017. During the first quarter of 2017, the currency translation losses were primarily due to the weakening of the Euro and British pound sterling against the U.S. dollar from April 1, 2016 to June 30, 2016.
(3)
The first quarter of 2018 includes net foreign currency translation gains of $115 million and the first quarter of 2017 includes net foreign currency translation losses of $67 million attributable to redeemable noncontrolling interests.
(4)
The first quarter of 2017 includes net foreign currency translation losses of $20 million reclassified from accumulated other comprehensive income (loss) to loss from discontinued operations, net of tax, within our condensed consolidated statements of operations due to the sale of our Brazilian pharmaceutical distribution business.
(5)
The first quarter of 2018 includes foreign currency losses of $114 million on the net investment hedges from the €1.2 billion Euro-denominated notes and £450 million British pound sterling-denominated notes.
(6)
The first quarters of 2018 and 2017 include net actuarial losses of $1 million attributable to redeemable noncontrolling interests.
(7)
Pre-tax amount reclassified into cost of sales and operating expenses in our condensed consolidated statements of operations. The related tax expense was reclassified into income tax expense in our condensed consolidated statements of operations.


23

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

Accumulated Other Comprehensive Income (Loss)
Information regarding changes in our accumulated other comprehensive income (loss), net of tax, by component for the first quarter of 2018 is as follows:
(In millions)
Foreign Currency Translation Adjustments, Net of Tax
 
Unrealized Losses on Net Investment Hedges,
Net of Tax
 
Unrealized Gains (Losses) on Cash Flow Hedges,
Net of Tax
 
Unrealized Net Gains (Losses) and Other Components of Benefit Plans, Net of Tax
 
Total Accumulated Other Comprehensive Income (Loss)
Balance at March 31, 2017
$
(1,873
)
 
$
(8
)
 
$
(31
)
 
$
(229
)
 
$
(2,141
)
 
 
 
 
 
 
 
 
 
 
Other comprehensive income (loss) before reclassifications
382

 
(70
)
 
14

 
(6
)
 
320

Amounts reclassified to earnings and other

 

 

 
1

 
1

Other comprehensive income (loss)
382

 
(70
)
 
14

 
(5
)
 
321

Less: amounts attributable to noncontrolling and redeemable noncontrolling interests
115

 

 

 
1

 
116

Other comprehensive income (loss) attributable to McKesson
267

 
(70
)
 
14

 
(6
)
 
205

Balance at June 30, 2017
$
(1,606
)
 
$
(78
)
 
$
(17
)
 
$
(235
)
 
$
(1,936
)


24

McKESSON CORPORATION
FINANCIAL NOTES (CONCLUDED)
(UNAUDITED)

16.
Segment Information
We report our operations in two operating segments: McKesson Distribution Solutions and McKesson Technology Solutions. The factors for determining the reportable segments included the manner in which management evaluates the performance of the Company combined with the nature of the individual business activities. We evaluate the performance of our operating segments on a number of measures, including operating profit before interest expense, income taxes and results from discontinued operations.
Financial information relating to our reportable operating segments and reconciliations to the condensed consolidated totals is as follows:
 
Quarter Ended June 30,
(In millions)
2017
 
2016
Revenues
 
 
 
Distribution Solutions (1)
 
 
 
North America pharmaceutical distribution and services
$
43,016

 
$
41,211

International pharmaceutical distribution and services
6,382

 
6,330

Medical-Surgical distribution and services
1,533

 
1,468

Total Distribution Solutions
50,931

 
49,009

 
 
 
 
Technology Solutions - products and services (2) 
120

 
724

Total Revenues
$
51,051

 
$
49,733

 
 
 
 
Operating profit
 
 
 
Distribution Solutions (3)
$
713

 
$
928

Technology Solutions (4)
(78
)
 
168

Total
635

 
1,096

Corporate Expenses, Net
(109
)
 
(105
)
Interest Expense
(68
)
 
(79
)
Income from Continuing Operations Before Income Taxes
$
458

 
$
912

(1)
Revenues derived from services represent less than 2% of this segment’s total revenues.
(2)
2018 revenues for the Technology Solutions segment include the results of our EIS business. Effective April 1, 2017, our RHP business was transitioned from the Technology Solutions segment to the Distribution Solutions segment. The first quarter of 2017 included the majority of our Core MTS Business which was contributed to Change Healthcare on March 1, 2017.
(3)
Distribution Solutions operating profit for the first quarters of 2018 and 2017 include $26 million and $47 million in pre-tax charges related to our last-in, first-out (“LIFO”) method of accounting for inventories. LIFO expense was less in 2018 primarily due to the lower full year expectations for net price increases compared to the same period a year ago. Additionally, the first quarter of 2017 includes $142 million of net cash proceeds representing our share of net settlements of antitrust class action lawsuits against drug manufacturers.
(4)
Operating profit for our Technology Solutions segment for the first quarter of 2018 includes our EIS business, our proportionate share of loss from Change Healthcare of $120 million and a pre-tax gain of $37 million from the Healthcare Technology Net Asset Exchange related to the final net working capital and other adjustments.



25

McKESSON CORPORATION
FINANCIAL REVIEW
(UNAUDITED)


Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations.

GENERAL
Management’s discussion and analysis of financial condition and results of operations, referred to as the Financial Review, is intended to assist the reader in the understanding and assessment of significant changes and trends related to the results of operations and financial position of the Company together with its subsidiaries. This discussion and analysis should be read in conjunction with the condensed consolidated financial statements and accompanying financial notes in Item 1 of Part I of this Quarterly Report on Form 10-Q and in Item 8 of Part II of our Annual Report on Form 10-K for the fiscal year ended March 31, 2017 previously filed with the SEC on May 22, 2017 (“2017 Annual Report”).
The Company’s fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year shall mean the Company’s fiscal year.
Certain statements in this report constitute forward-looking statements. See “Factors Affecting Forward-Looking Statements” included in this Quarterly Report on Form 10-Q.
Results of Operations
Overview:
(Dollars in millions, except per share data)
Quarter Ended June 30,
 
 
2017
 
2016
Change
Revenues
$
51,051

 
$
49,733

3

%
 
 
 
 
 
 
Gross Profit
$
2,560

 
$
2,907

(12
)
%
 
 
 
 
 
 
Operating Expenses:
 
 
 
 
 
Operating Expenses Excluding Gain on Healthcare Technology Net Asset Exchange
$
(1,964
)
 
$
(1,935
)
1

%
Gain on Healthcare Technology Net Asset Exchange
37

 

NM

 
Total Operating Expenses
$
(1,927
)
 
$
(1,935
)
-

 
 
 
 
 
 
 
Loss from Equity Method Investment in Change Healthcare
$
(120
)
 
$

NM

 
 
 
 
 
 
 
Income from Continuing Operations Before Income Taxes
$
458

 
$
912

(50
)
%
Income Tax Expense
(95
)
 
(239
)
(60
)
 
Income from Continuing Operations
363

 
673

(46
)
 
Income (Loss) from Discontinued Operations, Net of Tax
2

 
(113
)
(102
)
 
Net Income
365

 
560

(35
)
 
Net Income Attributable to Noncontrolling Interests
(56
)
 
(18
)
211

 
Net Income Attributable to McKesson Corporation
$
309

 
$
542

(43
)
%
 
 
 
 
 
 
Diluted Earnings (Loss) Per Common Share Attributable to McKesson Corporation
 
 
 
 
 
Continuing Operations
$
1.44

 
$
2.88

(50
)
%
Discontinued Operations
0.01

 
(0.50
)
(102
)
 
Total
$
1.45

 
$
2.38

(39
)
%
 
 
 
 
 
 
Weighted Average Diluted Common Shares
213

 
228

(7
)
%
NM - not meaningful


26

McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)


Revenues for the first quarter of 2018 increased compared to the same period a year ago primarily due to market growth, our business acquisitions and expanded business with existing customers within our North America pharmaceutical distribution businesses. Market growth includes growing drug utilization, price increases and newly launched products, partially offset by price deflation associated with brand to generic drug conversion.
Gross profit and gross profit margin for the first quarter of 2018 decreased compared to the same period a year ago. Gross profit margin decreased primarily due to the competitive sell-side pricing environment, weaker pharmaceutical manufacturer pricing trends and our mix of business. These decreases were partially offset by benefits from our acquisitions. Additionally, gross profit in the first quarter of 2017 included $142 million of cash receipts for our share of antitrust legal settlements.
Operating expenses for the first quarter of 2018 remained flat compared to the same period a year ago primarily due to our business acquisitions, which were offset by favorable foreign currency effects, a gain from the Healthcare Technology Net Asset Exchange and the deconsolidation of the majority of our McKesson Technology Solutions businesses (“Core MTS Business”), as further described below.
On June 28, 2016, we entered into a contribution agreement (“Contribution Agreement”) with Change Healthcare Holdings, Inc. (“Change”) and others including shareholders of Change to form a joint venture, Change Healthcare, LLC (“Change Healthcare”). On March 1, 2017, the transaction closed upon satisfaction of all closing conditions pursuant to the Contribution Agreement. Under the terms of the Contribution Agreement, we contributed the Core MTS Business to Change Healthcare. We accounted for this transaction as a sale of the Core MTS Business and a subsequent purchase of a 70% interest in the newly formed joint venture. Accordingly, in the fourth quarter of 2017, we deconsolidated the Core MTS Business and recorded a pre-tax gain of $3,947 million (after-tax gain of $3,018 million) within operating expenses in our consolidated statements of operations.  During the first quarter of 2018, we recorded a pre-tax gain of $37 million (after-tax gain of $22 million) under the caption, “Gain on Healthcare Technology Net Asset Exchange,” upon the finalization of net working capital and other adjustments. 
Our investment in Change Healthcare is accounted for using the equity method of accounting. During the first quarter of 2018, we recorded our proportionate share of loss from Change Healthcare of $120 million. This amount was recorded under the caption, “Loss from Equity Method Investment in Change Healthcare,” in our condensed consolidated statement of operations. Refer to Financial Note 2, “Healthcare Technology Net Asset Exchange,” to the accompanying condensed consolidated financial statements appearing in this Quarterly Report on Form 10‑Q.
Income from continuing operations before income taxes for the first quarter of 2018 decreased compared to the same period a year ago primarily due to lower gross profit and the loss from the equity method investment in Change Healthcare.
Income tax expense for the first quarter of 2017 included a discrete income tax benefit of $37 million related to the early adoption of the amended accounting guidance on share-based compensation. Loss from discontinued operations, net of tax, for the first quarter of 2017 included an after-tax loss from discontinued operations of $113 million resulting from the sale of our Brazilian pharmaceutical distribution business.
Net income attributable to McKesson Corporation for the first quarters of 2018 and 2017 was $309 million and $542 million. Diluted earnings per common share attributable to McKesson for the first quarters of 2018 and 2017 were $1.45 and $2.38. Additionally, our 2018 diluted earnings per share reflect the cumulative effects of share repurchases.



27

McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)


Revenues:
 
Quarter Ended June 30,
 
 
 
(Dollars in millions)
2017
 
2016
 
Change
Distribution Solutions
 
 
 
 
 
 
North America pharmaceutical distribution and services
$
43,016

 
$
41,211

 
4

%
International pharmaceutical distribution and services
6,382

 
6,330

 
1

 
Medical-Surgical distribution and services
1,533

 
1,468

 
4

 
Total Distribution Solutions
50,931

 
49,009

 
4

 
 
 
 
 
 
 
 
Technology Solutions - products and services
120

 
724

 
(83
)
 
Total Revenues
$
51,051

 
$
49,733

 
3

%
Revenues for the first quarter of 2018 increased 3% compared to the same period a year ago primarily due to our Distribution Solutions segment.
Distribution Solutions
North America pharmaceutical distribution and services revenues for the first quarter of 2018 increased primarily due to market growth, our business acquisitions including Rexall Health in the third quarter of 2017 and CoverMyMeds (“CMM”) in the first quarter of 2018, and expanded business with existing customers. Market growth includes growing drug utilization, price increases and newly launched products, partially offset by price deflation associated with brand to generic drug conversions.
International pharmaceutical distribution and services revenues for the first quarter of 2018 increased 1% compared to the same period a year ago. Excluding unfavorable foreign currency effects of 5%, revenues increased 6% primarily due to our 2017 acquisitions in the United Kingdom and market growth.
Medical-Surgical distribution and services revenues increased 4% for the first quarter of 2018 primarily due to market growth.
Technology Solutions: Technology Solutions revenues for the first quarter of 2018 decreased primarily due to the deconsolidation of the Core MTS Business and the transition of our RelayHealth Pharmacy (“RHP”) business to our Distribution Solutions segment in April 2017. As a result, revenues for the first quarter of 2018 represent the results of our Enterprise Information Solutions business.


28

McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)


Gross Profit:
 
Quarter Ended June 30,
 
 
 
(Dollars in millions)
2017
 
2016
 
Change
Gross Profit
 
 
 
 
 
 
Distribution Solutions
$
2,500

 
$
2,513

 
(1
)
%
Technology Solutions
60

 
394

 
(85
)
 
Total
$
2,560

 
$
2,907

 
(12
)
%
Gross Profit Margin
 
 
 
 
 
 
Distribution Solutions
4.91

 
5.13

 
(22
)
bp 
Technology Solutions
50.00

 
54.42

 
(442
)
 
Total
5.01

 
5.85

 
(84
)
bp
bp - basis points
Gross profit and gross profit margin for the first quarter of 2018 decreased compared to the same period a year ago primarily due to our Technology Solutions segment.
Distribution Solutions
Distribution Solutions segment’s gross profit for the first quarter of 2018 decreased slightly compared to the same period a year ago. This segment’s gross profit margin decreased in 2018 primarily due to the competitive sell-side pricing environment, weaker pharmaceutical pricing trends and our mix of business. These decreases were partially offset by our business acquisitions, procurement benefits through the joint sourcing entity, ClarusONE Sourcing Services LLP (“ClarusONE”), the transition of our RHP business from our Technology Solutions segment and lower LIFO expense, as further discussed below. Additionally, gross profit for the first quarter of 2017 included $142 million of cash receipts representing our share of antitrust legal settlements.
LIFO inventory expense was $26 million and $47 million in the first quarters of 2018 and 2017. Our North America distribution business uses the LIFO method of accounting for the majority of its inventories, which results in cost of sales that more closely reflects replacement cost than under other accounting methods. The business’ practice is to pass on to customers published price changes from suppliers. Manufacturers generally provide us with price protection, which limits price-related inventory losses. A LIFO expense is recognized when the net effect of price increases on pharmaceutical and non-pharmaceutical products held in inventory exceeds the impact of price declines, including the effect of branded pharmaceutical products that have lost market exclusivity. A LIFO credit is recognized when the net effect of price declines exceeds the impact of price increases on pharmaceutical and non-pharmaceutical products held in inventory. Our quarterly LIFO expense is based on our estimates of annual LIFO expense which is impacted by expected changes in year-end inventory quantities, product mix and manufacturer pricing practices, which may be influenced by market and other external influences. Changes to any of the above factors could have a material impact to our annual LIFO expense. The actual valuation of inventory under the LIFO method is calculated at the end of the fiscal year. LIFO expense was less for the first quarter of 2018 primarily due to the lower full year expectations for net price increases compared to the same period a year ago.
Technology Solutions
Technology Solutions segment’s gross profit for the first quarter of 2018 decreased compared to the same period a year ago primarily due to the deconsolidation of the Core MTS Business in the fourth quarter of 2017.


29

McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)


Operating Expenses, Other Income, Net and Loss from Equity Method Investment: 
 
Quarter Ended June 30,
 
 
 
(Dollars in millions)
2017
 
2016
 
Change
Operating Expenses
 
 
 
 
 
 
Distribution Solutions
$
1,798

 
$
1,599

 
12

%
Technology Solutions 
55

 
226

 
(76
)
  
Gain on Healthcare Technology Net Asset Exchange - Technology Solutions
(37
)
 

 
NM

 
 Corporate
111

 
110

 
1

  
Total
$
1,927

 
$
1,935

 
-

%
 
 
 
 
 
 
 
Operating Expenses as a Percentage of Revenues
 
 
 
 
 
 
Distribution Solutions
3.53

 
3.26

 
27

bp 
Technology Solutions
15.00

 
31.22

 
(1,622
)
  
Total
3.77

 
3.89

 
(12
)
bp
 
 
 
 
 
 
 
Other Income, Net
 
 
 
 
 
 
Distribution Solutions
$
11

 
$
14

 
(21
)
%
Technology Solutions

 

 
-

  
Corporate
2

 
5

 
(60
)
 
Total
$
13

 
$
19

 
(32
)
%
 
 
 
 
 
 
 
Loss from Equity Method Investment in Change Healthcare - Technology Solutions
$
120

 
$

 
NM

 
Operating Expenses
Operating expenses for the first quarter of 2018 remained flat compared to the same period a year ago.
Distribution Solutions

Distribution Solutions segment’s operating expenses increased 12% for the first quarter of 2018 compared to the same prior year period. Excluding favorable foreign currency effects of 4%, operating expenses increased 16% in 2018 due to our business acquisitions.
Technology Solutions

Technology Solutions segment’s operating expenses and operating expenses as a percentage of revenues for the first quarter of 2018 decreased compared to the same period a year ago primarily due to the deconsolidation of our Core MTS Business and a pre-tax gain of $37 million (after-tax gain of $22 million) from the final net working capital adjustment related to the Healthcare Technology Net Asset Exchange.
Corporate

Corporate expenses remained relatively flat for the first quarter of 2018 compared to the same prior year period.
Other Income, Net: Other income, net, for the first quarter of 2018 decreased compared to the same period a year ago primarily due to lower equity investment income and interest income.


30

McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)


Loss from Equity Method Investment in Change Healthcare: The first quarter of 2018 included our proportionate share of loss from Change Healthcare of $120 million, which primarily consisted of transaction and integration expenses incurred by the joint venture and amortization expenses associated with equity method intangible assets.
Acquisition-Related Expenses and Adjustments
Acquisition-related expenses, which included transaction and integration expenses that were directly related to business acquisitions and the gain on Healthcare Technology Net Asset Exchange, were $38 million and $50 million in the first quarters of 2018 and 2017. 2018 reflects our proportionate share of transaction and integration expenses incurred by Change Healthcare, partially offset by the $37 million gain associated with the final net working capital and other adjustments.
Acquisition-related expenses and adjustments were as follows:
 
Quarter Ended June 30,
(Dollars in millions)
2017
 
2016
Operating Expenses
 
 
 
Integration related expenses
$
9

 
$
22

Restructuring, severance and relocation
5

 
8

Transaction closing expenses
12

 
16

Gain on Healthcare Technology Net Asset Exchange
(37
)
 

Other Expense (1)
49

 
4

Acquisition Expenses and Related Adjustments
$
38

 
$
50

(1)
2018 includes our proportionate share of transaction and integration expenses incurred by Change Healthcare, which was recorded within “Loss from Equity Method Investment in Change Healthcare”.
Acquisition-related expenses and adjustments by segment were as follows:
 
Quarter Ended June 30,
(Dollars in millions)
2017
 
2016
Distributions Solutions
$
16

 
$
44

Technology Solutions
23

 
4

Corporate
(1
)
 
2

Acquisition-Related Expenses and Adjustments (1)
$
38

 
$
50

(1)
The amounts were recorded in operating expenses and other income, net.
Amortization Expenses of Acquired Intangible Assets
Amortization expenses of intangible assets directly related to business acquisitions and the Healthcare Technology Net Asset Exchange were $192 million and $115 million for the first quarters of 2018 and 2017, which were primarily recorded in operating expenses and under the caption, “Loss from Equity Method Investment in Change Healthcare”.
Amortization expenses by segment were as follows:
 
Quarter Ended June 30,
(Dollars in millions)
2017
 
2016
Distribution Solutions
$
121

 
$
106

Technology Solutions (1)
71

 
9

Total
$
192

 
$
115

(1)
Represents amortization expenses of equity method intangibles associated with Change Healthcare.


31

McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)


Segment Operating Profit, Corporate Expenses, Net and Interest Expense:
 
Quarter Ended June 30,
 
 
 
(Dollars in millions)
2017
 
2016
 
Change
Segment Operating Profit (1)
 
 
 
 
 
 
Distribution Solutions
$
713

 
$
928

 
(23
)
%
Technology Solutions
(78
)
 
168

 
(146
)
 
Subtotal
635

 
1,096

 
(42
)
 
Corporate Expenses, Net
(109
)
 
(105
)
 
4

 
Interest Expense
(68
)
 
(79
)
 
(14
)
  
Income from Continuing Operations Before Income Taxes
$
458

 
$
912

 
(50
)
%
 
 
 
 
 
 
 
Segment Operating Profit Margin
 
 
 
 
 
 
Distribution Solutions
1.40

%
1.89

%
(49
)
bp 
Technology Solutions
(65.00
)
 
23.20

 
NM

 
(1)
Segment operating profit includes gross profit, net of operating expenses, as well as other income, net, for our two operating segments.
Segment Operating Profit
Distribution Solutions: Operating profit and operating profit margin decreased for the segment in 2018 compared to the same prior year period primarily due to lower gross profit margin reflecting the competitive sell-side pricing environment, weaker pharmaceutical manufacturer pricing trends and out mix of business as well as higher operating expenses as a percentage of revenues driven primarily by our business acquisitions.
Our U.K. retail business within our Distribution Solutions segment is impacted by a decline in its estimated future cash flows primarily driven by government reimbursement reductions. A further decrease in the estimated future cash flows, an increase in the discount rate and/or a decrease in the terminal growth rate, could result in goodwill impairment for the reporting unit that includes this business. 
Technology Solutions: Operating profit for the segment decreased in 2018 compared to the same prior year period primarily due to the deconsolidation of our Core MTS Business and a loss from the equity method investment in Change Healthcare, partially offset by a gain from the Healthcare Technology Net Asset Exchange.
Corporate: Corporate expenses, net, slightly increased for the first quarter of 2018 primarily due to a decrease in other income.
Interest Expense: Interest expense for the first quarter of 2018 decreased primarily due to the repayment of debt, partially offset by the issuance of the February 2017 foreign currency denominated bonds.
Income Taxes: Our reported income tax rates for the first quarters of 2018 and 2017 were 20.7% and 26.2%. Fluctuations in our reported income tax rates are primarily due to changes within our business mix, including varying proportions of income attributable to foreign countries that have lower income tax rates, discrete items and the impact of the intercompany sale of software. Income tax expense for the first quarters of 2018 and 2017 includes net discrete tax expense of $3 million and net discrete tax benefit of $35 million. Our discrete tax benefits for the 2017 first quarter included a $37 million tax benefit related to the early adoption of the amended accounting guidance on employee share-based compensation.
Loss from Discontinued Operations, Net of Tax: Loss from discontinued operations, net for the first quarter of 2017 included an after-tax loss of $113 million from the sale of our Brazilian pharmaceutical distribution business. Diluted loss per common share from discontinued operations for the first quarter of 2017 was $0.50.


32

McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)


Net Income Attributable to Noncontrolling Interests: Net income attributable to noncontrolling interests for the first quarter of 2018 primarily represents ClarusONE, Vantage Oncology Holdings, LLC (“Vantage”) and the accrual of the annual recurring compensation amount of €0.83 per Celesio share that McKesson is obligated to pay to the noncontrolling shareholders of Celesio under a domination and profit and loss transfer agreement (the “Domination Agreement”). Refer to Financial Note 7, “Redeemable Noncontrolling Interests and Noncontrolling Interests,” to the accompanying condensed consolidated financial statements appearing in this Quarterly Report on Form10-Q for additional information.
Net Income Attributable to McKesson Corporation: Net income attributable to McKesson Corporation was $309 million and $542 million, and diluted earnings per common share attributable to McKesson Corporation were $1.45 and $2.38 for the first quarters of 2018 and 2017.
Weighted Average Diluted Common Shares Outstanding: Diluted earnings per common share were calculated based on a weighted average number of shares outstanding of 213 million and 228 million for the first quarters of 2018 and 2017. Weighted average diluted shares for 2018 decreased from 2017 primarily reflecting common stock repurchases in the second half of 2017 and the first quarter of 2018.
Business Combinations
Refer to Financial Note 3, “Business Combinations,” to the accompanying condensed consolidated financial statements appearing in this Quarterly Report on Form 10‑Q for further information.
New Accounting Pronouncements
New accounting pronouncements that we have recently adopted as well as those that have been recently issued but not yet adopted by us are included in Financial Note 1, “Significant Accounting Policies,” to the accompanying condensed consolidated financial statements appearing in this Quarterly Report on Form 10-Q.


33

McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)


Financial Condition, Liquidity and Capital Resources
We expect our available cash generated from operations, together with our existing sources of liquidity from our credit facilities and commercial paper program will be sufficient to fund our long-term and short-term capital expenditures, working capital and other cash requirements. In addition, from time to time, we may access the long-term debt capital markets to discharge our other liabilities.
Operating activities generated cash of $741 million and $1,859 million during the first quarters of 2018 and 2017. Operating activities for the first quarters of 2018 and 2017 were affected by higher drafts and accounts payable and increases in receivables and inventories primarily associated with revenue growth. Cash flows from operations can be significantly impacted by factors such as timing of receipts from customers, inventory receipts and payments to vendors. Additionally, working capital is primarily a function of sale and purchase volumes, inventory requirements and vendor payment terms.
Investing activities utilized cash of $129 million and $1,154 million during the first quarters of 2018 and 2017. Investing activities for 2018 include $1,485 million of net cash payments for acquisitions, including $1.3 billion for our acquisition of CMM, which was prepaid before March 31, 2017 and was released from restricted cash balances in the first quarter of 2018. Investing activities for 2017 included $1,819 million of cash paid for acquisitions, of which $935 million was prepaid before March 31, 2016 and was released from restricted cash balances in the first quarter of 2017. Investing activities for 2017 also included a payment of approximately $100 million to sell our Brazilian business.
Financing activities utilized cash of $1,131 million and $82 million during the first quarters of 2018 and 2017. Financing activities for 2018 include cash receipts of $2,282 million and payments of $2,463 million for short-term borrowings. Financing activities for the first quarter of 2017 included cash receipts of $7 million and payments of $14 million for short-term borrowings. Additionally, financing activities for the first quarters of 2018 and 2017 include $300 million and $58 million of cash paid for stock repurchases, including shares surrendered for tax withholding.
The Company’s Board has authorized the repurchase of McKesson’s common stock from time-to-time in open market transactions, privately negotiated transactions, accelerated share repurchase programs, or by any combination of such methods. The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including our stock price, corporate and regulatory requirements, restrictions under our debt obligations and other market and economic conditions. In March 2017, we entered into an ASR program with a third-party financial institution to repurchase $250 million of the Company’s common stock. We received 1.4 million shares in March 2017 and 0.3 million additional shares in April 2017. In June 2017, we also entered into another ASR program with a third-party financial institution to repurchase $250 million of the Company’s common stock. During the first quarter of 2018, we received 1.2 million shares as the initial share settlement under this 2018 ASR program and may receive additional shares at the termination of the ASR. The total authorization outstanding for repurchases of the Company’s common stock was $2.5 billion at June 30, 2017.
We believe that our operating cash flow, financial assets and current access to capital and credit markets, including our existing credit facilities, will give us the ability to meet our financing needs for the foreseeable future. However, there can be no assurance that future volatility and disruption in the global capital and credit markets will not impair our liquidity or increase our costs of borrowing.
Selected Measures of Liquidity and Capital Resources
(Dollars in millions)
June 30, 2017
 
March 31, 2017
 
Cash and cash equivalents
$
2,339

 
$
2,783

 
Working capital
1,898

 
1,336

 
Debt to capital ratio (1)
37.5

%
39.2

%
Return on McKesson stockholders’ equity (2)
49.6

%
54.6

%
(1)
Ratio is computed as total debt divided by the sum of total debt and McKesson stockholders’ equity, which excludes noncontrolling and redeemable noncontrolling interests and accumulated other comprehensive income (loss).
(2)
Ratio is computed as net income attributable to McKesson Corporation for the last four quarters, divided by a five-quarter average of McKesson stockholders’ equity, which excludes noncontrolling and redeemable noncontrolling interests.


34

McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)


Cash equivalents, which are available-for-sale, are carried at fair value.  Cash equivalents are primarily invested in AAA rated prime and U.S. government money market funds denominated in U.S. dollars, AAA rated prime money market funds denominated in Euros, AAA rated prime money market funds denominated in British pound sterling, time deposits, and Canadian government debentures.
The remaining cash and cash equivalents are deposited with several financial institutions. We mitigate the risk of our short‑term investment portfolio by depositing funds with reputable financial institutions and monitoring risk profiles and investment strategies of money market funds.
Our cash and cash equivalents balance as of June 30, 2017 included approximately $1.7 billion of cash held by our subsidiaries outside of the United States. Our primary intent is to utilize this cash for foreign operations for an indefinite period of time. Although the vast majority of cash held outside the United States is available for repatriation, doing so could subject us to U.S. federal, state and local income tax.
Working capital primarily includes cash and cash equivalents, receivables and inventories net of drafts and accounts payable, short-term borrowings, current portion of long-term debt, deferred revenue and other current liabilities. Our Distribution Solutions segment requires a substantial investment in working capital that is susceptible to large variations during the year as a result of inventory purchase patterns and seasonal demands. Inventory purchase activity is a function of sales activity and other requirements.
Our debt to capital ratio decreased in 2018 primarily due to a decrease in our debt.
The Company currently pays quarterly cash dividend of $0.28 per common share. On July 26, 2017, the Company’s quarterly dividend was raised from $0.28 to $0.34 per common share for dividends declared on or after such date by the Board. The Company anticipates that it will continue to pay quarterly cash dividends in the future.  However, the payment and amount of future dividends remain within the discretion of the Board and will depend upon the Company's future earnings, financial condition, capital requirements and other factors.
The carrying value of redeemable noncontrolling interests related to Celesio was $1.39 billion at June 30, 2017, which exceeded the maximum redemption value of $1.24 billion. The balance of redeemable noncontrolling interests is reported at the greater of its carrying value or its maximum redemption value at each reporting date. Under the Domination Agreement, the noncontrolling shareholders of Celesio have a right to put (“Put Right”) their Celesio shares at €22.99 per share increased annually for interest in the amount of 5 percentage points above a base rate published by the German Bundesbank semiannually, less any compensation amount or guaranteed dividend already paid by McKesson in respect of the relevant time period (“Put Amount”). The exercise of the Put Right will reduce the balance of redeemable noncontrolling interests. Refer to Financial Note 7, “Redeemable Noncontrolling Interests and Noncontrolling Interests,” to the condensed consolidated financial statements appearing in this Quarterly Report on Form 10-Q for additional information.
Credit Resources
We fund our working capital requirements primarily with cash and cash equivalents as well as short-term borrowings from our credit facilities and commercial paper issuance.
Funds necessary for future debt maturities and our other cash requirements are expected to be met by existing cash balances, cash flow from operations, existing credit sources and other capital market transactions. Detailed information regarding our debt and financing activities is included in Financial Note 10, “Debt and Financing Activities,” to the accompanying condensed consolidated financial statements appearing in this Quarterly Report on Form 10-Q.


35

McKESSON CORPORATION
FINANCIAL REVIEW (CONCLUDED)
(UNAUDITED)


FACTORS AFFECTING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 2 of Part I of this report, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of these statements can be identified by the use of forward-looking terminology such as “believes,” “expects,” “anticipates,” “may,” “will,” “should,” “seeks,” “approximately,” “intends,” “plans,” “estimates,” or the negative of these words and other comparable terminology. The discussion of financial trends, strategy, plans or intentions may also include forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. Although it is not possible to predict or identify all such risks and uncertainties, they may include, but are not limited to, the following factors. The reader should not consider this list to be a complete statement of all potential risks and uncertainties:
changes in the U.S. healthcare industry and regulatory environment;
foreign operations subject us to a number of operating, economic, political and regulatory risks;
changes in the Canadian healthcare industry and regulatory environment;
general European economic conditions together with austerity measures taken by certain European governments;
changes in the European regulatory environment with respect to privacy and data protection regulations;
foreign currency fluctuations;
the Company’s ability to successfully identify, consummate, finance and integrate strategic acquisitions;
failure for the Company’s investment in Change Healthcare to perform;
the Company’s ability to manage and complete divestitures;
material adverse resolution of pending legal and regulatory proceedings;
competition;
substantial defaults in payments or a material reduction in purchases by, or the loss of, a large customer or group purchasing organization;
the loss of government contracts as a result of compliance or funding challenges;
public health issues in the United States or abroad;
cyberattack, disaster, or malfunction to computer systems;
the adequacy of insurance to cover property loss or liability claims;
the Company’s proprietary products and services may not be adequately protected, and its products and solutions may be found to infringe on the rights of others;
system errors or failure of our technology products and solutions to conform to specifications;
disaster or other event causing interruption of customer access to the data residing in our service centers;
changes in circumstances that could impair our goodwill or intangible assets;
new or revised tax legislation or challenges to our tax positions;
general economic conditions, including changes in the financial markets that may affect the availability and cost of credit to the Company, its customers or suppliers;
changes in accounting principles generally accepted in the United States of America;
withdrawal from participation in one or more multiemployer pension plans or if such plans are reported to have underfunded liabilities;
expected benefits from our restructuring and business process initiatives;
difficulties with outsourcing and similar third party relationships;
new challenges associated with our retail expansion; and
inability to keep existing retail store locations or open new retail locations in desirable places.

These and other risks and uncertainties are described herein and in other information contained in our publicly available Securities and Exchange Commission filings and press releases. Readers are cautioned not to place undue reliance on forward‑looking statements, which speak only as of the date such statements were first made. Except to the extent required by law, we undertake no obligation to publicly release the result of any revisions to our forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.


36

McKESSON CORPORATION

Item 3.
Quantitative and Qualitative Disclosures about Market Risk.
We believe there has been no material change in our exposure to risks associated with fluctuations in interest and foreign currency exchange rates as disclosed in our 2017 Annual Report on Form 10-K.
Item 4.
Controls and Procedures.
Our Chief Executive Officer and our Chief Financial Officer, with the participation of other members of the Company’s management, have evaluated the effectiveness of the Company’s “disclosure controls and procedures” (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”)) as of the end of the period covered by this quarterly report, and our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures are effective based on their evaluation of these controls and procedures as required by paragraph (b) of Exchange Act Rules 13a-15 or 15d-15.
There were no changes in our “internal control over financial reporting” (as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 and 15d-15 that occurred during our first quarter of 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II—OTHER INFORMATION
Item 1.
Legal Proceedings.
The information set forth in Financial Note 14, “Commitments and Contingent Liabilities,” to the accompanying condensed consolidated financial statements appearing in this Quarterly Report on Form 10-Q is incorporated herein by reference.
Item 1A.
Risk Factors.
There have been no material changes during the period covered by this Quarterly Report on Form 10-Q to the risk factors disclosed in Part I, Item 1A, of our 2017 Annual Report on Form 10-K.

Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds.
Stock repurchases may be made from time to time in open market transactions, privately negotiated transactions, through accelerated share repurchase programs, or by any combination of such methods.  The timing of any repurchases will depend on a variety of factors, including corporate and regulatory requirements.
In March 2017, we entered into an ASR program with a third-party financial institution to repurchase $250 million of the Company’s common stock. We received 1.4 million shares in March 2017 and additional 0.3 million shares in April 2017. In June 2017, we also entered into another ASR program with a third-party financial institution to repurchase $250 million of the Company’s common stock. During the first quarter of 2018, we received 1.2 million shares as the initial share settlement under this 2018 ASR program and may receive additional shares at the termination of the ASR. The total authorization outstanding for repurchases of the Company’s common stock was $2.5 billion at June 30, 2017.




37

McKESSON CORPORATION

The following table provides information on the Company’s share repurchases during the first quarter of 2018.
 
Share Repurchases (1)
(In millions, except price per share)
Total Number
of Shares
Purchased
 
Average Price
Paid Per Share
 
Total Number of
Shares Purchased
As Part of Publicly
Announced
Program
 
Approximate
Dollar Value of
Shares that May
Yet Be Purchased Under the Programs
April 1, 2017 – April 30, 2017
0.3
$
143.19
 
0.3
$
2,746
May 1, 2017 – May 31, 2017
 
 
 
2,746
June 1, 2017 – June 30, 2017
1.2
 
165.92 (2)
 
1.2
 
2,496
Total
1.5
 

 
1.5
 

(1)
This table does not include shares tendered to satisfy the exercise price in connection with cashless exercises of employee stock options or shares tendered to satisfy tax withholding obligations in connection with employee equity awards.
(2)
The price for the 2018 ASR program was the reference price used to determine the initial share settlement of 1.2 million shares. The actual average price of shares will be determined at the termination of the ASR program.
Item 3.
Defaults Upon Senior Securities.
None
Item 4.
Mine Safety Disclosures.
Not Applicable
Item 5.
Other Information.
None


38

McKESSON CORPORATION

Item 6.
Exhibits.
Exhibits identified in parentheses below are on file with the SEC and are incorporated by reference as exhibits hereto.
Exhibit
Number
Description
10.1*
 
 
31.1
 
 
31.2
 
 
32†
 
 
101
The following materials from the McKesson Corporation Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, formatted in Extensible Business Reporting Language (XBRL): (i) Condensed Consolidated Statements of Operations, (ii) Condensed Consolidated Statements of Comprehensive Income, (iii) Condensed Consolidated Balance Sheets, (iv) Condensed Consolidated Statements of Cash Flows, and (v) related Financial Notes.

*
Management contract or compensation plan or arrangement in which directors and/or executive officers are eligible to participate.
Furnished herewith.



39

McKESSON CORPORATION

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
 
MCKESSON CORPORATION
 
 
 
 
Date:
July 27, 2017
 
/s/ James A. Beer
 
 
 
James A. Beer
 
 
 
Executive Vice President and Chief Financial Officer
 

 
 
 
MCKESSON CORPORATION
 
 
 
 
Date:
July 27, 2017
 
/s/ Erin M. Lampert
 
 
 
Erin M. Lampert

 
 
 
Senior Vice President and Controller



40
EX-10.1 2 mck_exhibit101x06302017.htm FORMS OF ST&CS APPLICABLE TO AWARDS PURSUANT TO THE MCKESSON 2013 STOCK PLAN Exhibit

OUTSIDE DIRECTOR
McKESSON CORPORATION
STATEMENT OF TERMS AND CONDITIONS APPLICABLE TO
RESTRICTED STOCK UNITS GRANTED TO
OUTSIDE DIRECTORS PURSUANT TO THE 2013 STOCK PLAN
Effective for Grants Beginning July 29, 2015
I.
INTRODUCTION
The following terms and conditions shall apply to Restricted Stock Unit Awards granted under the Plan and are subject to the terms and conditions of the Plan. This Statement of Terms and Conditions is intended to meet the requirements of Code Section 409A and any regulations and rules promulgated thereunder. In the event of any inconsistency between this Statement of Terms and Conditions and the Plan, the Plan shall govern. Capitalized terms not otherwise defined in this Statement of Terms and Conditions shall have the meaning set forth in the Plan.
II.
RESTRICTED STOCK UNITS
1.    Award Agreement. A Restricted Stock Unit Award granted to an Outside Director under the Plan shall be evidenced by a Restricted Stock Unit Agreement to be executed by the Outside Director and the Corporation setting forth the terms and conditions of the Restricted Stock Unit Award. Each Restricted Stock Unit Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions and together both documents shall constitute the Restricted Stock Unit Agreement. The Restricted Stock Units are also subject to the terms and conditions of the Plan.
2.    Terms and Conditions. The Administrator administering the Plan has authority to determine the Outside Directors to whom, and the time or times at which, grants of Restricted Stock Units will be made, the number of Units to be awarded, and all other terms and conditions of such awards. With respect to annual Restricted Stock Unit Awards granted to Outside Directors under the Plan, such awards shall be subject to the following terms, conditions and restrictions.
(A)    Grant Date. Each Outside Director may be granted a Restricted Stock Unit Award on the date of each annual meeting of stockholders. An Outside Director that is elected to the Board between annual meetings of stockholders may also be granted a Restricted Stock Unit Award on the date that the Board determines in its sole discretion.

1



(B)    Number of Units. Unless otherwise determined by the Board or the Committee, the number of Units granted for the annual meeting grant will be determined by dividing the Fair Market Value of a Share on the date of grant into $180,000 (with any fractional Unit rounded up to the nearest whole Unit). In addition, unless otherwise determined by the Board or the Committee, the Lead Independent Director shall be granted an annual meeting grant determined by dividing the Fair Market Value of a Share on the date of grant into $25,000 (with any fractional Unit rounded up to the nearest whole Unit). Notwithstanding the foregoing, in no event shall the aggregate number of Units granted to a director pursuant to such annual meeting grant or grants exceed 5,000. A newly elected Outside Director may receive a prorated annual meeting grant effective upon the date of the Outside Director’s election to the Board.
(C)    No Restrictions. Each Restricted Stock Unit Award granted to an Outside Director will be fully vested on the date of grant.
3.    Dividend Equivalents. Dividend equivalents in respect of Restricted Stock Units may be credited on behalf of an Outside Director to a deferred cash account or converted into additional Restricted Stock Units, which will be subject to all of the terms and conditions of the underlying Restricted Stock Unit Award. Currently, dividend equivalents in respect of Restricted Stock Units granted to Outside Directors are credited to a deferred cash account and accrue interest at a rate determined by the Committee until such time as the underlying Shares are issued.
4.    Assignability. An Outside Director shall not be permitted to sell, transfer, pledge, assign or encumber Restricted Stock Units, other than pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act.
5.    No Stockholder Rights. Neither an Outside Director nor any person entitled to exercise an Outside Director’s rights in the event of the Outside Director’s death shall have any of the rights of a stockholder with respect to a Restricted Stock Unit Award except to the extent that a book entry has been entered in the records of the Corporation’s transfer agent with respect to the underlying Shares paid upon the settlement of any Restricted Stock Unit Award as described in Section II.6 below.
6.    Time of Payment of Restricted Stock Units. Except as noted in Section II.7 below, Restricted Stock Units granted to Outside Directors shall not be paid until after the Outside Director’s separation of service with the Corporation (“Automatic Deferral Requirement”). “Separation of service” shall have the meaning provided under the McKesson Corporation Deferred Compensation Administration Plan III (“DCAP III”). Payment shall be made in Shares in the form of an appropriate book entry entered in the records of the Corporation’s transfer agent recording the Outside Director’s unrestricted interest in the number of Shares subject to the Restricted Stock Unit Award.
7.    Satisfaction of Director Stock Ownership Guidelines. For those Outside Directors who have met the Director Stock Ownership Guidelines in effect at the time, Restricted Stock Unit grants shall not be subject to the Automatic Deferral Requirement and such grants will be immediately converted into Shares and distributed to the Outside Director; provided, however, that the Outside Director may elect to defer receipt of the Shares underlying the Restricted Stock Units.

2



8.    Deferrals of Restricted Stock Units. Deferrals of Restricted Stock Units, whether elective or pursuant to the Automatic Deferral Requirement, shall be subject to the terms and conditions of DCAP III.
III.
MISCELLANEOUS
1.    No Effect on Terms of Service with the Corporation. Nothing contained in this Statement of Terms and Conditions, the Plan or a Restricted Stock Unit Agreement shall affect the Corporation’s right to terminate the service of any Outside Director.
2.    Grants to Outside Directors in Foreign Countries. If an Outside Director is not a United States citizen, the Board has the full discretion to deviate from this Statement of Terms and Conditions in order to adjust a Restricted Stock Unit Award to prevailing local conditions, including custom and legal and tax requirements. Furthermore, the Corporation reserves the right to impose other requirements on the Outside Director’s participation in the Plan, on the Award and on any Shares acquired under the Plan, to the extent the Corporation determines it is necessary or advisable in order to comply with local law or facilitate the administration of the Plan, and to require the Outside Director to sign any additional agreements or undertaking that may be necessary to accomplish the foregoing.
3.    Information Notification. Any information required to be given under the terms of a Restricted Stock Unit Award shall be addressed to the Corporation in care of its Corporate Secretary at McKesson Corporation, One Post Street, San Francisco, California 94104, and any notice to be given to an Outside Director shall be addressed to the Outside Director at the address indicated beneath the Outside Director’s name on the Restricted Stock Unit Agreement or such other address as either party may designate in writing to the other. Any such notice shall be deemed to have been duly given when enclosed in a properly sealed envelope or wrapper addressed as aforesaid, registered or certified and deposited (postage or registration or certification fee prepaid) in a post office or branch post office.
4.    Administrator Decisions Conclusive. All decisions of the Administrator administering the Plan upon any questions arising under the Plan, under this Statement of Terms and Conditions, or under a Restricted Stock Unit Agreement, shall be conclusive and binding on all persons.
5.    No Effect on Other Benefit Plans. Nothing herein contained shall affect an Outside Director’s right, if any, to participate in and receive benefits from and in accordance with the then current provisions of any benefit plan or program offered by the Corporation.
6.    Withholding. Each Outside Director shall agree to make appropriate arrangements with the Corporation for satisfaction of any applicable federal, state or local income tax withholding requirements or payroll tax requirements, if any is required.
7.    Successors. This Statement of Terms and Conditions and the Restricted Stock Unit Agreements shall be binding upon and inure to the benefit of any successor or successors of the Corporation. “Outside Director” as used herein shall include the Outside Director’s Beneficiary.

3



8.    Delaware Law. The interpretation, performance, and enforcement of this Statement of Terms and Conditions and all Restricted Stock Unit Agreements shall be governed by the laws of the State of Delaware.


4



CHIEF EXECUTIVE OFFICER

McKESSON CORPORATION
STATEMENT OF TERMS AND CONDITIONS APPLICABLE TO
OPTIONS, RESTRICTED STOCK, RESTRICTED STOCK UNITS,
PERFORMANCE SHARES AND TSR UNIT AWARDS GRANTED TO
CHIEF EXECUTIVE OFFICER PURSUANT TO THE 2013 STOCK PLAN
Effective for Grants Beginning May 24, 2016
I.
INTRODUCTION
The following terms and conditions shall apply to an Award granted under the Plan and are subject to the terms and conditions of the Plan. This Statement of Terms and Conditions is intended to meet the requirements of Code Section 409A and any rules promulgated thereunder. In the event of any inconsistency between this Statement of Terms and Conditions and the Plan, the Plan shall govern. Capitalized terms not otherwise defined in this Statement of Terms and Conditions shall have the meaning set forth in the Plan.
II.
OPTIONS
1.    Option Agreement. An Option granted under the Plan shall be evidenced by an Option Agreement setting forth the terms and conditions of the Option, including whether the Option is an Incentive Stock Option or a Nonstatutory Stock Option and the number of Shares subject to the Option. Each Option Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions and together both documents shall constitute the Option Agreement. The Option is also subject to the terms and conditions of the Plan.
2.    Exercise Price. The Exercise Price of an Option, as specified in the Option Agreement, shall be equal to or greater than the Fair Market Value of the Shares underlying the Option on the Grant Date.
3.    Option Period. An Option shall be exercisable only during the applicable Option Period, and during such Option Period the exercisability of the Option shall be subject to the vesting provisions of Section II.4 as modified by the rules set forth in Sections II.5 and V. The Option Period shall be not more than seven years from the Grant Date.
4.    Vesting of Right to Exercise Options.
(A)    Except as provided in Sections II.5 and V, an Option shall be exercisable during the Option Period in accordance with the following vesting schedule:  (i) 25% of the Shares subject to the Option shall vest on the first anniversary of the Grant Date; (ii) an additional 25% of the Shares shall vest on the second anniversary of the Grant Date; (iii) an additional 25% of the Shares shall vest on the third anniversary of the Grant Date; and (iv) the remaining 25% of the Shares subject to the Option shall vest on the fourth anniversary of the Grant Date. Notwithstanding the foregoing, the Administrator may specify a different vesting schedule at the time the Option is granted, which will be specified in the Option Grant Notice.

1



(B)    Any vested portion of an Option not exercised hereunder shall accumulate and be exercisable at any time on or before the Expiration Date, subject to the rules set forth in Sections II.5 and V. No Option may be exercised for less than 5% of the total number of Shares then available for exercise under such Option. In no event shall the Corporation be required to issue fractional Shares.
5.    Limits on Option Period and Acceleration of Vesting. The Option Period may end before the Expiration Date, and in certain circumstances the vesting schedule of an Option may be accelerated (subject to the provisions of Section V), as follows:
(A)    If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period for reasons other than for Cause, Long‑Term Disability, Normal Retirement, Early Retirement, Severance under the circumstances provided in Section II.5(F)(ii), or death, the Option Period shall end on the earlier of (i) 90 days after the date of the Participant’s termination of employment and (ii) the Expiration Date, and in all cases the Option shall be exercisable only to the extent that it was exercisable under the provisions of the foregoing Section II.4 at the time of such termination of employment. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short‑Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Administrator may otherwise expressly determine.
(B)    Notwithstanding any other provision in this Section II.5, if a Participant’s employment is terminated for Cause during the Option Period, the Option Period shall end on the date of such termination of employment and the Option shall thereupon not be exercisable to any extent whatsoever.
(C)    If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Long-Term Disability, the vesting schedule of the Participant’s Option shall be accelerated, the Option shall become fully exercisable and the Option Period shall end on the earlier of (i) three years after the date of the Participant’s termination of employment and (ii) the Expiration Date.
(D)    If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Early Retirement, (i) the Option shall be exercisable only to the extent that it was exercisable under the provisions of the foregoing Section II.4 at the time of such retirement and (ii) the Option Period for that portion of the Option designated as a Nonstatutory Stock Option shall end on the earlier of (a) three years after the date of such retirement and (b) the Expiration Date.
(E)    If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Normal Retirement:
(i)    If such Normal Retirement occurs prior to the first anniversary of the Grant Date of the Option, such Option shall be subject to the provisions of Section II.5(D) as though the Participant were eligible for Early Retirement; and

2



(ii)    If such Normal Retirement occurs on or after the first anniversary of the Grant Date of an Option, (a) that portion of the Option designated as a Nonstatutory Stock Option shall continue to vest as set forth in the foregoing Section II.4 as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such vesting period, and (b) the Option Period for such portion of the Option designated as a Nonstatutory Stock Option shall end on the Expiration Date.
(F)    If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Severance, and
(i)    The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, and would not have attained the requirements for Normal Retirement within six months after the termination date, then (a) the vesting schedule of the Participant’s Option shall be accelerated as to the portion of the Option that would have vested in accordance with the vesting schedule set forth in the foregoing Section II.4 as if the Participant had continued to be employed by the Corporation or one of its Affiliates six months after the termination date, and (b) the expiration of the Option Period provided in Section II.5(A) shall apply; provided that if the Participant is also eligible for Early Retirement at the time of the termination of employment, then the expiration of the Option Period provided in Section II.5(D) shall apply; or
(ii)    The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, but would have attained the requirements for Normal Retirement within six months after the termination date, and:
(a)    The first anniversary of the Grant Date of the applicable Award has not occurred on or prior to the termination date, then such Option shall be subject to the Early Retirement provision in Section II.5(D); and
(b)    The first anniversary of the Grant Date of the applicable Award has occurred on or prior to the termination date, then (x) that portion of the Option designated as a Nonstatutory Stock Option shall continue to vest as set forth in the foregoing Section II.4 as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such vesting period, and (y) the Option Period for such portion of the Option designated as a Nonstatutory Stock Option shall end on the Expiration Date.
(G)    If a Participant should die (i) while in the employ of the Corporation or an Affiliate and (ii) during the Option Period, the vesting schedule of the Participant’s Option shall be accelerated and the Option shall become fully exercisable, the Option Period shall end on the earlier of (a) three years after the date of death and (b) the Expiration Date, and the Participant’s Beneficiary may exercise the entire unexercised portion of the then exercisable Shares covered by such Option (or any lesser amount) remaining on the date of death.

3



(H)    If a Participant who ceases to be a bona fide employee of the Corporation or an Affiliate is subsequently rehired prior to the expiration of the Participant's Option, then the Option shall continue to remain outstanding until the earlier of (i) such time as the Participant subsequently terminates employment and (ii) the Expiration Date. Upon the Participant’s subsequent termination of employment, the post‑termination exercise period calculated pursuant to the terms and conditions of this Section II.5 shall be reduced by the number of days between the date of the Participant’s initial termination of employment and the Participant's re‑hire date; provided, however, that if the rehired Participant continues to be employed by the Corporation or an Affiliate for at least one year from the Participant's rehire date, then the post termination exercise period for the Option shall be determined in accordance with Sections II.5(A) through (G) and shall not be adjusted as described in this Section II.5(H).
6.    Method of Exercise. A Participant may exercise an Option with respect to all or any part of the exercisable Shares as follows:
(A)    By giving the Corporation, or its authorized representative designated for this purpose, written notice of such exercise specifying the number of Shares as to which the Option is so exercised. Such notice shall be accompanied by an amount equal to the Exercise Price multiplied by the number of Shares exercised, in the form of any one or combination of the following:  cash or a certified check, bank draft, postal or express money order payable to the order of the Corporation in lawful money of the United States. Unless otherwise determined by the Administrator in its sole discretion, the Participant may pay the Exercise Price, in whole or in part, by tendering to the Corporation or its authorized representative Shares, which have been owned by the Participant for at least six months prior to said tender, and having a fair market value, as determined by the Corporation, equal to the Exercise Price, or in lieu of the delivery of actual Shares in such tender, the Corporation may accept an attestation by the Participant, in a form prescribed by the Corporation or its authorized representative, that the Participant owns sufficient Shares of record or in an account in street name to satisfy the Exercise Price, and such attestation will be deemed a tender of Shares for purposes of this method of exercise. The Corporation or its authorized representative may accept payment of the amount due upon the exercise of the Option in the form of a Participant’s personal check. Payment may also be made by delivery (including by FAX transmission) to the Corporation or its authorized representative of an executed irrevocable Option exercise form together with irrevocable instructions to an approved registered investment broker to sell Shares in an amount sufficient to pay the Exercise Price plus any applicable Tax-Related Items (as defined in Section VIII.6) and to transfer the proceeds of such sale to the Corporation.
(B)    If required by the Corporation, by giving satisfactory assurance in writing, signed by the Participant, the Participant shall give the Participant's assurance that the Shares subject to the Option are being purchased for investment and not with a view to the distribution thereof; provided that such assurance shall be deemed inapplicable to (i) any sale of the Shares by such Participant made in accordance with the terms of a registration statement covering such sale, which has heretofore been (or may hereafter be) filed and become effective under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and with respect to which no stop order suspending the effectiveness thereof has been issued, and (ii) any other sale of the Shares with respect to which, in the opinion of counsel for the Corporation, such assurance is not required to be given in order to comply with the provisions of the Securities Act.

4



(C)    As soon as practicable after receipt of the notice and the assurance described in Sections II.6(A) and (B), the Corporation shall, without transfer or issue tax (except for withholding tax arrangements contemplated in Section VIII.6) and without other incidental expense to the Participant, credit the purchased Shares to the Participant’s brokerage account of record. If the Participant does not have a brokerage account of record, then the Corporation shall cause an appropriate book entry to be entered in the records of the Corporation’s transfer agent recording the Participant’s unrestricted interest in the purchased Shares; provided, however, that the time of such delivery may be postponed by the Corporation for such period as may be required for it with reasonable diligence to comply with applicable registration requirements under the Securities Act, the Exchange Act, any applicable listing requirements of any national securities exchange and requirements under any other law or regulation applicable to the issuance or transfer of the Shares.
7.    Limitations on Transfer. An Option shall, during a Participant’s lifetime, be exercisable only by the Participant. No Option or any right granted thereunder shall be transferable by the Participant by operation of law or otherwise, other than by will or the laws of descent and distribution. Notwithstanding the foregoing: (A) a Participant may designate a beneficiary to succeed, after the Participant’s death, to all of the Participant’s Options outstanding on the date of death; (B) a Nonstatutory Stock Option may be transferable pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act; and (C) any Participant, who is a senior executive officer recommended by the Chief Executive Officer of the Corporation and approved by the Administrator may voluntarily transfer any Nonstatutory Stock Option to a Family Member as a gift or through a transfer to an entity in which more than 50% of the voting interests are owned by Family Members (or the Participant) in exchange for an interest in that entity. In the event of any attempt by a Participant to alienate, assign, pledge, hypothecate, or otherwise dispose of an Option or of any right thereunder, except as provided herein, or in the event of the levy of any attachment, execution, or similar process upon the rights or interest hereby conferred, the Corporation at its election may terminate the affected Option by notice to the Participant and the Option shall thereupon become null and void.
8.    No Stockholder Rights. Neither a Participant nor any person entitled to exercise a Participant’s rights in the event of the Participant’s death shall have any of the rights of a stockholder with respect to the Shares subject to an Option except to the extent that a book entry has been entered in the records of the Corporation’s transfer agent with respect to such Shares upon the exercise of an Option.
III.
RESTRICTED STOCK
1.    Restricted Stock Agreement. A Restricted Stock Award granted under the Plan shall be evidenced by a Restricted Stock Agreement to be executed by the Participant and the Corporation setting forth the terms and conditions of the Restricted Stock Award. Each Restricted Stock Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions and together both documents shall constitute the Restricted Stock Agreement. The Restricted Stock Award is also subject to the terms and conditions of the Plan.

5



2.    Rights with Respect to Shares of Restricted Stock. Upon written acceptance of a Restricted Stock Award by a Participant, including the restrictions and other terms and conditions described in the Plan and the Restricted Stock Agreement, the Corporation shall cause an appropriate book entry to be entered in the records of the Corporation’s transfer agent recording the Participant’s interest in the Restricted Stock. From and after the Grant Date, the Participant shall have the rights of Common Stock ownership, including the right to vote and to receive dividends on Shares of Restricted Stock, subject to the terms, conditions and restrictions described in the Plan and the Restricted Stock Agreement.
3.    Special Restrictions. Each Restricted Stock Award made under the Plan shall be subject to the following terms, conditions and restrictions and such additional terms, conditions and restrictions as may be determined by the Administrator; provided, however, that no Restricted Stock grant shall be subject to additional terms, conditions and restrictions which are more favorable to a Participant than the terms, conditions and restrictions set forth elsewhere in the Plan or the Restricted Stock Agreement.
(A)    Restrictions. Until the restrictions imposed on any Restricted Stock grant shall lapse (the “Restriction Period”), Shares of Restricted Stock granted to a Participant (i) shall not be sold, assigned, transferred, pledged, hypothecated, or otherwise disposed of, other than pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act and (ii) shall, if the Participant’s continuous employment with the Corporation or any of its Affiliates shall terminate for any reason (except as otherwise provided in the Plan, or in Section III.3(B) or Section III.3(C)) be returned to the Corporation forthwith, and all the rights of the Participant to such Shares shall immediately terminate. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short‑Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Administrator may otherwise expressly determine.
(B)    Termination of Employment by Reason of Death, Long‑Term Disability or Normal Retirement. Notwithstanding any provision to the contrary contained in the Restricted Stock Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of a Restricted Stock Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of:
(i)    Death or Long‑Term Disability, then the restrictions imposed on any Restricted Stock Award shall lapse as to all Shares granted to such Participant pursuant to such Restricted Stock Award on the date of such termination; or

6



(ii)    Normal Retirement on or after the first anniversary of the Grant Date of any time-based vesting Restricted Stock Award, the restrictions applicable to such Restricted Stock Award shall continue to lapse at such time(s) as are set forth in the applicable Grant Notice, as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such restricted period; provided, that notwithstanding any other provision of the Plan or this Statement of Terms and Conditions, this Section III.3(B)(ii) shall not apply to any Restricted Stock Award the vesting of which is based, in whole or in part, on attainment of performance objectives. The procedures set forth in Section VIII.6 will be applied for any taxes due upon the lapse of restrictions imposed on a Restricted Stock Award due to a Participant’s Normal Retirement eligibility.
(C)    Termination of Employment by Reason of Severance. Notwithstanding any provision to the contrary contained in the Restricted Stock Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of a Restricted Stock Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of Severance, and:

(i)    The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, and would not have attained the requirements for Normal Retirement within six months after the termination date, then the restrictions applicable to any time-based vesting Restricted Stock Award shall lapse upon the Participant’s termination date, as to such Shares of Restricted Stock that would have vested at such time(s) as are set forth in the applicable Grant Notice as if the Participant had continued to be employed by the Corporation or one of its Affiliates during the six-month period after the Participant’s termination date; or

(ii)    The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, but would have attained the requirements for Normal Retirement within six months after the termination date and the first anniversary of the Grant Date of the Restricted Stock Award has occurred on or prior to the termination date, then the restrictions applicable to the time-based vesting Restricted Stock Award shall continue to lapse at such time(s) as are set forth in the applicable Grant Notice, as though the Participant had continued to be employed by the Corporation or one of its Affiliates during the restricted period; provided that if the first anniversary of the Grant Date of the Restricted Stock Award has not occurred on or prior to the termination date, then the additional vesting terms and conditions provided in Section III.3(C)(i) shall apply to such award.

Notwithstanding the foregoing, this Section III.3(C) shall not apply to any Restricted Stock Award the vesting of which is based, in whole or in part, on attainment of performance objectives. The procedures set forth in Section VII.6 will be applied for any taxes due upon the lapse of restrictions imposed on a Restricted Stock Award due to a Participant’s Normal Retirement eligibility.


7



(D)    Restriction on Sale. The Compensation Committee reserves the right to impose a restriction on the sale of Shares that the Participant receives upon the vesting and settlement of a Restricted Stock Award, unless the Participant has satisfied the ownership targets applicable to the Participant as provided in the Stock Ownership Policy.
4.    Dividends. Cash dividends paid with respect to Restricted Stock during the Restriction Period shall be credited on behalf of the Participant to a deferred cash account (in a manner designed to comply with Code Section 409A) and the restrictions on such cash dividends shall lapse at the same time that the restrictions lapse on the associated Restricted Stock Award. Stock dividends paid with respect to Restricted Stock during the Restriction Period shall be treated as Restricted Stock which shall be subject to the same restrictions as the original award for the duration of the Restriction Period.
5.    Election to Recognize Gross Income in the Year of Grant. If any Participant validly elects within 30 days of the Grant Date, to include in gross income for federal income tax purposes an amount equal to the fair market value of the Shares of Restricted Stock granted on the Grant Date, such Participant shall (at the same time or prior to the date that the Participant files the Participant's election with the Internal Revenue Service) (A) pay to the Corporation, or make arrangements satisfactory to the Administrator to pay to the Corporation in the year of such grant, any federal, state or local taxes required to be withheld with respect to such Shares in accordance with Section VIII.6, and (B) provide the Administrator with a copy of the election filed with the Internal Revenue Service.
6.    Restrictive Legend. Each book entry in the records of the Corporation’s transfer agent evidencing Shares granted pursuant to a Restricted Stock grant may bear an appropriate legend referring to the terms, conditions and restrictions described in the Plan and/or the Restricted Stock Agreement.
7.    Expiration of Restriction Period. If and when the Restriction Period applicable to the Restricted Stock expires without a prior forfeiture, Shares shall be credited to the Participant’s brokerage account of record. If the Participant does not have a brokerage account of record, then an appropriate book entry recording the Participant’s interest in the unrestricted Shares shall be entered on the records of the Corporation’s transfer agent.
IV.
RESTRICTED STOCK UNITS AND PERFORMANCE SHARES
1.    Award Agreement.
(A)    Restricted Stock Units granted under the Plan shall be evidenced by a Restricted Stock Unit Agreement to be executed by the Participant and the Corporation setting forth the terms and conditions of the Restricted Stock Units. Each Restricted Stock Unit Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions and together both documents shall constitute the Restricted Stock Unit Agreement. The Restricted Stock Units are also subject to the terms and conditions of the Plan.

8



(B)    Performance Shares granted under the Plan shall be evidenced by a Performance Share Agreement to be executed by the Participant and the Corporation setting forth the terms and conditions of the Performance Shares. Each Performance Share Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions and together both documents shall constitute the Performance Share Agreement. Performance Shares are also subject to the terms and conditions of the Plan.
2.    Special Restrictions. Restricted Stock Units and Performance Shares granted under the Plan shall be subject to the following terms, conditions and restrictions and such additional terms, conditions and restrictions as may be determined by the Administrator, consistent with the terms of the Plan.
(A)    Restrictions. If a Participant ceases to be a bona fide employee of the Corporation or any Affiliate (except as otherwise provided in the Plan, or in Section IV.2(B) or Section IV.2(C)) prior to the lapse of the restrictions imposed on the Award, the unvested Restricted Stock Units or Performance Shares shall be canceled, and all the rights of the Participant to such Awards shall immediately terminate. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short‑Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Administrator may otherwise expressly determine.
(B)    Termination of Employment by Reason of Death, Long‑Term Disability or Normal Retirement. Notwithstanding any provision contained to the contrary in the Restricted Stock Unit Grant Notice or Performance Share Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date shall, while in such employment, be terminated as a result of:
(i)    Death or Long‑Term Disability, then the restrictions imposed on any Award of Restricted Stock Units or Performance Shares shall lapse on the date of such termination; or
(ii)    Normal Retirement on or after the first anniversary of the Grant Date of any time-based vesting Restricted Stock Units, the restrictions applicable to such Restricted Stock Units shall continue to lapse at such time(s) as are set forth in the applicable Grant Notice, as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such restricted period; provided, that notwithstanding any other provision of the Plan or this Statement of Terms and Conditions, this Section IV.2(B)(ii) shall not apply to any Performance Shares or any Restricted Stock Units the vesting of which is based, in whole or in part, on attainment of performance objectives.
(C)    Termination of Employment by Reason of Severance. Notwithstanding any provision to the contrary contained in the Restricted Stock Unit Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of a Restricted Stock Unit Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of Severance, and:

9



(i)    The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, and would not have attained the requirements for Normal Retirement within six months after the termination date, then the restrictions applicable to any time-based vesting Restricted Stock Unit Award shall lapse upon the termination date, as to such Restricted Stock Units that would have vested at such time(s) as are set forth in the applicable Grant Notice as if the Participant had continued to be employed by the Corporation or one of its Affiliates during the six-month period after the termination date; or
(ii)    The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, but would have attained the requirements for Normal Retirement within six months after the termination date and the first anniversary of the Grant Date has occurred on or prior to the termination date, then the restrictions applicable to any time-based vesting Restricted Stock Units shall continue to lapse at such time(s) as are set forth in the applicable Grant Notice, as though the Participant had continued to be employed by the Corporation or one of its Affiliates during the restricted period; provided that if the first anniversary of the Grant Date of the Restricted Stock Unit Award has not occurred on or prior to the termination date, then the additional vesting terms provided in Section IV.2(C)(i) will apply to such award.
Notwithstanding the foregoing, this Section IV.2(C) shall not apply to any Restricted Stock Units the vesting of which is based, in whole or in part, on attainment of performance objectives.
(D)    Restriction on Sale. The Compensation Committee reserves the right to impose a restriction on the sale of Shares that the Participant receives upon the settlement of Restricted Stock Units or Performance Shares, unless the Participant has satisfied the ownership targets applicable to the Participant as provided in the Stock Ownership Policy.
3.    Dividend Equivalents. Subject to the discretion of the Compensation Committee, dividend equivalents shall be credited in respect of Restricted Stock Units and Performance Shares. Cash dividends shall be credited on behalf of the Participant to a deferred cash account (in a manner designed to comply with Code Section 409A) and the restrictions on such cash dividends shall lapse at the same time that the restrictions lapse on the associated Award of Restricted Stock Units or Performance Shares (as applicable), and cash dividends, along with accrued interest (if any) on such cash dividends, shall be paid in a lump sum at the same time that the Shares underlying the Restricted Stock Unit or Performance Share Award, and to which the cash dividends relate, are distributed. Stock dividends shall be converted into additional Restricted Stock Units or Performance Shares, which will be subject to all of the terms and conditions of the underlying Restricted Stock Units or Performance Shares, including the same vesting restrictions as the underlying Award.
4.    Assignability. A Participant shall not be permitted to sell, transfer, pledge, assign or encumber Restricted Stock Units or Performance Shares, other than pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act.

10



5.    No Stockholder Rights. Neither a Participant nor any person entitled to exercise a Participant’s rights in the event of the Participant’s death shall have any of the rights of a stockholder with respect to an Award of Restricted Stock Units or Performance Shares except to the extent that a book entry has been entered in the records of the Corporation’s transfer agent with respect to the Shares paid upon the settlement of any vested Restricted Stock Units or Performance Shares.
6.    Time of Payment of Restricted Stock Units and Performance Shares. Upon the lapse of the restriction imposed on Restricted Stock Units or Performance Shares, all Restricted Stock Units and Performance Shares that were not forfeited pursuant to Section IV.2(A), Section IV.2(B)(i), Section IV.2(C)(i), or Section V shall be paid to the Participant as soon as reasonably practicable after the restrictions lapse. Payment shall be made in Shares to the Participant’s brokerage account of record. If the Participant does not have a brokerage account of record, then in the form of an appropriate book entry entered in the records of the Corporation’s transfer agent recording the Participant’s unrestricted interest in the number of Shares subject to the Restricted Stock Units or Performance Shares.
Notwithstanding the foregoing, if a Participant becomes eligible for Normal Retirement, or is eligible for additional vesting under Section IV.2(C)(ii), prior to the date of the lapse of restrictions imposed on Restricted Stock Units and the vesting provisions of Section IV.2(B)(ii) or Section IV.2(C)(ii) apply, then such Restricted Stock Units shall be paid to the Participant’s brokerage account of record as soon as reasonably practicable after the earlier of the Participant’s Separation from Service or the originally scheduled vesting date (in any event before the end of the calendar year in which such date occurs), subject to the delay of payment (if applicable) provided in Section VIII.14. The procedures set forth in Section VIII.6 will be applied for any taxes due upon the lapse of restrictions imposed on the Restricted Stock Units due to a Participant’s Normal Retirement eligibility or additional vesting as provided in Section IV.2(C)(ii).
V.
TOTAL SHAREHOLDER RETURN (“TSR”) UNIT AWARDS
1.    Award Agreement. TSR Unit Awards shall be evidenced by a TSR Unit Target Award Notification to be executed by the Participant and the Corporation setting forth the terms and conditions of the TSR Unit Award. TSR Unit Awards are “Other Share-Based Awards” as provided under Section 11 of the Plan. Each TSR Unit Target Notification shall incorporate by reference and be subject to this Statement of Terms and Conditions, and together both documents shall constitute the TSR Unit Award Agreement. TSR Unit Awards are also subject to the terms and conditions of the Plan.
2.    Number of Shares Granted Based on Performance. The performance period of a TSR Unit Award shall be greater than one year, and performance shall be based on such criteria as the Compensation Committee shall determine in its discretion at the beginning of the performance period. Following the end of the performance period, the Compensation Committee shall determine the extent to which the criteria have been achieved, and shall authorize the grant and issuance of Shares in respect of the TSR Unit Award.
3.    Special Conditions. TSR Unit Awards shall be subject to the following terms, conditions and restrictions and such additional terms, conditions and restrictions as may be determined by the Compensation Committee, consistent with the terms of the Plan.

11



(A)    Forfeiture. If a Participant ceases to be a bona fide employee of the Corporation or any Affiliate (except as otherwise provided in the Plan or in Section V.3(B)) prior to the end of the performance period, any then-outstanding TSR Unit Awards shall be canceled, and all the rights of the Participant to such Awards shall immediately terminate. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short-Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Compensation Committee may otherwise expressly determine.
(B)    Termination of Employment by Reason of Death, Long-Term Disability or Normal Retirement. Notwithstanding any provision contained herein or in the Plan, the TSR Unit Award Agreement to the contrary, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of such Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of:
(i)    Death or Long-Term Disability, the Participant shall be eligible to receive, following completion of the applicable performance period, an amount in cash equal to the value of a prorated portion of each such TSR Unit Award, equal to (1) the target number of TSR Units subject to such Award, multiplied by (2) the performance criteria determined by the Compensation Committee to apply to such Award, multiplied by (3) a fraction, the numerator of which is the number of whole calendar months, rounded down to the nearest whole month, during which the Participant provided Service to the Corporation or an Affiliate during the performance period applicable to such Award, and the denominator of which is the number of calendar months in such performance period; provided, that for purposes of this clause (3), “whole calendar months” shall be calculated commencing on the applicable Grant Date; and provided, however, that in no event shall such amount exceed any applicable cap or limitation set forth in the TSR Unit Target Award Notification; or
(ii)    Normal Retirement on or after the first anniversary of the Grant Date, the Participant shall be eligible to receive, following completion of the applicable performance period, an amount in cash equal to the value of such TSR Unit Award, calculated as though the Participant had continued to be employed by the Corporation or one of its Affiliates during the entire performance period.
Amounts, if any, to be paid under this Section V.3(B) shall be paid in accordance with Section V.7 and, if applicable, Section VIII.14.
(C)    Restriction on Sale of Shares. The Compensation Committee reserves the right to impose a restriction on the sale of Shares that the Participant receives with respect to the settlement of a TSR Unit Award, unless the Participant has satisfied the ownership targets applicable to the Participant as provided in the Stock Ownership Policy.
4.    Dividend Equivalents. Unless otherwise determined by the Administrator in its sole discretion, Dividend Equivalents shall not be accrued with respect to TSR Unit Awards during the performance period.

12



5.    Assignability. A Participant shall not be permitted to sell, transfer, pledge, assign or encumber all or any portion of a TSR Unit Award.
6.    No Stockholder Rights. Neither a Participant nor any person entitled to exercise a Participant’s rights in the event of the Participant’s death shall have any of the rights of a stockholder with respect to a TSR Unit Award, except to the extent that a book entry has been entered in the records of the Corporation’s transfer agent with respect to the Shares paid upon the settlement of any TSR Unit Award.
7.    Time of Payment of TSR Unit Awards. The Compensation Committee shall determine the extent to which Shares are payable pursuant to a TSR Unit Award as soon as practicable following the end of the performance period, and such Shares shall be paid as soon as practicable thereafter and in any event no later than the end of the period under which payment would be deemed to be a “short-term deferral” as defined in the regulations under Code Section 409A. Except as provided in Section V.3(B), payment shall be made in the form of Shares to the Participant’s brokerage account of record. If the Participant does not have a brokerage account of record, then in the form of an appropriate book entry entered in the records of the Corporation’s transfer agent recording the Participant’s unrestricted interest in the number of Shares earned pursuant to the TSR Unit Award.
VI.
SPECIAL FORFEITURE AND REPAYMENT RULES
Any other provision of this Statement of Terms and Conditions to the contrary notwithstanding, if the Administrator determines that a Participant has engaged in any of the actions described in 3 below, the consequences set forth in 1 and 2 below shall result:
1.    Any outstanding Option shall immediately and automatically terminate, be forfeited and shall cease to be exercisable, without limitation. In addition, any Award of Restricted Stock, Restricted Stock Units, or Performance Shares as to which the restrictions have not lapsed shall immediately and automatically be forfeited, TSR Unit Awards shall immediately and automatically be forfeited and any such Shares of Restricted Stock shall be returned to the Corporation and all of the rights of the Participant to such Awards and the underlying Shares shall immediately terminate.
2.    If the Participant exercised an Option within 12 months prior to the date upon which the Corporation discovered that the Participant engaged in any actions described in 3 below, the Participant, upon written notice from the Corporation, shall immediately pay to the Corporation the economic value realized or obtained by the exercise of such Option measured at the date of exercise. In addition, if the restrictions imposed on any Award of Restricted Stock, Restricted Stock Units or Performance Shares (including any unpaid dividends or Dividend Equivalents) lapsed, or any TSR Unit Award was settled, within 12 months prior to the date the Corporation discovered that the Participant engaged in any action described in 3 below, the Participant, upon written notice from the Corporation, shall immediately pay to the Corporation the economic value realized or obtained with respect to such Award, measured at the date such Award vested.
3.    The consequences described in 1 and 2 above shall apply if the Participant, either before or after termination of employment with the Corporation or its Affiliates:

13



(A)    Discloses to others, or takes or uses for the Participant’s own purpose or the purpose of others, any trade secrets, confidential information, knowledge, data or know‑how or any other proprietary information or intellectual property belonging to the Corporation or its Affiliates and obtained by the Participant during the term of the Participant’s employment, whether or not they are the Participant’s work product. Examples of such confidential information or trade secrets include, without limitation, customer lists, supplier lists, pricing and cost data, computer programs, delivery routes, advertising plans, wage and salary data, financial information, research and development plans, processes, equipment, product information and all other types and categories of information as to which the Participant knows or has reason to know that the Corporation or its Affiliates intends or expects secrecy to be maintained;
(B)    Fails to promptly return all documents and other tangible items belonging to the Corporation or its Affiliates in the Participant’s possession or control, including all complete or partial copies, recordings, abstracts, notes or reproductions of any kind made from or about such documents or information contained therein, upon termination of employment, whether pursuant to retirement or otherwise;
(C)    Fails to provide the Corporation with at least 30 days’ written notice prior to directly or indirectly engaging in, becoming employed by, or rendering services, advice or assistance to any business in competition with the Corporation or its Affiliates. As used herein, “business in competition” means any person, organization or enterprise which is engaged in or is about to become engaged in any line of business engaged in by the Corporation or its Affiliates at the time of the termination of the Participant’s employment with the Corporation or its Affiliates;
(D)    Fails to inform any new employer, before accepting employment, of the terms of this paragraph and of the Participant’s continuing obligation to maintain the confidentiality of the trade secrets and other confidential information belonging to the Corporation or its Affiliates and obtained by the Participant during the term of the Participant’s employment with the Corporation or any of its Affiliates;
(E)    Induces or attempts to induce, directly or indirectly, any of the customers of the Corporation or its Affiliates, employees, representatives or consultants to terminate, discontinue or cease working with or for the Corporation or its Affiliates, or to breach any contract with the Corporation or any of its Affiliates, in order to work with or for, or enter into a contract with, the Participant or any third party;
(F)    Engages in conduct which is not in good faith and which disrupts, damages, impairs or interferes with the business, reputation or employees of the Corporation or its Affiliates; or
(G)    Fails to meet the Participant’s continuing obligations with respect to non-disclosure, non-competition and/or non-solicitation under the Participant’s agreement with the Corporation or any Affiliate.
The Administrator shall determine in its sole discretion whether the Participant has engaged in any of the acts set forth in (A) through (G) above, and its determination shall be conclusive and binding on all interested persons.

14



Any provision of this Section VI which is determined by a court of competent jurisdiction to be invalid or unenforceable should be construed or limited in a manner that is valid and enforceable and that comes closest to the business objectives intended by such invalid or unenforceable provision, without invalidating or rendering unenforceable the remaining provisions of this Section VI.
VII.
CHANGE IN CONTROL
If as a result of a Change in Control, the Common Stock ceases to be listed for trading on a national securities exchange (an “Exchange”), any Option, Restricted Stock Award, Restricted Stock Unit Award, Performance Share Award or TSR Unit Award that is unvested on the effective date of the Change in Control shall continue to vest according to the terms and conditions of such Award, provided that such Award is replaced with an award for voting securities of the resulting corporation or the acquiring corporation, as the case may be, (including without limitation, the voting securities of any corporation which as a result of the Change in Control owns the Corporation or all or substantially all of the Corporation’s assets either directly or through one or more subsidiaries) (the “Surviving Company”) which are traded on an Exchange (a “Replacement Award”), which Replacement Award, (i) in the case of an Option, shall consist of an option with the number of underlying shares and exercise price determined in a manner consistent with Code Section 424(a) with vesting and any other terms continuing in the same manner as the replaced Option; (ii) in the case of a Performance Share Award or TSR Unit Award, shall consist of restricted stock or restricted stock units with a value (determined using the Surviving Company’s stock price as of the effective date of the Change in Control) equal to the value of the Performance Share Award or TSR Unit Award (determined using the Corporation’s stock price and assuming attainment of target performance or actual performance achieved, if greater, as of the effective date of the Change in Control), with any restrictions on such restricted stock or restricted stock units lapsing at the end of the measuring period over which performance for the replaced Performance Share Award or TSR Unit Award was to be measured prior to the granting of the Replacement Award; and (iii) in the case of a Restricted Stock Award or Restricted Stock Unit Award, shall consist of restricted stock or restricted stock units with a value (determined using the Surviving Company’s stock price as of the effective date of the Change in Control) equal to the value of the Restricted Stock Award or Restricted Stock Unit Award (determined using the Corporation’s stock price as of the effective date of the Change in Control), with any restrictions on such restricted stock or restricted stock units lapsing at the same time and manner as the replaced Award; provided, however, that in the event of the Participant’s involuntary Separation from Service by the Corporation without Cause or Separation from Service by the Participant for Good Reason during the vesting period of any Replacement Award, the Replacement Award shall immediately vest and be paid as soon as practicable following such Separation from Service (subject to Section VIII.14), based on the fair market value of the underlying shares on the vesting date, or in the case of options, based on the excess of the fair market value of the underlying shares over the option exercise price on the vesting date. If any Option, Restricted Stock Award, Restricted Stock Unit Award, Performance Share Award or TSR Unit Award that is unvested at the effective time of the Change in Control is not replaced with a Replacement Award, such Award shall immediately vest and, in the case of a Performance Share Award or TSR Unit Award, shall vest based upon deemed attainment of target performance or actual performance achieved, if greater.

15



If as a result of a Change in Control, the Common Stock continues to be listed for trading on an Exchange, any unvested Option, Restricted Stock Award, or Restricted Stock Unit Award shall continue to vest according to the terms and conditions of such Award and any Performance Share Award or TSR Unit Award shall be replaced with a Restricted Stock Award or Restricted Stock Unit Award where the number of shares subject to such Restricted Stock Award or Restricted Stock Unit Award shall be equal to the number of Shares assuming attainment of target performance or actual performance achieved, if greater, as of the effective date of the Change in Control with any restrictions on such Restricted Stock Award or Restricted Stock Unit Award lapsing at the end of the measuring period over which performance for the replaced Performance Share Award or TSR Unit Award was to be measured prior to the granting of the replacement Award; provided however, that, in the event of the Participant’s involuntary Separation from Service by the Corporation without Cause or Separation from Service by the Participant for Good Reason during the vesting period of an Award, such Award shall immediately vest and be paid as soon as practicable following such Separation from Service (subject to Section VIII.14).
VIII.
MISCELLANEOUS
1.    No Effect on Terms of Employment. Participation in the Plan shall not create a right to further employment with the Participant’s employer (the “Employer”) and shall not interfere with the ability of the Employer to terminate, with or without cause, or change the terms of employment of a Participant at any time.
2.    Grants to Participants in Foreign Countries. In making grants to Participants in foreign countries, the Administrator has the full discretion to deviate from this Statement of Terms and Conditions in order to adjust grants under the Plan to prevailing local conditions, including custom and legal and tax requirements. Furthermore, the Corporation reserves the right to impose other requirements on the Participant’s participation in the Plan on the Award and on any Shares acquired under the Plan, to the extent the Corporation determines it is necessary or advisable in order to comply with local law or facilitate the administration of the Plan, and to require the Participant to sign any additional agreements or undertaking that may be necessary to accomplish the foregoing.
3.    Information Notification. Any information required to be given under the terms of an Award shall be addressed to the Corporation in care of its Corporate Secretary at McKesson Corporation, One Post Street, San Francisco, California 94104, and any notice to be given to a Participant shall be addressed to such Participant at the address indicated beneath the Participant's name on the Award Agreement or such other address as either party may designate in writing to the other. Any such notice shall be deemed to have been duly given when enclosed in a properly sealed envelope or wrapper addressed as aforesaid, registered or certified and deposited (postage or registration or certification fee prepaid) in a post office or branch post office.
4.    Administrator Decisions Conclusive. All decisions of the Administrator administering the Plan upon any questions arising under the Plan or under an Award Agreement, shall be conclusive and binding on all interested persons.

16



5.    No Effect on Other Benefit Plans. Nothing herein contained shall affect a Participant’s right to participate in and receive benefits from and in accordance with the then current provisions of any pensions, insurance or other employment welfare plan or program offered by the Corporation.
6.    Withholding. Regardless of any action the Corporation or the Employer takes with respect to any federal, state or local income tax, social insurance, payroll tax, payment on account or other tax-related items related to the Participant’s participation in the Plan and legally applicable to the Participant (“Tax-Related Items”), the Participant acknowledges that the ultimate liability for all Tax-Related Items is and remains the Participant's responsibility and may exceed the amount actually withheld by the Corporation or the Employer. The Participant further acknowledges that the Corporation and/or the Employer (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Award, including the grant, vesting or exercise of the Award, as applicable, the subsequent sale of Shares acquired pursuant to the Plan and the receipt of any dividends and/or dividend equivalents; and (2) do not commit and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Participant’s liability for Tax-Related Items or achieve any particular tax result. Further, if the Participant has become subject to tax in more than one jurisdiction between the Grant Date and the date of any relevant taxable event, the Participant acknowledges that the Corporation and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.
Prior to any relevant taxable or tax withholding event, as applicable, the Participant will pay or make adequate arrangements satisfactory to the Corporation and/or the Employer, or their respective agents, at their discretion, to satisfy the obligations with regard to all Tax-Related Items by one or a combination of the following: (1) withholding from the Participant’s wages or other cash compensation paid to the Participant by the Corporation and/or the Employer; (2) withholding from proceeds of the sale of Shares acquired under the Plan either through a voluntary sale or through a mandatory sale arranged by the Corporation (on the Participant’s behalf pursuant to this authorization and any other authorization the Corporation and/or the broker designated by the Corporation may require the Participant to sign in connection with the sale of Shares); or (3) withholding Shares to be issued upon grant, vesting/settlement or exercise, as applicable. Calculation of the number of Shares to be withheld shall be made based on the closing price of the Common Stock on the New York Stock Exchange on the date that the amount of tax to be withheld is determined. In no event, however, shall the Corporation be required to issue fractional Shares. With respect to an Award other than an Option, if adequate arrangements to satisfy the obligations with regard to all Tax-Related Items are not made by the Participant with the Corporation and/or the Employer prior to the relevant taxable event, the Corporation will satisfy such obligations as provided above in clause (3) of this paragraph.
To avoid negative accounting treatment, the Corporation may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates. If the obligation for Tax-Related Items is satisfied by withholding in Shares, for tax purposes, the Participant will be deemed to have been issued the full number of Shares subject to the Award, notwithstanding that a number of the Shares are held back solely for the purpose of paying the Tax-Related Items due as a result of any aspect of the Participant’s participation in the Plan.

17



Finally, the Participant shall pay to the Corporation or the Employer any amount of Tax-Related Items that the Corporation or the Employer may be required to withhold or account for as a result of the Participant’s participation in the Plan that cannot be satisfied by the means previously described. The Corporation may refuse to issue or deliver the Shares or the proceeds of the sale of Shares if the Participant fails to comply with the Participant's obligations in connection with the Tax-Related Items.
The Administrator shall be authorized to establish such rules, forms and procedures as it deems necessary to implement the foregoing.
7.    Successors. The Award Agreements shall be binding upon and inure to the benefit of any successor or successors of the Corporation. “Participant” as used herein shall include the Participant’s Beneficiary.
8.    Delaware Law. The interpretation, performance, and enforcement of all Award Agreements shall be governed by the laws of the State of Delaware.
9.    Nature of Grant. In accepting the grant, the Participant acknowledges that:
(A)    the Plan is established voluntarily by the Corporation, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Corporation at any time;
(B)    the grant of the Award is voluntary and occasional and does not create any contractual or other right to receive future Award grants, or benefits in lieu of Awards, even if Awards have been granted repeatedly in the past;
(C)    all decisions with respect to future Awards, if any, will be at the sole discretion of the Corporation;
(D)    the Participant is voluntarily participating in the Plan;
(E)    the Award is not part of normal or expected compensation for any purpose, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments;
(F)    the Award will not be interpreted to form an employment contract or relationship with the Corporation; and furthermore, the Award will not be interpreted to form an employment contract with any subsidiary or Affiliate of the Corporation;
(G)    the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty;
(H)    if the underlying Shares do not increase in value, the Options will have no value;

18



(I)    in consideration of the grant of the Award, no claim or entitlement to compensation or damages shall arise from forfeiture of the Award which results from termination of the Participant’s employment with the Employer or the Corporation or one of its Affiliates (for any reason whatsoever) and the Participant irrevocably releases the Corporation or its Affiliates from any such claim that may arise; if, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen, then, by accepting the Award, the Participant shall be deemed irrevocably to have waived the Participant's entitlement to pursue such claim;
(J)    for purposes of an Award, the Participant’s employment relationship will be considered terminated as of the date the Participant is no longer a bona fide employee of the Corporation or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of the employment laws in the jurisdiction where the Participant is employed or the terms of the Participant’s employment agreement, if any), and unless otherwise expressly provided in this Award Agreement or determined by the Corporation in its sole discretion, the Participant’s right to receive Awards and vest in Awards under the Plan, if any, will terminate effective as of such date and will not be extended by any notice period mandated under local law; similarly, any right to exercise Options under the Plan after termination of employment will be measured as of the date the Participant is no longer a bona fide employee of the Corporation or one of its Affiliates and will not be extended by any notice period mandated under local law; the Administrator shall have the sole discretion to determine when the Participant is no longer a bona fide employee;
(K)    the Corporation is not providing any tax, legal or financial advice, nor is the Corporation making any recommendations regarding participation in the Plan or the Participant’s acquisition or sale of Shares; and
(L)    Participant is hereby advised to consult with the Participant's own personal tax, legal and financial advisors regarding Participant’s participation in the Plan before taking any action related to the Plan.
10.    Data Privacy. By accepting the Award, the Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of the Participant's personal data as described in this document by and among, as applicable, the Employer and the Corporation and its Affiliates for the exclusive purpose of implementing, administering and managing participation in the Plan.

19



The Participant understands that the Corporation and the Employer hold certain personal information about the Participant, including, but not limited, the Participant's name, home address and telephone number, date of birth, social insurance or other identification number, salary, nationality, job title, any Shares or directorships held in the Corporation, details of all Options, Restricted Stock, Restricted Stock Units, Performance Shares, Other Share-Based Awards, or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in the Participant’s favor, for the purpose of implementing, administering and managing the Plan (“Data”). The Participant understands that Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, that recipients of Data may be located in the United States or elsewhere, and that the recipient’s country may have different data privacy laws and protections than the Participant’s country. The Participant understands that if the Participant resides outside of the United States, the Participant may request a list with the names and addresses of any potential recipients of the Data by contacting the local human resources representative. The Participant authorizes the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom the Participant may elect to deposit any Shares acquired under the Plan. The Participant understands that Data will be held only as long as is necessary to implement, administer and manage the Participant's participation in the Plan. The Participant understands that if the Participant resides outside of the United States, the Participant may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, without cost, by contacting in writing the local human resources representative. Further, the Participant understands that the Participant is providing the consents herein on a purely voluntary basis. If the Participant does not consent, or if the Participant later seeks to revoke the Participant's consent, the Participant’s employment status or service and career with the Employer will not be adversely affected; the only adverse consequence of refusing or withdrawing the Participant's consent is that the Corporation would not be able to grant the Participant Awards or administer or maintain such Awards. Therefore, the Participant understands that refusing or withdrawing consent may affect the Participant's ability to participate in the Plan. For more information on the consequences of refusal to consent or withdrawal of consent, the Participant understands that the Participant may contact the local human resources representative.
11.    Severability. The provisions in this Statement of Terms and Conditions are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.
12.    Language. If the Participant has received this Statement of Terms and Conditions or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.
13.    Electronic Delivery. The Corporation may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Corporation or a third party designated by the Corporation.

20



14.    Employment Agreement. Notwithstanding any provision contained in these Statement of Terms and Conditions, the Plan or the Grant Notice to the contrary, if there is a conflict between Statement of Terms and Conditions, the Plan or the Grant Notice and the employment agreement by and between the Participant and the Corporation, as amended from time to time (the “Employment Agreement”), then the Employment Agreement shall govern.
15.    Section 409A. If (A) the Participant is a Specified Employee at the time of the Participant’s Separation from Service, and (B) some or any portion of the amounts payable to the Participant, if any, when considered together with any other payments or benefits which may be considered deferred compensation under section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”) and subject to the plan aggregation rules under Treasury Regulation section 1.409A-1(c)(3)(viii) (together, the “Deferred Compensation Benefits”) would result in the imposition of additional tax under Section 409A if paid to the Participant on or within the six month period following the Separation from Service, then to the extent such portion of the Deferred Compensation Benefits resulting in the imposition of additional tax would otherwise have been payable on or within the first six months following the Separation from Service, it will instead become payable on the first payroll date that occurs in the seventh month following the Separation from Service (or such longer period as is required to avoid the imposition of additional tax under Section 409A). All subsequent Deferred Compensation Separation Benefits, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit.
IX.
DEFINITIONS
When capitalized in this Statement of Terms and Conditions, the following terms shall have the meaning set forth below:
1.    Award Agreement” means an agreement between the Participant and the Corporation evidencing the grant of an Option, Restricted Stock Award, Restricted Stock Award, Performance Shares or Other Share-Based Award, as applicable.
2.    Cause” means termination of the Participant’s employment with the Corporation or an Affiliate upon the Participant’s negligent or willful engagement in misconduct which, in the sole determination of the Board (or its designee), is injurious to the Corporation, its employees, or its customers.
3.    Early Retirement” means a termination of employment (other than due to death, Long-Term Disability or for Cause) which occurs prior to Normal Retirement but on or after the date on which the Participant’s age (expressed in terms of years and completed months) plus service with the Corporation or an Affiliate equals 65. For purposes of determining eligibility for Early Retirement, the term “service” shall include years and completed whole months of service.
4.    Family Member” means any person identified as an “immediate family” member in Rule 16(a)‑1(e) of the Exchange Act, as such Rule may be amended from time to time. Notwithstanding the foregoing, the Administrator may designate any other person(s) or entity(ies) as a “family member.”

21



5.    “Good Reason” means any of the following actions, if taken without the express written consent of the Participant, which shall not be affected by the Participant’s incapacity due to physical or mental illness:
(A)    Any material change by the Corporation in the Participant’s functions, duties or responsibilities as President and Chief Executive Officer, which change would cause the Participant’s position with the Corporation to become of less dignity, responsibility, importance, or scope as compared to the position and attributes that applied to the Participant immediately prior to the Change in Control, or an adverse change in the Participant’s title, position or the Participant’s obligation and right to report directly to the Board, provided, however that Good Reason shall not be deemed to exist if the Participant ceases to serve as Chairman;
(B)    Any reduction in the Participant’s base annual salary, MIP target or Long Term Incentive compensation (LTI) targets, which LTI targets include cash awards with performance periods greater than one year and equity based grants, except for reductions that are equivalent to reductions applicable to executive officers of the Corporation;
(C)    Any material failure by the Corporation to comply with any of the provisions of an award (or of any employment agreement between the parties) subsequent to a Change in Control;
(D)    The Corporation’s requiring the Participant to be based at any office or location more than 25 miles from the office at which the Participant is based on the date immediately preceding the Change in Control, except for travel reasonably required in the performance of the Participant’s responsibilities;
(E)    Cancellation of the automatic renewal mechanism set forth in the Participant’s employment agreement;
(F)    If the Board removes the Participant as Chairman at or after a Change in Control (or prior to a Change in Control if at the request of any third party participating in or causing the Change in Control), unless such removal is required by then‑applicable law; or
(G)    A change in the majority of the members of the Board as it was construed immediately prior to the Change in Control;
Provided that the Participant gives notice to the Corporation of the existence of the Good Reason condition within 30 days of the initial existence of the Good Reason condition and the Corporation is provided 30 days after receipt of the Participant’s notice to remedy the Good Reason condition; provided further that the Participant’s Separation from Service must occur within six months from the initial existence of the Good Reason condition if the Corporation does not remedy such condition for such separation to be considered to be for Good Reason.
6.    “Expiration Date” means the date that an Option expires as set forth in the Option Grant Notice as the “Expiration Date.”
7.    “Grant Date” means the date the Administrator grants the Award.

22



8.    “Grant Notice” means the notice of an Award granted to the Participant, which sets forth certain terms of such Award.
9.    “Long‑Term Disability” means a physical or mental condition in respect of which the administrator of the Corporation’s long-term disability plan has determined that the Participant is eligible to receive income replacement benefits; or, if the Participant is not then a participant in the Corporation’s long-term disability plan, a physical or mental condition that the administrator of the Corporation’s long-term disability plan determines would have rendered the Participant eligible to receive income replacement benefits, had the Participant been enrolled in such plan.
10.    “Normal Retirement” means termination of employment (other than due to death, Long-Term Disability or for Cause) at or after age 60 (57, in the case of a participant in the McKesson Corporation 1984 Executive Benefit Retirement Plan) with at least 10 years of service with the Corporation or an Affiliate. For purposes of determining eligibility for Normal Retirement, “service” shall mean completed whole years of service (12 consecutive months).
11.    “Option Period” means the period commencing on the Grant Date of an Option and, except at otherwise provided in Section II.5, ending on the Expiration Date.
12.    “Separation from Service” means termination of employment with the Corporation or an affiliate. A Participant shall be deemed to have had a Separation from Service if the Participant’s service with the Corporation or an affiliate is reduced to an annual rate that is equal to or less than 20% of the services rendered, on average, during the immediately preceding three years of service with the Corporation or an affiliate (or, if providing service to the Corporation or an affiliate for less than three years, such lesser period).
13.    “Severance” means termination of employment with the Corporation or an affiliate, and qualified for participation in and entitlement to benefits under the McKesson Corporation Severance Pay Plan, in accordance with the terms and conditions of such plan.
14.    “Short‑Term Disability” means short‑term disability as defined in the Corporation’s short‑term disability plan.
15.    “Specified Employee” means those employees identified by the Corporation as "Specified Employees" for purposes of Code Section 409A.
16.    “Stock Ownership Policy” means the Corporation’s Stock Ownership Policy, as amended from time to time, which can be found on McKNet. A Participant or a Participant’s beneficiary may also request a copy of the Stock Ownership Policy by writing to the Corporate Secretary at McKesson Corporation, One Post Street, San Francisco, CA 94104.

23




EXECUTIVE OFFICERS OTHER THAN THE CEO

McKESSON CORPORATION
STATEMENT OF TERMS AND CONDITIONS APPLICABLE TO
OPTIONS, RESTRICTED STOCK, RESTRICTED STOCK UNITS,
PERFORMANCE SHARES AND TSR UNIT AWARDS GRANTED TO
OFFICERS PURSUANT TO THE 2013 STOCK PLAN
Effective for Grants Beginning May 23, 2017
I.
INTRODUCTION
The following terms and conditions shall apply to an Award granted under the Plan and are subject to the terms and conditions of the Plan. This Statement of Terms and Conditions is intended to meet the requirements of Code Section 409A and any rules promulgated thereunder. In the event of any inconsistency between this Statement of Terms and Conditions and the Plan, the Plan shall govern. Capitalized terms not otherwise defined in this Statement of Terms and Conditions shall have the meaning set forth in the Plan.
II.
OPTIONS
1.    Option Agreement. An Option granted under the Plan shall be evidenced by an Option Agreement setting forth the terms and conditions of the Option, including whether the Option is an Incentive Stock Option or a Nonstatutory Stock Option and the number of Shares subject to the Option. Each Option Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant’s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Option Agreement. The Option is also subject to the terms and conditions of the Plan.
2.    Exercise Price. The Exercise Price of an Option, as specified in the Option Agreement, shall be equal to or greater than the Fair Market Value of the Shares underlying the Option on the Grant Date.
3.    Option Period. An Option shall be exercisable only during the applicable Option Period, and during such Option Period the exercisability of the Option shall be subject to the vesting provisions of Section II.4 as modified by the rules set forth in Sections II.5 and V. The Option Period shall be not more than seven years from the Grant Date.

1



4.    Vesting of Right to Exercise Options.
(A)    Except as provided in Sections II.5 and V, an Option shall be exercisable during the Option Period in accordance with the following vesting schedule:  (i) 25% of the Shares subject to the Option shall vest on the first anniversary of the Grant Date; (ii) an additional 25% of the Shares shall vest on the second anniversary of the Grant Date; (iii) an additional 25% of the Shares shall vest on the third anniversary of the Grant Date; and (iv) the remaining 25% of the Shares subject to the Option shall vest on the fourth anniversary of the Grant Date. Notwithstanding the foregoing, the Administrator may specify a different vesting schedule at the time the Option is granted, which will be specified in the Option Grant Notice.
(B)    Any vested portion of an Option not exercised hereunder shall accumulate and be exercisable at any time on or before the Expiration Date, subject to the rules set forth in Sections II.5 and V. No Option may be exercised for less than 5% of the total number of Shares then available for exercise under such Option. In no event shall the Corporation be required to issue fractional Shares.
5.    Limits on Option Period and Acceleration of Vesting. The Option Period may end before the Expiration Date, and in certain circumstances the vesting schedule of an Option may be accelerated (subject to the provisions of Section V), as follows:
(A)    If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period for reasons other than for Cause, Long-Term Disability, Normal Retirement, Early Retirement, Severance under the circumstances provided in Section II.5(F)(ii), or death, the Option Period shall end on the earlier of (i) 90 days after the date of the Participant’s termination of employment and (ii) the Expiration Date, and in all cases the Option shall be exercisable only to the extent that it was exercisable under the provisions of the foregoing Section II.4 at the time of such termination of employment. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short-Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Administrator may otherwise expressly determine.
(B)    Notwithstanding any other provision in this Section II.5, if a Participant’s employment is terminated for Cause during the Option Period, the Option Period shall end on the date of such termination of employment and the Option shall thereupon not be exercisable to any extent whatsoever.
(C)    If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Long-Term Disability, the vesting schedule of the Participant’s Option shall be accelerated, the Option shall become fully exercisable and the Option Period shall end on the earlier of (i) three years after the date of the Participant’s termination of employment and (ii) the Expiration Date.

2



(D)    If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Early Retirement, (i) the Option shall be exercisable only to the extent that it was exercisable under the provisions of the foregoing Section II.4 at the time of such retirement and (ii) the Option Period for that portion of the Option designated as a Nonstatutory Stock Option shall end on the earlier of (a) three years after the date of such retirement and (b) the Expiration Date.
(E)    If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Normal Retirement:
(i)    If such Normal Retirement occurs prior to the first anniversary of the Grant Date of the Option, such Option shall be subject to the provisions of Section II.5(D) as though the Participant were eligible for Early Retirement; and
(ii)    If such Normal Retirement occurs on or after the first anniversary of the Grant Date of an Option, (a) that portion of the Option designated as a Nonstatutory Stock Option shall continue to vest as set forth in the foregoing Section II.4 as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such vesting period, and (b) the Option Period for such portion of the Option designated as a Nonstatutory Stock Option shall end on the Expiration Date.
(F)    If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Severance, and
(i)    The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, and would not have attained the requirements for Normal Retirement within six months after the termination date, then (a) the vesting schedule of the Participant’s Option shall be accelerated as to the portion of the Option that would have vested in accordance with the vesting schedule set forth in the foregoing Section II.4 as if the Participant had continued to be employed by the Corporation or one of its Affiliates six months after the termination date, and (b) the expiration of the Option Period provided in Section II.5(A) shall apply; provided that if the Participant is also eligible for Early Retirement at the time of the termination of employment, then the expiration of the Option Period provided in Section II.5(D) shall apply; or
(ii)    The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, but would have attained the requirements for Normal Retirement within six months after the termination date, and:
(a)    The first anniversary of the Grant Date of the applicable Award has not occurred on or prior to the termination date, then such Option shall be subject to the Early Retirement provision in Section II.5(D); and
(b)    The first anniversary of the Grant Date of the applicable Award has occurred on or prior to the termination date, then (x) that portion of the Option designated as a Nonstatutory Stock Option shall continue to vest as set forth in the foregoing Section II.4 as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such vesting period, and (y) the Option Period for such portion of the Option designated as a Nonstatutory Stock Option shall end on the Expiration Date.

3



(G)    If a Participant should die (i) while in the employ of the Corporation or an Affiliate and (ii) during the Option Period, the vesting schedule of the Participant’s Option shall be accelerated and the Option shall become fully exercisable, the Option Period shall end on the earlier of (a) three years after the date of death and (b) the Expiration Date, and the Participant’s Beneficiary may exercise the entire unexercised portion of the then exercisable Shares covered by such Option (or any lesser amount) remaining on the date of death.
(H)    If a Participant who ceases to be a bona fide employee of the Corporation or an Affiliate is subsequently rehired prior to the expiration of the Participant's Option, then the Option shall continue to remain outstanding until the earlier of (i) such time as the Participant subsequently terminates employment and (ii) the Expiration Date. Upon the Participant’s subsequent termination of employment, the post-termination exercise period calculated pursuant to the terms and conditions of this Section II.5 shall be reduced by the number of days between the date of the Participant’s initial termination of employment and the Participant's re-hire date; provided, however, that if the rehired Participant continues to be employed by the Corporation or an Affiliate for at least one year from the Participant's rehire date, then the post termination exercise period for the Option shall be determined in accordance with Sections II.5(A) through (G) and shall not be adjusted as described in this Section II.5(H).
6.    Method of Exercise. A Participant may exercise an Option with respect to all or any part of the exercisable Shares as follows:
(A)    By giving the Corporation, or its authorized representative designated for this purpose, written notice of such exercise specifying the number of Shares as to which the Option is so exercised. Such notice shall be accompanied by an amount equal to the Exercise Price multiplied by the number of Shares exercised, in the form of any one or combination of the following:  cash or a certified check, bank draft, postal or express money order payable to the order of the Corporation in lawful money of the United States. Unless otherwise determined by the Administrator in its sole discretion, the Participant may pay the Exercise Price, in whole or in part, by tendering to the Corporation or its authorized representative Shares, which have been owned by the Participant for at least six months prior to said tender, and having a fair market value, as determined by the Corporation, equal to the Exercise Price, or in lieu of the delivery of actual Shares in such tender, the Corporation may accept an attestation by the Participant, in a form prescribed by the Corporation or its authorized representative, that the Participant owns sufficient Shares of record or in an account in street name to satisfy the Exercise Price, and such attestation will be deemed a tender of Shares for purposes of this method of exercise. The Corporation or its authorized representative may accept payment of the amount due upon the exercise of the Option in the form of a Participant’s personal check. Payment may also be made by delivery (including by FAX transmission) to the Corporation or its authorized representative of an executed irrevocable Option exercise form together with irrevocable instructions to an approved registered investment broker to sell Shares in an amount sufficient to pay the Exercise Price plus any applicable Tax-Related Items (as defined in Section VIII.6) and to transfer the proceeds of such sale to the Corporation.

4



(B)    If required by the Corporation, by giving satisfactory assurance in writing, signed by the Participant, the Participant shall give the Participant's assurance that the Shares subject to the Option are being purchased for investment and not with a view to the distribution thereof; provided that such assurance shall be deemed inapplicable to (i) any sale of the Shares by such Participant made in accordance with the terms of a registration statement covering such sale, which has heretofore been (or may hereafter be) filed and become effective under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and with respect to which no stop order suspending the effectiveness thereof has been issued, and (ii) any other sale of the Shares with respect to which, in the opinion of counsel for the Corporation, such assurance is not required to be given in order to comply with the provisions of the Securities Act.
(C)    As soon as practicable after receipt of the notice and the assurance described in Sections II.6(A) and (B), the Corporation shall, without transfer or issue tax (except for withholding tax arrangements contemplated in Section VIII.6) and without other incidental expense to the Participant, credit the purchased Shares to the Participant’s brokerage account of record. If the Participant does not have a brokerage account of record, then the Corporation shall cause an appropriate book entry to be entered in the records of the Corporation’s transfer agent recording the Participant’s unrestricted interest in the purchased Shares; provided, however, that the time of such delivery may be postponed by the Corporation for such period as may be required for it with reasonable diligence to comply with applicable registration requirements under the Securities Act, the Exchange Act, any applicable listing requirements of any national securities exchange and requirements under any other law or regulation applicable to the issuance or transfer of the Shares.
7.    Limitations on Transfer. An Option shall, during a Participant’s lifetime, be exercisable only by the Participant. No Option or any right granted thereunder shall be transferable by the Participant by operation of law or otherwise, other than by will or the laws of descent and distribution. Notwithstanding the foregoing: (A) a Participant may designate a beneficiary to succeed, after the Participant’s death, to all of the Participant’s Options outstanding on the date of death; (B) a Nonstatutory Stock Option may be transferable pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act; and (C) any Participant, who is a senior executive officer recommended by the Chief Executive Officer of the Corporation and approved by the Administrator may voluntarily transfer any Nonstatutory Stock Option to a Family Member as a gift or through a transfer to an entity in which more than 50% of the voting interests are owned by Family Members (or the Participant) in exchange for an interest in that entity. In the event of any attempt by a Participant to alienate, assign, pledge, hypothecate, or otherwise dispose of an Option or of any right thereunder, except as provided herein, or in the event of the levy of any attachment, execution, or similar process upon the rights or interest hereby conferred, the Corporation at its election may terminate the affected Option by notice to the Participant and the Option shall thereupon become null and void.
8.    No Stockholder Rights. Neither a Participant nor any person entitled to exercise a Participant’s rights in the event of the Participant’s death shall have any of the rights of a stockholder with respect to the Shares subject to an Option except to the extent that a book entry has been entered in the records of the Corporation’s transfer agent with respect to such Shares upon the exercise of an Option.

5



III.
RESTRICTED STOCK
1.    Restricted Stock Agreement. A Restricted Stock Award granted under the Plan shall be evidenced by a Restricted Stock Agreement to be executed by the Participant and the Corporation setting forth the terms and conditions of the Restricted Stock Award. Each Restricted Stock Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant’s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Restricted Stock Agreement. The Restricted Stock Award is also subject to the terms and conditions of the Plan.
2.    Rights with Respect to Shares of Restricted Stock. Upon written acceptance of a Restricted Stock Award by a Participant, including the restrictions and other terms and conditions described in the Plan and the Restricted Stock Agreement, the Corporation shall cause an appropriate book entry to be entered in the records of the Corporation’s transfer agent recording the Participant’s interest in the Restricted Stock. From and after the Grant Date, the Participant shall have the rights of Common Stock ownership, including the right to vote and to receive dividends on Shares of Restricted Stock, subject to the terms, conditions and restrictions described in the Plan and the Restricted Stock Agreement.
3.    Special Restrictions. Each Restricted Stock Award made under the Plan shall be subject to the following terms, conditions and restrictions and such additional terms, conditions and restrictions as may be determined by the Administrator; provided, however, that no Restricted Stock grant shall be subject to additional terms, conditions and restrictions which are more favorable to a Participant than the terms, conditions and restrictions set forth elsewhere in the Plan or the Restricted Stock Agreement.
(A)    Restrictions. Until the restrictions imposed on any Restricted Stock grant shall lapse (the “Restriction Period”), Shares of Restricted Stock granted to a Participant (i) shall not be sold, assigned, transferred, pledged, hypothecated, or otherwise disposed of, other than pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act and (ii) shall, if the Participant’s continuous employment with the Corporation or any of its Affiliates shall terminate for any reason (except as otherwise provided in the Plan, or in Section III.3(B) or Section III.3(C)) be returned to the Corporation forthwith, and all the rights of the Participant to such Shares shall immediately terminate. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short‑Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Administrator may otherwise expressly determine.
(B)    Termination of Employment by Reason of Death, Long-Term Disability or Normal Retirement. Notwithstanding any provision to the contrary contained in the Restricted Stock Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of a Restricted Stock Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of:

6



(i)    Death or Long-Term Disability, then the restrictions imposed on any Restricted Stock Award shall lapse as to all Shares granted to such Participant pursuant to such Restricted Stock Award on the date of such termination; or
(ii)    Normal Retirement on or after the first anniversary of the Grant Date of any time-based vesting Restricted Stock Award, the restrictions applicable to such Restricted Stock Award shall continue to lapse at such time(s) as are set forth in the applicable Grant Notice, as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such restricted period; provided, that notwithstanding any other provision of the Plan or this Statement of Terms and Conditions, this Section III.3(B)(ii) shall not apply to any Restricted Stock Award the vesting of which is based, in whole or in part, on attainment of performance objectives. The procedures set forth in Section VIII.6 will be applied for any taxes due upon the lapse of restrictions imposed on a Restricted Stock Award due to a Participant’s Normal Retirement eligibility.
(C)    Termination of Employment by Reason of Severance. Notwithstanding any provision to the contrary contained in the Restricted Stock Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of a Restricted Stock Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of Severance, and:

(i)    The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, and would not have attained the requirements for Normal Retirement within six months after the termination date, then the restrictions applicable to any time-based vesting Restricted Stock Award shall lapse upon the Participant’s termination date, as to such Shares of Restricted Stock that would have vested at such time(s) as are set forth in the applicable Grant Notice as if the Participant had continued to be employed by the Corporation or one of its Affiliates during the six-month period after the Participant’s termination date; or

(ii)    The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, but would have attained the requirements for Normal Retirement within six months after the termination date and the first anniversary of the Grant Date of the Restricted Stock Award has occurred on or prior to the termination date, then the restrictions applicable to the time-based vesting Restricted Stock Award shall continue to lapse at such time(s) as are set forth in the applicable Grant Notice, as though the Participant had continued to be employed by the Corporation or one of its Affiliates during the restricted period; provided that if the first anniversary of the Grant Date of the Restricted Stock Award has not occurred on or prior to the termination date, then the additional vesting terms and conditions provided in Section III.3(C)(i) shall apply to such award.

Notwithstanding the foregoing, this Section III.3(C) shall not apply to any Restricted Stock Award the vesting of which is based, in whole or in part, on attainment of performance objectives. The procedures set forth in Section VII.6 will be applied for any taxes due upon the lapse of restrictions imposed on a Restricted Stock Award due to a Participant’s Normal Retirement eligibility.


7



(D)    Restriction on Sale. The Administrator reserves the right to impose a restriction on the sale of Shares that the Participant receives upon the vesting and settlement of a Restricted Stock Award, unless the Participant has satisfied the ownership targets applicable to the Participant as provided in the Stock Ownership Policy.
4.    Dividends. Cash dividends paid with respect to Restricted Stock during the Restriction Period shall be credited on behalf of the Participant to a deferred cash account (in a manner designed to comply with Code Section 409A) and the restrictions on such cash dividends shall lapse at the same time that the restrictions lapse on the associated Restricted Stock Award. Stock dividends paid with respect to Restricted Stock during the Restriction Period shall be treated as Restricted Stock which shall be subject to the same restrictions as the original award for the duration of the Restriction Period.
5.    Election to Recognize Gross Income in the Year of Grant. If any Participant validly elects within 30 days of the Grant Date, to include in gross income for federal income tax purposes an amount equal to the fair market value of the Shares of Restricted Stock granted on the Grant Date, such Participant shall (at the same time or prior to the date that the Participant files the Participant's election with the Internal Revenue Service) (A) pay to the Corporation, or make arrangements satisfactory to the Administrator to pay to the Corporation in the year of such grant, any federal, state or local taxes required to be withheld with respect to such Shares in accordance with Section VIII.6, and (B) provide the Administrator with a copy of the election filed with the Internal Revenue Service.
6.    Restrictive Legend. Each book entry in the records of the Corporation’s transfer agent evidencing Shares granted pursuant to a Restricted Stock grant may bear an appropriate legend referring to the terms, conditions and restrictions described in the Plan and/or the Restricted Stock Agreement.
7.    Expiration of Restriction Period. If and when the Restriction Period applicable to the Restricted Stock expires without a prior forfeiture, Shares shall be credited to the Participant’s brokerage account of record. If the Participant does not have a brokerage account of record, then an appropriate book entry recording the Participant’s interest in the unrestricted Shares shall be entered on the records of the Corporation’s transfer agent.
IV.
RESTRICTED STOCK UNITS AND PERFORMANCE SHARES
1.    Award Agreement.
(A)    Restricted Stock Units granted under the Plan shall be evidenced by a Restricted Stock Unit Agreement to be executed by the Participant and the Corporation setting forth the terms and conditions of the Restricted Stock Units. Each Restricted Stock Unit Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant’s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Restricted Stock Unit Agreement. The Restricted Stock Units are also subject to the terms and conditions of the Plan.

8



(B)    Performance Shares granted under the Plan shall be evidenced by a Performance Share Agreement to be executed by the Participant and the Corporation setting forth the terms and conditions of the Performance Shares. Each Performance Share Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant’s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Performance Share Agreement. Performance Shares are also subject to the terms and conditions of the Plan.
2.    Special Restrictions. Restricted Stock Units and Performance Shares granted under the Plan shall be subject to the following terms, conditions and restrictions and such additional terms, conditions and restrictions as may be determined by the Administrator, consistent with the terms of the Plan.
(A)    Restrictions. If a Participant ceases to be a bona fide employee of the Corporation or any Affiliate (except as otherwise provided in the Plan, or in Section IV.2(B) or Section IV.2(C)) prior to the lapse of the restrictions imposed on the Award, the unvested Restricted Stock Units or Performance Shares shall be canceled, and all the rights of the Participant to such Awards shall immediately terminate. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short-Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Administrator may otherwise expressly determine.
(B)    Termination of Employment by Reason of Death, Long-Term Disability or Normal Retirement. Notwithstanding any provision contained to the contrary in the Restricted Stock Unit Grant Notice or Performance Share Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of such Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of:
(i)    Death or Long-Term Disability, then the restrictions imposed on any Award of Restricted Stock Units or Performance Shares shall lapse on the date of such termination; or
(ii)    Normal Retirement on or after the first anniversary of the Grant Date of any time-based vesting Restricted Stock Units, the restrictions applicable to such Restricted Stock Units shall continue to lapse at such time(s) as are set forth in the applicable Grant Notice, as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such restricted period; provided, that notwithstanding any other provision of the Plan or this Statement of Terms and Conditions, this Section IV.2(B)(ii) shall not apply to any Performance Shares or any Restricted Stock Units the vesting of which is based, in whole or in part, on attainment of performance objectives.

(C)    Termination of Employment by Reason of Severance. Notwithstanding
any provision to the contrary contained in the Restricted Stock Unit Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of a Restricted Stock Unit Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of Severance, and:


9



(i)    The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, and would not have attained the requirements for Normal Retirement within six months after the termination date, then the restrictions applicable to any time-based vesting Restricted Stock Unit Award shall lapse upon the termination date, as to such Restricted Stock Units that would have vested at such time(s) as are set forth in the applicable Grant Notice as if the Participant had continued to be employed by the Corporation or one of its Affiliates during the six-month period after the termination date; or

(ii)    The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, but would have attained the requirements for Normal Retirement within six months after the termination date and the first anniversary of the Grant Date has occurred on or prior to the termination date, then the restrictions applicable to any time-based vesting Restricted Stock Units shall continue to lapse at such time(s) as are set forth in the applicable Grant Notice, as though the Participant had continued to be employed by the Corporation or one of its Affiliates during the restricted period; provided that if the first anniversary of the Grant Date of the Restricted Stock Unit Award has not occurred on or prior to the termination date, then the additional vesting terms provided in Section IV.2(C)(i) will apply to such award.

Notwithstanding the foregoing, this Section IV.2(C) shall not apply to any Restricted Stock Units the vesting of which is based, in whole or in part, on attainment of performance objectives.

(D)    Restriction on Sale. The Compensation Committee reserves the right to impose a restriction on the sale of Shares that the Participant receives upon the settlement of Restricted Stock Units or Performance Shares, unless the Participant has satisfied the ownership targets applicable to the Participant as provided in the Stock Ownership Policy.
3.    Dividend Equivalents. Subject to the discretion of the Compensation Committee, dividend equivalents shall be credited in respect of Restricted Stock Units and Performance Shares. Cash dividends shall be credited on behalf of the Participant to a deferred cash account (in a manner designed to comply with Code Section 409A) and the restrictions on such cash dividends shall lapse at the same time that the restrictions lapse on the associated Award of Restricted Stock Units or Performance Shares (as applicable), and cash dividends, along with accrued interest (if any) on such cash dividends, shall be paid in a lump sum at the same time that the Shares underlying the Restricted Stock Unit or Performance Share Award, and to which the cash dividends relate, are distributed. Stock dividends shall be converted into additional Restricted Stock Units or Performance Shares, which will be subject to all of the terms and conditions of the underlying Restricted Stock Units or Performance Shares, including the same vesting restrictions as the underlying Award.
4.    Assignability. A Participant shall not be permitted to sell, transfer, pledge, assign or encumber Restricted Stock Units or Performance Shares, other than pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act.

10



5.    No Stockholder Rights. Neither a Participant nor any person entitled to exercise a Participant’s rights in the event of the Participant’s death shall have any of the rights of a stockholder with respect to an Award of Restricted Stock Units or Performance Shares except to the extent that a book entry has been entered in the records of the Corporation’s transfer agent with respect to the Shares paid upon the settlement of any vested Restricted Stock Units or Performance Shares.
6.    Time of Payment of Restricted Stock Units and Performance Shares. Upon the lapse of the restriction imposed on Restricted Stock Units or Performance Shares, all Restricted Stock Units and Performance Shares that were not forfeited pursuant to Section IV.2(A), Section IV.2(B)(i), Section IV.2(C)(i), or Section V shall be paid to the Participant as soon as reasonably practicable after the restrictions lapse. Payment shall be made in Shares to the Participant’s brokerage account of record. If the Participant does not have a brokerage account of record, then in the form of an appropriate book entry entered in the records of the Corporation’s transfer agent recording the Participant’s unrestricted interest in the number of Shares subject to the Restricted Stock Units or Performance Shares.
Notwithstanding the foregoing, if a Participant becomes eligible for Normal Retirement, or is eligible for additional vesting under Section IV.2(C)(ii), prior to the date of the lapse of restrictions imposed on Restricted Stock Units and the vesting provisions of Section IV.2(B)(ii) or Section IV.2(C)(ii) apply, then such Restricted Stock Units shall be paid to the Participant’s brokerage account of record as soon as reasonably practicable after the earlier of the Participant’s Separation from Service or the originally scheduled vesting date (in any event before the end of the calendar year in which such date occurs), subject to the delay of payment (if applicable) provided in Section VIII.14. The procedures set forth in Section VIII.6 will be applied for any taxes due upon the lapse of restrictions imposed on a Restricted Stock Award due to a Participant’s Normal Retirement eligibility or additional vesting as provided in Section IV.2(C)(ii).
V.
TOTAL SHAREHOLDER RETURN (“TSR”) UNIT AWARDS
1.    Award Agreement. TSR Unit Awards shall be evidenced by a TSR Unit Target Award Notification to be executed by the Participant and the Corporation setting forth the terms and conditions of the TSR Unit Award. TSR Unit Awards are “Other Share-Based Awards” as provided under Section 11 of the Plan. Each TSR Unit Target Notification shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant’s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the TSR Unit Award Agreement. The TSR Unit Awards are also subject to the terms and conditions of the Plan.
2.    Number of Shares Granted Based on Performance. The performance period of a TSR Unit Award shall be greater than one year, and performance shall be based on such criteria as the Compensation Committee shall determine in its discretion at the beginning of the performance period. Following the end of the performance period, the Compensation Committee shall determine the extent to which the criteria have been achieved, and shall authorize the grant and issuance of Shares in respect of the TSR Unit Award.
3.    Special Conditions. TSR Unit Awards shall be subject to the following terms, conditions and restrictions and such additional terms, conditions and restrictions as may be determined by the Compensation Committee, consistent with the terms of the Plan.

11



(A)    Forfeiture. If a Participant ceases to be a bona fide employee of the Corporation or any Affiliate (except as otherwise provided in the Plan or in Section V.3(B)) prior to the end of the performance period, any then-outstanding TSR Unit Awards shall be canceled, and all the rights of the Participant to such Awards shall immediately terminate. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short-Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Compensation Committee may otherwise expressly determine.
(B)    Termination of Employment by Reason of Death, Long-Term Disability or Normal Retirement. Notwithstanding any provision contained herein or in the Plan, the TSR Unit Award Agreement to the contrary, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of such Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of:
(i)    Death or Long-Term Disability, the Participant shall be eligible to receive, following completion of the applicable performance period, an amount in cash equal to the value of a prorated portion of each such TSR Unit Award, equal to (1) the target number of TSR Units subject to such Award, multiplied by (2) the performance criteria determined by the Compensation Committee to apply to such Award, multiplied by (3) a fraction, the numerator of which is the number of whole calendar months, rounded down to the nearest whole month, during which the Participant provided Service to the Corporation or an Affiliate during the performance period applicable to such Award, and the denominator of which is the number of calendar months in such performance period; provided, that for purposes of this clause (3), “whole calendar months” shall be calculated commencing on the applicable Grant Date; provided, however, that in no event shall such amount exceed any applicable cap or limitation set forth in the TSR Unit Target Award Notification; or
(ii)    Normal Retirement on or after the first anniversary of the Grant Date, the Participant shall be eligible to receive, following completion of the applicable performance period, an amount in cash equal to the value of such TSR Unit Award, calculated as though the Participant had continued to be employed by the Corporation or one of its Affiliates during the entire performance period.
Amounts, if any, to be paid under this Section V.3(B) shall be paid in accordance with Section V.7 and, if applicable, Section VIII.14.
(C)    Restriction on Sale of Shares. The Compensation Committee reserves the right to impose a restriction on the sale of Shares that the Participant receives with respect to the settlement of a TSR Unit Award, unless the Participant has satisfied the ownership targets applicable to the Participant as provided in the Stock Ownership Policy.
4.    Dividend Equivalents. Unless otherwise determined by the Administrator in its sole discretion, Dividend Equivalents shall not be accrued with respect to TSR Unit Awards during the performance period.
5.    Assignability. A Participant shall not be permitted to sell, transfer, pledge, assign or encumber all or any portion of a TSR Unit Award.

12



6.    No Stockholder Rights. Neither a Participant nor any person entitled to exercise a Participant’s rights in the event of the Participant’s death shall have any of the rights of a stockholder with respect to a TSR Unit Award, except to the extent that a book entry has been entered in the records of the Corporation’s transfer agent with respect to the Shares paid upon the settlement of any TSR Unit Award.
7.    Time of Payment of TSR Unit Awards. The Compensation Committee shall determine the extent to which Shares are payable pursuant to a TSR Unit Award as soon as practicable following the end of the performance period, and such Shares shall be paid as soon as practicable thereafter and in any event no later than the end of the period under which payment would be deemed to be a “short-term deferral” as defined in the regulations under Code Section 409A. Except as provided in Section V.3(B), payment shall be made in the form of Shares to the Participant’s brokerage account of record. If the Participant does not have a brokerage account of record, then in the form of an appropriate book entry entered in the records of the Corporation’s transfer agent recording the Participant’s unrestricted interest in the number of Shares earned pursuant to the TSR Unit Award.
VI.
SPECIAL FORFEITURE AND REPAYMENT RULES
Any other provision of this Statement of Terms and Conditions to the contrary notwithstanding, if the Administrator determines that a Participant has engaged in any of the actions described in 3 below, the consequences set forth in 1 and 2 below shall result:
1.    Any outstanding Option shall immediately and automatically terminate, be forfeited and shall cease to be exercisable, without limitation. In addition, any Award of Restricted Stock, Restricted Stock Units or Performance Shares as to which the restrictions have not lapsed shall immediately and automatically be forfeited, TSR Unit Awards shall immediately and automatically be forfeited and any such Shares of Restricted Stock shall be returned to the Corporation and all of the rights of the Participant to such Awards and the underlying Shares shall immediately terminate.
2.    If the Participant exercised an Option within 12 months prior to the date upon which the Corporation discovered that the Participant engaged in any actions described in 3 below, the Participant, upon written notice from the Corporation, shall immediately pay to the Corporation the economic value realized or obtained by the exercise of such Option measured at the date of exercise. In addition, if the restrictions imposed on any Award of Restricted Stock, Restricted Stock Units or Performance Shares (including any unpaid dividends or Dividend Equivalents) lapsed, or any TSR Unit Award was settled, within 12 months prior to the date the Corporation discovered that the Participant engaged in any action described in 3 below, the Participant, upon written notice from the Corporation, shall immediately pay to the Corporation the economic value realized or obtained with respect to such Award, measured at the date such Award vested.
3.    The consequences described in 1 and 2 above shall apply if the Participant, either before or after termination of employment with the Corporation or its Affiliates:

13



(A)    Discloses to others, or takes or uses for the Participant’s own purpose or the purpose of others, any trade secrets, confidential information, knowledge, data or know‑how or any other proprietary information or intellectual property belonging to the Corporation or its Affiliates and obtained by the Participant during the term of the Participant’s employment, whether or not they are the Participant’s work product. Examples of such confidential information or trade secrets include, without limitation, customer lists, supplier lists, pricing and cost data, computer programs, delivery routes, advertising plans, wage and salary data, financial information, research and development plans, processes, equipment, product information and all other types and categories of information as to which the Participant knows or has reason to know that the Corporation or its Affiliates intends or expects secrecy to be maintained;
(B)    Fails to promptly return all documents and other tangible items belonging to the Corporation or its Affiliates in the Participant’s possession or control, including all complete or partial copies, recordings, abstracts, notes or reproductions of any kind made from or about such documents or information contained therein, upon termination of employment, whether pursuant to retirement or otherwise;
(C)    Fails to provide the Corporation with at least 30 days’ written notice prior to directly or indirectly engaging in, becoming employed by, or rendering services, advice or assistance to any business in competition with the Corporation or its Affiliates. As used herein, “business in competition” means any person, organization or enterprise which is engaged in or is about to become engaged in any line of business engaged in by the Corporation or its Affiliates at the time of the termination of the Participant’s employment with the Corporation or its Affiliates;
(D)    Fails to inform any new employer, before accepting employment, of the terms of this paragraph and of the Participant’s continuing obligation to maintain the confidentiality of the trade secrets and other confidential information belonging to the Corporation or its Affiliates and obtained by the Participant during the term of the Participant’s employment with the Corporation or any of its Affiliates;
(E)    Induces or attempts to induce, directly or indirectly, any of the customers of the Corporation or its Affiliates, employees, representatives or consultants to terminate, discontinue or cease working with or for the Corporation or its Affiliates, or to breach any contract with the Corporation or any of its Affiliates, in order to work with or for, or enter into a contract with, the Participant or any third party;
(F)    Engages in conduct which is not in good faith and which disrupts, damages, impairs or interferes with the business, reputation or employees of the Corporation or its Affiliates; or
(G)    Fails to meet the Participant’s continuing obligations with respect to non-disclosure, non-competition and/or non-solicitation under the Participant’s agreement with the Corporation or any Affiliate.
The Administrator shall determine in its sole discretion whether the Participant has engaged in any of the acts set forth in (A) through (G) above, and its determination shall be conclusive and binding on all interested persons.

14



Any provision of this Section VI which is determined by a court of competent jurisdiction to be invalid or unenforceable should be construed or limited in a manner that is valid and enforceable and that comes closest to the business objectives intended by such invalid or unenforceable provision, without invalidating or rendering unenforceable the remaining provisions of this Section VI.
VII.
CHANGE IN CONTROL
If as a result of a Change in Control, the Common Stock ceases to be listed for trading on a national securities exchange (an “Exchange”), any Option, Restricted Stock Award, Restricted Stock Unit Award, Performance Share Award or TSR Unit Award that is unvested on the effective date of the Change in Control shall continue to vest according to the terms and conditions of such Award, provided that such Award is replaced with an award for voting securities of the resulting corporation or the acquiring corporation, as the case may be, (including without limitation, the voting securities of any corporation which as a result of the Change in Control owns the Corporation or all or substantially all of the Corporation’s assets either directly or through one or more subsidiaries) (the “Surviving Company”) which are traded on an Exchange (a “Replacement Award”), which Replacement Award, (i) in the case of an Option, shall consist of an option with the number of underlying shares and exercise price determined in a manner consistent with Code Section 424(a) with vesting and any other terms continuing in the same manner as the replaced Option; (ii) in the case of a Performance Share Award or TSR Unit Award, shall consist of restricted stock or restricted stock units with a value (determined using the Surviving Company’s stock price as of the effective date of the Change in Control) equal to the value of the Performance Share Award or TSR Unit Award (determined using the Corporation’s stock price and assuming attainment of target performance or actual performance achieved, if greater, as of the effective date of the Change in Control), with any restrictions on such restricted stock or restricted stock units lapsing at the end of the measuring period over which performance for the replaced Performance Share Award or TSR Unit Award was to be measured prior to the granting of the Replacement Award; and (iii) in the case of a Restricted Stock Award or Restricted Stock Unit Award, shall consist of restricted stock or restricted stock units with a value (determined using the Surviving Company’s stock price as of the effective date of the Change in Control) equal to the value of the Restricted Stock Award or Restricted Stock Unit Award (determined using the Corporation’s stock price as of the effective date of the Change in Control), with any restrictions on such restricted stock or restricted stock units lapsing at the same time and manner as the replaced Award; provided, however, that in the event of the Participant’s involuntary Separation from Service by the Corporation without Cause or Separation from Service by the Participant for Good Reason during the vesting period of any Replacement Award, the Replacement Award shall immediately vest and be paid as soon as practicable following such Separation from Service (subject to Section VIII.14), based on the fair market value of the underlying shares on the vesting date, or in the case of options, based on the excess of the fair market value of the underlying shares over the option exercise price on the vesting date. If any Option, Restricted Stock Award, Restricted Stock Unit Award, Performance Share Award or TSR Unit Award that is unvested at the effective time of the Change in Control is not replaced with a Replacement Award, such Award shall immediately vest and, in the case of a Performance Share Award or TSR Unit Award, shall vest based upon deemed attainment of target performance or actual performance achieved, if greater.

15



If as a result of a Change in Control, the Common Stock continues to be listed for trading on an Exchange, any unvested Option, Restricted Stock Award, or Restricted Stock Unit Award shall continue to vest according to the terms and conditions of such Award and any Performance Share Award or TSR Unit Award shall be replaced with a Restricted Stock Award or Restricted Stock Unit Award where the number of shares subject to such Restricted Stock Award or Restricted Stock Unit Award shall be equal to the number of Shares assuming attainment of target performance or actual performance achieved, if greater, as of the effective date of the Change in Control with any restrictions on such Restricted Stock Award or Restricted Stock Unit Award lapsing at the end of the measuring period over which performance for the replaced Performance Share Award or TSR Unit Award was to be measured prior to the granting of the replacement Award; provided however, that, in the event of the Participant’s involuntary Separation from Service by the Corporation without Cause or Separation from Service by the Participant for Good Reason during the vesting period of an Award, such Award shall immediately vest and be paid as soon as practicable following such Separation from Service (subject to Section VIII.14).
VIII.
MISCELLANEOUS
1.    No Effect on Terms of Employment. Participation in the Plan shall not create a right to further employment with the Participant’s employer (the “Employer”) and shall not interfere with the ability of the Employer to terminate, with or without cause, or change the terms of employment of a Participant at any time.
2.    Grants to Participants in Foreign Countries. In making grants to Participants in foreign countries, the Administrator has the full discretion to deviate from this Statement of Terms and Conditions in order to adjust grants under the Plan to prevailing local conditions, including custom and legal and tax requirements. Furthermore, the Corporation reserves the right to impose other requirements on the Participant’s participation in the Plan on the Award and on any Shares acquired under the Plan, to the extent the Corporation determines it is necessary or advisable in order to comply with local law or facilitate the administration of the Plan, and to require the Participant to sign any additional agreements or undertaking that may be necessary to accomplish the foregoing.
3.    Information Notification. Any information required to be given under the terms of an Award shall be addressed to the Corporation in care of its Corporate Secretary at McKesson Corporation, One Post Street, San Francisco, California 94104, and any notice to be given to a Participant shall be addressed to such Participant at the address indicated beneath the Participant's name on the Award Agreement or such other address as either party may designate in writing to the other. Any such notice shall be deemed to have been duly given when enclosed in a properly sealed envelope or wrapper addressed as aforesaid, registered or certified and deposited (postage or registration or certification fee prepaid) in a post office or branch post office.
4.    Administrator Decisions Conclusive. All decisions of the Administrator administering the Plan upon any questions arising under the Plan or under an Award Agreement, shall be conclusive and binding on all interested persons.
5.    No Effect on Other Benefit Plans. Nothing herein contained shall affect a Participant’s right to participate in and receive benefits from and in accordance with the then current provisions of any pensions, insurance or other employment welfare plan or program offered by the Corporation.

16



6.    Withholding. Regardless of any action the Corporation or the Employer takes with respect to any federal, state or local income tax, social insurance, payroll tax, payment on account or other tax-related items related to the Participant’s participation in the Plan and legally applicable to the Participant (“Tax-Related Items”), the Participant acknowledges that the ultimate liability for all Tax-Related Items is and remains the Participant's responsibility and may exceed the amount actually withheld by the Corporation or the Employer. The Participant further acknowledges that the Corporation and/or the Employer (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Award, including the grant, vesting or exercise of the Award, as applicable, the subsequent sale of Shares acquired pursuant to the Plan and the receipt of any dividends and/or dividend equivalents; and (2) do not commit and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Participant’s liability for Tax-Related Items or achieve any particular tax result. Further, if the Participant has become subject to tax in more than one jurisdiction between the Grant Date and the date of any relevant taxable event, the Participant acknowledges that the Corporation and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.
Prior to any relevant taxable or tax withholding event, as applicable, the Participant will pay or make adequate arrangements satisfactory to the Corporation and/or the Employer, or their respective agents, at their discretion, to satisfy the obligations with regard to all Tax-Related Items by one or a combination of the following: (1) withholding from the Participant’s wages or other cash compensation paid to the Participant by the Corporation and/or the Employer; (2) withholding from proceeds of the sale of Shares acquired under the Plan either through a voluntary sale or through a mandatory sale arranged by the Corporation (on the Participant’s behalf pursuant to this authorization and any other authorization the Corporation and/or the broker designated by the Corporation may require the Participant to sign in connection with the sale of Shares); or (3) withholding Shares to be issued upon grant, vesting/settlement or exercise, as applicable. Calculation of the number of Shares to be withheld shall be made based on the closing price of the Common Stock on the New York Stock Exchange on the date that the amount of tax to be withheld is determined. In no event, however, shall the Corporation be required to issue fractional Shares. With respect to an Award other than an Option, if adequate arrangements to satisfy the obligations with regard to all Tax-Related Items are not made by the Participant with the Corporation and/or the Employer prior to the relevant taxable event, the Corporation will satisfy such obligations as provided above in clause (3) of this paragraph.
To avoid negative accounting treatment, the Corporation may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates. If the obligation for Tax-Related Items is satisfied by withholding in Shares, for tax purposes, the Participant will be deemed to have been issued the full number of Shares subject to the Award, notwithstanding that a number of the Shares are held back solely for the purpose of paying the Tax-Related Items due as a result of any aspect of the Participant’s participation in the Plan.
Finally, the Participant shall pay to the Corporation or the Employer any amount of Tax-Related Items that the Corporation or the Employer may be required to withhold or account for as a result of the Participant’s participation in the Plan that cannot be satisfied by the means previously described. The Corporation may refuse to issue or deliver the Shares or the proceeds of the sale of Shares if the Participant fails to comply with the Participant's obligations in connection with the Tax-Related Items.

17



The Administrator shall be authorized to establish such rules, forms and procedures as it deems necessary to implement the foregoing.
7.    Successors. The Award Agreements shall be binding upon and inure to the benefit of any successor or successors of the Corporation. “Participant” as used herein shall include the Participant’s Beneficiary.
8.    Delaware Law. The interpretation, performance, and enforcement of all Award Agreements shall be governed by the laws of the State of Delaware.
9.    Nature of Grant. In accepting the grant, the Participant acknowledges that:
(A)    the Plan is established voluntarily by the Corporation, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Corporation at any time;
(B)    the grant of the Award is voluntary and occasional and does not create any contractual or other right to receive future Award grants, or benefits in lieu of Awards, even if Awards have been granted repeatedly in the past;
(C)    all decisions with respect to future Awards, if any, will be at the sole discretion of the Corporation;
(D)    the Participant is voluntarily participating in the Plan;
(E)    the Award is not part of normal or expected compensation for any purpose, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments;
(F)    the Award will not be interpreted to form an employment contract or relationship with the Corporation; and furthermore, the Award will not be interpreted to form an employment contract with any subsidiary or Affiliate of the Corporation;
(G)    the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty;
(H)    if the underlying Shares do not increase in value, the Options will have no value;
(I)    in consideration of the grant of the Award, no claim or entitlement to compensation or damages shall arise from forfeiture of the Award which results from termination of the Participant’s employment with the Employer or the Corporation or one of its Affiliates (for any reason whatsoever) and the Participant irrevocably releases the Corporation or its Affiliates from any such claim that may arise; if, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen, then, by accepting the Award, the Participant shall be deemed irrevocably to have waived the Participant's entitlement to pursue such claim;

18



(J)    for purposes of an Award, the Participant’s employment relationship will be considered terminated as of the date the Participant is no longer a bona fide employee of the Corporation or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of the employment laws in the jurisdiction where the Participant is employed or the terms of the Participant’s employment agreement, if any), and unless otherwise expressly provided in this Award Agreement or determined by the Corporation in its sole discretion, the Participant’s right to receive Awards and vest in Awards under the Plan, if any, will terminate effective as of such date and will not be extended by any notice period mandated under local law; similarly, any right to exercise Options under the Plan after termination of employment will be measured as of the date the Participant is no longer a bona fide employee of the Corporation or one of its Affiliates and will not be extended by any notice period mandated under local law; the Administrator shall have the sole discretion to determine when the Participant is no longer a bona fide employee;
(K)    the Corporation is not providing any tax, legal or financial advice, nor is the Corporation making any recommendations regarding participation in the Plan or the Participant’s acquisition or sale of Shares; and
(L)    Participant is hereby advised to consult with the Participant's own personal tax, legal and financial advisors regarding Participant’s participation in the Plan before taking any action related to the Plan.
10.    Data Privacy. By accepting the Award, the Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of the Participant's personal data as described in this document by and among, as applicable, the Employer and the Corporation and its Affiliates for the exclusive purpose of implementing, administering and managing participation in the Plan.

19



The Participant understands that the Corporation and the Employer hold certain personal information about the Participant, including, but not limited, the Participant's name, home address and telephone number, date of birth, social insurance or other identification number, salary, nationality, job title, any Shares or directorships held in the Corporation, details of all Options, Restricted Stock, Restricted Stock Units, Performance Shares, Other Share-Based Awards, or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in the Participant’s favor, for the purpose of implementing, administering and managing the Plan (“Data”). The Participant understands that Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, that recipients of Data may be located in the United States or elsewhere, and that the recipient’s country may have different data privacy laws and protections than the Participant’s country. The Participant understands that if the Participant resides outside of the United States, the Participant may request a list with the names and addresses of any potential recipients of the Data by contacting the local human resources representative. The Participant authorizes the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom the Participant may elect to deposit any Shares acquired under the Plan. The Participant understands that Data will be held only as long as is necessary to implement, administer and manage the Participant's participation in the Plan. The Participant understands that if the Participant resides outside of the United States, the Participant may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, without cost, by contacting in writing the local human resources representative. Further, the Participant understands that the Participant is providing the consents herein on a purely voluntary basis. If the Participant does not consent, or if the Participant later seeks to revoke the Participant's consent, the Participant’s employment status or service and career with the Employer will not be adversely affected; the only adverse consequence of refusing or withdrawing the Participant's consent is that the Corporation would not be able to grant the Participant Awards or administer or maintain such Awards. Therefore, the Participant understands that refusing or withdrawing consent may affect the Participant's ability to participate in the Plan. For more information on the consequences of refusal to consent or withdrawal of consent, the Participant understands that the Participant may contact the local human resources representative.
11.    Severability. The provisions in this Statement of Terms and Conditions are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.
12.    Language. If the Participant has received this Statement of Terms and Conditions or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.
13.    Electronic Delivery. The Corporation may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Corporation or a third party designated by the Corporation.

20



14.    Section 409A. If (A) the Participant is a Specified Employee at the time of the Participant’s Separation from Service, and (B) some or any portion of the amounts payable to the Participant, if any, when considered together with any other payments or benefits which may be considered deferred compensation under section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”) and subject to the plan aggregation rules under Treasury Regulation section 1.409A-1(c)(3)(viii) (together, the “Deferred Compensation Benefits”) would result in the imposition of additional tax under Section 409A if paid to the Participant on or within the six month period following the Separation from Service, then to the extent such portion of the Deferred Compensation Benefits resulting in the imposition of additional tax would otherwise have been payable on or within the first six months following the Separation from Service, it will instead become payable on the first payroll date that occurs in the seventh month following the Separation from Service (or such longer period as is required to avoid the imposition of additional tax under Section 409A). All subsequent Deferred Compensation Separation Benefits, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit.
IX.
DEFINITIONS
When capitalized in this Statement of Terms and Conditions, the following terms shall have the meaning set forth below:
1.    Award Agreement” means an agreement between the Participant and the Corporation evidencing the grant of an Option, Restricted Stock Award, Restricted Stock Award, Performance Shares or Other Share-Based Award, as applicable.
2.    Cause” means termination of the Participant’s employment with the Corporation or an Affiliate upon the Participant’s negligent or willful engagement in misconduct which, in the sole determination of the Chief Executive Officer of the Corporation (or the Chief Executive Officer’s designee), is injurious to the Corporation, its employees, or its customers.
3.    Early Retirement” means a termination of employment (other than due to death, Long-Term Disability or for Cause) which occurs prior to Normal Retirement but on or after the date on which the Participant’s age (expressed in terms of years and completed months) plus service with the Corporation or an Affiliate equals 65. For purposes of determining eligibility for Early Retirement, the term “service” shall include years and completed whole months of service.
4.    Family Member” means any person identified as an “immediate family” member in Rule 16(a)‑1(e) of the Exchange Act, as such Rule may be amended from time to time. Notwithstanding the foregoing, the Administrator may designate any other person(s) or entity(ies) as a “family member.”
5.    “Good Reason” means any of the following actions, if taken without the express written consent of the Participant:
(A)    Any material change by the Corporation in the Participant’s functions, duties, or responsibilities, which change would cause the Participant’s position with the Corporation to become of less dignity, responsibility, importance, or scope from the position and attributes that applied to the Participant immediately prior to the Change in Control;
(B)    Any significant reduction in the Participant’s aggregate base annual salary and target incentive opportunity, as in effect immediately prior to the Change in Control;

21



(C)    Any material failure by the Corporation to comply with any of the provisions of an Award subsequent to a Change in Control;
(D)    The Corporation’s requiring the Participant to be based at any location which would increase the Participant’s regular one-way commute by more than 25 miles from that in effect immediately preceding the Change in Control, except for travel reasonably required in the performance of the Participant’s responsibilities; or
(E)    Any change in the person to whom the Participant reports, as this relationship existed immediately prior to a Change in Control;
Provided that the Participant gives notice to the Corporation of the existence of the Good Reason condition within 30 days of the initial existence of the Good Reason condition and the Corporation is provided 30 days after receipt of the Participant’s notice to remedy the Good Reason condition; provided further that the Participant’s Separation from Service must occur within six months from the initial existence of the Good Reason condition if the Corporation does not remedy such condition for such separation to be considered to be for Good Reason.
6.    “Expiration Date” means the date that an Option expires as set forth in the Option Grant Notice as the “Expiration Date.”
7.    “Grant Date” means the date the Administrator grants the Award.
8.    “Grant Notice” means the notice of an Award granted to the Participant, which sets forth certain terms of such Award.
9.    “Long‑Term Disability” means a physical or mental condition in respect of which the administrator of the Corporation’s long-term disability plan has determined that the Participant is eligible to receive income replacement benefits; or, if the Participant is not then a participant in the Corporation’s long-term disability plan, a physical or mental condition that the administrator of the Corporation’s long-term disability plan determines would have rendered the Participant eligible to receive income replacement benefits, had the Participant been enrolled in such plan.
10.    “Normal Retirement” means termination of employment (other than due to death, Long-Term Disability or for Cause) at or after age 60 (57, in the case of a participant in the McKesson Corporation 1984 Executive Benefit Retirement Plan) with at least 10 years of service with the Corporation or an Affiliate. For purposes of determining eligibility for Normal Retirement, “service” shall mean completed whole years of service (12 consecutive months).
11.    “Option Period” means the period commencing on the Grant Date of an Option and, except at otherwise provided in Section II.5, ending on the Expiration Date.
12.    “Separation from Service” means termination of employment with the Corporation or an affiliate. A Participant shall be deemed to have had a Separation from Service if the Participant’s service with the Corporation or an affiliate is reduced to an annual rate that is equal to or less than 20% of the services rendered, on average, during the immediately preceding three years of service with the Corporation or an affiliate (or, if providing service to the Corporation or an affiliate for less than three years, such lesser period).

22



13.    “Severance” means termination of employment with the Corporation or an affiliate, and qualified for participation in and entitlement to benefits under the McKesson Corporation Severance Pay Plan, in accordance with the terms and conditions of such plan.
14.     “Short-Term Disability” means short-term disability as defined in the Corporation’s short-term disability plan.
15.    “Specified Employee” means those employees identified by the Corporation as "Specified Employees" for purposes of Code Section 409A.
16.    “Stock Ownership Policy” means the Corporation’s Stock Ownership Policy, as amended from time to time, which can be found on McKNet. A Participant or a Participant’s beneficiary may also request a copy of the Stock Ownership Policy by writing to the Corporate Secretary at McKesson Corporation, One Post Street, San Francisco, CA 94104.


23



EMPLOYEES SUBJECT TO STOCK OWNERSHIP POLICY

McKESSON CORPORATION
STATEMENT OF TERMS AND CONDITIONS APPLICABLE TO
OPTIONS, RESTRICTED STOCK, RESTRICTED STOCK UNITS AND
PERFORMANCE SHARES GRANTED TO EMPLOYEES
SUBJECT TO STOCK OWNERSHIP POLICY PURSUANT
TO THE 2013 STOCK PLAN
Effective for Grants Beginning May 24, 2016
I.
INTRODUCTION
The following terms and conditions shall apply to an Award granted under the Plan and are subject to the terms and conditions of the Plan. This Statement of Terms and Conditions is intended to meet the requirements of Code Section 409A and any rules promulgated thereunder. In the event of any inconsistency between this Statement of Terms and Conditions and the Plan, the Plan shall govern. Capitalized terms not otherwise defined in this Statement of Terms and Conditions shall have the meaning set forth in the Plan.
II.
OPTIONS
1.    Option Agreement. An Option granted under the Plan shall be evidenced by an Option Agreement setting forth the terms and conditions of the Option, including whether the Option is an Incentive Stock Option or a Nonstatutory Stock Option and the number of Shares subject to the Option. Each Option Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant’s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Option Agreement. The Option is also subject to the terms and conditions of the Plan.
2.    Exercise Price. The Exercise Price of an Option, as specified in the Option Agreement, shall be equal to or greater than the Fair Market Value of the Shares underlying the Option on the Grant Date.
3.    Option Period. An Option shall be exercisable only during the applicable Option Period, and during such Option Period the exercisability of the Option shall be subject to the vesting provisions of Section II.4 as modified by the rules set forth in Sections II.5 and V. The Option Period shall be not more than seven years from the Grant Date.
4.    Vesting of Right to Exercise Options.

1



(A)    Except as provided in Sections II.5 and V, an Option shall be exercisable during the Option Period in accordance with the following vesting schedule:  (i) 25% of the Shares subject to the Option shall vest on the first anniversary of the Grant Date; (ii) an additional 25% of the Shares shall vest on the second anniversary of the Grant Date; (iii) an additional 25% of the Shares shall vest on the third anniversary of the Grant Date; and (iv) the remaining 25% of the Shares subject to the Option shall vest on the fourth anniversary of the Grant Date. Notwithstanding the foregoing, the Administrator may specify a different vesting schedule at the time the Option is granted, which will be specified in the Option Grant Notice.
(B)    Any vested portion of an Option not exercised hereunder shall accumulate and be exercisable at any time on or before the Expiration Date, subject to the rules set forth in Sections II.5 and V. No Option may be exercised for less than 5% of the total number of Shares then available for exercise under such Option. In no event shall the Corporation be required to issue fractional Shares.
5.    Limits on Option Period and Acceleration of Vesting. The Option Period may end before the Expiration Date, and in certain circumstances, the vesting schedule of an Option may be accelerated (subject to the provisions of Section V), as follows:
(A)    If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period for reasons other than for Cause, Long‑Term Disability, Normal Retirement, Early Retirement, Severance under the circumstances provided in Section II.5(F)(ii), or death, the Option Period shall end on the earlier of (i) 90 days after the date of the Participant’s termination of employment and (ii) the Expiration Date, and in all cases the Option shall be exercisable only to the extent that it was exercisable under the provisions of the foregoing Section II.4 at the time of such termination of employment. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short‑Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Administrator may otherwise expressly determine.
(B)    Notwithstanding any other provision in this Section II.5, if a Participant’s employment is terminated for Cause during the Option Period, the Option Period shall end on the date of such termination of employment and the Option shall thereupon not be exercisable to any extent whatsoever.
(C)    If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Long-Term Disability, the vesting schedule of the Participant’s Option shall be accelerated, the Option shall become fully exercisable and the Option Period shall end on the earlier of (i) three years after the date of the Participant’s termination of employment and (ii) the Expiration Date.
(D)    If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Early Retirement, (i) the Option shall be exercisable only to the extent that it was exercisable under the provisions of the foregoing Section II.4 at the time of such retirement and (ii) the Option Period for that portion of the Option designated as a Nonstatutory Stock Option shall end on the earlier of (a) three years after the date of such retirement and (b) the Expiration Date.

2



(E)    If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Normal Retirement:
(i)    If such Normal Retirement occurs prior to the first anniversary of the Grant Date of the Option, such Option shall be subject to the provisions of Section II.5(D) as though the Participant were eligible for Early Retirement; and
(ii)    If such Normal Retirement occurs on or after the first anniversary of the Grant Date of an Option, (a) that portion of the Option designated as a Nonstatutory Stock Option shall continue to vest as set forth in the foregoing Section II.4 as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such vesting period, and (b) the Option Period for such portion of the Option designated as a Nonstatutory Stock Option shall end on the Expiration Date.
(F)    If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Severance, and
(i)    The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, and would not have attained the requirements for Normal Retirement within six months after the termination date, then (a) the vesting schedule of the Participant’s Option shall be accelerated as to the portion of the Option that would have vested in accordance with the vesting schedule set forth in the foregoing Section II.4 as if the Participant had continued to be employed by the Corporation or one of its Affiliates six months after the termination date, and (b) the expiration of the Option Period provided in Section II.5(A) shall apply; provided that if the Participant is also eligible for Early Retirement at the time of the termination of employment, then the expiration of the Option Period provided in Section II.5(D) shall apply; or
(ii)    The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, but would have attained the requirements for Normal Retirement within six months after the termination date, and:
(a)    The first anniversary of the Grant Date of the applicable Award has not occurred on or prior to the termination date, then such Option shall be subject to the Early Retirement provision in Section II.5(D); and
(b)    The first anniversary of the Grant Date of the applicable Award has occurred on or prior to the termination date, then (x) that portion of the Option designated as a Nonstatutory Stock Option shall continue to vest as set forth in the foregoing Section II.4 as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such vesting period, and (y) the Option Period for such portion of the Option designated as a Nonstatutory Stock Option shall end on the Expiration Date.

3



(G)    If a Participant should die (i) while in the employ of the Corporation or an Affiliate and (ii) during the Option Period, the vesting schedule of the Participant’s Option shall be accelerated and the Option shall become fully exercisable, the Option Period shall end on the earlier of (a) three years after the date of death and (b) the Expiration Date, and the Participant’s Beneficiary may exercise the entire unexercised portion of the then exercisable Shares covered by such Option (or any lesser amount) remaining on the date of death.
(H)    If a Participant who ceases to be a bona fide employee of the Corporation or an Affiliate is subsequently rehired prior to the expiration of the Participant's Option, then the Option shall continue to remain outstanding until the earlier of (i) such time as the Participant subsequently terminates employment and (ii) the Expiration Date. Upon the Participant’s subsequent termination of employment, the post‑termination exercise period calculated pursuant to the terms and conditions of this Section II.5 shall be reduced by the number of days between the date of the Participant’s initial termination of employment and the Participant's re‑hire date; provided, however, that if the rehired Participant continues to be employed by the Corporation or an Affiliate for at least one year from the Participant's rehire date, then the post termination exercise period for the Option shall be determined in accordance with Sections II.5(A) through (G) and shall not be adjusted as described in this Section II.5(H).
6.    Method of Exercise. A Participant may exercise an Option with respect to all or any part of the exercisable Shares as follows:
(A)    By giving the Corporation, or its authorized representative designated for this purpose, written notice of such exercise specifying the number of Shares as to which the Option is so exercised. Such notice shall be accompanied by an amount equal to the Exercise Price multiplied by the number of Shares exercised, in the form of any one or combination of the following:  cash or a certified check, bank draft, postal or express money order payable to the order of the Corporation in lawful money of the United States. Unless otherwise determined by the Administrator in its sole discretion, the Participant may pay the Exercise Price, in whole or in part, by tendering to the Corporation or its authorized representative Shares, which have been owned by the Participant for at least six months prior to said tender, and having a fair market value, as determined by the Corporation, equal to the Exercise Price, or in lieu of the delivery of actual Shares in such tender, the Corporation may accept an attestation by the Participant, in a form prescribed by the Corporation or its authorized representative, that the Participant owns sufficient Shares of record or in an account in street name to satisfy the Exercise Price, and such attestation will be deemed a tender of Shares for purposes of this method of exercise. The Corporation or its authorized representative may accept payment of the amount due upon the exercise of the Option in the form of a Participant’s personal check. Payment may also be made by delivery (including by FAX transmission) to the Corporation or its authorized representative of an executed irrevocable Option exercise form together with irrevocable instructions to an approved registered investment broker to sell Shares in an amount sufficient to pay the Exercise Price plus any applicable Tax-Related Items (as defined in Section VII.6) and to transfer the proceeds of such sale to the Corporation.

4



(B)    If required by the Corporation, by giving satisfactory assurance in writing, signed by the Participant, the Participant shall give the Participant's assurance that the Shares subject to the Option are being purchased for investment and not with a view to the distribution thereof; provided that such assurance shall be deemed inapplicable to (i) any sale of the Shares by such Participant made in accordance with the terms of a registration statement covering such sale, which has heretofore been (or may hereafter be) filed and become effective under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and with respect to which no stop order suspending the effectiveness thereof has been issued, and (ii) any other sale of the Shares with respect to which, in the opinion of counsel for the Corporation, such assurance is not required to be given in order to comply with the provisions of the Securities Act.
(C)    As soon as practicable after receipt of the notice and the assurance described in Sections II.6(A) and (B), the Corporation shall, without transfer or issue tax (except for withholding tax arrangements contemplated in Section VII.6) and without other incidental expense to the Participant, credit the purchased Shares to the Participant’s brokerage account of record. If the Participant does not have a brokerage account of record, then the Corporation shall cause an appropriate book entry to be entered in the records of the Corporation’s transfer agent recording the Participant’s unrestricted interest in the purchased Shares; provided, however, that the time of such delivery may be postponed by the Corporation for such period as may be required for it with reasonable diligence to comply with applicable registration requirements under the Securities Act, the Exchange Act, any applicable listing requirements of any national securities exchange and requirements under any other law or regulation applicable to the issuance or transfer of the Shares.
7.    Limitations on Transfer. An Option shall, during a Participant’s lifetime, be exercisable only by the Participant. No Option or any right granted thereunder shall be transferable by the Participant by operation of law or otherwise, other than by will or the laws of descent and distribution. Notwithstanding the foregoing: (A) a Participant may designate a beneficiary to succeed, after the Participant’s death, to all of the Participant’s Options outstanding on the date of death; (B) a Nonstatutory Stock Option may be transferable pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act; and (C) any Participant, who is a senior executive officer recommended by the Chief Executive Officer of the Corporation and approved by the Administrator may voluntarily transfer any Nonstatutory Stock Option to a Family Member as a gift or through a transfer to an entity in which more than 50% of the voting interests are owned by Family Members (or the Participant) in exchange for an interest in that entity. In the event of any attempt by a Participant to alienate, assign, pledge, hypothecate, or otherwise dispose of an Option or of any right thereunder, except as provided herein, or in the event of the levy of any attachment, execution, or similar process upon the rights or interest hereby conferred, the Corporation at its election may terminate the affected Option by notice to the Participant and the Option shall thereupon become null and void.
8.    No Stockholder Rights. Neither a Participant nor any person entitled to exercise a Participant’s rights in the event of the Participant’s death shall have any of the rights of a stockholder with respect to the Shares subject to an Option except to the extent that a book entry has been entered in the records of the Corporation’s transfer agent with respect to such Shares upon the exercise of an Option.

5



III.
RESTRICTED STOCK
1.    Restricted Stock Agreement. A Restricted Stock Award granted under the Plan shall be evidenced by a Restricted Stock Agreement to be executed by the Participant and the Corporation setting forth the terms and conditions of the Restricted Stock Award. Each Restricted Stock Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant’s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Restricted Stock Agreement. The Restricted Stock Award is also subject to the terms and conditions of the Plan.
2.    Rights with Respect to Shares of Restricted Stock. Upon written acceptance of a Restricted Stock Award by a Participant, including the restrictions and other terms and conditions described in the Plan and the Restricted Stock Agreement, the Corporation shall cause an appropriate book entry to be entered in the records of the Corporation’s transfer agent recording the Participant’s interest in the Restricted Stock. From and after the Grant Date, the Participant shall have the rights of Common Stock ownership, including the right to vote and to receive dividends on Shares of Restricted Stock, subject to the terms, conditions and restrictions described in the Plan and the Restricted Stock Agreement.
3.    Special Restrictions. Each Restricted Stock Award made under the Plan shall be subject to the following terms, conditions and restrictions and such additional terms, conditions and restrictions as may be determined by the Administrator; provided, however, that no Restricted Stock grant shall be subject to additional terms, conditions and restrictions which are more favorable to a Participant than the terms, conditions and restrictions set forth elsewhere in the Plan or the Restricted Stock Agreement.
(A)    Restrictions. Until the restrictions imposed on any Restricted Stock grant shall lapse (the “Restriction Period”), Shares of Restricted Stock granted to a Participant (i) shall not be sold, assigned, transferred, pledged, hypothecated, or otherwise disposed of, other than pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act and (ii) shall, if the Participant’s continuous employment with the Corporation or any of its Affiliates shall terminate for any reason (except as otherwise provided in the Plan, or in Section III.3(B) or Section III.3(C)) be returned to the Corporation forthwith, and all the rights of the Participant to such Shares shall immediately terminate. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short‑Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Administrator may otherwise expressly determine.
(B)    Termination of Employment by Reason of Death, Long‑Term Disability or Normal Retirement. Notwithstanding any provision to the contrary contained in the Restricted Stock Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of a Restricted Stock Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of:

6



(i)    Death or Long‑Term Disability, then the restrictions imposed on any Restricted Stock Award shall lapse as to all Shares granted to such Participant pursuant to such Restricted Stock Award on the date of such termination; or
(ii)    Normal Retirement on or after the first anniversary of the Grant Date of any time-based vesting Restricted Stock Award, the restrictions applicable to such Restricted Stock Award shall continue to lapse at such time(s) as are set forth in the applicable Grant Notice, as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such restricted period; provided, that notwithstanding any other provision of the Plan or this Statement of Terms and Conditions, this Section III.3(B)(ii) shall not apply to any Restricted Stock Award the vesting of which is based, in whole or in part, on attainment of performance objectives. The procedures set forth in Section VIII.6 will be applied for any taxes due upon the lapse of restrictions imposed on a Restricted Stock Award due to a Participant’s Normal Retirement eligibility.
(C)    Termination of Employment by Reason of Severance. Notwithstanding any provision to the contrary contained in the Restricted Stock Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of a Restricted Stock Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of Severance, and:

(i)    The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, and would not have attained the requirements for Normal Retirement within six months after the termination date, then the restrictions applicable to any time-based vesting Restricted Stock Award shall lapse upon the Participant’s termination date, as to such Shares of Restricted Stock that would have vested at such time(s) as are set forth in the applicable Grant Notice as if the Participant had continued to be employed by the Corporation or one of its Affiliates during the six-month period after the Participant’s termination date; or

(ii)    The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, but would have attained the requirements for Normal Retirement within six months after the termination date and the first anniversary of the Grant Date of the Restricted Stock Award has occurred on or prior to the termination date, then the restrictions applicable to the time-based vesting Restricted Stock Award shall continue to lapse at such time(s) as are set forth in the applicable Grant Notice, as though the Participant had continued to be employed by the Corporation or one of its Affiliates during the restricted period; provided that if the first anniversary of the Grant Date of the Restricted Stock Award has not occurred on or prior to the termination date, then the additional vesting terms and conditions provided in Section III.3(C)(i) shall apply to such award.

Notwithstanding the foregoing, this Section III.3(C) shall not apply to any Restricted Stock Award the vesting of which is based, in whole or in part, on attainment of performance objectives. The procedures set forth in Section VII.6 will be applied for any taxes due upon the lapse of restrictions imposed on a Restricted Stock Award due to a Participant’s Normal Retirement eligibility.

7




(D)    Restriction on Sale. The Compensation Committee reserves the right to impose a restriction on the sale of Shares that the Participant receives upon the vesting and settlement of a Restricted Stock Award, unless the Participant has satisfied the ownership targets applicable to the Participant as provided in the Stock Ownership Policy.
4.    Dividends. Cash dividends paid with respect to Restricted Stock during the Restriction Period shall be credited on behalf of the Participant to a deferred cash account (in a manner designed to comply with Code Section 409A) and the restrictions on such cash dividends shall lapse at the same time that the restrictions lapse on the associated Restricted Stock Award. Stock dividends paid with respect to Restricted Stock during the Restriction Period shall be treated as Restricted Stock which shall be subject to the same restrictions as the original award for the duration of the Restriction Period.
5.    Election to Recognize Gross Income in the Year of Grant. If any Participant validly elects within 30 days of the Grant Date, to include in gross income for federal income tax purposes an amount equal to the fair market value of the Shares of Restricted Stock granted on the Grant Date, such Participant shall (at the same time or prior to the date that the Participant files the Participant's election with the Internal Revenue Service) (A) pay to the Corporation, or make arrangements satisfactory to the Administrator to pay to the Corporation in the year of such grant, any federal, state or local taxes required to be withheld with respect to such Shares in accordance with Section VII.6, and (B) provide the Administrator with a copy of the election filed with the Internal Revenue Service.
6.    Restrictive Legend. Each book entry in the records of the Corporation’s transfer agent evidencing Shares granted pursuant to a Restricted Stock grant may bear an appropriate legend referring to the terms, conditions and restrictions described in the Plan and/or the Restricted Stock Agreement.
7.    Expiration of Restriction Period. If and when the Restriction Period applicable to the Restricted Stock expires without a prior forfeiture, Shares shall be credited to the Participant’s brokerage account of record. If the Participant does not have a brokerage account of record, then an appropriate book entry recording the Participant’s interest in the unrestricted Shares shall be entered on the records of the Corporation’s transfer agent.
IV.
RESTRICTED STOCK UNITS AND PERFORMANCE SHARES
1.    Award Agreement.
(A)    Restricted Stock Units granted under the Plan shall be evidenced by a Restricted Stock Unit Agreement to be executed by the Participant and the Corporation setting forth the terms and conditions of the Restricted Stock Units. Each Restricted Stock Unit Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant’s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Restricted Stock Unit Agreement. The Restricted Stock Units are also subject to the terms and conditions of the Plan.

8



(B)    Performance Shares granted under the Plan shall be evidenced by a Performance Share Agreement to be executed by the Participant and the Corporation setting forth the terms and conditions of the Performance Shares. Each Performance Share Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant’s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Performance Share Agreement. Performance Shares are also subject to the terms and conditions of the Plan.
2.    Special Restrictions. Restricted Stock Units and Performance Shares granted under the Plan shall be subject to the following terms, conditions and restrictions and such additional terms, conditions and restrictions as may be determined by the Administrator, consistent with the terms of the Plan.
(A)    Restrictions. If a Participant ceases to be a bona fide employee of the Corporation or any Affiliate (except as otherwise provided in the Plan, or in Section IV.2(B) or Section IV.2(C)) prior to the lapse of the restrictions imposed on the Award, the unvested Restricted Stock Units or Performance Shares shall be canceled, and all the rights of the Participant to such Awards shall immediately terminate. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short‑Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Administrator may otherwise expressly determine.
(B)    Termination of Employment by Reason of Death, Long‑Term Disability or Normal Retirement. Notwithstanding any provision contained to the contrary in the Restricted Stock Unit Grant Notice or Performance Share Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of such Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of:
(i)    Death or Long‑Term Disability, then the restrictions imposed on any Award of Restricted Stock Units or Performance Shares shall lapse on the date of such termination; or
(ii)    Normal Retirement on or after the first anniversary of the Grant Date of any time-based vesting Restricted Stock Units, the restrictions applicable to such Restricted Stock Units shall continue to lapse at such time(s) as are set forth in the applicable Grant Notice, as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such restricted period; provided, that notwithstanding any other provision of the Plan or this Statement of Terms and Conditions, this Section IV.2(B)(ii) shall not apply to any Performance Shares or any Restricted Stock Units the vesting of which is based, in whole or in part, on attainment of performance objectives.

(C)    Termination of Employment by Reason of Severance. Notwithstanding
any provision to the contrary contained in the Restricted Stock Unit Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of a Restricted Stock Unit Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of Severance, and:

9




(i)    The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, and would not have attained the requirements for Normal Retirement within six months after the termination date, then the restrictions applicable to any time-based vesting Restricted Stock Unit Award shall lapse upon the termination date, as to such Restricted Stock Units that would have vested at such time(s) as are set forth in the applicable Grant Notice as if the Participant had continued to be employed by the Corporation or one of its Affiliates during the six-month period after the termination date; or

(ii)    The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, but would have attained the requirements for Normal Retirement within six months after the termination date and the first anniversary of the Grant Date has occurred on or prior to the termination date, then the restrictions applicable to any time-based vesting Restricted Stock Units shall continue to lapse at such time(s) as are set forth in the applicable Grant Notice, as though the Participant had continued to be employed by the Corporation or one of its Affiliates during the restricted period; provided that if the first anniversary of the Grant Date of the Restricted Stock Unit Award has not occurred on or prior to the termination date, then the additional vesting terms provided in Section IV.2(C)(i) will apply to such award.

Notwithstanding the foregoing, this Section IV.2(C) shall not apply to any Restricted Stock Units the vesting of which is based, in whole or in part, on attainment of performance objectives.
(D)    Restriction on Sale. The Compensation Committee reserves the right to impose a restriction on the sale of Shares that the Participant receives upon the settlement of Restricted Stock Units or Performance Shares, unless the Participant has satisfied the ownership targets applicable to the Participant as provided in the Stock Ownership Policy.
3.    Dividend Equivalents. Subject to the discretion of the Compensation Committee, dividend equivalents shall be credited in respect of Restricted Stock Units and Performance Shares. Cash dividends shall be credited on behalf of the Participant to a deferred cash account (in a manner designed to comply with Code Section 409A) and the restrictions on such cash dividends shall lapse at the same time that the restrictions lapse on the associated Award of Restricted Stock Units or Performance Shares (as applicable), and cash dividends, along with accrued interest (if any) on such cash dividends, shall be paid in a lump sum at the same time that the Shares underlying the Restricted Stock Unit or Performance Share Award, and to which the cash dividends relate, are distributed. Stock dividends shall be converted into additional Restricted Stock Units or Performance Shares, which will be subject to all of the terms and conditions of the underlying Restricted Stock Units or Performance Shares, including the same vesting restrictions as the underlying Award.
4.    Assignability. A Participant shall not be permitted to sell, transfer, pledge, assign or encumber Restricted Stock Units or Performance Shares, other than pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act.

10



5.    No Stockholder Rights. Neither a Participant nor any person entitled to exercise a Participant’s rights in the event of the Participant’s death shall have any of the rights of a stockholder with respect to an Award of Restricted Stock Units or Performance Shares except to the extent that a book entry has been entered in the records of the Corporation’s transfer agent with respect to the Shares paid upon the settlement of any vested Restricted Stock Units or Performance Shares.
6.    Time of Payment of Restricted Stock Units and Performance Shares. Upon the lapse of the restriction imposed on Restricted Stock Units or Performance Shares, all Restricted Stock Units and Performance Shares that were not forfeited pursuant to Section IV.2(A), Section IV.2(B)(i), Section IV.2(C)(i), or Section V shall be paid to the Participant as soon as reasonably practicable after the restrictions lapse. Payment shall be made in Shares to the Participant’s brokerage account of record. If the Participant does not have a brokerage account of record, then in the form of an appropriate book entry entered in the records of the Corporation’s transfer agent recording the Participant’s unrestricted interest in the number of Shares subject to the Restricted Stock Units or Performance Shares.
Notwithstanding the foregoing, if a Participant becomes eligible for Normal Retirement, or is eligible for additional vesting under Section IV.2(C)(ii), prior to the date of the lapse of restrictions imposed on Restricted Stock Units and the vesting provisions of Section IV.2(B)(ii) or Section IV.2(C)(ii) apply, then such Restricted Stock Units shall be paid to the Participant’s brokerage account of record as soon as reasonably practicable after the earlier of the Participant’s Separation from Service or the originally scheduled vesting date (in any event before the end of the calendar year in which such date occurs), subject to the delay of payment (if applicable) provided in Section VII.14. The procedures set forth in Section VII.6 will be applied for any taxes due upon the lapse of restrictions imposed on the Restricted Stock Units due to a Participant’s Normal Retirement eligibility or additional vesting as provided in Section IV.2(C)(ii).
V.
SPECIAL FORFEITURE AND REPAYMENT RULES
Any other provision of this Statement of Terms and Conditions to the contrary notwithstanding, if the Administrator determines that a Participant has engaged in any of the actions described in 3 below, the consequences set forth in 1 and 2 below shall result:
1.    Any outstanding Option shall immediately and automatically terminate, be forfeited and shall cease to be exercisable, without limitation. In addition, any Award of Restricted Stock, Restricted Stock Units or Performance Shares as to which the restrictions have not lapsed shall immediately and automatically be forfeited and such Shares of Restricted Stock shall be returned to the Corporation and all of the rights of the Participant to such Awards and the underlying Shares shall immediately terminate.

11



2.    If the Participant exercised an Option within 12 months prior to the date upon which the Corporation discovered that the Participant engaged in any actions described in 3 below, the Participant, upon written notice from the Corporation, shall immediately pay to the Corporation the economic value realized or obtained by the exercise of such Option measured at the date of exercise. In addition, if the restrictions imposed on any Award of Restricted Stock, Restricted Stock Units or Performance Shares (including any unpaid dividends or Dividend Equivalents) lapsed within 12 months prior to the date the Corporation discovered that the Participant engaged in any action described in 3 below, the Participant, upon written notice from the Corporation, shall immediately pay to the Corporation the economic value realized or obtained with respect to such Award, measured at the date such Award vested.
3.    The consequences described in 1 and 2 above shall apply if the Participant, either before or after termination of employment with the Corporation or its Affiliates:
(A)    Discloses to others, or takes or uses for the Participant’s own purpose or the purpose of others, any trade secrets, confidential information, knowledge, data or know‑how or any other proprietary information or intellectual property belonging to the Corporation or its Affiliates and obtained by the Participant during the term of the Participant’s employment, whether or not they are the Participant’s work product. Examples of such confidential information or trade secrets include, without limitation, customer lists, supplier lists, pricing and cost data, computer programs, delivery routes, advertising plans, wage and salary data, financial information, research and development plans, processes, equipment, product information and all other types and categories of information as to which the Participant knows or has reason to know that the Corporation or its Affiliates intends or expects secrecy to be maintained;
(B)    Fails to promptly return all documents and other tangible items belonging to the Corporation or its Affiliates in the Participant’s possession or control, including all complete or partial copies, recordings, abstracts, notes or reproductions of any kind made from or about such documents or information contained therein, upon termination of employment, whether pursuant to retirement or otherwise;
(C)    Fails to provide the Corporation with at least 30 days’ written notice prior to directly or indirectly engaging in, becoming employed by, or rendering services, advice or assistance to any business in competition with the Corporation or its Affiliates. As used herein, “business in competition” means any person, organization or enterprise which is engaged in or is about to become engaged in any line of business engaged in by the Corporation or its Affiliates at the time of the termination of the Participant’s employment with the Corporation or its Affiliates;
(D)    Fails to inform any new employer, before accepting employment, of the terms of this paragraph and of the Participant’s continuing obligation to maintain the confidentiality of the trade secrets and other confidential information belonging to the Corporation or its Affiliates and obtained by the Participant during the term of the Participant’s employment with the Corporation or any of its Affiliates;

12



(E)    Induces or attempts to induce, directly or indirectly, any of the customers of the Corporation or its Affiliates, employees, representatives or consultants to terminate, discontinue or cease working with or for the Corporation or its Affiliates, or to breach any contract with the Corporation or any of its Affiliates, in order to work with or for, or enter into a contract with, the Participant or any third party;
(F)    Engages in conduct which is not in good faith and which disrupts, damages, impairs or interferes with the business, reputation or employees of the Corporation or its Affiliates; or
(G)    Fails to meet the Participant’s continuing obligations with respect to non-disclosure, non-competition and/or non-solicitation under the Participant’s agreement with the Corporation or any Affiliate.
The Administrator shall determine in its sole discretion whether the Participant has engaged in any of the acts set forth in (A) through (G) above, and its determination shall be conclusive and binding on all interested persons.
Any provision of this Section V which is determined by a court of competent jurisdiction to be invalid or unenforceable should be construed or limited in a manner that is valid and enforceable and that comes closest to the business objectives intended by such invalid or unenforceable provision, without invalidating or rendering unenforceable the remaining provisions of this Section V.

13



VI.
CHANGE IN CONTROL
If as a result of a Change in Control, the Common Stock ceases to be listed for trading on a national securities exchange (an “Exchange”), any Option, Restricted Stock Award, Restricted Stock Unit Award, or Performance Share Award that is unvested on the effective date of the Change in Control shall continue to vest according to the terms and conditions of such Award, provided that such Award is replaced with an award for voting securities of the resulting corporation or the acquiring corporation, as the case may be, (including without limitation, the voting securities of any corporation which as a result of the Change in Control owns the Corporation or all or substantially all of the Corporation’s assets either directly or through one or more subsidiaries) (the “Surviving Company”) which are traded on an Exchange (a “Replacement Award”), which Replacement Award, (i) in the case of an Option, shall consist of an option with the number of underlying shares and exercise price determined in a manner consistent with Code Section 424(a) with vesting and any other terms continuing in the same manner as the replaced Option; (ii) in the case of a Performance Share Award, shall consist of restricted stock or restricted stock units with a value (determined using the Surviving Company’s stock price as of the effective date of the Change in Control) equal to the value of the Performance Share Award (determined using the Corporation’s stock price and assuming attainment of target performance or actual performance achieved, if greater, as of the effective date of the Change in Control), with any restrictions on such restricted stock or restricted stock units lapsing at the end of the measuring period over which performance for the replaced Performance Share Award was to be measured prior to the granting of the Replacement Award; and (iii) in the case of a Restricted Stock Award or Restricted Stock Unit Award, shall consist of restricted stock or restricted stock units with a value (determined using the Surviving Company’s stock price as of the effective date of the Change in Control) equal to the value of the Restricted Stock Award or Restricted Stock Unit Award (determined using the Corporation’s stock price as of the effective date of the Change in Control), with any restrictions on such restricted stock or restricted stock units lapsing at the same time and manner as the replaced Award; provided, however, that in the event of the Participant’s involuntary Separation from Service by the Corporation without Cause or Separation from Service by the Participant for Good Reason during the vesting period of any Replacement Award, the Replacement Award shall immediately vest and be paid as soon as practicable following such Separation from Service (subject to Section VII.14), based on the fair market value of the underlying shares on the vesting date, or in the case of options, based on the excess of the fair market value of the underlying shares over the option exercise price on the vesting date. If any Option, Restricted Stock Award, Restricted Stock Unit Award, or Performance Share Award that is unvested at the effective time of the Change in Control is not replaced with a Replacement Award, such Award shall immediately vest and, in the case of a Performance Share Award, shall vest based upon deemed attainment of target performance or actual performance achieved, if greater.

14



If as a result of a Change in Control, the Common Stock continues to be listed for trading on an Exchange, any unvested Option, Restricted Stock Award, or Restricted Stock Unit Award shall continue to vest according to the terms and conditions of such Award and any Performance Share Award shall be replaced with a Restricted Stock Award or Restricted Stock Unit Award where the number of shares subject to such Restricted Stock Award or Restricted Stock Unit Award shall be equal to the number of Performance Shares assuming attainment of target performance or actual performance achieved, if greater, as of the effective date of the Change in Control with any restrictions on such Restricted Stock Award or Restricted Stock Unit Award lapsing at the end of the measuring period over which performance for the replaced Performance Share Award was to be measured prior to the granting of the replacement Award; provided however, that, in the event of the Participant’s involuntary Separation from Service by the Corporation without Cause or Separation from Service by the Participant for Good Reason during the vesting period of an Award, such Award shall immediately vest and be paid as soon as practicable following such Separation from Service (subject to Section VII.14).
VII.
MISCELLANEOUS
1.    No Effect on Terms of Employment. Participation in the Plan shall not create a right to further employment with the Participant’s employer (the “Employer”) and shall not interfere with the ability of the Employer to terminate, with or without cause, or change the terms of employment of a Participant at any time.
2.    Grants to Participants in Foreign Countries. In making grants to Participants in foreign countries, the Administrator has the full discretion to deviate from this Statement of Terms and Conditions in order to adjust grants under the Plan to prevailing local conditions, including custom and legal and tax requirements. Furthermore, the Corporation reserves the right to impose other requirements on the Participant’s participation in the Plan on the Award and on any Shares acquired under the Plan, to the extent the Corporation determines it is necessary or advisable in order to comply with local law or facilitate the administration of the Plan, and to require the Participant to sign any additional agreements or undertaking that may be necessary to accomplish the foregoing.
3.    Information Notification. Any information required to be given under the terms of an Award shall be addressed to the Corporation in care of its Corporate Secretary at McKesson Corporation, One Post Street, San Francisco, California 94104, and any notice to be given to a Participant shall be addressed to such Participant at the address indicated beneath the Participant's name on the Award Agreement or such other address as either party may designate in writing to the other. Any such notice shall be deemed to have been duly given when enclosed in a properly sealed envelope or wrapper addressed as aforesaid, registered or certified and deposited (postage or registration or certification fee prepaid) in a post office or branch post office.
4.    Administrator Decisions Conclusive. All decisions of the Administrator administering the Plan upon any questions arising under the Plan or under an Award Agreement, shall be conclusive and binding on all interested persons.

15



5.    No Effect on Other Benefit Plans. Nothing herein contained shall affect a Participant’s right to participate in and receive benefits from and in accordance with the then current provisions of any pensions, insurance or other employment welfare plan or program offered by the Corporation.
6.    Withholding. Regardless of any action the Corporation or the Employer takes with respect to any federal, state or local income tax, social insurance, payroll tax, payment on account or other tax-related items related to the Participant’s participation in the Plan and legally applicable to the Participant (“Tax-Related Items”), the Participant acknowledges that the ultimate liability for all Tax-Related Items is and remains the Participant's responsibility and may exceed the amount actually withheld by the Corporation or the Employer. The Participant further acknowledges that the Corporation and/or the Employer (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Award, including the grant, vesting or exercise of the Award, as applicable, the subsequent sale of Shares acquired pursuant to the Plan and the receipt of any dividends and/or dividend equivalents; and (2) do not commit and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Participant’s liability for Tax-Related Items or achieve any particular tax result. Further, if the Participant has become subject to tax in more than one jurisdiction between the Grant Date and the date of any relevant taxable event, the Participant acknowledges that the Corporation and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.
Prior to any relevant taxable or tax withholding event, as applicable, the Participant will pay or make adequate arrangements satisfactory to the Corporation and/or the Employer, or their respective agents, at their discretion, to satisfy the obligations with regard to all Tax-Related Items by one or a combination of the following: (1) withholding from the Participant’s wages or other cash compensation paid to the Participant by the Corporation and/or the Employer; (2) withholding from proceeds of the sale of Shares acquired under the Plan either through a voluntary sale or through a mandatory sale arranged by the Corporation (on the Participant’s behalf pursuant to this authorization and any other authorization the Corporation and/or the broker designated by the Corporation may require the Participant to sign in connection with the sale of Shares); or (3) withholding Shares to be issued upon grant, vesting/settlement or exercise, as applicable. Calculation of the number of Shares to be withheld shall be made based on the closing price of the Common Stock on the New York Stock Exchange on the date that the amount of tax to be withheld is determined. In no event, however, shall the Corporation be required to issue fractional Shares. With respect to an Award other than an Option, if adequate arrangements to satisfy the obligations with regard to all Tax-Related Items are not made by the Participant with the Corporation and/or the Employer prior to the relevant taxable event, the Corporation will satisfy such obligations as provided above in clause (3) of this paragraph.
To avoid negative accounting treatment, the Corporation may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates. If the obligation for Tax-Related Items is satisfied by withholding in Shares, for tax purposes, the Participant will be deemed to have been issued the full number of Shares subject to the Award, notwithstanding that a number of the Shares are held back solely for the purpose of paying the Tax-Related Items due as a result of any aspect of the Participant’s participation in the Plan.

16



Finally, the Participant shall pay to the Corporation or the Employer any amount of Tax-Related Items that the Corporation or the Employer may be required to withhold or account for as a result of the Participant’s participation in the Plan that cannot be satisfied by the means previously described. The Corporation may refuse to issue or deliver the Shares or the proceeds of the sale of Shares if the Participant fails to comply with the Participant's obligations in connection with the Tax-Related Items.
The Administrator shall be authorized to establish such rules, forms and procedures as it deems necessary to implement the foregoing.
7.    Successors. The Award Agreements shall be binding upon and inure to the benefit of any successor or successors of the Corporation. “Participant” as used herein shall include the Participant’s Beneficiary.
8.    Delaware Law. The interpretation, performance, and enforcement of all Award Agreements shall be governed by the laws of the State of Delaware.
9.    Nature of Grant. In accepting the grant, the Participant acknowledges that:
(A)    the Plan is established voluntarily by the Corporation, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Corporation at any time;
(B)    the grant of the Award is voluntary and occasional and does not create any contractual or other right to receive future Award grants, or benefits in lieu of Awards, even if Awards have been granted repeatedly in the past;
(C)    all decisions with respect to future Awards, if any, will be at the sole discretion of the Corporation;
(D)    the Participant is voluntarily participating in the Plan;
(E)    the Award is not part of normal or expected compensation for any purpose, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments;
(F)    the Award will not be interpreted to form an employment contract or relationship with the Corporation; and furthermore, the Award will not be interpreted to form an employment contract with any subsidiary or Affiliate of the Corporation;
(G)    the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty;
(H)    if the underlying Shares do not increase in value, the Options will have no value;

17



(I)    in consideration of the grant of the Award, no claim or entitlement to compensation or damages shall arise from forfeiture of the Award which results from termination of the Participant’s employment with the Employer or the Corporation or one of its Affiliates (for any reason whatsoever) and the Participant irrevocably releases the Corporation or its Affiliates from any such claim that may arise; if, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen, then, by accepting the Award, the Participant shall be deemed irrevocably to have waived the Participant's entitlement to pursue such claim;
(J)    for purposes of an Award, the Participant’s employment relationship will be considered terminated as of the date the Participant is no longer a bona fide employee of the Corporation or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of the employment laws in the jurisdiction where the Participant is employed or the terms of the Participant’s employment agreement, if any), and unless otherwise expressly provided in this Award Agreement or determined by the Corporation in its sole discretion, the Participant’s right to receive Awards and vest in Awards under the Plan, if any, will terminate effective as of such date and will not be extended by any notice period mandated under local law; similarly, any right to exercise Options under the Plan after termination of employment will be measured as of the date the Participant is no longer a bona fide employee of the Corporation or one of its Affiliates and will not be extended by any notice period mandated under local law; the Administrator shall have the sole discretion to determine when the Participant is no longer a bona fide employee;
(K)    the Corporation is not providing any tax, legal or financial advice, nor is the Corporation making any recommendations regarding participation in the Plan or the Participant’s acquisition or sale of Shares; and
(L)    Participant is hereby advised to consult with the Participant's own personal tax, legal and financial advisors regarding Participant’s participation in the Plan before taking any action related to the Plan.
10.    Data Privacy. By accepting the Award, the Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of the Participant's personal data as described in this document by and among, as applicable, the Employer and the Corporation and its Affiliates for the exclusive purpose of implementing, administering and managing participation in the Plan.

18



The Participant understands that the Corporation and the Employer hold certain personal information about the Participant, including, but not limited, the Participant's name, home address and telephone number, date of birth, social insurance or other identification number, salary, nationality, job title, any Shares or directorships held in the Corporation, details of all Options, Restricted Stock, Restricted Stock Units, Performance Shares, Other Share-Based Awards, or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in the Participant’s favor, for the purpose of implementing, administering and managing the Plan (“Data”). The Participant understands that Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, that recipients of Data may be located in the United States or elsewhere, and that the recipient’s country may have different data privacy laws and protections than the Participant’s country. The Participant understands that if the Participant resides outside of the United States, the Participant may request a list with the names and addresses of any potential recipients of the Data by contacting the local human resources representative. The Participant authorizes the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom the Participant may elect to deposit any Shares acquired under the Plan. The Participant understands that Data will be held only as long as is necessary to implement, administer and manage the Participant's participation in the Plan. The Participant understands that if the Participant resides outside of the United States, the Participant may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, without cost, by contacting in writing the local human resources representative. Further, the Participant understands that the Participant is providing the consents herein on a purely voluntary basis. If the Participant does not consent, or if the Participant later seeks to revoke the Participant's consent, the Participant’s employment status or service and career with the Employer will not be adversely affected; the only adverse consequence of refusing or withdrawing the Participant's consent is that the Corporation would not be able to grant the Participant Awards or administer or maintain such Awards. Therefore, the Participant understands that refusing or withdrawing consent may affect the Participant's ability to participate in the Plan. For more information on the consequences of refusal to consent or withdrawal of consent, the Participant understands that the Participant may contact the local human resources representative.
11.    Severability. The provisions in this Statement of Terms and Conditions are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.
12.    Language. If the Participant has received this Statement of Terms and Conditions or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.
13.    Electronic Delivery. The Corporation may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Corporation or a third party designated by the Corporation.

19



14.    Section 409A. If (A) the Participant is a Specified Employee at the time of the Participant’s Separation from Service, and (B) some or any portion of the amounts payable to the Participant, if any, when considered together with any other payments or benefits which may be considered deferred compensation under section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”) and subject to the plan aggregation rules under Treasury Regulation section 1.409A-1(c)(3)(viii) (together, the “Deferred Compensation Benefits”) would result in the imposition of additional tax under Section 409A if paid to the Participant on or within the six month period following the Separation from Service, then to the extent such portion of the Deferred Compensation Benefits resulting in the imposition of additional tax would otherwise have been payable on or within the first six months following the Separation from Service, it will instead become payable on the first payroll date that occurs in the seventh month following the Separation from Service (or such longer period as is required to avoid the imposition of additional tax under Section 409A). All subsequent Deferred Compensation Separation Benefits, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit.
VIII.
DEFINITIONS
When capitalized in this Statement of Terms and Conditions, the following terms shall have the meaning set forth below:
1.    Award Agreement” means an agreement between the Participant and the Corporation evidencing the grant of an Option, Restricted Stock Award, Restricted Stock Award, Performance Shares or Other Share-Based Award, as applicable.
2.    Cause” means termination of the Participant’s employment with the Corporation or an Affiliate upon the Participant’s negligent or willful engagement in misconduct which, in the sole determination of the Chief Executive Officer of the Corporation (or the Chief Executive Officer’s designee), is injurious to the Corporation, its employees, or its customers.
3.    Early Retirement” means a termination of employment (other than due to death, Long-Term Disability or for Cause) which occurs prior to Normal Retirement but on or after the date on which the Participant’s age (expressed in terms of years and completed months) plus service with the Corporation or an Affiliate equals 65. For purposes of determining eligibility for Early Retirement, the term “service” shall include years and completed whole months of service.
4.    Family Member” means any person identified as an “immediate family” member in Rule 16(a)‑1(e) of the Exchange Act, as such Rule may be amended from time to time. Notwithstanding the foregoing, the Administrator may designate any other person(s) or entity(ies) as a “family member.”
5.    “Good Reason” means any of the following actions, if taken without the express written consent of the Participant:

20



(A)    Any material change by the Corporation in the Participant’s functions, duties, or responsibilities, which change would cause the Participant’s position with the Corporation to become of less dignity, responsibility, importance, or scope from the position and attributes that applied to the Participant immediately prior to the Change in Control; provided, however, that, any such change attributable to the Corporation’s no longer being a company with publicly traded common stock shall not constitute Good Reason; and provided, further, that a reduction in the Participant’s functions, duties or responsibilities solely by virtue of the Corporation being acquired and made part of a larger entity (for example, if following a Change in Control the Participant retains the Participant’s position, or has a comparable position, with respect to a division or subsidiary of the acquirer that contains the Corporation’s business) shall not constitute Good Reason;
(B)    Any significant reduction in the Participant’s aggregate base annual salary and target incentive opportunity, as in effect immediately prior to the Change in Control;
(C)    Any material failure by the Corporation to comply with any of the provisions of an Award subsequent to a Change in Control; or
(D)    The Corporation’s requiring the Participant to be based at any location which would increase the Participant’s regular one-way commute by more than 25 miles from that in effect immediately preceding the Change in Control, except for travel reasonably required in the performance of the Participant’s responsibilities;
Provided that the Participant gives notice to the Corporation of the existence of the Good Reason condition within 30 days of the initial existence of the Good Reason condition and the Corporation is provided 30 days after receipt of the Participant’s notice to remedy the Good Reason condition; provided further that the Participant’s Separation from Service must occur within six months from the initial existence of the Good Reason condition if the Corporation does not remedy such condition for such separation to be considered to be for Good Reason.
6.    “Expiration Date” means the date that an Option expires as set forth in the Option Grant Notice as the “Expiration Date.”
7.    “Grant Date” means the date the Administrator grants the Award.
8.    “Grant Notice” means the notice of an Award granted to the Participant, which sets forth certain terms of such Award.
9.    “Long‑Term Disability” means a physical or mental condition in respect of which the administrator of the Corporation’s long-term disability plan has determined that the Participant is eligible to receive income replacement benefits; or, if the Participant is not then a participant in the Corporation’s long-term disability plan, a physical or mental condition that the administrator of the Corporation’s long-term disability plan determines would have rendered the Participant eligible to receive income replacement benefits, had the Participant been enrolled in such plan.

21



10.    “Normal Retirement” means termination of employment (other than due to death, Long-Term Disability or for Cause) at or after age 60 (57, in the case of a participant in the McKesson Corporation 1984 Executive Benefit Retirement Plan) with at least 10 years of service with the Corporation or an Affiliate. For purposes of determining eligibility for Normal Retirement, “service” shall mean completed whole years of service (12 consecutive months).
11.    “Option Period” means the period commencing on the Grant Date of an Option and, except at otherwise provided in Section II.5, ending on the Expiration Date.
12.    “Separation from Service” means termination of employment with the Corporation or an affiliate. A Participant shall be deemed to have had a Separation from Service if the Participant’s service with the Corporation or an affiliate is reduced to an annual rate that is equal to or less than 20% of the services rendered, on average, during the immediately preceding three years of service with the Corporation or an affiliate (or, if providing service to the Corporation or an affiliate for less than three years, such lesser period).
13.    “Severance” means termination of employment with the Corporation or an affiliate, and qualified for participation in and entitlement to benefits under the McKesson Corporation Severance Pay Plan, in accordance with the terms and conditions of such plan.
14.    “Short‑Term Disability” means short‑term disability as defined in the Corporation’s short‑term disability plan.
15.    “Specified Employee” means those employees identified by the Corporation as "Specified Employees" for purposes of Code Section 409A.
16.    “Stock Ownership Policy” means the Corporation’s Stock Ownership Policy, as amended from time to time, which can be found on McKNet. A Participant or a Participant’s beneficiary may also request a copy of the Stock Ownership Policy by writing to the Corporate Secretary at McKesson Corporation, One Post Street, San Francisco, CA 94104.


22




EMPLOYEE

McKESSON CORPORATION
STATEMENT OF TERMS AND CONDITIONS APPLICABLE TO
OPTIONS, RESTRICTED STOCK, RESTRICTED STOCK UNITS AND
PERFORMANCE SHARES GRANTED TO EMPLOYEES PURSUANT
TO THE 2013 STOCK PLAN
Effective for Grants Beginning May 24, 2016
I.
INTRODUCTION
The following terms and conditions shall apply to an Award granted under the Plan and are subject to the terms and conditions of the Plan. This Statement of Terms and Conditions is intended to meet the requirements of Code Section 409A and any rules promulgated thereunder. In the event of any inconsistency between this Statement of Terms and Conditions and the Plan, the Plan shall govern. Capitalized terms not otherwise defined in this Statement of Terms and Conditions shall have the meaning set forth in the Plan.
II.
OPTIONS
1.    Option Agreement. An Option granted under the Plan shall be evidenced by an Option Agreement setting forth the terms and conditions of the Option, including whether the Option is an Incentive Stock Option or a Nonstatutory Stock Option and the number of Shares subject to the Option. Each Option Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant’s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Option Agreement. The Option is also subject to the terms and conditions of the Plan.
2.    Exercise Price. The Exercise Price of an Option, as specified in the Option Agreement, shall be equal to or greater than the Fair Market Value of the Shares underlying the Option on the Grant Date.
3.    Option Period. An Option shall be exercisable only during the applicable Option Period, and during such Option Period the exercisability of the Option shall be subject to the vesting provisions of Section II.4 as modified by the rules set forth in Sections II.5 and V. The Option Period shall be not more than seven years from the Grant Date.

1



4.    Vesting of Right to Exercise Options.
(A)    Except as provided in Sections II.5 and V, an Option shall be exercisable during the Option Period in accordance with the following vesting schedule:  (i) 25% of the Shares subject to the Option shall vest on the first anniversary of the Grant Date; (ii) an additional 25% of the Shares shall vest on the second anniversary of the Grant Date; (iii) an additional 25% of the Shares shall vest on the third anniversary of the Grant Date; and (iv) the remaining 25% of the Shares subject to the Option shall vest on the fourth anniversary of the Grant Date. Notwithstanding the foregoing, the Administrator may specify a different vesting schedule at the time the Option is granted, which will be specified in the Option Grant Notice.
(B)    Any vested portion of an Option not exercised hereunder shall accumulate and be exercisable at any time on or before the Expiration Date, subject to the rules set forth in Sections II.5 and V. No Option may be exercised for less than 5% of the total number of Shares then available for exercise under such Option. In no event shall the Corporation be required to issue fractional Shares.
5.    Limits on Option Period and Acceleration of Vesting. The Option Period may end before the Expiration Date, and in certain circumstances the vesting schedule of an Option may be accelerated (subject to the provisions of Section V), as follows:
(A)    If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period for reasons other than for Cause, Long‑Term Disability, Normal Retirement, Early Retirement, Severance under the circumstances provided in Section II.5(F)(ii), or death, the Option Period shall end on the earlier of (i) 90 days after the date of the Participant’s termination of employment and (ii) the Expiration Date, and in all cases the Option shall be exercisable only to the extent that it was exercisable under the provisions of the foregoing Section II.4 at the time of such termination of employment. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short‑Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Administrator may otherwise expressly determine.
(B)    Notwithstanding any other provision in this Section II.5, if a Participant’s employment is terminated for Cause during the Option Period, the Option Period shall end on the date of such termination of employment and the Option shall thereupon not be exercisable to any extent whatsoever.
(C)    If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Long‑Term Disability, the vesting schedule of the Participant’s Option shall be accelerated, the Option shall become fully exercisable and the Option Period shall end on the earlier of (i) three years after the date of the Participant’s termination of employment and (ii) the Expiration Date.

2



(D)    If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Early Retirement, (i) the Option shall be exercisable only to the extent that it was exercisable under the provisions of the foregoing Section II.4 at the time of such retirement and (ii) the Option Period for that portion of the Option designated as a Nonstatutory Stock Option shall end on the earlier of (a) three years after the date of such retirement and (b) the Expiration Date.
(E)    If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Normal Retirement:
(i)    If such Normal Retirement occurs prior to the first anniversary of the Grant Date of the Option, such Option shall be subject to the provisions of Section II.5(D) as though the Participant were eligible for Early Retirement; and
(ii)    If such Normal Retirement occurs on or after the first anniversary of the Grant Date of an Option, (a) that portion of the Option designated as a Nonstatutory Stock Option shall continue to vest as set forth in the foregoing Section II.4 as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such vesting period, and (b) the Option Period for such portion of the Option designated as a Nonstatutory Stock Option shall end on the Expiration Date.
(F)    If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Severance, and
(i)    The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, and would not have attained the requirements for Normal Retirement within six months after the termination date, then (a) the vesting schedule of the Participant’s Option shall be accelerated as to the portion of the Option that would have vested in accordance with the vesting schedule set forth in the foregoing Section II.4 as if the Participant had continued to be employed by the Corporation or one of its Affiliates six months after the termination date, and (b) the expiration of the Option Period provided in Section II.5(A) shall apply; provided that if the Participant is also eligible for Early Retirement at the time of the termination of employment, then the expiration of the Option Period provided in Section II.5(D) shall apply; or
(ii)    The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, but would have attained the requirements for Normal Retirement within six months after the termination date, and:
1.    The first anniversary of the Grant Date of the applicable Award has not occurred on or prior to the termination date, then such Option shall be subject to the Early Retirement provision in Section II.5(D); and

3



2.    The first anniversary of the Grant Date of the applicable Award has occurred on or prior to the termination date, then (x)  that portion of the Option designated as a Nonstatutory Stock Option shall continue to vest as set forth in the foregoing Section II.4 as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such vesting period, and (y) the Option Period for such portion of the Option designated as a Nonstatutory Stock Option shall end on the Expiration Date.
(G)    If a Participant should die (i) while in the employ of the Corporation or an Affiliate and (ii) during the Option Period, the vesting schedule of the Participant’s Option shall be accelerated and the Option shall become fully exercisable, the Option Period shall end on the earlier of (a) three years after the date of death and (b) the Expiration Date, and the Participant’s Beneficiary may exercise the entire unexercised portion of the then exercisable Shares covered by such Option (or any lesser amount) remaining on the date of death.
(H)    If a Participant who ceases to be a bona fide employee of the Corporation or an Affiliate is subsequently rehired prior to the expiration of the Participant's Option, then the Option shall continue to remain outstanding until the earlier of (i) such time as the Participant subsequently terminates employment and (ii) the Expiration Date. Upon the Participant’s subsequent termination of employment, the post‑termination exercise period calculated pursuant to the terms and conditions of this Section II.5 shall be reduced by the number of days between the date of the Participant’s initial termination of employment and the Participant's re‑hire date; provided, however, that if the rehired Participant continues to be employed by the Corporation or an Affiliate for at least one year from the Participant's rehire date, then the post termination exercise period for the Option shall be determined in accordance with Sections II.5(A) through (G) and shall not be adjusted as described in this Section II.5(H).
6.    Method of Exercise. A Participant may exercise an Option with respect to all or any part of the exercisable Shares as follows:

4



(A)    By giving the Corporation, or its authorized representative designated for this purpose, written notice of such exercise specifying the number of Shares as to which the Option is so exercised. Such notice shall be accompanied by an amount equal to the Exercise Price multiplied by the number of Shares exercised, in the form of any one or combination of the following:  cash or a certified check, bank draft, postal or express money order payable to the order of the Corporation in lawful money of the United States. Unless otherwise determined by the Administrator in its sole discretion, the Participant may pay the Exercise Price, in whole or in part, by tendering to the Corporation or its authorized representative Shares, which have been owned by the Participant for at least six months prior to said tender, and having a fair market value, as determined by the Corporation, equal to the Exercise Price, or in lieu of the delivery of actual Shares in such tender, the Corporation may accept an attestation by the Participant, in a form prescribed by the Corporation or its authorized representative, that the Participant owns sufficient Shares of record or in an account in street name to satisfy the Exercise Price, and such attestation will be deemed a tender of Shares for purposes of this method of exercise. The Corporation or its authorized representative may accept payment of the amount due upon the exercise of the Option in the form of a Participant’s personal check. Payment may also be made by delivery (including by FAX transmission) to the Corporation or its authorized representative of an executed irrevocable Option exercise form together with irrevocable instructions to an approved registered investment broker to sell Shares in an amount sufficient to pay the Exercise Price plus any applicable Tax-Related Items (as defined in Section VII.6) and to transfer the proceeds of such sale to the Corporation.
(B)    If required by the Corporation, by giving satisfactory assurance in writing, signed by the Participant, the Participant shall give the Participant's assurance that the Shares subject to the Option are being purchased for investment and not with a view to the distribution thereof; provided that such assurance shall be deemed inapplicable to (i) any sale of the Shares by such Participant made in accordance with the terms of a registration statement covering such sale, which has heretofore been (or may hereafter be) filed and become effective under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and with respect to which no stop order suspending the effectiveness thereof has been issued, and (ii) any other sale of the Shares with respect to which, in the opinion of counsel for the Corporation, such assurance is not required to be given in order to comply with the provisions of the Securities Act.
(C)    As soon as practicable after receipt of the notice and the assurance described in Sections II.6(A) and (B), the Corporation shall, without transfer or issue tax (except for withholding tax arrangements contemplated in Section VII.6) and without other incidental expense to the Participant, credit the purchased Shares to the Participant’s brokerage account of record. If the Participant does not have a brokerage account of record, then the Corporation shall cause an appropriate book entry to be entered in the records of the Corporation’s transfer agent recording the Participant’s unrestricted interest in the purchased Shares; provided, however, that the time of such delivery may be postponed by the Corporation for such period as may be required for it with reasonable diligence to comply with applicable registration requirements under the Securities Act, the Exchange Act, any applicable listing requirements of any national securities exchange and requirements under any other law or regulation applicable to the issuance or transfer of the Shares.

5



7.    Limitations on Transfer. An Option shall, during a Participant’s lifetime, be exercisable only by the Participant. No Option or any right granted thereunder shall be transferable by the Participant by operation of law or otherwise, other than by will or the laws of descent and distribution. Notwithstanding the foregoing: (A) a Participant may designate a beneficiary to succeed, after the Participant’s death, to all of the Participant’s Options outstanding on the date of death; (B) a Nonstatutory Stock Option may be transferable pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act; and (C) any Participant, who is a senior executive officer recommended by the Chief Executive Officer of the Corporation and approved by the Administrator may voluntarily transfer any Nonstatutory Stock Option to a Family Member as a gift or through a transfer to an entity in which more than 50% of the voting interests are owned by Family Members (or the Participant) in exchange for an interest in that entity. In the event of any attempt by a Participant to alienate, assign, pledge, hypothecate, or otherwise dispose of an Option or of any right thereunder, except as provided herein, or in the event of the levy of any attachment, execution, or similar process upon the rights or interest hereby conferred, the Corporation at its election may terminate the affected Option by notice to the Participant and the Option shall thereupon become null and void.
8.    No Stockholder Rights. Neither a Participant nor any person entitled to exercise a Participant’s rights in the event of the Participant’s death shall have any of the rights of a stockholder with respect to the Shares subject to an Option except to the extent that a book entry has been entered in the records of the Corporation’s transfer agent with respect to such Shares upon the exercise of an Option.
III.
RESTRICTED STOCK
1.    Restricted Stock Agreement. A Restricted Stock Award granted under the Plan shall be evidenced by a Restricted Stock Agreement to be executed by the Participant and the Corporation setting forth the terms and conditions of the Restricted Stock Award. Each Restricted Stock Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant’s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Restricted Stock Agreement. The Restricted Stock Award is also subject to the terms and conditions of the Plan.
2.    Rights with Respect to Shares of Restricted Stock. Upon written acceptance of a Restricted Stock Award by a Participant, including the restrictions and other terms and conditions described in the Plan and the Restricted Stock Agreement, the Corporation shall cause an appropriate book entry to be entered in the records of the Corporation’s transfer agent recording the Participant’s interest in the Restricted Stock. From and after the Grant Date, the Participant shall have the rights of Common Stock ownership, including the right to vote and to receive dividends on Shares of Restricted Stock, subject to the terms, conditions and restrictions described in the Plan and the Restricted Stock Agreement.

6



3.    Special Restrictions. Each Restricted Stock Award made under the Plan shall be subject to the following terms, conditions and restrictions and such additional terms, conditions and restrictions as may be determined by the Administrator; provided, however, that no Restricted Stock grant shall be subject to additional terms, conditions and restrictions which are more favorable to a Participant than the terms, conditions and restrictions set forth elsewhere in the Plan or the Restricted Stock Agreement.
(A)    Restrictions. Until the restrictions imposed on any Restricted Stock grant shall lapse (the “Restriction Period”), Shares of Restricted Stock granted to a Participant (i) shall not be sold, assigned, transferred, pledged, hypothecated, or otherwise disposed of, other than pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act and (ii) shall, if the Participant’s continuous employment with the Corporation or any of its Affiliates shall terminate for any reason (except as otherwise provided in the Plan, or in Section III.3(B) or Section III.3(C)) be returned to the Corporation forthwith, and all the rights of the Participant to such Shares shall immediately terminate. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short‑Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Administrator may otherwise expressly determine.
(B)    Termination of Employment by Reason of Death, Long‑Term Disability or Normal Retirement. Notwithstanding any provision to the contrary contained in the Restricted Stock Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of a Restricted Stock Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of:
(i)    Death or Long‑Term Disability, then the restrictions imposed on any Restricted Stock Award shall lapse as to all Shares granted to such Participant pursuant to such Restricted Stock Award on the date of such termination; or
(ii)    Normal Retirement on or after the first anniversary of the Grant Date of any time-based vesting Restricted Stock Award, the restrictions applicable to such Restricted Stock Award shall continue to lapse at such time(s) as are set forth in the applicable Grant Notice, as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such restricted period; provided, that notwithstanding any other provision of the Plan or this Statement of Terms and Conditions, this Section III.3(B)(ii) shall not apply to any Restricted Stock Award the vesting of which is based, in whole or in part, on attainment of performance objectives. The procedures set forth in Section VII.6 will be applied for any taxes due upon the lapse of restrictions imposed on a Restricted Stock Award due to a Participant’s Normal Retirement eligibility.
(C)    Termination of Employment by Reason of Severance. Notwithstanding any provision to the contrary contained in the Restricted Stock Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of a Restricted Stock Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of Severance, and:

7



(i)    The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, and would not have attained the requirements for Normal Retirement within six months after the termination date, then the restrictions applicable to any time-based vesting Restricted Stock Award shall lapse upon the Participant’s termination date, as to such Shares of Restricted Stock that would have vested at such time(s) as are set forth in the applicable Grant Notice as if the Participant had continued to be employed by the Corporation or one of its Affiliates during the six-month period after the Participant’s termination date; or
(ii)    The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, but would have attained the requirements for Normal Retirement within six months after the termination date and the first anniversary of the Grant Date of the Restricted Stock Award has occurred on or prior to the termination date, then the restrictions applicable to the time-based vesting Restricted Stock Award shall continue to lapse at such time(s) as are set forth in the applicable Grant Notice, as though the Participant had continued to be employed by the Corporation or one of its Affiliates during the restricted period; provided that if the first anniversary of the Grant Date of the Restricted Stock Award has not occurred on or prior to the termination date, then the additional vesting terms and conditions provided in Section III.3(C)(i) shall apply to such award.
Notwithstanding the foregoing, this Section III.3(C) shall not apply to any Restricted Stock Award the vesting of which is based, in whole or in part, on attainment of performance objectives. The procedures set forth in Section VII.6 will be applied for any taxes due upon the lapse of restrictions imposed on a Restricted Stock Award due to a Participant’s Normal Retirement eligibility.
4.    Dividends. Cash dividends paid with respect to Restricted Stock during the Restriction Period shall be credited on behalf of the Participant to a deferred cash account (in a manner designed to comply with Code Section 409A) and the restrictions on such cash dividends shall lapse at the same time that the restrictions lapse on the associated Restricted Stock Award. Stock dividends paid with respect to Restricted Stock during the Restriction Period shall be treated as Restricted Stock which shall be subject to the same restrictions as the original award for the duration of the Restriction Period.
5.    Election to Recognize Gross Income in the Year of Grant. If any Participant validly elects within 30 days of the Grant Date, to include in gross income for federal income tax purposes an amount equal to the fair market value of the Shares of Restricted Stock granted on the Grant Date, such Participant shall (at the same time or prior to the date that the Participant files the Participant's election with the Internal Revenue Service) (A) pay to the Corporation, or make arrangements satisfactory to the Administrator to pay to the Corporation in the year of such grant, any federal, state or local taxes required to be withheld with respect to such Shares in accordance with Section VII.6, and (B) provide the Administrator with a copy of the election filed with the Internal Revenue Service.

8



6.    Restrictive Legend. Each book entry in the records of the Corporation’s transfer agent evidencing Shares granted pursuant to a Restricted Stock grant may bear an appropriate legend referring to the terms, conditions and restrictions described in the Plan and/or the Restricted Stock Agreement.
7.    Expiration of Restriction Period. If and when the Restriction Period applicable to the Restricted Stock expires without a prior forfeiture, Shares shall be credited to the Participant’s brokerage account of record. If the Participant does not have a brokerage account of record, then an appropriate book entry recording the Participant’s interest in the unrestricted Shares shall be entered on the records of the Corporation’s transfer agent.
IV.
RESTRICTED STOCK UNITS AND PERFORMANCE SHARES
1.    Award Agreement.
(A)    Restricted Stock Units granted under the Plan shall be evidenced by a Restricted Stock Unit Agreement to be executed by the Participant and the Corporation setting forth the terms and conditions of the Restricted Stock Units. Each Restricted Stock Unit Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant’s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Restricted Stock Unit Agreement. The Restricted Stock Units are also subject to the terms and conditions of the Plan.
(B)    Performance Shares granted under the Plan shall be evidenced by a Performance Share Agreement to be executed by the Participant and the Corporation setting forth the terms and conditions of the Performance Shares. Each Performance Share Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant’s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Performance Share Agreement. Performance Shares are also subject to the terms and conditions of the Plan.
2.    Special Restrictions. Restricted Stock Units and Performance Shares granted under the Plan shall be subject to the following terms, conditions and restrictions and such additional terms, conditions and restrictions as may be determined by the Administrator, consistent with the terms of the Plan.
(A)    Restrictions. If a Participant ceases to be a bona fide employee of the Corporation or any Affiliate (except as otherwise provided in the Plan, or in Section IV.2(B) or Section IV.2(C)) prior to the lapse of the restrictions imposed on the Award, the unvested Restricted Stock Units or Performance Shares shall be canceled, and all the rights of the Participant to such Awards shall immediately terminate. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short‑Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Administrator may otherwise expressly determine.

9



(B)    Termination of Employment by Reason of Death, Long‑Term Disability or Normal Retirement. Notwithstanding any provision contained to the contrary in the Restricted Stock Unit Grant Notice or Performance Share Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of such Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of:
(i)    Death or Long‑Term Disability, then the restrictions imposed on any Award of Restricted Stock Units or Performance Shares shall lapse on the date of such termination; or
(ii)    Normal Retirement on or after the first anniversary of the Grant Date of any time-based vesting Restricted Stock Units, the restrictions applicable to such Restricted Stock Units shall continue to lapse at such time(s) as are set forth in the applicable Grant Notice, as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such restricted period; provided, that notwithstanding any other provision of the Plan or this Statement of Terms and Conditions, this Section IV.2(B)(ii) shall not apply to any Performance Shares or to any Restricted Stock Units the vesting of which is based, in whole or in part, on attainment of performance objectives.
(C)    Termination of Employment by Reason of Severance. Notwithstanding any provision to the contrary contained in the Restricted Stock Unit Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of a Restricted Stock Unit Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of Severance, and:
(i)    The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, and would not have attained the requirements for Normal Retirement within six months after the termination date, then the restrictions applicable to any time-based vesting Restricted Stock Unit Award shall lapse upon the termination date, as to such Restricted Stock Units that would have vested at such time(s) as are set forth in the applicable Grant Notice as if the Participant had continued to be employed by the Corporation or one of its Affiliates during the six-month period after the termination date; or
(ii)    The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, but would have attained the requirements for Normal Retirement within six months after the termination date and the first anniversary of the Grant Date has occurred on or prior to the termination date, then the restrictions applicable to any time-based vesting Restricted Stock Units shall continue to lapse at such time(s) as are set forth in the applicable Grant Notice, as though the Participant had continued to be employed by the Corporation or one of its Affiliates during the restricted period; provided that if the first anniversary of the Grant Date of the Restricted Stock Unit Award has not occurred on or prior to the termination date, then the additional vesting terms provided in Section IV.2(C)(i) will apply to such award.
Notwithstanding the foregoing, this Section IV.2(C) shall not apply to any Restricted Stock Units the vesting of which is based, in whole or in part, on attainment of performance objectives.

10



3.    Dividend Equivalents. Subject to the discretion of the Compensation Committee, dividend equivalents shall be credited in respect of Restricted Stock Units and Performance Shares. Cash dividends shall be credited on behalf of the Participant to a deferred cash account (in a manner designed to comply with Code Section 409A) and the restrictions on such cash dividends shall lapse at the same time that the restrictions lapse on the associated Award of Restricted Stock Units or Performance Shares (as applicable), and cash dividends, along with accrued interest (if any) on such cash dividends, shall be paid in a lump sum at the same time that the Shares underlying the Restricted Stock Unit or Performance Share Award, and to which the cash dividends relate, are distributed. Stock dividends shall be converted into additional Restricted Stock Units or Performance Shares, which will be subject to all of the terms and conditions of the underlying Restricted Stock Units or Performance Shares, including the same vesting restrictions as the underlying Award.
4.    Assignability. A Participant shall not be permitted to sell, transfer, pledge, assign or encumber Restricted Stock Units or Performance Shares, other than pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act.
5.    No Stockholder Rights. Neither a Participant nor any person entitled to exercise a Participant’s rights in the event of the Participant’s death shall have any of the rights of a stockholder with respect to an Award of Restricted Stock Units or Performance Shares except to the extent that a book entry has been entered in the records of the Corporation’s transfer agent with respect to the Shares paid upon the settlement of any vested Restricted Stock Units or Performance Shares.
6.    Time of Payment of Restricted Stock Units and Performance Shares. Upon the lapse of the restriction imposed on Restricted Stock Units or Performance Shares, all Restricted Stock Units and Performance Shares that were not forfeited pursuant to Section IV.2(A), Section IV.2(B)(i), Section IV.2(C)(i), or Section V shall be paid to the Participant as soon as reasonably practicable after the restrictions lapse. Payment shall be made in Shares to the Participant’s brokerage account of record. If the Participant does not have a brokerage account of record, then in the form of an appropriate book entry entered in the records of the Corporation’s transfer agent recording the Participant’s unrestricted interest in the number of Shares subject to the Restricted Stock Units or Performance Shares.
Notwithstanding the foregoing, if a Participant becomes eligible for Normal Retirement, or is eligible for additional vesting under Section IV.2(C)(ii), prior to the date of the lapse of restrictions imposed on Restricted Stock Units and the vesting provisions of Section IV.2(B)(ii) or Section IV.2(C)(ii) apply, then such Restricted Stock Units shall be paid to the Participant’s brokerage account of record as soon as reasonably practicable after the earlier of the Participant’s Separation from Service or the originally scheduled vesting date (in any event before the end of the calendar year in which such date occurs), subject to the delay of payment (if applicable) provided in Section VII.14. The procedures set forth in Section VII.6 will be applied for any taxes due upon the lapse of restrictions imposed on the Restricted Stock Units due to a Participant’s Normal Retirement eligibility or additional vesting as provided in Section IV.2(C)(ii).

11



V.
SPECIAL FORFEITURE AND REPAYMENT RULES
Any other provision of this Statement of Terms and Conditions to the contrary notwithstanding, if the Administrator determines that a Participant has engaged in any of the actions described in 3 below, the consequences set forth in 1 and 2 below shall result:
1.    Any outstanding Option shall immediately and automatically terminate, be forfeited and shall cease to be exercisable, without limitation. In addition, any Award of Restricted Stock, Restricted Stock Units or Performance Shares as to which the restrictions have not lapsed shall immediately and automatically be forfeited and such Shares of Restricted Stock shall be returned to the Corporation and all of the rights of the Participant to such Awards and the underlying Shares shall immediately terminate.
2.    If the Participant exercised an Option within 12 months prior to the date upon which the Corporation discovered that the Participant engaged in any actions described in 3 below, the Participant, upon written notice from the Corporation, shall immediately pay to the Corporation the economic value realized or obtained by the exercise of such Option measured at the date of exercise. In addition, if the restrictions imposed on any Award of Restricted Stock, Restricted Stock Units or Performance Shares (including any unpaid dividends or Dividend Equivalents) lapsed within 12 months prior to the date the Corporation discovered that the Participant engaged in any action described in 3 below, the Participant, upon written notice from the Corporation, shall immediately pay to the Corporation the economic value realized or obtained with respect to such Award, measured at the date such Award vested.
3.    The consequences described in 1 and 2 above shall apply if the Participant, either before or after termination of employment with the Corporation or its Affiliates:
(A)    Discloses to others, or takes or uses for the Participant’s own purpose or the purpose of others, any trade secrets, confidential information, knowledge, data or know‑how or any other proprietary information or intellectual property belonging to the Corporation or its Affiliates and obtained by the Participant during the term of the Participant’s employment, whether or not they are the Participant’s work product. Examples of such confidential information or trade secrets include, without limitation, customer lists, supplier lists, pricing and cost data, computer programs, delivery routes, advertising plans, wage and salary data, financial information, research and development plans, processes, equipment, product information and all other types and categories of information as to which the Participant knows or has reason to know that the Corporation or its Affiliates intends or expects secrecy to be maintained;
(B)    Fails to promptly return all documents and other tangible items belonging to the Corporation or its Affiliates in the Participant’s possession or control, including all complete or partial copies, recordings, abstracts, notes or reproductions of any kind made from or about such documents or information contained therein, upon termination of employment, whether pursuant to retirement or otherwise;

12



(C)    Fails to provide the Corporation with at least 30 days’ written notice prior to directly or indirectly engaging in, becoming employed by, or rendering services, advice or assistance to any business in competition with the Corporation or its Affiliates. As used herein, “business in competition” means any person, organization or enterprise which is engaged in or is about to become engaged in any line of business engaged in by the Corporation or its Affiliates at the time of the termination of the Participant’s employment with the Corporation or its Affiliates;
(D)    Fails to inform any new employer, before accepting employment, of the terms of this paragraph and of the Participant’s continuing obligation to maintain the confidentiality of the trade secrets and other confidential information belonging to the Corporation or its Affiliates and obtained by the Participant during the term of the Participant’s employment with the Corporation or any of its Affiliates;
(E)    Induces or attempts to induce, directly or indirectly, any of the customers of the Corporation or its Affiliates, employees, representatives or consultants to terminate, discontinue or cease working with or for the Corporation or its Affiliates, or to breach any contract with the Corporation or any of its Affiliates, in order to work with or for, or enter into a contract with, the Participant or any third party;
(F)    Engages in conduct which is not in good faith and which disrupts, damages, impairs or interferes with the business, reputation or employees of the Corporation or its Affiliates; or
(G)    Fails to meet the Participant’s continuing obligations with respect to non-disclosure, non-competition and/or non-solicitation under the Participant’s agreement with the Corporation or any Affiliate.
The Administrator shall determine in its sole discretion whether the Participant has engaged in any of the acts set forth in (A) through (G) above, and its determination shall be conclusive and binding on all interested persons.
Any provision of this Section V which is determined by a court of competent jurisdiction to be invalid or unenforceable should be construed or limited in a manner that is valid and enforceable and that comes closest to the business objectives intended by such invalid or unenforceable provision, without invalidating or rendering unenforceable the remaining provisions of this Section V.

13



VI.
CHANGE IN CONTROL
If as a result of a Change in Control, the Common Stock ceases to be listed for trading on a national securities exchange (an “Exchange”), any Option, Restricted Stock Award, Restricted Stock Unit Award, or Performance Share Award that is unvested on the effective date of the Change in Control shall continue to vest according to the terms and conditions of such Award, provided that such Award is replaced with an award for voting securities of the resulting corporation or the acquiring corporation, as the case may be, (including without limitation, the voting securities of any corporation which as a result of the Change in Control owns the Corporation or all or substantially all of the Corporation’s assets either directly or through one or more subsidiaries) (the “Surviving Company”) which are traded on an Exchange (a “Replacement Award”), which Replacement Award, (i) in the case of an Option, shall consist of an option with the number of underlying shares and exercise price determined in a manner consistent with Code Section 424(a) with vesting and any other terms continuing in the same manner as the replaced Option; (ii) in the case of a Performance Share Award, shall consist of restricted stock or restricted stock units with a value (determined using the Surviving Company’s stock price as of the effective date of the Change in Control) equal to the value of the Performance Share Award (determined using the Corporation’s stock price and assuming attainment of target performance or actual performance achieved, if greater, as of the effective date of the Change in Control), with any restrictions on such restricted stock or restricted stock units lapsing at the end of the measuring period over which performance for the replaced Performance Share Award was to be measured prior to the granting of the Replacement Award; and (iii) in the case of a Restricted Stock Award or Restricted Stock Unit Award, shall consist of restricted stock or restricted stock units with a value (determined using the Surviving Company’s stock price as of the effective date of the Change in Control) equal to the value of the Restricted Stock Award or Restricted Stock Unit Award (determined using the Corporation’s stock price as of the effective date of the Change in Control), with any restrictions on such restricted stock or restricted stock units lapsing at the same time and manner as the replaced Award; provided, however, that in the event of the Participant’s involuntary Separation from Service by the Corporation without Cause or Separation from Service by the Participant for Good Reason during the vesting period of any Replacement Award, the Replacement Award shall immediately vest and be paid as soon as practicable following such Separation from Service (subject to Section VII.14), based on the fair market value of the underlying shares on the vesting date, or in the case of options, based on the excess of the fair market value of the underlying shares over the option exercise price on the vesting date. If any Option, Restricted Stock Award, Restricted Stock Unit Award, or Performance Share Award that is unvested at the effective time of the Change in Control is not replaced with a Replacement Award, such Award shall immediately vest and, in the case of a Performance Share Award, shall vest based upon deemed attainment of target performance or actual performance achieved, if greater.

14



If as a result of a Change in Control, the Common Stock continues to be listed for trading on an Exchange, any unvested Option, Restricted Stock Award, or Restricted Stock Unit Award shall continue to vest according to the terms and conditions of such Award and any Performance Share Award shall be replaced with a Restricted Stock Award or Restricted Stock Unit Award where the number of shares subject to such Restricted Stock Award or Restricted Stock Unit Award shall be equal to the number of Performance Shares assuming attainment of target performance or actual performance achieved, if greater, as of the effective date of the Change in Control with any restrictions on such Restricted Stock Award or Restricted Stock Unit Award lapsing at the end of the measuring period over which performance for the replaced Performance Share Award was to be measured prior to the granting of the replacement Award; provided however, that, in the event of the Participant’s involuntary Separation from Service by the Corporation without Cause or Separation from Service by the Participant for Good Reason during the vesting period of an Award, such Award shall immediately vest and be paid as soon as practicable following such Separation from Service (subject to Section VII.14).
VII.
MISCELLANEOUS
1.    No Effect on Terms of Employment. Participation in the Plan shall not create a right to further employment with the Participant’s employer (the “Employer”) and shall not interfere with the ability of the Employer to terminate, with or without cause, or change the terms of employment of a Participant at any time.
2.    Grants to Participants in Foreign Countries. In making grants to Participants in foreign countries, the Administrator has the full discretion to deviate from this Statement of Terms and Conditions in order to adjust grants under the Plan to prevailing local conditions, including custom and legal and tax requirements. Furthermore, the Corporation reserves the right to impose other requirements on the Participant’s participation in the Plan on the Award and on any Shares acquired under the Plan, to the extent the Corporation determines it is necessary or advisable in order to comply with local law or facilitate the administration of the Plan, and to require the Participant to sign any additional agreements or undertaking that may be necessary to accomplish the foregoing.
3.    Information Notification. Any information required to be given under the terms of an Award shall be addressed to the Corporation in care of its Corporate Secretary at McKesson Corporation, One Post Street, San Francisco, California 94104, and any notice to be given to a Participant shall be addressed to such Participant at the address indicated beneath the Participant's name on the Award Agreement or such other address as either party may designate in writing to the other. Any such notice shall be deemed to have been duly given when enclosed in a properly sealed envelope or wrapper addressed as aforesaid, registered or certified and deposited (postage or registration or certification fee prepaid) in a post office or branch post office.
4.    Administrator Decisions Conclusive. All decisions of the Administrator administering the Plan upon any questions arising under the Plan or under an Award Agreement, shall be conclusive and binding on all interested persons.

15



5.    No Effect on Other Benefit Plans. Nothing herein contained shall affect a Participant’s right to participate in and receive benefits from and in accordance with the then current provisions of any pensions, insurance or other employment welfare plan or program offered by the Corporation.
6.    Withholding. Regardless of any action the Corporation or the Employer takes with respect to any federal, state or local income tax, social insurance, payroll tax, payment on account or other tax-related items related to the Participant’s participation in the Plan and legally applicable to the Participant (“Tax-Related Items”), the Participant acknowledges that the ultimate liability for all Tax-Related Items is and remains the Participant's responsibility and may exceed the amount actually withheld by the Corporation or the Employer. The Participant further acknowledges that the Corporation and/or the Employer (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Award, including the grant, vesting or exercise of the Award, as applicable, the subsequent sale of Shares acquired pursuant to the Plan and the receipt of any dividends and/or dividend equivalents; and (2) do not commit and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Participant’s liability for Tax-Related Items or achieve any particular tax result. Further, if the Participant has become subject to tax in more than one jurisdiction between the Grant Date and the date of any relevant taxable event, the Participant acknowledges that the Corporation and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.
Prior to any relevant taxable or tax withholding event, as applicable, the Participant will pay or make adequate arrangements satisfactory to the Corporation and/or the Employer, or their respective agents, at their discretion, to satisfy the obligations with regard to all Tax-Related Items by one or a combination of the following: (1) withholding from the Participant’s wages or other cash compensation paid to the Participant by the Corporation and/or the Employer; (2) withholding from proceeds of the sale of Shares acquired under the Plan either through a voluntary sale or through a mandatory sale arranged by the Corporation (on the Participant’s behalf pursuant to this authorization and any other authorization the Corporation and/or the broker designated by the Corporation may require the Participant to sign in connection with the sale of Shares); or (3) withholding Shares to be issued upon grant, vesting/settlement or exercise, as applicable. Calculation of the number of Shares to be withheld shall be made based on the closing price of the Common Stock on the New York Stock Exchange on the date that the amount of tax to be withheld is determined. In no event, however, shall the Corporation be required to issue fractional Shares. With respect to an Award other than an Option, if adequate arrangements to satisfy the obligations with regard to all Tax-Related Items are not made by the Participant with the Corporation and/or the Employer prior to the relevant taxable event, the Corporation will satisfy such obligations as provided above in clause (3) of this paragraph.

16



To avoid negative accounting treatment, the Corporation may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates. If the obligation for Tax-Related Items is satisfied by withholding in Shares, for tax purposes, the Participant will be deemed to have been issued the full number of Shares subject to the Award, notwithstanding that a number of the Shares are held back solely for the purpose of paying the Tax-Related Items due as a result of any aspect of the Participant’s participation in the Plan.
Finally, the Participant shall pay to the Corporation or the Employer any amount of Tax-Related Items that the Corporation or the Employer may be required to withhold or account for as a result of the Participant’s participation in the Plan that cannot be satisfied by the means previously described. The Corporation may refuse to issue or deliver the Shares or the proceeds of the sale of Shares if the Participant fails to comply with the Participant's obligations in connection with the Tax-Related Items.
The Administrator shall be authorized to establish such rules, forms and procedures as it deems necessary to implement the foregoing.
7.    Successors. The Award Agreements shall be binding upon and inure to the benefit of any successor or successors of the Corporation. “Participant” as used herein shall include the Participant’s Beneficiary.
8.    Delaware Law. The interpretation, performance, and enforcement of all Award Agreements shall be governed by the laws of the State of Delaware.
9.    Nature of Grant. In accepting the grant, the Participant acknowledges that:
(A)    the Plan is established voluntarily by the Corporation, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Corporation at any time;
(B)    the grant of the Award is voluntary and occasional and does not create any contractual or other right to receive future Award grants, or benefits in lieu of Awards, even if Awards have been granted repeatedly in the past;
(C)    all decisions with respect to future Awards, if any, will be at the sole discretion of the Corporation;
(D)    the Participant is voluntarily participating in the Plan;
(E)    the Award is not part of normal or expected compensation for any purpose, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments;
(F)    the Award will not be interpreted to form an employment contract or relationship with the Corporation; and furthermore, the Award will not be interpreted to form an employment contract with any subsidiary or Affiliate of the Corporation;

17



(G)    the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty;
(H)    if the underlying Shares do not increase in value, the Options will have no value;
(I)    in consideration of the grant of the Award, no claim or entitlement to compensation or damages shall arise from forfeiture of the Award which results from termination of the Participant’s employment with the Employer or the Corporation or one of its Affiliates (for any reason whatsoever) and the Participant irrevocably releases the Corporation or its Affiliates from any such claim that may arise; if, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen, then, by accepting the Award, the Participant shall be deemed irrevocably to have waived the Participant's entitlement to pursue such claim;
(J)    for purposes of an Award, the Participant’s employment relationship will be considered terminated as of the date the Participant is no longer a bona fide employee of the Corporation or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of the employment laws in the jurisdiction where the Participant is employed or the terms of the Participant’s employment agreement, if any), and unless otherwise expressly provided in this Award Agreement or determined by the Corporation in its sole discretion, the Participant’s right to receive Awards and vest in Awards under the Plan, if any, will terminate effective as of such date and will not be extended by any notice period mandated under local law; similarly, any right to exercise Options under the Plan after termination of employment will be measured as of the date the Participant is no longer a bona fide employee of the Corporation or one of its Affiliates and will not be extended by any notice period mandated under local law; the Administrator shall have the sole discretion to determine when the Participant is no longer a bona fide employee;
(K)    the Corporation is not providing any tax, legal or financial advice, nor is the Corporation making any recommendations regarding participation in the Plan or the Participant’s acquisition or sale of Shares; and
(L)    Participant is hereby advised to consult with the Participant's own personal tax, legal and financial advisors regarding Participant’s participation in the Plan before taking any action related to the Plan.
10.    Data Privacy. By accepting the Award, the Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of the Participant's personal data as described in this document by and among, as applicable, the Employer and the Corporation and its Affiliates for the exclusive purpose of implementing, administering and managing participation in the Plan.

18



The Participant understands that the Corporation and the Employer hold certain personal information about the Participant, including, but not limited, the Participant's name, home address and telephone number, date of birth, social insurance or other identification number, salary, nationality, job title, any Shares or directorships held in the Corporation, details of all Options, Restricted Stock, Restricted Stock Units, Performance Shares, Other Share-Based Awards, or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in the Participant’s favor, for the purpose of implementing, administering and managing the Plan (“Data”). The Participant understands that Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, that recipients of Data may be located in the United States or elsewhere, and that the recipient’s country may have different data privacy laws and protections than the Participant’s country. The Participant understands that if the Participant resides outside of the United States, the Participant may request a list with the names and addresses of any potential recipients of the Data by contacting the local human resources representative. The Participant authorizes the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party with whom the Participant may elect to deposit any Shares acquired under the Plan. The Participant understands that Data will be held only as long as is necessary to implement, administer and manage the Participant's participation in the Plan. The Participant understands that if the Participant resides outside of the United States, the Participant may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, without cost, by contacting in writing the local human resources representative. Further, the Participant understands that the Participant is providing the consents herein on a purely voluntary basis. If the Participant does not consent, or if the Participant later seeks to revoke the Participant's consent, the Participant’s employment status or service and career with the Employer will not be adversely affected; the only adverse consequence of refusing or withdrawing the Participant's consent is that the Corporation would not be able to grant the Participant Awards or administer or maintain such Awards. Therefore, the Participant understands that refusing or withdrawing consent may affect the Participant's ability to participate in the Plan. For more information on the consequences of refusal to consent or withdrawal of consent, the Participant understands that the Participant may contact the local human resources representative.
11.    Severability. The provisions in this Statement of Terms and Conditions are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.
12.    Language. If the Participant has received this Statement of Terms and Conditions or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.

19



13.    Electronic Delivery. The Corporation may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Corporation or a third party designated by the Corporation.
14.    Section 409A. If (A) the Participant is a Specified Employee at the time of the Participant’s Separation from Service, and (B) some or any portion of the amounts payable to the Participant, if any, when considered together with any other payments or benefits which may be considered deferred compensation under section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”) and subject to the plan aggregation rules under Treasury Regulation section 1.409A-1(c)(3)(viii) (together, the “Deferred Compensation Benefits”) would result in the imposition of additional tax under Section 409A if paid to the Participant on or within the six month period following the Separation from Service, then to the extent such portion of the Deferred Compensation Benefits resulting in the imposition of additional tax would otherwise have been payable on or within the first six months following the Separation from Service, it will instead become payable on the first payroll date that occurs in the seventh month following the Separation from Service (or such longer period as is required to avoid the imposition of additional tax under Section 409A). All subsequent Deferred Compensation Separation Benefits, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit.
VIII.
DEFINITIONS
When capitalized in this Statement of Terms and Conditions, the following terms shall have the meaning set forth below:
1.    Award Agreement” means an agreement between the Participant and the Corporation evidencing the grant of an Option, Restricted Stock Award, Restricted Stock Award, Performance Shares or Other Share-Based Award, as applicable.
2.    Cause” means termination of the Participant’s employment with the Corporation or an Affiliate upon the Participant’s negligent or willful engagement in misconduct which, in the sole determination of the Chief Executive Officer of the Corporation (or the Chief Executive Officer’s designee), is injurious to the Corporation, its employees, or its customers.
3.    Early Retirement” means a termination of employment (other than due to death, Long-Term Disability or for Cause) which occurs prior to Normal Retirement but on or after the date on which the Participant’s age (expressed in terms of years and completed months) plus service with the Corporation or an Affiliate equals 65. For purposes of determining eligibility for Early Retirement, the term “service” shall include years and completed whole months of service.
4.    Family Member” means any person identified as an “immediate family” member in Rule 16(a)‑1(e) of the Exchange Act, as such Rule may be amended from time to time. Notwithstanding the foregoing, the Administrator may designate any other person(s) or entity(ies) as a “family member.”

20



5.    Good Reason” means any of the following actions, if taken without the express written consent of the Participant:
(A)    Any material change by the Corporation in the Participant’s functions, duties, or responsibilities, which change would cause the Participant’s position with the Corporation to become of less dignity, responsibility, importance, or scope from the position and attributes that applied to the Participant immediately prior to the Change in Control; provided, however, that, any such change attributable to the Corporation’s no longer being a company with publicly traded common stock shall not constitute Good Reason; and provided, further, that a reduction in the Participant’s functions, duties or responsibilities solely by virtue of the Corporation being acquired and made part of a larger entity (for example, if following a Change in Control the Participant retains the Participant’s position, or has a comparable position, with respect to a division or subsidiary of the acquirer that contains the Corporation’s business) shall not constitute Good Reason;
(B)    Any significant reduction in the Participant’s aggregate base annual salary and target incentive opportunity, as in effect immediately prior to the Change in Control;
(C)    Any material failure by the Corporation to comply with any of the provisions of an Award subsequent to a Change in Control; or
(D)    The Corporation’s requiring the Participant to be based at any location which would increase the Participant’s regular one-way commute by more than 25 miles from that in effect immediately preceding the Change in Control, except for travel reasonably required in the performance of the Participant’s responsibilities;
Provided that the Participant gives notice to the Corporation of the existence of the Good Reason condition within 30 days of the initial existence of the Good Reason condition and the Corporation is provided 30 days after receipt of the Participant’s notice to remedy the Good Reason condition; provided further that the Participant’s Separation from Service must occur within six months from the initial existence of the Good Reason condition if the Corporation does not remedy such condition for such separation to be considered to be for Good Reason.
6.    Expiration Date” means the date that an Option expires as set forth in the Option Grant Notice as the “Expiration Date.”
7.    Grant Date” means the date the Administrator grants the Award.
8.    Grant Notice” means the notice of an Award granted to the Participant, which sets forth certain terms of such Award.
9.    Long‑Term Disability” means a physical or mental condition in respect of which the administrator of the Corporation’s long-term disability plan has determined that the Participant is eligible to receive income replacement benefits; or, if the Participant is not then a participant in the Corporation’s long-term disability plan, a physical or mental condition that the administrator of the Corporation’s long-term disability plan determines would have rendered the Participant eligible to receive income replacement benefits, had the Participant been enrolled in such plan.

21



10.    Normal Retirement” means termination of employment (other than due to death, Long-Term Disability or for Cause) at or after age 60 (57, in the case of a participant in the McKesson Corporation 1984 Executive Benefit Retirement Plan) with at least 10 years of service with the Corporation or an Affiliate. For purposes of determining eligibility for Normal Retirement, “service” shall mean completed whole years of service (12 consecutive months).
11.    Option Period” means the period commencing on the Grant Date of an Option and, except at otherwise provided in Section II.5, ending on the Expiration Date.
12.    Separation from Service” means termination of employment with the Corporation or an affiliate. A Participant shall be deemed to have had a Separation from Service if the Participant’s service with the Corporation or an affiliate is reduced to an annual rate that is equal to or less than 20% of the services rendered, on average, during the immediately preceding three years of service with the Corporation or an affiliate (or, if providing service to the Corporation or an affiliate for less than three years, such lesser period).
13.    Severance” means termination of employment with the Corporation or an affiliate, and qualified for participation in and entitlement to benefits under the McKesson Corporation Severance Pay Plan, in accordance with the terms and conditions of such plan.
14.    Short‑Term Disability” means short‑term disability as defined in the Corporation’s short‑term disability plan.
15.    Specified Employee” means those employees identified by the Corporation as "Specified Employees" for purposes of Code Section 409A.


22



OUTSIDE DIRECTOR

FORM OF
MCKESSON CORPORATION 2013 STOCK PLAN
RESTRICTED STOCK UNIT GRANT NOTICE

    

Grantee Name:
 

Grantee Address:

 

Number of RSUs Granted:
 

Date of Grant:
 

Vesting Dates:
 

Vesting Schedule: 100% vested on grant date.

McKesson Corporation (the “Company”) is pleased to grant you restricted stock units (“RSUs”) under the Company’s 2013 Stock Plan, as may be amended from time to time (the “Plan”) to receive ownership of shares of common stock of the Company (“Shares”). This Grant Notice (“Notice”), together with the Statement of Terms and Conditions, as provided as an attachment to this Notice (the “ST&Cs”), constitute your Restricted Stock Unit Agreement, which along with the Plan set forth the terms of your grant.

Below is a list of documents that are made available to you in connection with this Notice. PLEASE BE SURE TO READ THESE DOCUMENTS BECAUSE THEY CONTAIN IMPORTANT INFORMATION SPECIFIC TO THIS GRANT OF RSUs. This grant, along with any other grants you may have received in the past can be viewed on the Merrill Lynch web site at www.benefits.ml.com.

By signing below, I acknowledge that:
1.
I agree to receive copies of the stockholder information, including copies of any annual report, proxy and Form 10-K, from the Investor Resources section of the McKesson website at www.mckesson.com; and
2.
I also acknowledge that copies of the Plan, Plan prospectus, Plan information and stockholder information are available upon written or telephonic request to the Corporate Secretary (1-800-826-9360); and
3.
I have access to the Company’s web site; and
4.
I consent to receiving electronically a copy of the documents set forth above and attachments to this Notice; and
5.
The Plan and ST&Cs are incorporated by reference to this Notice; and
6.
The Company recommends that the Grantee consult with a tax advisor prior to accepting or vesting of this grant of RSUs; and
7.
I accept ALL the terms and conditions as set forth in the Plan and the ST&Cs applicable to this grant of RSUs.

1




IN WITNESS WHEREOF, the Grantee has executed this Agreement, and the Company has caused these presents to be executed in its name and on its behalf, all as of the Grant Date.
                     
By:

 
 
 
 
 
 
 
John H. Hammergren
 
Date
 
Grantee Signature
 
Date
Chairman, President and Chief Executive Officer
 
 
 
 
McKesson Corporation
 
 
 
 

PLEASE RETURN ONE SIGNED COPY OF THIS AGREEMENT TO:
      McKesson Corporation
      Stock Administration
      One Post Street, 32nd Floor, San Francisco, CA 94104
        ATTACHMENTS:
    2013 Stock Plan
    2013 Stock Plan Prospectus for Non-Employee Directors
    ST&Cs Applicable to Outside Director
    Hedging & Pledging Policy
    Insider Trading Policy
    Designation of Beneficiary Form
July 2014


2



CEO / EO / Employees Subject to SOP

FORM OF
MCKESSON CORPORATION 2013 STOCK PLAN
STOCK OPTION GRANT NOTICE

Optionee Name:
 
Optionee Address:
 
Type of Option:
Nonstatutory Stock Option
Grant Date:
 
Shares Granted:
 
Price per Share:
 
Vesting Schedule:
 
Expiration Date:
 

McKesson Corporation (the “Company”) is pleased to grant you a nonstatutory stock option under the Company’s 2013 Stock Plan (the “Plan”) to purchase shares of common stock of the Company (“Shares”). This Grant Notice (“Notice”), together with the Statement of Terms and Conditions, as provided as an attachment to this Notice (the “ST&Cs”), constitute your Stock Option Agreement, which along with the Plan (note that the Plan incorporates by reference the Company’s Compensation Recoupment Policy (the “Recoupment Policy”) and the Company’s Stock Ownership Policy (the “Company Stock Ownership Policy”) as both are amended from time to time) set forth the terms of your grant.

Below is a list of documents that are made available to you in connection with this Notice. PLEASE BE SURE TO READ THESE DOCUMENTS BECAUSE THEY CONTAIN IMPORTANT INFORMATION SPECIFIC TO THIS GRANT OF AN OPTION. This grant, along with any other grants you may have received in the past can be viewed on the Merrill Lynch web site at www.benefits.ml.com.

This Option is subject to earlier termination than the expiration date set above in certain circumstances, as set forth in the Plan and ST&Cs. For more information about stock options, including information on how to exercise your Option, visit the Corporate Secretary’s Website on McKNET under About McKesson/Legal/Office of the General Counsel/Corporate Secretary/Stock Administration.

By signing below, I acknowledge that:
1.
I agree to receive copies of the Plan, the Plan prospectus and other Plan information, including information prepared to comply with the laws outside the United States, from the Company’s website and stockholder information, including copies of any annual report, proxy and Form
10-K, from the Investor Resources section of the McKesson website at www.mckesson.com; and
2.
I also acknowledge that copies of the Plan, Plan prospectus, Plan information and stockholder information are available upon written or telephonic request to the Corporate Secretary (1-800-826-9360); and
3.
I have access to the Company’s web site; and
4.
I consent to receiving electronically a copy of the document set forth above and attachments to this Notice; and
5.
The Plan, (including the Recoupment Policy and Stock Ownership Policy) and ST&Cs are incorporated by reference to this Notice; and
6.
The Company recommends that the Optionee consult with a tax advisor prior to accepting or exercising this Option; and
7.
I accept ALL the terms and conditions as set forth in the Plan and ST&Cs applicable to this Option.

IN WITNESS WHEREOF, the Optionee has executed this Agreement, and the Company has caused these presents to be executed in its name and on its behalf, all as of the Grant Date.
   
 
 
Name Date
 
Optionee Signature    Date
Title        
McKesson Corporation

ATTACHMENTS:
* 2013 Stock Plan
* ST&Cs Applicable to _____________
* Compensation Recoupment Policy
* Stock Ownership Policy
* 2013 Stock Plan Prospectus

May 2017

1



EMPLOYEE


FORM OF
MCKESSON CORPORATION 2013 STOCK PLAN
STOCK OPTION GRANT NOTICE

Optionee Name:
 
Optionee Address:
 
Type of Option:
Nonstatutory Stock Option
Grant Date:
 
Shares Granted:
 
Price per Share:
 
Vesting Schedule:
 
Expiration Date:
 

McKesson Corporation (the “Company”) is pleased to grant you a nonstatutory stock option under the Company’s 2013 Stock Plan (the “Plan”) to purchase shares of common stock of the Company (“Shares”). This Grant Notice (“Notice”), together with the Statement of Terms and Conditions, as provided as an attachment to this Notice (the “ST&Cs”), constitute your Stock Option Agreement, which along with the Plan (note that the Plan incorporates by reference the Company’s Compensation Recoupment Policy, as amended from time to time (the “Recoupment Policy”)) set forth the terms of your grant.

Below is a list of documents that are made available to you in connection with this Notice. PLEASE BE SURE TO READ THESE DOCUMENTS BECAUSE THEY CONTAIN IMPORTANT INFORMATION SPECIFIC TO THIS GRANT OF AN OPTION. This grant, along with any other grants you may have received in the past can be viewed on the Merrill Lynch web site at www.benefits.ml.com.

This Option is subject to earlier termination than the expiration date set above in certain circumstances, as set forth in the Plan and ST&Cs. For more information about stock options, including information on how to exercise your Option, visit the Corporate Secretary’s Website on McKNET under About McKesson/Legal//Corporate Secretary/Stock Administration.

By signing below, I acknowledge that:
1.
I agree to receive copies of the Plan, the Plan prospectus and other Plan information, including information prepared to comply with the laws outside the United States, from the Company’s website and stockholder information, including copies of any annual report, proxy and Form
10-K, from the Investor Resources section of the McKesson website at www.mckesson.com; and
2.
I also acknowledge that copies of the Plan, Plan prospectus, Plan information and stockholder information are available upon written or telephonic request to the Corporate Secretary (1-800-826-9360); and
3.
I have access to the Company’s web site; and
4.
I consent to receiving electronically a copy of the document set forth above and attachments to this Notice; and
5.
The Plan (including the Recoupment Policy) and ST&Cs are incorporated by reference to this Notice; and
6.
The Company recommends that the Optionee consult with a tax advisor prior to accepting or exercising this Option; and
7.
I accept ALL the terms and conditions as set forth in the Plan and the ST&Cs applicable to this Option.

IN WITNESS WHEREOF, the Optionee has executed this Agreement, and the Company has caused these presents to be executed in its name and on its behalf, all as of the Grant Date.
   
 
 
Name Date
 
Optionee Signature    Date
Title    
McKesson Corporation

ATTACHMENTS:
* ST&Cs Applicable to Employee
* 2013 Stock Plan
* 2013 Stock Plan Prospectus
* Compensation Recoupment Policy
* Insider Trading Policy
* Appendix – (country specific)

October 2013

1



McKESSON CORPORATION
Total Shareholder Return Unit (“TSRU”)
TARGET AWARD NOTIFICATION
Fiscal Year 20__

The Compensation Committee (the “Committee”) of the Board of Directors of McKesson Corporation has approved your target number of Total Shareholder Return Units (TSRUs) under the TSRU Program for the three-year performance period beginning ______, 20__ and ending on ______, 20__ (the “Performance Period”). The final number of shares of McKesson Corporation common stock that may be issued to you under the TSRU Program will be based on achievement against performance criteria determined by the Committee. Your participation in the TSRU Program will be subject to the terms of the McKesson Corporation 2013 Stock Plan (the “2013 Stock Plan”), which includes the Statement of Terms and Conditions that is delivered with this notice. In the event of any conflict between the 2013 Stock Plan and this document, the 2013 Stock Plan will control. This notice of your participation in the TSRU Program sets forth your TSRU Target.

Participant Name
 
Target Number of Units
 
Date Target Approved
 
Performance Period
 

Award and Vesting
Provided that:
You continue to be employed by McKesson Corporation or one of its affiliates through the date on which the Committee meets to determine achievement against the performance criteria, and
The Committee determines that, based on achievement of the performance criteria, a grant of shares of McKesson common stock will be made to you under the TSRU Program for _____-_____, then
You will receive a grant of shares following the date the Committee meets in _____ 20__. No additional vesting period will apply.

Performance Criteria
Performance Criteria for your TSRU target award will be determined by the Committee at the beginning of the performance period and communicated to you. The performance criteria will include a goal based on McKesson’s total shareholder return (TSR) over the performance period.
If the performance criteria are met at no less than the threshold level determined by the Committee, you will receive a grant of shares.
You may earn from 0% to 200% of the Target Number of Units set forth above.

The Committee has the authority to adjust the performance criteria and the amount of your final award. The Committee will make the final determination of the TSR calculation and determine the achievement with respect to any other performance criteria, in its discretion. The Committee may adjust the final award in its discretion.

I acknowledge that I have received, read and understand this Total Shareholder Return Restricted Stock Unit (TSRU) Target Award Notification.

 
 
 
Employee Signature
 
Date

                        
Encl – 2013 Stock Plan and Statement of Terms and Conditions

1



CEO / EO / Employees Subject to SOP

FORM OF
MCKESSON CORPORATION 2013 STOCK PLAN
RESTRICTED STOCK UNIT GRANT NOTICE

Grantee Name:
 
Grantee Address:


Number of RSUs Granted:
 
Date of Grant:
 
Vesting Dates:
 

Vesting Schedule: Provided you continue to provide service to the company or any Affiliate of the Company through the vesting date, the RSUs will become vested _________ on ___________________.

McKesson Corporation (the “Company”) is pleased to grant you restricted stock units (“RSUs”) under the Company’s 2013 Stock Plan (the “Plan”) to receive ownership of shares of common stock of the Company (“Shares”). This Grant Notice (“Notice”), together with the Statement of Terms and Conditions, as provided as an attachment to this Notice (the “ST&Cs”), constitute your Restricted Stock Unit Agreement, which along with the Plan (note that the Plan incorporates by reference the Company’s Compensation Recoupment Policy (the “Recoupment Policy”) and the Company’s Stock Ownership Policy (the “Company Stock Ownership Policy”), as both are amended from time to time) set forth the terms of your grant.

Below is a list of documents that are made available to you in connection with this Notice. PLEASE BE SURE TO READ THESE DOCUMENTS BECAUSE THEY CONTAIN IMPORTANT INFORMATION SPECIFIC TO THIS GRANT OF RSUs. This grant, along with any other grants you may have received in the past can be viewed on the Merrill Lynch web site at www.benefits.ml.com.

By signing below, I acknowledge that:
1.
I agree to receive copies of the Plan, the Plan prospectus and other Plan information, including information prepared to comply with the laws outside the United States, from the Company’s website and stockholder information, including copies of any annual report, proxy and Form 10-K, from the Investor Resources section of the McKesson website at www.mckesson.com; and
2.
I also acknowledge that copies of the Plan, Plan prospectus, Plan information and stockholder information are available upon written or telephonic request to the Corporate Secretary (1-800-826-9360); and
3.
I have access to the Company’s web site; and
4.
I consent to receiving electronically a copy of the documents set forth above and attachments to this Notice; and
5.
The Plan (including the Recoupment Policy and Stock Ownership Policy) and ST&Cs are incorporated by reference to this Notice; and
6.
The Company recommends that the Grantee consult with a tax advisor prior to accepting or vesting of this grant of RSUs; and
7.
I accept ALL the terms and conditions as set forth in the Plan and ST&Cs applicable to this grant of RSUs.

IN WITNESS WHEREOF, the Grantee has executed this Agreement, and the Company has caused these presents to be executed in its name and on its behalf, all as of the Grant Date.
 
 
 
 
John H. Hammergren
 
Grantee Signature
Date
Chairman, President and Chief Executive Officer
 
 
 
McKesson Corporation
 
 
 

ATTACHMENTS:
* 2013 Stock Plan
* 2013 Stock Plan Prospectus
* ST&Cs Applicable to __________
* Hedging and Pledging Policy (Section 16 only)
* Compensation Recoupment Policy
* Stock Ownership Policy
* Insider Trading Policy

May 2017

1



EMPLOYEE


FORM OF
MCKESSON CORPORATION 2013 STOCK PLAN
RESTRICTED STOCK UNIT GRANT NOTICE

Grantee Name:
 
Grantee Address:
 
Number of RSUs Granted:
 
Date of Grant:
 
Vesting Dates:
 


Vesting Schedule: Provided you continue to provide service to the company or any Affiliate of the Company through the vesting date, the RSUs will become vested ____ on __________________.

McKesson Corporation (the “Company”) is pleased to grant you restricted stock units (“RSUs”) under the Company’s 2013 Stock Plan (the “Plan”) to receive ownership of shares of common stock of the Company (“Shares”). This Grant Notice (“Notice”), together with the Statement of Terms and Conditions, as provided as an attachment to this Notice (the “ST&Cs”), constitute your Restricted Stock Unit Agreement, which along with the Plan (note that the Plan incorporates by reference the Company’s Compensation Recoupment Policy, as amended from time to time (the “Recoupment Policy”)) set forth the terms of your grant.

Below is a list of documents that are made available to you in connection with this Notice. PLEASE BE SURE TO READ THESE DOCUMENTS BECAUSE THEY CONTAIN IMPORTANT INFORMATION SPECIFIC TO THIS GRANT OF RSUs. This grant, along with any other grants you may have received in the past can be viewed on the Merrill Lynch web site at www.benefits.ml.com.

By signing below, I acknowledge that:
1.
I agree to receive copies of the Plan, the Plan prospectus and other Plan information, including information prepared to comply with the laws outside the United States, from the Company’s website and stockholder information, including copies of any annual report, proxy and Form 10-K, from the Investor Resources section of the McKesson website at www.mckesson.com; and
2.
I also acknowledge that copies of the Plan, Plan prospectus, Plan information and stockholder information are available upon written or telephonic request to the Corporate Secretary (1-800-826-9360); and
3.
I have access to the Company’s web site; and
4.
I consent to receiving electronically a copy of the documents set forth above and attachments to this Notice; and
5.
The Plan (including the Recoupment Policy) and ST&Cs are incorporated by reference to this Notice; and
6.
The Company recommends that the Grantee consult with a tax advisor prior to accepting or vesting of this grant of RSUs; and
7.
I accept ALL the terms and conditions as set forth in the Plan and the ST&Cs applicable to this grant of RSUs.

IN WITNESS WHEREOF, the Grantee has executed this Agreement, and the Company has caused these presents to be executed in its name and on its behalf, all as of the Grant Date.
 
 
 
 
John H. Hammergren
 
Grantee Signature
Date
Chairman, President and Chief Executive Officer
 
 
 
McKesson Corporation
 
 
 
ATTACHMENTS:
* ST&Cs Applicable to Employees
* 2013 Stock Plan
* 2013 Stock Plan Prospectus
* Compensation Recoupment Policy
* Insider Trading Policy
* Appendix – (country specific)

October 2013

1

EX-31.1 3 mck_exhibit311x06302017.htm CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 Exhibit


Exhibit 31.1
CERTIFICATION PURSUANT TO
RULE 13a-14(a) AND RULE 15d-14(a) OF THE SECURITIES EXCHANGE ACT, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, John H. Hammergren, certify that:
1.
I have reviewed this quarterly report on Form 10-Q of McKesson Corporation;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:
July 27, 2017
 
/s/  John H. Hammergren
 
 
 
John H. Hammergren
 
 
 
Chairman of the Board, President and Chief Executive Officer




EX-31.2 4 mck_exhibit312x06302017.htm CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 Exhibit


Exhibit 31.2
CERTIFICATION PURSUANT TO
RULE 13a-14(a) AND RULE 15d-14(a) OF THE SECURITIES EXCHANGE ACT, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, James A. Beer, certify that:
1.
I have reviewed this quarterly report on Form 10-Q of McKesson Corporation;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:
July 27, 2017
 
/s/ James A. Beer
 
 
 
James A. Beer
 
 
 
Executive Vice President and Chief Financial Officer



EX-32 5 mck_exhibit32x06302017.htm CERTIFICATION PURSUANT TO 18 U.S.C.SECTION 1350 Exhibit


Exhibit 32
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the quarterly report of McKesson Corporation (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacities and on the dates indicated below, each hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of their knowledge:
1.
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/  John H. Hammergren
 
 
John H. Hammergren
 
 
Chairman of the Board, President and Chief Executive Officer
 
 
July 27, 2017
 
 
 
 
 
/s/ James A. Beer
 
 
James A. Beer
 
 
Executive Vice President and Chief Financial Officer
 
 
July 27, 2017
 
 
 
 
 

This certification accompanies the Report pursuant to § 906 of the Sarbanes-Oxley Act of 2002, and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
A signed original of this written statement required by Section 906 has been provided to McKesson Corporation and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.



EX-101.INS 6 mck-20170630.xml XBRL INSTANCE DOCUMENT 0000927653 2017-04-01 2017-06-30 0000927653 2016-04-01 2016-06-30 0000927653 2017-06-30 0000927653 2017-03-31 0000927653 2016-06-30 0000927653 2016-03-31 0000927653 us-gaap:OperatingSegmentsMember mck:CoreMTSBusinessesMember mck:ChangeHealthcareLLCChangeHealthcareMember mck:TechnologySolutionsMember 2017-01-01 2017-03-31 0000927653 mck:TransitionServicesAgreementsTSAMember us-gaap:CorporateJointVentureMember 2017-04-01 2017-06-30 0000927653 mck:ChangeHealthcareLLCChangeHealthcareMember 2017-04-01 2017-06-30 0000927653 us-gaap:CorporateJointVentureMember mck:ChangeHealthcareLLCChangeHealthcareMember 2017-06-30 0000927653 us-gaap:OperatingSegmentsMember mck:CoreMTSBusinessesMember mck:ChangeHealthcareLLCChangeHealthcareMember mck:TechnologySolutionsMember 2017-04-01 2017-06-30 0000927653 us-gaap:CorporateJointVentureMember mck:ChangeHealthcareLLCChangeHealthcareMember 2017-04-01 2017-06-30 0000927653 us-gaap:CorporateJointVentureMember mck:ChangeHealthcareLLCChangeHealthcareMember 2017-03-01 0000927653 mck:TaxReceivableAgreementTRAMember mck:ChangeHealthcareLLCChangeHealthcareMember 2017-06-30 0000927653 mck:TaxReceivableAgreementTRAMember mck:ChangeHealthcareLLCChangeHealthcareMember 2017-03-31 0000927653 mck:RexallHealthMember us-gaap:TradeNamesMember country:CA 2016-12-28 2016-12-28 0000927653 mck:RexallHealthMember country:CA 2017-04-01 2017-06-30 0000927653 mck:CoverMyMedsLLCMember 2017-04-03 0000927653 mck:RexallHealthMember country:CA 2016-12-28 0000927653 mck:RexallHealthMember country:CA 2016-12-28 2016-12-28 0000927653 mck:RexallHealthMember us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember country:CA 2016-12-28 0000927653 mck:CoverMyMedsLLCMember us-gaap:CustomerRelationshipsMember 2017-04-03 2017-04-03 0000927653 mck:CoverMyMedsLLCMember 2017-04-03 2017-04-03 0000927653 mck:CoverMyMedsLLCMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-04-03 0000927653 mck:CoverMyMedsLLCMember us-gaap:ScenarioForecastMember 2018-03-31 0000927653 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember 2017-06-30 0000927653 mck:RexallHealthMember us-gaap:CustomerRelationshipsMember country:CA 2016-12-28 2016-12-28 0000927653 mck:BrazilDistributionMember 2016-04-01 2016-06-30 0000927653 mck:CostAlignmentPlanMember 2016-03-14 2017-06-30 0000927653 us-gaap:OtherCurrentLiabilitiesMember mck:CostAlignmentPlanMember 2017-03-31 0000927653 us-gaap:EmployeeSeveranceMember mck:CostAlignmentPlanMember 2016-04-01 2016-06-30 0000927653 us-gaap:OtherNoncurrentLiabilitiesMember mck:CostAlignmentPlanMember 2017-06-30 0000927653 us-gaap:MinimumMember mck:CostAlignmentPlanMember 2017-06-30 0000927653 us-gaap:MaximumMember mck:CostAlignmentPlanMember 2017-06-30 0000927653 us-gaap:OtherCurrentLiabilitiesMember mck:CostAlignmentPlanMember 2017-06-30 0000927653 mck:CostAlignmentPlanMember 2016-04-01 2016-06-30 0000927653 us-gaap:EmployeeSeveranceMember mck:CostAlignmentPlanMember 2017-04-01 2017-06-30 0000927653 us-gaap:OtherNoncurrentLiabilitiesMember mck:CostAlignmentPlanMember 2017-03-31 0000927653 us-gaap:NoncontrollingInterestMember 2017-06-30 0000927653 mck:RedeemableNoncontrollingInterestMember 2017-04-01 2017-06-30 0000927653 mck:RedeemableNoncontrollingInterestMember 2017-03-31 0000927653 mck:RedeemableNoncontrollingInterestMember 2017-06-30 0000927653 us-gaap:NoncontrollingInterestMember 2017-03-31 0000927653 us-gaap:NoncontrollingInterestMember 2017-04-01 2017-06-30 0000927653 mck:RedeemableNoncontrollingInterestMember 2016-06-30 0000927653 mck:RedeemableNoncontrollingInterestMember 2016-04-01 2016-06-30 0000927653 us-gaap:NoncontrollingInterestMember 2016-04-01 2016-06-30 0000927653 us-gaap:NoncontrollingInterestMember 2016-06-30 0000927653 us-gaap:NoncontrollingInterestMember 2016-03-31 0000927653 mck:RedeemableNoncontrollingInterestMember 2016-03-31 0000927653 mck:CelesioMember 2017-04-01 2017-06-30 0000927653 mck:CelesioMember 2016-04-01 2016-06-30 0000927653 mck:CelesioMember 2014-01-01 2014-12-31 0000927653 us-gaap:AdditionalPaidInCapitalMember 2017-04-01 2017-06-30 0000927653 us-gaap:ServiceAgreementsMember 2017-03-31 0000927653 us-gaap:TrademarksAndTradeNamesMember 2017-03-31 0000927653 us-gaap:OtherIntangibleAssetsMember 2017-03-31 0000927653 us-gaap:TechnologyBasedIntangibleAssetsMember 2017-06-30 0000927653 mck:PharmacyLicensesMember 2017-06-30 0000927653 us-gaap:TechnologyBasedIntangibleAssetsMember 2017-04-01 2017-06-30 0000927653 us-gaap:ServiceAgreementsMember 2017-06-30 0000927653 us-gaap:OtherIntangibleAssetsMember 2017-06-30 0000927653 us-gaap:CustomerRelationshipsMember 2017-06-30 0000927653 us-gaap:CustomerRelationshipsMember 2017-03-31 0000927653 mck:PharmacyLicensesMember 2017-04-01 2017-06-30 0000927653 us-gaap:OtherIntangibleAssetsMember 2017-04-01 2017-06-30 0000927653 us-gaap:TrademarksAndTradeNamesMember 2017-06-30 0000927653 mck:PharmacyLicensesMember 2017-03-31 0000927653 us-gaap:TechnologyBasedIntangibleAssetsMember 2017-03-31 0000927653 us-gaap:TrademarksAndTradeNamesMember 2017-04-01 2017-06-30 0000927653 us-gaap:CustomerRelationshipsMember 2017-04-01 2017-06-30 0000927653 us-gaap:ServiceAgreementsMember 2017-04-01 2017-06-30 0000927653 mck:TechnologySolutionsMember 2017-04-01 2017-06-30 0000927653 mck:TechnologySolutionsMember 2017-06-30 0000927653 mck:DistributionSolutionsMember 2017-04-01 2017-06-30 0000927653 mck:DistributionSolutionsMember 2017-06-30 0000927653 mck:DistributionSolutionsMember 2017-03-31 0000927653 mck:TechnologySolutionsMember 2017-03-31 0000927653 us-gaap:CommercialPaperMember 2017-03-31 0000927653 us-gaap:CommercialPaperMember 2017-06-30 0000927653 us-gaap:RevolvingCreditFacilityMember mck:SeniorUnsecuredRevolvingCreditFacilityGlobalFacilityMember 2017-06-30 0000927653 mck:FourPointFivePercentBondsDueAprilTwentySixTwoThousandSeventeenMember us-gaap:LoansPayableMember 2017-04-01 2017-06-30 0000927653 us-gaap:LineOfCreditMember 2017-06-30 0000927653 us-gaap:RevolvingCreditFacilityMember mck:SeniorUnsecuredRevolvingCreditFacilityGlobalFacilityMember 2017-04-01 2017-06-30 0000927653 mck:LongtermDebtCurrentMaturitiesMember 2017-06-30 0000927653 mck:LongtermDebtCurrentMaturitiesMember 2017-03-31 0000927653 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CurrencySwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-06-30 0000927653 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-03-31 0000927653 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CurrencySwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-03-31 0000927653 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-06-30 0000927653 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2017-03-31 0000927653 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CurrencySwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-06-30 0000927653 us-gaap:OtherNoncurrentAssetsMember us-gaap:CurrencySwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-03-31 0000927653 us-gaap:NondesignatedMember 2017-06-30 0000927653 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-06-30 0000927653 us-gaap:DesignatedAsHedgingInstrumentMember 2017-03-31 0000927653 us-gaap:DesignatedAsHedgingInstrumentMember 2017-06-30 0000927653 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2017-03-31 0000927653 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-03-31 0000927653 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2017-06-30 0000927653 us-gaap:NondesignatedMember 2017-03-31 0000927653 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2017-06-30 0000927653 us-gaap:CurrencySwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-03-31 0000927653 mck:BritishPoundSterlingDenominatedNotesMember us-gaap:LoansPayableMember 2017-06-30 0000927653 us-gaap:CurrencySwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-06-30 0000927653 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2017-03-31 0000927653 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember 2017-03-31 0000927653 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember 2017-06-30 0000927653 us-gaap:NetInvestmentHedgingMember 2017-04-01 2017-06-30 0000927653 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-06-30 0000927653 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2017-06-30 0000927653 mck:EuroDenominatedNotesMember us-gaap:LoansPayableMember 2017-06-30 0000927653 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2017-03-31 0000927653 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000927653 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0000927653 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-03-31 0000927653 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-03-31 0000927653 mck:AcceleratedShareRepurchaseMember 2017-06-01 2017-06-30 0000927653 mck:AcceleratedShareRepurchaseMember 2017-04-01 2017-06-30 0000927653 mck:AcceleratedShareRepurchaseMember 2017-03-01 2017-03-31 0000927653 us-gaap:SubsequentEventMember 2017-07-26 2017-07-26 0000927653 mck:AcceleratedShareRepurchaseMember 2017-04-01 2017-04-30 0000927653 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2017-04-01 2017-06-30 0000927653 mck:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceandNetGainLossIncludingPortionAttributabletoNoncontrollingInterestMember 2017-04-01 2017-06-30 0000927653 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2017-04-01 2017-06-30 0000927653 mck:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceandNetGainLossIncludingPortionAttributabletoNoncontrollingInterestMember 2016-04-01 2016-06-30 0000927653 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2016-04-01 2016-06-30 0000927653 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2017-04-01 2017-06-30 0000927653 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2016-04-01 2016-06-30 0000927653 mck:AccumulatedDefinedBenefitPlansForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember 2017-04-01 2017-06-30 0000927653 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2016-04-01 2016-06-30 0000927653 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2016-04-01 2016-06-30 0000927653 mck:AccumulatedDefinedBenefitPlansAdjustmentAmortizationofActuarialLossPriorServiceCostandTransitionObligationIncludingPortionAttributabletoNoncontrollingInterestMember 2016-04-01 2016-06-30 0000927653 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2017-04-01 2017-06-30 0000927653 mck:AccumulatedDefinedBenefitPlansForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember 2016-04-01 2016-06-30 0000927653 mck:AccumulatedDefinedBenefitPlansAdjustmentAmortizationofActuarialLossPriorServiceCostandTransitionObligationIncludingPortionAttributabletoNoncontrollingInterestMember 2017-04-01 2017-06-30 0000927653 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember 2017-04-01 2017-06-30 0000927653 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2017-06-30 0000927653 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember 2017-06-30 0000927653 us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember 2017-03-31 0000927653 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2017-03-31 0000927653 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2017-06-30 0000927653 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2017-03-31 0000927653 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2017-06-30 0000927653 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-03-31 0000927653 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-06-30 0000927653 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember 2017-03-31 0000927653 us-gaap:OperatingSegmentsMember mck:DistributionSolutionsMember 2016-04-01 2016-06-30 0000927653 us-gaap:CorporateNonSegmentMember 2016-04-01 2016-06-30 0000927653 us-gaap:OperatingSegmentsMember 2016-04-01 2016-06-30 0000927653 us-gaap:OperatingSegmentsMember mck:DistributionSolutionsMember 2017-04-01 2017-06-30 0000927653 us-gaap:OperatingSegmentsMember mck:DistributionSolutionsMember mck:InternationalDistributionandServicesMember us-gaap:ReportableSubsegmentsMember 2016-04-01 2016-06-30 0000927653 us-gaap:OperatingSegmentsMember 2017-04-01 2017-06-30 0000927653 us-gaap:OperatingSegmentsMember mck:DistributionSolutionsMember mck:InternationalDistributionandServicesMember us-gaap:ReportableSubsegmentsMember 2017-04-01 2017-06-30 0000927653 us-gaap:OperatingSegmentsMember mck:DistributionSolutionsMember mck:DistributionSolutionsMedicalSurgicalDistributionAndServicesMember us-gaap:ReportableSubsegmentsMember 2017-04-01 2017-06-30 0000927653 us-gaap:OperatingSegmentsMember mck:TechnologySolutionsMember 2017-04-01 2017-06-30 0000927653 us-gaap:OperatingSegmentsMember mck:DistributionSolutionsMember mck:NorthAmericaDistributionAndServicesMember us-gaap:ReportableSubsegmentsMember 2016-04-01 2016-06-30 0000927653 us-gaap:CorporateNonSegmentMember 2017-04-01 2017-06-30 0000927653 us-gaap:OperatingSegmentsMember mck:TechnologySolutionsMember 2016-04-01 2016-06-30 0000927653 us-gaap:MaterialReconcilingItemsMember 2016-04-01 2016-06-30 0000927653 us-gaap:OperatingSegmentsMember mck:DistributionSolutionsMember mck:DistributionSolutionsMedicalSurgicalDistributionAndServicesMember us-gaap:ReportableSubsegmentsMember 2016-04-01 2016-06-30 0000927653 us-gaap:OperatingSegmentsMember mck:DistributionSolutionsMember mck:NorthAmericaDistributionAndServicesMember us-gaap:ReportableSubsegmentsMember 2017-04-01 2017-06-30 0000927653 us-gaap:MaterialReconcilingItemsMember 2017-04-01 2017-06-30 0000927653 us-gaap:OperatingSegmentsMember mck:LIFOmethodofaccountingMember mck:DistributionSolutionsMember 2017-04-01 2017-06-30 0000927653 us-gaap:OperatingSegmentsMember mck:LIFOmethodofaccountingMember mck:DistributionSolutionsMember 2016-04-01 2016-06-30 iso4217:EUR iso4217:GBP iso4217:EUR xbrli:shares iso4217:USD iso4217:CAD mck:segment xbrli:pure xbrli:shares iso4217:USD xbrli:shares mck:pharmacy mck:vote false --03-31 Q1 2018 2017-06-30 10-Q 0000927653 210260531 Large Accelerated Filer MCKESSON CORP 2663000000 243000000 62000000 173000000 3223000000 243000000 167000000 177000000 674000000 54000000 1 105000000 109000000 -113000000 37000000 3018000000 22000000 -35000000 3000000 3150000000 0 -1000000 0 3000000 22.99 2000000 4000000 -1000000 -1000000 -67000000 115000000 0 0 0.05 11000000 9000000 1210000000 1240000000 1900000 0.02 0.02 31022000000 32015000000 3004000000 2977000000 -2141000000 -1936000000 P19Y P19Y P17Y 6028000000 6080000000 115000000 121000000 2000000 2000000 60969000000 61816000000 36948000000 37697000000 193000000 200000000 113000000 17000000 872000000 502000000 212000000 8000000 4048000000 4659000000 2783000000 2339000000 478000000 443000000 611000000 -444000000 101000000 0.83 0.34 0.28 0.28 0.01 0.01 800000000 800000000 273000000 274000000 3000000 3000000 364000000 514000000 -48000000 172000000 316000000 686000000 312000000 3000000 46826000000 48491000000 8700000000 8400000000 P5Y 0.0120 60000000 346000000 279000000 3678000000 3752000000 4000000 3000000 0.1 6000000 6000000 242000000 227000000 2489000000 162000000 174000000 81000000 198000000 162000000 3049000000 174000000 81000000 139000000 0 90000000 32000000 17000000 17000000 1000000 156000000 1000000 0 30000000 0 11000000 16000000 1000000 57000000 1000000 0 0 0 0 0 0 0 0 4000000 0 26000000 0 0 0 26000000 4000000 -114000000 37000000 205000000 126000000 2.41 1.46 2.38 1.45 -12000000 75000000 0.262 0.207 4768000000 0.70 -84000000 -84000000 -59000000 865000000 4063000000 3855000000 3855000000 2093000000 150000000 1295000000 144000000 316000000 64000000 124000000 2250000000 164000000 1392000000 155000000 332000000 71000000 136000000 2331000000 328000000 361000000 393000000 405000000 420000000 5758000000 741000000 2893000000 201000000 1009000000 69000000 845000000 6488000000 772000000 3411000000 261000000 1023000000 151000000 870000000 3665000000 591000000 1598000000 57000000 693000000 5000000 721000000 4238000000 608000000 2019000000 106000000 691000000 80000000 734000000 P25Y P12Y P5Y P13Y P5Y P15Y -113000000 1000000 0 3947000000 37000000 37000000 10586000000 10132000000 454000000 11750000000 11626000000 124000000 950000000 854000000 940000000 940000000 0 230000000 230000000 0 290000000 290000000 -6000000 324000000 -330000000 2907000000 2560000000 655000000 307000000 912000000 458000000 673000000 363000000 2.91 1.46 2.88 1.44 -113000000 2000000 -0.50 0.00 -0.50 0.01 0 -120000000 -120000000 239000000 95000000 1549000000 463000000 95000000 -18000000 -31000000 -85000000 -113000000 -73000000 121000000 59000000 273000000 39000000 300000000 363000000 -935000000 -1469000000 1000000 1000000 2000000 1000000 79000000 79000000 68000000 68000000 47000000 26000000 15278000000 15498000000 60969000000 61816000000 35612000000 35799000000 136000000 136000000 0 3500000000.0 244000000 3500000000.0 183000000 0 8362000000 8400000000 1057000000 7949000000 7900000000 525000000 450000000 1200000000 1057000000 525000000 7305000000 7424000000 84000000 242000000 178000000 178000000 210000000 210000000 0 18000000 53000000 0 0.76 0.77 -82000000 -1131000000 -1154000000 -129000000 1859000000 741000000 542000000 309000000 18000000 7000000 56000000 47000000 11000000 11000000 9000000 9000000 0 152000000 2 27 470 1935000000 1964000000 1935000000 1927000000 1096000000 47000000 928000000 168000000 972000000 635000000 26000000 713000000 -78000000 633000000 3415000000 1927000000 12000000 0 1000000 0 3000000 0 8000000 -275000000 0 1000000 0 -6000000 -6000000 382000000 14000000 -70000000 320000000 0 -44000000 0 14000000 0 0 -255000000 382000000 -20000000 0 0 11000000 -255000000 0 0 -244000000 -5000000 -5000000 382000000 14000000 -70000000 321000000 -66000000 0 1000000 115000000 0 0 116000000 116000000 0 -6000000 267000000 14000000 -70000000 205000000 -11000000 5000000 0 0 1774000000 1938000000 -29000000 -8000000 19000000 13000000 100000000 55000000 -2000000 58000000 300000000 50000000 45000000 14000000 66000000 62000000 2900000000 2100000000 1300000000 1819000000 1485000000 76000000 75000000 38000000 43000000 0.01 0.01 100000000 100000000 0 0 0 0 0 0 672000000 728000000 3000000 36000000 27000000 142000000 14000000 -74000000 -1000000 -541000000 7000000 2282000000 560000000 365000000 2292000000 2349000000 0.65 18215000000 19132000000 -20000000 0 -1000000 0 0 0 -1000000 0 0 1406000000 1340000000 1330000000 1327000000 1327000000 1390000000 1390000000 37000000 500000000 14000000 2463000000 270000000 250000000 246000000 9000000 71000000 35000000 64000000 35000000 13189000000 13442000000 49733000000 49009000000 1468000000 6330000000 41211000000 724000000 49733000000 51051000000 50931000000 1533000000 6382000000 43016000000 120000000 51051000000 183000000 3000000 2500000000 11095000000 11303000000 11273000000 -229000000 -1873000000 -31000000 -8000000 -2141000000 11513000000 -235000000 -1606000000 -17000000 -78000000 -1936000000 0 -70000000 62000000 64000000 1400000 300000 1200000 5982000000 6282000000 250000000 250000000 516000000 371000000 228000000 213000000 225000000 211000000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation: </font><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements of McKesson Corporation (&#8220;McKesson,&#8221; the &#8220;Company,&#8221; or &#8220;we&#8221; and other similar pronouns) include the financial statements of all wholly-owned subsidiaries and majority&#8209;owned or controlled companies. For those consolidated subsidiaries where our ownership is less than 100%, the portion of the net income or loss allocable to the noncontrolling interests is reported as &#8220;Net Income Attributable to Noncontrolling Interests&#8221; on the condensed consolidated statements of operations. All significant intercompany balances and transactions have been eliminated in consolidation including the intercompany portion of transactions with equity method investees. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We consider ourselves to control an entity if we are the majority owner of and have voting control over such entity. We also assess control through means other than voting rights (&#8220;variable interest entities&#8221; or &#8220;VIEs&#8221;) and determine which business entity is the primary beneficiary of the VIE. We consolidate VIEs when it is determined that we are the primary beneficiary of the VIE. Investments in business entities in which we do not have control, but have the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method. Refer to Financial Note 2, &#8220;Healthcare Technology Net Asset Exchange&#8221; for further information on our equity method investment in Change Healthcare, LLC. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial reporting and the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) and, therefore, do not include all information and disclosures normally included in the annual consolidated financial statements. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To prepare the financial statements in conformity with GAAP, management must make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of these financial statements and income and expenses during the reporting period. Actual amounts may differ from these estimated amounts. In our opinion, the accompanying unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair presentation of our financial position, results of operations and cash flows for the interim periods presented. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of operations for the quarter ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results that may be expected for the entire year. These interim financial statements should be read in conjunction with the annual audited financial statements, accounting policies and financial notes included in our Annual Report on Form 10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> previously filed with the SEC on May 22, 2017 (&#8220;2017 Annual Report&#8221;). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year shall mean the Company&#8217;s fiscal year.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investments:</font><font style="font-family:inherit;font-size:10pt;"> In the first quarter of 2018, we adopted amended guidance for the equity method of accounting. The amended guidance simplifies the transition to the equity method of accounting. This standard eliminates the requirement that when an existing cost method investment qualifies for use of the equity method, an investor must restate its historical financial statements, as if the equity method had been used during all previous periods. Additionally, at the point an investment qualifies for the equity method, any unrealized gain or loss in accumulated other comprehensive income (loss) will be recognized through earnings. The adoption of this amended guidance did not have a material effect on our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives and Hedging:</font><font style="font-family:inherit;font-size:10pt;"> In the first quarter of 2018, we adopted amended guidance for derivative instrument novations. The amendments clarify that a novation, a change in the counterparty, to a derivative instrument that has been designated as a hedging instrument does not, in and of itself, require dedesignation of that hedging relationship provided all other hedge accounting criteria continue to be met. The adoption of this amended guidance did not have an effect on our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Consolidation:</font><font style="font-family:inherit;font-size:10pt;">&#160;In the first quarter of 2018, we adopted amended guidance for VIEs. The amended guidance requires a single decision maker of a VIE to consider indirect economic interests in the entity held through related parties that are under common control on a proportionate basis when determining whether it is the primary beneficiary of that VIE.&#160; This amendment does not change the existing characteristics of a primary beneficiary. The adoption of this amended guidance did not have a material effect on our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inventory: </font><font style="font-family:inherit;font-size:10pt;">In the first quarter of 2018, we adopted amended guidance for the subsequent measurement of inventory. The amended guidance requires entities to measure inventory at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The requirement would replace the current lower of cost or market evaluation. Accounting guidance is unchanged for inventory measured using last-in, first-out (&#8220;LIFO&#8221;) or the retail method. The adoption of this amended guidance did not have a material effect on our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Issued Accounting Pronouncements Not Yet Adopted</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Share-Based Payments:</font><font style="font-family:inherit;font-size:10pt;">&#160;In May 2017, amended guidance was issued for employee share-based payment awards. This amendment provides guidance on which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. Under the amended guidance, we are required to account for the effects of a modification if the fair value, the vesting conditions or the classification (as an equity instrument or a liability instrument) of the modified award change from that of the original award immediately before the modification. The amended guidance is effective for us on a prospective basis commencing in the first quarter of 2019.&#160; Early adoption is permitted.&#160; We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Premium Amortization of Purchased Callable Debt Securities:</font><font style="font-family:inherit;font-size:10pt;">&#160;In March 2017, amended guidance was issued to shorten the amortization period for certain callable debt securities held at a premium.&#160; The amended guidance requires the premium of callable debt securities to be amortized to the earliest call date but does not require an accounting change for securities held at a discount as they would still be amortized to maturity.&#160; The amended guidance is effective for us on a modified retrospective basis commencing in the first quarter of 2020.&#160; Early adoption is permitted.&#160; We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Retirement Benefits:</font><font style="font-family:inherit;font-size:10pt;"> In March 2017, amended guidance was issued which requires us to report the service cost component of defined benefit pension plans and other postretirement plans in the same line item as other compensation costs arising from services rendered by the pertinent employees during the period. Other components of net benefit cost are required to be presented in the statements of operations separately from the service cost component. This amended guidance is effective for us in the first quarter of 2019 on a retrospective basis. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derecognition of Nonfinancial Assets:</font><font style="font-family:inherit;font-size:10pt;">&#160;In February 2017, amended guidance was issued that defines the term &#8220;in substance nonfinancial asset&#8221; as a financial asset promised to a counterparty in a contract if substantially all of the fair value of the asset that is promised is concentrated in nonfinancial assets. The scope of this amendment includes nonfinancial assets transferred within a legal entity including a parent entity&#8217;s transfer of nonfinancial assets by transferring ownership interests in consolidated subsidiaries. The amendment excludes all businesses and nonprofit activities from its scope and therefore all entities, with limited exceptions, are required to account for the derecognition of a business or nonprofit activity in accordance with the consolidation guidance once this amended guidance becomes effective. We are required to apply this amended guidance at the same time we apply the amended revenue guidance in the first quarter of 2019. It allows for either full retrospective adoption or modified retrospective adoption.&#160; Early adoption is permitted.&#160; We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill Impairment Testing:</font><font style="font-family:inherit;font-size:10pt;">&#160;In January 2017, amended guidance was issued to simplify goodwill impairment testing by eliminating the second step of the impairment test. Under the second step, the implied fair value of goodwill is calculated in a hypothetical analysis by subtracting the fair value of all assets and liabilities of the reporting unit, including any unrecognized intangible assets, from the fair value of the reporting unit calculated in the first step of the impairment test. If the carrying value of goodwill for the reporting unit exceeds the implied fair value of goodwill, an impairment charge is recorded for that excess. The amended guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value, if any. The amended guidance is effective for us on a prospective basis commencing in the first quarter of 2021. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Business Combinations:</font><font style="font-family:inherit;font-size:10pt;">&#160;In January 2017, amended guidance was issued to clarify the definition of a business to assist entities in evaluating whether transactions should be accounted for as acquisitions of assets or businesses. The amended guidance provides a practical screen to determine when an integrated set of assets and activities (collectively referred to as a &#8220;set&#8221;) is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. If the screen is not met, the amended guidance requires that to be considered a business, a set must include an input and a substantive process that together significantly contribute to the ability to create output. The amended guidance is effective for us commencing in the first quarter of 2019 on a prospective basis. Early adoption is permitted in certain circumstances.&#160; We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Cash:</font><font style="font-family:inherit;font-size:10pt;">&#160;In November 2016, amended guidance was issued that requires restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total cash amounts shown on the statement of cash flows. Transfers between cash and cash equivalents and restricted cash or restricted cash equivalents are not reported as cash flow activities in the statement of cash flows.&#160; The amended guidance is effective for us commencing in the first quarter of 2019 on a retrospective basis. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes - Intra-Entity Transfers of Assets Other Than Inventory:</font><font style="font-family:inherit;font-size:10pt;">&#160;In October 2016, amended guidance was issued to require entities to recognize income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The amended guidance is effective for us commencing in the first quarter of 2019 on a modified retrospective basis. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments:</font><font style="font-family:inherit;font-size:10pt;">&#160;In August 2016, amended guidance was issued to provide clarification on cash flow classification related to eight specific issues including contingent consideration payments made after a business combination and distributions received from equity method investees.&#160; The amended guidance&#160;is effective for us commencing in the first quarter of 2019 on a retrospective basis. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses:</font><font style="font-family:inherit;font-size:10pt;"> In June 2016, amended guidance was issued, which will change the impairment model for most financial assets and require additional disclosures. The amended guidance requires financial assets that are measured at amortized cost, be presented at the net amount&#160;expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of financial assets. The amended guidance also requires us to consider historical experience, current conditions, and reasonable and supportable forecasts that affect the collectibility of the reported amount in estimating credit losses. The amended guidance becomes effective for us commencing in the first quarter of 2021 and will be applied through a cumulative-effect adjustment to the beginning retained earnings in the year of adoption. Early adoption is permitted.&#160; We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases:</font><font style="font-family:inherit;font-size:10pt;"> In February 2016, amended guidance was issued for lease arrangements. The amended standard will require lessees to recognize assets and liabilities on the balance sheet for all leases with terms longer than 12 months and provide enhanced disclosures on key information of leasing arrangements.&#160; The amended guidance is effective for us commencing in the first quarter of 2020, on a modified retrospective basis.&#160; Early adoption is permitted.&#160; We plan to adopt the new standard on the effective date and are currently evaluating the impact of this amended guidance on our consolidated financial statements. We anticipate that the adoption of the amended lease guidance will materially affect our condensed consolidated balance sheet and will require certain changes to our systems and processes.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments: </font><font style="font-family:inherit;font-size:10pt;">In January 2016, amended guidance was issued that requires equity investments to be measured at fair value with changes in fair value recognized in net income and enhanced disclosures about those investments. This guidance also simplifies the impairment assessments of equity investments without readily determinable fair value. The investments that are accounted for under the equity method of accounting or result in consolidation of the investee are excluded from the scope of this amended guidance. The amended guidance will become effective for us commencing in the first quarter of 2019 and will be adopted through a cumulative-effect adjustment. Early adoption is not permitted except for certain provisions.&#160; We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition: </font><font style="font-family:inherit;font-size:10pt;">In May 2014, amended guidance was issued for recognizing revenue from contracts with customers.&#160; The amended guidance eliminates industry specific guidance and applies to all companies.&#160; Revenues will be recognized when an entity satisfies a performance obligation by transferring control of a promised good or service to a customer in an amount that reflects the consideration to which the entity expects to be entitled for that good or service.&#160; Revenue from a contract that contains multiple performance obligations is allocated to each performance obligation generally on a relative standalone selling price basis.&#160; The amended guidance also requires additional quantitative and qualitative disclosures.&#160; In March, April and May 2016, amended guidance was further issued including clarifying guidance on principal versus agent considerations, ability to choose an accounting policy election to account for shipping and handling activities that occur after the customer has obtained control of a good as an activity to fulfill the promise to transfer the good, and provided certain scope improvements and practical expedients.&#160; The amended standard is effective for us commencing in the first quarter of 2019 and allows for either full retrospective adoption or modified retrospective adoption.&#160; Early adoption is permitted.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While we continue to evaluate the effect of the amended standard, we have conducted a preliminary assessment for our Distribution Solutions segment and do not expect adoption of the amended standard to have a material impact on our consolidated financial statements.&#160; The majority of our Distribution Solutions segment&#8217;s revenue is generated from sales of pharmaceutical products, which will continue to be recognized when control of the goods is transferred to the customer. We generally anticipate having substantially similar performance obligations under the amended guidance as compared with deliverables and units of account currently being recognized. We intend to make policy elections within the amended standard that are consistent with our current accounting. Our preliminary assessment does not include certain businesses for which we are exploring strategic alternatives and we continue to evaluate the potential impact of the recent acquisitions. This preliminary assessment is subject to change prior to adoption. Additionally, we anticipate adopting this amended standard on a modified retrospective basis in our first quarter of 2019.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Business Combinations</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">CoverMyMeds LLC (&#8220;CMM&#8221;)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 3, 2017, we completed our acquisition of CMM, a privately-owned company headquartered in Columbus, Ohio. CMM provides electronic prior authorization solutions to pharmacies, providers, payers, and pharmaceutical manufacturers. The net purchase consideration of </font><font style="font-family:inherit;font-size:10pt;">$1.3 billion</font><font style="font-family:inherit;font-size:10pt;"> was funded from cash on hand. The cash consideration was initially paid into an escrow account prior to our 2017 fiscal year end, and was included in &#8220;Other Noncurrent Assets&#8221; within our consolidated balance sheet at March 31, 2017. Pursuant to the agreement, McKesson may pay up to an additional </font><font style="font-family:inherit;font-size:10pt;">$0.2 billion</font><font style="font-family:inherit;font-size:10pt;"> of contingent consideration based on CMM&#8217;s financial performance for 2018 and 2019. We recorded a liability for this remaining contingent consideration at its estimated fair value of </font><font style="font-family:inherit;font-size:10pt;">$113 million</font><font style="font-family:inherit;font-size:10pt;"> as of the acquisition date on our condensed consolidated balance sheet.&#160;&#160;The contingent consideration was estimated using a Monte Carlo simulation, which utilizes Level 3 inputs under the fair value measurement and disclosure guidance, including estimated financial forecasts. The contingent liability is re-measured at fair value at each reporting date until the liability is extinguished with changes in fair value being recorded to our statements of operations.&#160;&#160;There was no material change in the contingent liability&#8217;s fair value during the first quarter of 2018. The initial fair value of this contingent consideration is a non-cash investing activity. The financial results of CMM are included in our North America pharmaceutical distribution and services business within our Distribution Solutions segment since the acquisition date. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The provisional fair value of assets acquired and liabilities assumed as of the acquisition date, excluding goodwill and intangibles, were </font><font style="font-family:inherit;font-size:10pt;">$54 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$8 million</font><font style="font-family:inherit;font-size:10pt;">. Approximately </font><font style="font-family:inherit;font-size:10pt;">$854 million</font><font style="font-family:inherit;font-size:10pt;"> of the preliminary purchase price allocation has been assigned to goodwill, which reflects the expected future benefits of certain synergies and intangible assets that do not qualify for separate recognition. The amount of goodwill is fully deductible for tax purposes. Included in the preliminary purchase price allocation are acquired identifiable intangibles of </font><font style="font-family:inherit;font-size:10pt;">$502 million</font><font style="font-family:inherit;font-size:10pt;"> primarily representing customer relationships with a weighted average life of </font><font style="font-family:inherit;font-size:10pt;">17</font><font style="font-family:inherit;font-size:10pt;"> years. Amounts recognized as of the acquisition date are provisional and subject to change within the measurement period as our fair value assessments are finalized. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rexall Health</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 28, 2016, we completed our acquisition of Rexall Health which operates approximately </font><font style="font-family:inherit;font-size:10pt;">470</font><font style="font-family:inherit;font-size:10pt;"> retail pharmacies in Canada, particularly in Ontario and Western Canada. The net cash purchase consideration of </font><font style="font-family:inherit;font-size:10pt;">$2.9 billion</font><font style="font-family:inherit;font-size:10pt;"> Canadian dollars (or, approximately </font><font style="font-family:inherit;font-size:10pt;">$2.1 billion</font><font style="font-family:inherit;font-size:10pt;">) was funded from cash on hand. As part of the transaction, McKesson agreed to divest </font><font style="font-family:inherit;font-size:10pt;">27</font><font style="font-family:inherit;font-size:10pt;"> local stores that the Competition Bureau of Canada (the &#8220;Bureau&#8221;) identified during its review of the transaction. We expect to complete the sale of these local market divestitures during the first half of 2018. The financial results of Rexall Health are included in our North America pharmaceutical distribution and services business within our Distribution Solutions segment since the acquisition date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the first quarter of 2018, we recorded certain measurement period adjustments to the provisional fair value of assets acquired and liabilities assumed as of the acquisition date (primarily an increase of </font><font style="font-family:inherit;font-size:10pt;">$17 million</font><font style="font-family:inherit;font-size:10pt;"> to intangibles). The amounts as of the acquisition date are provisional and subject to change within the measurement period as our fair value assessments are finalized. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total adjusted provisional fair value of assets acquired and liabilities assumed as of the acquisition date, excluding goodwill and intangibles, were </font><font style="font-family:inherit;font-size:10pt;">$674 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$212 million</font><font style="font-family:inherit;font-size:10pt;">. Approximately </font><font style="font-family:inherit;font-size:10pt;">$950 million</font><font style="font-family:inherit;font-size:10pt;"> of the adjusted preliminary purchase price allocation has been assigned to goodwill, which primarily reflects the expected future benefits of certain synergies and intangible assets that do not qualify for separate recognition. Included in the adjusted preliminary purchase price allocation are acquired identifiable intangibles of </font><font style="font-family:inherit;font-size:10pt;">$872 million</font><font style="font-family:inherit;font-size:10pt;">, net of intangibles classified as held for sale, primarily representing trade names with a weighted average life of </font><font style="font-family:inherit;font-size:10pt;">19</font><font style="font-family:inherit;font-size:10pt;"> years and customer relationships with a weighted average life of </font><font style="font-family:inherit;font-size:10pt;">19</font><font style="font-family:inherit;font-size:10pt;"> years. At June 30, 2017, assets of those stores to be divested were approximately </font><font style="font-family:inherit;font-size:10pt;">$193 million</font><font style="font-family:inherit;font-size:10pt;"> and were included under the captions, &#8220;Prepaid expenses and other&#8221; in the accompanying condensed consolidated balance sheet. There were no material liabilities associated with those stores at June 30, 2017. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of acquired intangibles from these acquisitions was primarily determined by applying the income approach, using several significant unobservable inputs for projected cash flows and a discount rate. These inputs are considered Level 3 inputs.</font></div><div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2017 Acquisitions</font></div><div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the first quarter of 2017, we completed our acquisitions of Vantage Oncology Holdings, LLC (&#8220;Vantage&#8221;), Biologics, Inc., UDG Healthcare Plc (&#8220;UDG&#8221;) and other businesses for net cash payments of </font><font style="font-family:inherit;font-size:10pt;">$1.8 billion</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Acquisitions</font></div><div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the last two years, we also completed other acquisitions within both of our operating segments. Financial results for our business acquisitions have been included in our consolidated financial statements since their respective acquisition dates. Purchase prices for our business acquisitions have been allocated based on estimated fair values at the date of acquisition.</font></div><div style="line-height:120%;text-align:justify;text-indent:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill recognized for our business acquisitions is generally not expected to be deductible for tax purposes. However, if we acquire the assets of a company, the goodwill may be deductible for tax purposes.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingent Liabilities</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to commitments and obligations in the ordinary course of business, we are subject to various claims, including claims with customers and vendors, pending and potential legal actions for damages, investigations relating to governmental laws and regulations and other matters arising out of the normal conduct of our business. As described below, many of these proceedings are at preliminary stages and many seek an indeterminate amount of damages.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When a loss is considered probable and reasonably estimable, we record a liability in the amount of our best estimate for the ultimate loss. However, the likelihood of a loss with respect to a particular contingency is often difficult to predict and determining a meaningful estimate of the loss or a range of loss may not be practicable based on the information available and the potential effect of future events and decisions by third parties that will determine the ultimate resolution of the contingency. Moreover, it is not uncommon for such matters to be resolved over many years, during which time relevant developments and new information must be reevaluated at least quarterly to determine both the likelihood of potential loss and whether it is possible to reasonably estimate a range of possible loss. When a loss is probable but a reasonable estimate cannot be made, disclosure of the proceeding is provided.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. We review all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or range of loss can be made. As discussed above, development of a meaningful estimate of loss or a range of potential loss is complex when the outcome is directly dependent on negotiations with or decisions by third parties, such as regulatory agencies, the court system and other interested parties. Such factors bear directly on whether it is possible to reasonably estimate a range of potential loss and boundaries of high and low estimates.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant developments in previously reported proceedings and in other litigation and claims, since the filing of our 2017 Annual Report are set out below. We are party to the legal proceedings described below. Unless otherwise stated, we are currently unable to estimate a range of reasonably possible losses for the unresolved proceedings described below. Should any one or a combination of more than one of these proceedings be successful, or should we determine to settle any or a combination of these matters, we may be required to pay substantial sums, become subject to the entry of an injunction or be forced to change the manner in which we operate our business, which could have a material adverse impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Litigation, Government Subpoenas and Investigations </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As previously disclosed, following removal of the action captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">State of West Virginia ex rel. Morrisey v. McKesson Corporation </font><font style="font-family:inherit;font-size:10pt;">to the United States District Court for the Southern District of West Virginia, the court remanded the matter back to state court. On July 7, 2017, the Company again removed the matter to the United States District Court for the Southern District of West Virginia (Civil Action No. 2:16-cv-03555.)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since May 24, 2017, the Company has been served with seven complaints filed in state courts in West Virginia alleging claims related to the distribution of controlled substances to pharmacies in West Virginia. These lawsuits are </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Mayor Reba Honaker, on behalf of the City of Welch v. West Virginia Board of Pharmacy, et al.,</font><font style="font-family:inherit;font-size:10pt;"> Cabell County, West Virginia Circuit Court, Civil Action 17-C-18, removed to the United States District Court for the Southern District of West Virginia, Civil Action 1:17-cv-03364; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">County Commission of Lincoln County v. West Virginia Board of Pharmacy, et al.,</font><font style="font-family:inherit;font-size:10pt;"> Lincoln County, West Virginia Circuit Court, Civil Action 17-C-46, removed to the United States District Court for the Southern District of West Virginia, Civil Action 2:17-cv-03366; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Mayor Vivian Livinggood on behalf of the Town of Gilbert&#160;v. West Virginia Board of Pharmacy, et al.,</font><font style="font-family:inherit;font-size:10pt;"> Mingo County, West Virginia Circuit Court, Civil Action 17-C-94, removed to the United States District Court for the Southern District of West Virginia, Civil Action 2:17-cv-03369; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Mayor Charles Sparks on behalf of the Town of Kermit v. West Virginia Board of Pharmacy, et al.,</font><font style="font-family:inherit;font-size:10pt;"> Mingo County, West Virginia Circuit Court, Civil Action 17-C-13, removed to the United States District Court for the Southern District of West Virginia, Civil Action 2:17-cv-03372; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Mayor Robert Carlton on behalf of the City of Williamson v. West Virginia Board of Pharmacy, et al.,</font><font style="font-family:inherit;font-size:10pt;"> Mingo County, West Virginia Circuit Court, Civil Action 17-C-99, removed to the United States District Court for the Southern District of West Virginia, Civil Action 2:17-cv-03532; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">The County Commission of Mercer County v. West Virginia Board of Pharmacy, et al.,</font><font style="font-family:inherit;font-size:10pt;"> Mercer County, West Virginia Circuit Court, Civil Action 17-C-236; and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Mayor Raaimie Barker on behalf of the Town of Chapmanville&#160;v. West Virginia Board of Pharmacy, et al.,</font><font style="font-family:inherit;font-size:10pt;"> Logan County, West Virginia Circuit Court, Civil Action 17-C-168. The Company has filed motions to dismiss in all cases in which responses were due.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In response to the previously disclosed case captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cherokee Nation v. McKesson Corporation, et al., </font><font style="font-family:inherit;font-size:10pt;">on June 8, 2017, the Company and the other defendants in this action filed suit in the United States District Court for the Northern District of Oklahoma, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">McKesson Corporation, et al. v. Todd Hembree, Attorney General of the Cherokee Nation, et al., </font><font style="font-family:inherit;font-size:10pt;">No. 4:17-cv-00323, seeking a declaratory judgment that the Cherokee Nation District Court has no jurisdiction over the claims asserted by the Cherokee Nation. On that same day, the Company and the other plaintiffs in the federal action filed a motion for a preliminary injunction enjoining the defendants from taking any action in the case pending in the tribal court. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 25, 2017, a lawsuit was filed in Stockton County, California Superior Court against various pharmaceutical manufacturers and the Company by the County of San Joaquin, City of Stockton and Montezuma Fire Protection District. </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">City of Stockton, et al. v. Purdue Pharma LP, et al., </font><font style="font-family:inherit;font-size:10pt;">Case No. STK-CV-UBT-2017-5325.The suit seeks damages for the funds spent by plaintiffs on municipal services due to alleged excessive sales of opioids. The causes of action against the Company are unjust enrichment and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">parens patriaie</font><font style="font-family:inherit;font-size:10pt;"> claims. On July 17, 2017, this case was removed to the United States District Court for the Eastern District of California (Case No. 2:17-at-00719.)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Two municipalities in Ohio, the City of Dayton and the City of Lorain, have individually filed suit against various pharmaceutical manufacturers and three wholesalers, including the Company, as well as four individual physicians. </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">City of Dayton v. Purdue Pharma LP, et al., </font><font style="font-family:inherit;font-size:10pt;">Montgomery County, Ohio Court of Common Pleas, No. 2017 CV 02647, filed on June 5, 2017; and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">City of Lorain v. Purdue Pharma LP, et al</font><font style="font-family:inherit;font-size:10pt;">., Lorain County, Ohio Court of Common Pleas, No. 17 CV 192705, filed on June 29, 2017. In each case, the plaintiff claims that all of the defendants engaged in unfair and deceptive acts or practices involving the marketing and sales of opioids, and created a public nuisance. Each plaintiff also contends that the distributor defendants failed to take any action to prevent or reduce the distribution of opioids. The suits contain causes of action for violation of the Ohio Consumer Sales Practices Act; deceptive trade practices; public nuisance; fraud, unjust enrichment; and negligence. On July 7, 2017, the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">City of Dayton</font><font style="font-family:inherit;font-size:10pt;"> case was removed to the United States District Court for the Southern District of Ohio (Case No. 3:17-cv-229). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 12, 2017, the County of Nassau, New York filed suit against various pharmaceutical manufacturers and three wholesalers, including the Company, as well as four individual physicians. </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">The County of Nassau v. Purdue Pharma LP, et al., </font><font style="font-family:inherit;font-size:10pt;">Supreme Court of the State of New York, County of Nassau, Index No. 605477/2017. The plaintiff claims that all of the defendants engaged in unfair and deceptive acts or practices involving the marketing and sales of opioids, and created a public nuisance. Each plaintiff also contends that the distributor defendants failed to take any action to prevent or reduce the distribution of opioids. The suit contains causes of action for deceptive acts and practices under New York General Business Law &#167;&#160;349; false advertising under New York General Business Law &#167;&#160;350; public nuisance; violation of New York Social Services Law &#167;&#160;145-B; fraud, unjust enrichment; and negligence. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 19, 2017, the plaintiff in the previously disclosed case captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Silverman v. McKesson Corporation,</font><font style="font-family:inherit;font-size:10pt;"> filed a voluntary withdrawal of this action.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, the Company receives subpoenas or requests for information from various government agencies. The Company generally responds to such subpoenas and requests in a cooperative, thorough and timely manner. These responses sometimes require time and effort and can result in considerable costs being incurred by the Company. For example, the Company has received a request for information from the U.S. Attorney&#8217;s Office for the Eastern District of Pennsylvania relating to the use of a Company pharmacy management software system to process partially-filled prescriptions.&#160;The Company is currently responding to this request. Such subpoenas and requests also can lead to the assertion of claims or the commencement of civil or criminal legal proceedings against the Company and other members of the health care industry, as well as to settlements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When a loss is considered probable and reasonably estimable, we record a liability in the amount of our best estimate for the ultimate loss. However, the likelihood of a loss with respect to a particular contingency is often difficult to predict and determining a meaningful estimate of the loss or a range of loss may not be practicable based on the information available and the potential effect of future events and decisions by third parties that will determine the ultimate resolution of the contingency. Moreover, it is not uncommon for such matters to be resolved over many years, during which time relevant developments and new information must be reevaluated at least quarterly to determine both the likelihood of potential loss and whether it is possible to reasonably estimate a range of possible loss. When a loss is probable but a reasonable estimate cannot be made, disclosure of the proceeding is provided.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. We review all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or range of loss can be made. As discussed above, development of a meaningful estimate of loss or a range of potential loss is complex when the outcome is directly dependent on negotiations with or decisions by third parties, such as regulatory agencies, the court system and other interested parties. Such factors bear directly on whether it is possible to reasonably estimate a range of potential loss and boundaries of high and low estimates.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in redeemable noncontrolling interests and noncontrolling interests for the first quarter of 2018 were as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Noncontrolling Interests</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Redeemable</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Noncontrolling</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Interests</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance, March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">178</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,327</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income attributable to noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reclassification of recurring compensation to other accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments to noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercises of Put Right</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(53</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance, June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">210</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,390</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in redeemable noncontrolling interests and noncontrolling interests for the first quarter of 2017 were as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Noncontrolling Interests</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Redeemable</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Noncontrolling</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Interests</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance, March 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,406</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income attributable to noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reclassification of recurring compensation to other accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase of noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance, June 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">242</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,340</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation: </font><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements of McKesson Corporation (&#8220;McKesson,&#8221; the &#8220;Company,&#8221; or &#8220;we&#8221; and other similar pronouns) include the financial statements of all wholly-owned subsidiaries and majority&#8209;owned or controlled companies. For those consolidated subsidiaries where our ownership is less than 100%, the portion of the net income or loss allocable to the noncontrolling interests is reported as &#8220;Net Income Attributable to Noncontrolling Interests&#8221; on the condensed consolidated statements of operations. All significant intercompany balances and transactions have been eliminated in consolidation including the intercompany portion of transactions with equity method investees. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We consider ourselves to control an entity if we are the majority owner of and have voting control over such entity. We also assess control through means other than voting rights (&#8220;variable interest entities&#8221; or &#8220;VIEs&#8221;) and determine which business entity is the primary beneficiary of the VIE. We consolidate VIEs when it is determined that we are the primary beneficiary of the VIE. Investments in business entities in which we do not have control, but have the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method. Refer to Financial Note 2, &#8220;Healthcare Technology Net Asset Exchange&#8221; for further information on our equity method investment in Change Healthcare, LLC. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial reporting and the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) and, therefore, do not include all information and disclosures normally included in the annual consolidated financial statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Debt and Financing Activities</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Long-Term Debt</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our long-term debt includes both U.S. dollar and foreign currency (primarily Euro and British pound sterling) denominated borrowings. At June 30, 2017 and March 31, 2017, </font><font style="font-family:inherit;font-size:10pt;">$7,949 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$8,362&#160;million</font><font style="font-family:inherit;font-size:10pt;"> of total long-term debt were outstanding, of which </font><font style="font-family:inherit;font-size:10pt;">$525 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1,057 million</font><font style="font-family:inherit;font-size:10pt;"> were included under the caption &#8220;Current portion of long-term debt&#8221; within the condensed consolidated balance sheets. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the first quarter of 2018, we repaid our </font><font style="font-family:inherit;font-size:10pt;">&#8364;500 million</font><font style="font-family:inherit;font-size:10pt;">&#160;bond that matured on April 26, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revolving Credit Facilities</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have a syndicated </font><font style="font-family:inherit;font-size:10pt;">$3.5 billion</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year senior unsecured revolving credit facility (the &#8220;Global Facility&#8221;), which has a </font><font style="font-family:inherit;font-size:10pt;">$3.15 billion</font><font style="font-family:inherit;font-size:10pt;"> aggregate sublimit of availability in Canadian dollars, British pound sterling and Euros. Borrowings under the Global Facility bear interest based upon the London Interbank Offered Rate, Canadian Dealer Offered Rate for credit extensions denominated in Canadian Dollars, a prime rate, or alternative overnight rates as applicable, plus agreed margins. The Global Facility contains a financial covenant which obligates the Company to maintain a debt to capital ratio of no greater than </font><font style="font-family:inherit;font-size:10pt;">65%</font><font style="font-family:inherit;font-size:10pt;"> and other customary investment grade covenants. If we do not comply with these covenants, our ability to use the Global Facility may be suspended and repayment of any outstanding balances under the Global Facility may be required. At June 30, 2017, we were in compliance with all covenants. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> borrowings outstanding under this facility during the first quarter of 2018, and as of June 30, 2017. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also maintain bilateral credit lines primarily denominated in Euros with a total committed and uncommitted balance of </font><font style="font-family:inherit;font-size:10pt;">$244 million</font><font style="font-family:inherit;font-size:10pt;">. Borrowings and repayments were not material during the first quarters of 2018 and 2017. As of June 30, 2017 and March 31, 2017, amounts outstanding under these credit lines were not material. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Commercial Paper</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We maintain a commercial paper program to support our working capital requirements and for other general corporate purposes. Under the program, the Company can issue up to </font><font style="font-family:inherit;font-size:10pt;">$3.5 billion</font><font style="font-family:inherit;font-size:10pt;"> in outstanding notes. As of June 30, 2017, there were&#160;</font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> borrowings outstanding under the commercial paper program. As of March 31, 2017, we had </font><font style="font-family:inherit;font-size:10pt;">$183 million</font><font style="font-family:inherit;font-size:10pt;">&#160;commercial paper notes outstanding with a weighted average interest rate of&#160;</font><font style="font-family:inherit;font-size:10pt;">1.20%</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Hedging Activities</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the normal course of business, we are exposed to interest rate and foreign exchange rate fluctuations. At times, we limit these risks through the use of derivatives such as interest rate swaps, cross currency swaps and foreign currency forward contracts. In accordance with our policy, derivatives are only used for hedging purposes. We do not use derivatives for trading or speculative purposes. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Foreign currency exchange risk</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We conduct our business worldwide in U.S. dollars and the functional currencies of our foreign subsidiaries, including Euro, British pound sterling and Canadian dollars. Changes in foreign currency exchange rates could have a material adverse impact on our financial results that are reported in U.S. dollars. We are also exposed to foreign currency exchange rate risk related to our foreign subsidiaries, including intercompany loans denominated in non-functional currencies. We have certain foreign currency exchange rate risk programs that use foreign currency forward contracts and cross currency swaps. These forward contracts and cross currency swaps are generally used to offset the potential income statement effects from intercompany loans denominated in non-functional currencies. These programs reduce but do not eliminate foreign exchange rate risk.</font></div><div style="line-height:174%;padding-bottom:16px;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Investment Hedges and Derivatives Designated as Hedges</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have </font><font style="font-family:inherit;font-size:10pt;">&#8364;1.2 billion</font><font style="font-family:inherit;font-size:10pt;">&#160;Euro-denominated notes and&#160;</font><font style="font-family:inherit;font-size:10pt;">&#163;450 million</font><font style="font-family:inherit;font-size:10pt;">&#160;British pound sterling-denominated notes which hedge portions of our net investments in non-U.S. subsidiaries against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar (&#8220;Net Investment Hedges&#8221;). For all notes that are designated as net investment hedges and meet effectiveness requirements, the changes in carrying value of the notes attributable to the change in spot rates are recorded in accumulated other comprehensive income (loss) within the condensed consolidated balance sheet where they offset foreign currency translation gains and losses recorded on our net investments.&#160; To the extent foreign currency denominated notes designated as net investment hedges are ineffective, changes in value are recorded in earnings. &#160;Losses from net investment hedges recorded in other comprehensive income were&#160;</font><font style="font-family:inherit;font-size:10pt;">$114 million</font><font style="font-family:inherit;font-size:10pt;"> during the first quarter of&#160;2018. We did not have any ineffective portion of the net investment hedges as of June 30, 2017 and March 31, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At June 30, 2017 and March 31, 2017, we had forward contracts to hedge the U.S. dollar against cash flows denominated in Canadian dollars with total gross notional values of </font><font style="font-family:inherit;font-size:10pt;">$243 million</font><font style="font-family:inherit;font-size:10pt;">, which were designated as cash flow hedges. These contracts will mature between </font><font style="font-family:inherit;font-size:10pt;">March 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">March 2020</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we enter into cross currency swaps to hedge intercompany loans denominated in non-functional currencies. For our cross currency swap transactions, we agree with another party to exchange, at specified intervals, one currency for another currency at a fixed exchange rate, generally set at inception, calculated by reference to agreed upon notional amounts. These cross currency swaps are designed to reduce the income statement effects arising from fluctuations in foreign exchange rates and have been designated as cash flow hedges.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> At June 30, 2017 and March 31, 2017, we had cross currency swaps with total gross notional amounts of approximately&#160;</font><font style="font-family:inherit;font-size:10pt;">$3,223 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2,663 million</font><font style="font-family:inherit;font-size:10pt;">, which are designated as cash flow hedges. These swaps will mature between February 2018 and January 2024.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For forward contracts and cross currency swaps that are designated as cash flow hedges, the effective portion of changes in the fair value&#160;of the hedges is recorded into accumulated other comprehensive income (loss) and reclassified into earnings in the same period in which the hedged transaction affects earnings. Changes in fair values representing hedge ineffectiveness are recognized in current earnings. Gains or losses on these hedges recorded in other comprehensive income and earnings were not material in the first quarters of 2018 and 2017.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives Not Designated as Hedges</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At June 30, 2017 and March 31, 2017, we had forward contracts to primarily hedge the U.S. dollar against cash flows denominated in Canadian dollars with total gross notional value of&#160;</font><font style="font-family:inherit;font-size:10pt;">$177 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$173 million</font><font style="font-family:inherit;font-size:10pt;">. These contracts will mature through August 2017 and none of these contracts were designated for hedge accounting. Losses from these contracts were not material for the first quarters of 2018 and 2017.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also have a number of forward contracts to hedge the Euro against cash flows denominated primarily in British pound sterling and other European currencies. At June 30, 2017 and March 31, 2017, the total gross notional amounts of these contracts were </font><font style="font-family:inherit;font-size:10pt;">$167&#160;million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$62 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These contracts will mature through </font><font style="font-family:inherit;font-size:10pt;">December 2017</font><font style="font-family:inherit;font-size:10pt;"> and none of these contracts were designated for hedge accounting. Changes in the fair values of contracts not designated as hedges are recorded directly into earnings. Gains from these contracts were recorded within operating expenses and were not material for the first quarters of 2018 and 2017. The gains or losses from these contracts are largely offset by changes in the value of the underlying intercompany foreign currency loans. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information regarding the fair value of derivatives on a gross basis is as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21" rowspan="1"></td></tr><tr><td style="width:28%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance Sheet </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Caption</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value of </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivative</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">U.S. Dollar Notional</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value of </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivative</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">U.S. Dollar Notional</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Asset</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liability</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Asset</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liability</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Derivatives designated for hedge accounting</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange contracts (current)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange contracts (non-current)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other Noncurrent Assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cross currency swaps (current)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">174</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">174</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cross currency swaps (non-current)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other Noncurrent Assets/Liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,049</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,489</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Derivatives not designated for hedge accounting</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange contracts (current)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">198</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange contracts (current)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">205</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Refer to Financial Note 13, "Fair Value Measurements," for more information on these recurring fair value measurements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Discontinued Operations</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the fourth quarter of 2016, we entered into an agreement to sell our Brazilian pharmaceutical distribution business to a third party from our Distribution Solutions segment. In the first quarter of 2017, we completed the sale of this business and recognized an after-tax loss of </font><font style="font-family:inherit;font-size:10pt;">$113 million</font><font style="font-family:inherit;font-size:10pt;">&#160;within discontinued operations primarily for the settlement of certain indemnification matters as well as the release of the cumulative translation losses. We made a payment of approximately </font><font style="font-family:inherit;font-size:10pt;">$100 million</font><font style="font-family:inherit;font-size:10pt;"> related to the sale of this business in the first quarter of 2017. The results of this business have been classified as discontinued operations since 2015. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of discontinued operations for the first quarters of 2018 and 2017 were not material except for the loss recognized upon the disposition of our Brazilian business in 2017. As of June 30, 2017 and March 31, 2017, the carrying amounts of total assets and liabilities of discontinued operations were not material.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Earnings Per Common Share</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic earnings per common share are computed by dividing net income by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share are computed similar to basic earnings per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The computations for basic and diluted earnings per common share are as follows:</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarter Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(In millions, except per share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">363</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">673</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income attributable to noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(56</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income from continuing operations attributable to McKesson</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">307</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">655</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(113</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income attributable to McKesson</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">309</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">542</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">225</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options to purchase common stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">213</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Earnings (loss) per common share attributable to McKesson: </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.44</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.88</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.01</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.50</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.45</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.38</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.46</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.91</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.50</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.46</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.41</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Certain computations may reflect rounding adjustments.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Potentially dilutive securities include outstanding stock options, restricted stock units, and performance-based and other restricted stock units. Approximately </font><font style="font-family:inherit;font-size:10pt;">2 million</font><font style="font-family:inherit;font-size:10pt;"> potentially dilutive securities were excluded from the computations of diluted net earnings per common share for each of the quarters ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, as they were anti-dilutive.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Healthcare Technology Net Asset Exchange</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 28, 2016, we entered into a contribution agreement (&#8220;Contribution Agreement&#8221;) with Change Healthcare Holdings, Inc. (&#8220;Change&#8221;), a Delaware corporation, and others including shareholders of Change to form a joint venture, Change Healthcare, LLC (&#8220;Change Healthcare&#8221;), a Delaware limited liability company. On March 1, 2017, the transaction closed upon satisfaction of all closing conditions pursuant to the Contribution Agreement. Under the terms of the Contribution Agreement, we contributed the majority of our McKesson Technology Solutions businesses (&#8220;Core MTS Business&#8221;) to the newly formed joint venture, Change Healthcare. We retained our RelayHealth Pharmacy (&#8220;RHP&#8221;) and Enterprise Information Solutions (&#8220;EIS&#8221;) businesses. Change contributed substantially all of its businesses to the joint venture excluding its pharmacy switch and prescription routing business. In exchange for the contribution, we own </font><font style="font-family:inherit;font-size:10pt;">70%</font><font style="font-family:inherit;font-size:10pt;"> of the joint venture with the remaining equity ownership held by Change shareholders. The joint venture is jointly governed by us and Change shareholders. Change Healthcare is a healthcare technology company which provides software and analytics, network solutions and technology-enabled services that will deliver wide-ranging financial, operational and clinical benefits to payers, providers and consumers. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">McKesson and Change shareholders have agreed to take steps to launch an initial public offering of an entity which holds equity in Change Healthcare, subject to market conditions. Sometime thereafter, we expect to exit our investment in Change Healthcare through a distribution to McKesson shareholders.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Gain from Healthcare Technology</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Asset Exchange</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We accounted for this transaction as a sale of the Core MTS Business and a subsequent purchase of a </font><font style="font-family:inherit;font-size:10pt;">70%</font><font style="font-family:inherit;font-size:10pt;"> interest in the newly formed joint venture. Accordingly, in the fourth quarter of 2017, we deconsolidated the Core MTS Business and recorded a pre-tax gain of </font><font style="font-family:inherit;font-size:10pt;">$3,947 million</font><font style="font-family:inherit;font-size:10pt;"> (after-tax gain of </font><font style="font-family:inherit;font-size:10pt;">$3,018 million</font><font style="font-family:inherit;font-size:10pt;">) within operating expenses in our consolidated statements of operations. This transaction did not meet the criteria to be reported as a discontinued operation since it did not constitute a significant strategic business shift for the Company. During the first quarter of 2018, we recorded a pre-tax gain of approximately </font><font style="font-family:inherit;font-size:10pt;">$37 million</font><font style="font-family:inherit;font-size:10pt;"> (after-tax gain of </font><font style="font-family:inherit;font-size:10pt;">$22 million</font><font style="font-family:inherit;font-size:10pt;">) under the caption, &#8220;Gain on Healthcare Technology Net Asset Exchange,&#8221; upon the finalization of net working capital and other adjustments. At June 30, 2017, we had a receivable of </font><font style="font-family:inherit;font-size:10pt;">$126 million</font><font style="font-family:inherit;font-size:10pt;"> from Change Healthcare representing the final settlement of the net working capital and other adjustments. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equity Method Investment in Change Healthcare</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our investment in the joint venture is accounted for using the equity method of accounting. We disclose intervening events at the joint venture in the lag period that could materially affect our consolidated financial statements, if applicable. There were no material intervening events at the joint venture during June 2017. During the first quarter of 2018, we recorded our proportionate share of loss from Change Healthcare of </font><font style="font-family:inherit;font-size:10pt;">$120 million</font><font style="font-family:inherit;font-size:10pt;">, which included transaction and integration expenses incurred by the joint venture and amortization expenses associated with equity method intangible assets. This amount was recorded under the caption, &#8220;Loss from Equity Method Investment in Change Healthcare,&#8221; in our condensed consolidated statement of operations. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> At June 30, 2017, the carrying value of our investment was </font><font style="font-family:inherit;font-size:10pt;">$3,855 million</font><font style="font-family:inherit;font-size:10pt;">, which exceeded our proportionate share of the joint venture&#8217;s book value of net assets by approximately </font><font style="font-family:inherit;font-size:10pt;">$4,768 million</font><font style="font-family:inherit;font-size:10pt;">, primarily reflecting equity method intangible assets and goodwill and other fair value adjustments. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized financial information (unaudited) of Change Healthcare is as follows: </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarter Ended June 30, 2017 </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">865</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from Continuing Operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(84</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net Loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(84</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our proportionate share of </font><font style="font-family:inherit;font-size:10pt;color:#424242;">Change Healthcare</font><font style="font-family:Arial;font-size:10pt;color:#424242;">&#8217;</font><font style="font-family:inherit;font-size:10pt;color:#424242;">s net loss as reported was </font><font style="font-family:inherit;font-size:10pt;color:#424242;">$59 million</font><font style="font-family:inherit;font-size:10pt;color:#424242;"> (</font><font style="font-family:inherit;font-size:10pt;color:#424242;">$84 million</font><font style="font-family:inherit;font-size:10pt;color:#424242;"> at our </font><font style="font-family:inherit;font-size:10pt;">70%</font><font style="font-family:inherit;font-size:10pt;color:#424242;"> ownership).&#160; Adjustments from their carrying value to our initial fair value basis of accounting resulted in a total reported net loss of </font><font style="font-family:inherit;font-size:10pt;">$120 million</font><font style="font-family:inherit;font-size:10pt;color:#424242;"> for McKesson.&#160; The amortization of fair value adjustments included incremental intangible amortization and removal of profit associated with the recognition of deferred revenue, as well as basis differences in long-term debt.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Agreements with Change Healthcare and Related Party Transactions</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the closing of the transaction, McKesson, Change Healthcare and certain Change shareholders also entered into various ancillary agreements, including transition services agreements (&#8220;TSA&#8221;), a transaction and advisory fee agreement (&#8220;Advisory Agreement&#8221;), a tax receivable agreement (&#8220;TRA&#8221;) and certain other commercial agreements. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the TRA, McKesson may be required to make certain payments or may be entitled to receive certain payments related to the cash tax savings attributable to the utilization of certain tax attributes, including certain amortizable tax basis in software contributed by McKesson to Change Healthcare. At June 30, 2017 and March 31, 2017, we had a </font><font style="font-family:inherit;font-size:10pt;">$136 million</font><font style="font-family:inherit;font-size:10pt;"> noncurrent liability payable to Change Healthcare shareholders associated with the TRA. The amount is based on certain estimates and could become payable in periods after a disposition of our investment in Change Healthcare. No such payments were required to be made or received during the first quarter of 2018.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the TSA, McKesson provides various transitional services to the joint venture to support certain operations including information technology, accounting and other administrative services. The total fees charged by us for such transition services were </font><font style="font-family:inherit;font-size:10pt;">$37 million</font><font style="font-family:inherit;font-size:10pt;"> for the first quarter of 2018. Transition services fees are included within operating expenses in our condensed consolidated statements of operations. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the Advisory Agreement, the joint venture pays McKesson and Change shareholders an agreed upon amount for each fiscal year on a quarterly basis. The foregoing advisory and transaction fees are non-refundable and allocated to McKesson and Change shareholders based on their respective equity ownership percentages. In the first quarter of 2018, we did not earn material advisory fees and transaction fees.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues recorded and expenses incurred under commercial arrangements with Change Healthcare were not material during the first quarter of 2018. At June 30, 2017 and March 31, 2017, receivables from and payables to the joint venture were not material.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ummarized financial information (unaudited) of Change Healthcare is as follows: </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarter Ended June 30, 2017 </font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">865</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from Continuing Operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(84</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net Loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(84</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information regarding the fair value of derivatives on a gross basis is as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21" rowspan="1"></td></tr><tr><td style="width:28%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance Sheet </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Caption</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value of </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivative</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">U.S. Dollar Notional</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value of </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivative</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">U.S. Dollar Notional</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Asset</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liability</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Asset</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liability</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Derivatives designated for hedge accounting</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange contracts (current)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange contracts (non-current)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other Noncurrent Assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cross currency swaps (current)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">174</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">174</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cross currency swaps (non-current)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other Noncurrent Assets/Liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,049</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,489</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Derivatives not designated for hedge accounting</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange contracts (current)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">198</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange contracts (current)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">205</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the carrying amounts of cash, certain cash equivalents, restricted cash, marketable securities, receivables, drafts and accounts payable, short-term borrowings and other current liabilities approximated their estimated fair values because of the short maturity of these financial instruments. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of our commercial paper was determined using quoted prices in active markets for identical liabilities, which are considered to be Level 1 inputs.</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Assets Measured at Fair Value on a Recurring Basis</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our long-term debt is carried at amortized cost. The carrying amounts and estimated fair values of these liabilities were </font><font style="font-family:inherit;font-size:10pt;">$7.9 billion</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$8.4 billion</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$8.4 billion</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$8.7 billion</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. The estimated fair value of our long-term debt was determined using quoted market prices in a less active market and other observable inputs from available market information, which are considered to be Level 2 inputs, and may not be representative of actual values that could have been realized or that will be realized in the future.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in cash and cash equivalents at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> were mainly investments in money market funds of </font><font style="font-family:inherit;font-size:10pt;">$443 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$478 million</font><font style="font-family:inherit;font-size:10pt;">, which are reported at fair value. The fair value of the money market funds was determined by using quoted prices for identical investments in active markets, which are considered to be Level&#160;1 inputs under the fair value measurements and disclosure guidance. The carrying value of all other cash equivalents approximates their fair value due to their relatively short-term nature.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair values of our forward foreign currency derivatives were determined using quoted market prices of similar instruments in an active market and other observable inputs from available market information.&#160; Fair values of our foreign currency swaps were determined using the quoted foreign currency exchange rates and other observable inputs from available market information. These inputs are considered Level 2 under the fair value measurements and disclosure guidance, and may not be representative of actual values that could have been realized or that will be realized in the future. Refer to Financial Note 12, "Hedging Activities," for more information on our forward foreign currency derivatives including foreign currency forward contracts and swaps.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> transfers between Level 1, Level 2 or Level 3 of the fair value hierarchy during the quarters ended June 30,&#160;</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Liabilities Measured at Fair Value on a Nonrecurring Basis</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At June 30, 2017, we measured the contingent consideration liability related to our acquisition of CMM at fair value on a nonrecurring basis. Refer to Financial Note 3, &#8220;Business Combinations&#8221;. There were no assets measured at fair value on a nonrecurring basis at June 30, 2017.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year shall mean the Company&#8217;s fiscal year.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Goodwill and Intangible Assets, Net </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in the carrying amount of goodwill were as follows:</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Distribution</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Solutions</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Technology</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Solutions</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance, March&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill acquired</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">940</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">940</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition accounting, transfers and other adjustments </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(330</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">230</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">230</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance, June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,626</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,750</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Effective April 1, 2017, our RHP business was transitioned from the Technology Solutions segment to the Distribution Solutions segment.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, accumulated goodwill impairment losses were </font><font style="font-family:inherit;font-size:10pt;">$290 million</font><font style="font-family:inherit;font-size:10pt;"> primarily in our Technology Solutions segment. </font></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information regarding intangible assets is as follows:</font></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26" rowspan="1"></td></tr><tr><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;">(Dollars in millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Period</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(years)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,411</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,392</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,893</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,295</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,598</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Service agreements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,023</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(332</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">691</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,009</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(316</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">693</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmacy licenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">741</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">591</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trademarks and trade names</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">870</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(136</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">734</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">845</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(124</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">721</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Technology</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(71</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">261</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(155</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(144</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,488</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,250</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,238</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,758</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,093</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,665</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization expense of intangible assets was </font><font style="font-family:inherit;font-size:10pt;">$121 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$115 million</font><font style="font-family:inherit;font-size:10pt;"> for the quarters ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and 2016. Estimated annual amortization expense of these assets is as follows: </font><font style="font-family:inherit;font-size:10pt;">$328 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$420 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$405 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$393 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$361 million</font><font style="font-family:inherit;font-size:10pt;"> for the remainder of 2018 and each of the succeeding years through 2022 and </font><font style="font-family:inherit;font-size:10pt;">$2,331 million</font><font style="font-family:inherit;font-size:10pt;"> thereafter. All intangible assets were subject to amortization as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the first quarters of 2018 and 2017, income tax expense related to continuing operations was </font><font style="font-family:inherit;font-size:10pt;">$95&#160;million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$239&#160;million</font><font style="font-family:inherit;font-size:10pt;"> and included net discrete tax expense of </font><font style="font-family:inherit;font-size:10pt;">$3 million</font><font style="font-family:inherit;font-size:10pt;"> and net discrete tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$35 million</font><font style="font-family:inherit;font-size:10pt;">. Our discrete tax benefits for the first quarter of 2017 included </font><font style="font-family:inherit;font-size:10pt;">$37 million</font><font style="font-family:inherit;font-size:10pt;"> related to the adoption of the amended accounting guidance on employee share-based compensation. Our reported income tax rates for the first quarters of 2018 and 2017 were </font><font style="font-family:inherit;font-size:10pt;">20.7%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">26.2%</font><font style="font-family:inherit;font-size:10pt;">. Fluctuations in our reported income tax rates are primarily due to changes within our business mix, including varying proportions of income attributable to foreign countries that have lower income tax rates, discrete items and the impact of the intercompany sale of software.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;">$516&#160;million</font><font style="font-family:inherit;font-size:10pt;"> of unrecognized tax benefits, of which </font><font style="font-family:inherit;font-size:10pt;">$371 million</font><font style="font-family:inherit;font-size:10pt;"> would reduce income tax expense and the effective tax rate, if recognized. During the next twelve months, it is reasonably possible that audit resolutions could potentially reduce our unrecognized tax benefits by up to </font><font style="font-family:inherit;font-size:10pt;">$60 million</font><font style="font-family:inherit;font-size:10pt;">. However, this amount may change as we continue to have ongoing negotiations with various taxing authorities throughout the year.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. During the first quarter of 2017, we reached an agreement with the Internal Revenue Service (&#8220;IRS&#8221;) to settle all outstanding issues relating to the fiscal years 2007 through 2009. This settlement did not have a material impact on our provision for income taxes. We are subject to audit by the IRS for fiscal years 2010 through the current fiscal year. We are generally subject to audit by taxing authorities in various U.S. states and in foreign jurisdictions for fiscal years 2006 through the current fiscal year.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Redeemable Noncontrolling Interests and Noncontrolling Interests</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Redeemable Noncontrolling Interests</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our redeemable noncontrolling interests relate to our consolidated subsidiary, Celesio AG (&#8220;Celesio&#8221;). The domination and profit and loss transfer agreement (the &#8220;Domination Agreement&#8221;) was entered into between McKesson and Celesio in connection with our 2014 acquisition of Celesio and became effective in December 2014. Under the Domination Agreement, the noncontrolling shareholders of Celesio have a right to put (&#8220;Put Right&#8221;) their Celesio shares at </font><font style="font-family:inherit;font-size:10pt;">&#8364;22.99</font><font style="font-family:inherit;font-size:10pt;"> per share increased annually for interest in the amount of </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;"> percentage points above a base rate published by the German Bundesbank semiannually, less any compensation amount or guaranteed dividend already paid by McKesson in respect of the relevant time period (&#8220;Put Amount&#8221;). The exercise of the Put Right will reduce the balance of redeemable noncontrolling interests. During the first quarter of 2018, we paid </font><font style="font-family:inherit;font-size:10pt;">$50 million</font><font style="font-family:inherit;font-size:10pt;"> to purchase </font><font style="font-family:inherit;font-size:10pt;">1.9 million</font><font style="font-family:inherit;font-size:10pt;"> shares of Celesio through the exercises of the Put Right by the noncontrolling shareholders, which decreased the carrying value of redeemable noncontrolling interests by </font><font style="font-family:inherit;font-size:10pt;">$53 million</font><font style="font-family:inherit;font-size:10pt;">. The balance of redeemable noncontrolling interests is reported at the greater of its carrying value or its maximum redemption value at each reporting date. The redemption value is the Put Amount adjusted for exchange rate fluctuations each period. At June 30,&#160;2017 and March 31, 2017, the carrying value of redeemable noncontrolling interests of </font><font style="font-family:inherit;font-size:10pt;">$1.39&#160;billion</font><font style="font-family:inherit;font-size:10pt;"> and&#160;</font><font style="font-family:inherit;font-size:10pt;">$1.33 billion</font><font style="font-family:inherit;font-size:10pt;"> exceeded the maximum redemption value of </font><font style="font-family:inherit;font-size:10pt;">$1.24 billion</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.21&#160;billion</font><font style="font-family:inherit;font-size:10pt;">. At June&#160;30,&#160;2017 and March 31, 2017, we owned approximately </font><font style="font-family:inherit;font-size:10pt;">77%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">76%</font><font style="font-family:inherit;font-size:10pt;"> of Celesio&#8217;s outstanding common shares.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Domination Agreement, the noncontrolling shareholders of Celesio received a one-time guaranteed dividend of </font><font style="font-family:inherit;font-size:10pt;">&#8364;0.83</font><font style="font-family:inherit;font-size:10pt;"> per Celesio share for the 2014 calendar year and are also entitled to receive an annual recurring compensation amount of </font><font style="font-family:inherit;font-size:10pt;">&#8364;0.83</font><font style="font-family:inherit;font-size:10pt;"> per Celesio share since January 2015. As a result, during the first quarters of 2018 and 2017, we recorded a total attribution of net income to the noncontrolling shareholders of Celesio of&#160;</font><font style="font-family:inherit;font-size:10pt;">$9 million</font><font style="font-family:inherit;font-size:10pt;"> and&#160;</font><font style="font-family:inherit;font-size:10pt;">$11 million</font><font style="font-family:inherit;font-size:10pt;">. All amounts were recorded in our condensed consolidated statement of operations within the caption, &#8220;Net Income Attributable to Noncontrolling Interests,&#8221; and the corresponding liability balance was recorded within other accrued liabilities on our condensed consolidated balance sheet.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During fiscal 2014, subsequent to the effectiveness of the Domination Agreement, certain noncontrolling shareholders of Celesio initiated appraisal proceedings (&#8220;Appraisal Proceedings&#8221;) with the Stuttgart Regional Court to challenge the adequacy of the compensation amount, the guaranteed dividend and/or the Put Amount. As long as any Appraisal Proceedings are pending, the compensation amount, guaranteed dividend and/or Put Amount will be paid as specified currently in the Domination Agreement. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Noncontrolling Interests</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our noncontrolling interests represent third-party equity interests in our consolidated entities, primarily Vantage and ClarusONE Sourcing Services LLP, were&#160;</font><font style="font-family:inherit;font-size:10pt;">$210 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$178 million</font><font style="font-family:inherit;font-size:10pt;"> at June 30, 2017 and March 31, 2017. During the first quarters of 2018 and 2017, we allocated a total of&#160;</font><font style="font-family:inherit;font-size:10pt;">$47 million</font><font style="font-family:inherit;font-size:10pt;"> and&#160;</font><font style="font-family:inherit;font-size:10pt;">$7 million</font><font style="font-family:inherit;font-size:10pt;">&#160;of net income to noncontrolling interests.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in redeemable noncontrolling interests and noncontrolling interests for the first quarter of 2018 were as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Noncontrolling Interests</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Redeemable</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Noncontrolling</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Interests</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance, March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">178</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,327</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income attributable to noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reclassification of recurring compensation to other accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments to noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercises of Put Right</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(53</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance, June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">210</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,390</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in redeemable noncontrolling interests and noncontrolling interests for the first quarter of 2017 were as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Noncontrolling Interests</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Redeemable</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Noncontrolling</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Interests</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance, March 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,406</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income attributable to noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reclassification of recurring compensation to other accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase of noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance, June 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">242</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,340</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The effect of changes in our ownership interests with noncontrolling interests on our equity of </font><font style="font-family:inherit;font-size:10pt;">$3 million</font><font style="font-family:inherit;font-size:10pt;"> was recorded as a net increase to McKesson&#8217;s stockholders&#8217; paid-in capital during the first quarter of 2018. Net income attributable to McKesson and transfers from noncontrolling interests amounted to </font><font style="font-family:inherit;font-size:10pt;">$312 million</font><font style="font-family:inherit;font-size:10pt;"> during the first quarter of 2018.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investments:</font><font style="font-family:inherit;font-size:10pt;"> In the first quarter of 2018, we adopted amended guidance for the equity method of accounting. The amended guidance simplifies the transition to the equity method of accounting. This standard eliminates the requirement that when an existing cost method investment qualifies for use of the equity method, an investor must restate its historical financial statements, as if the equity method had been used during all previous periods. Additionally, at the point an investment qualifies for the equity method, any unrealized gain or loss in accumulated other comprehensive income (loss) will be recognized through earnings. The adoption of this amended guidance did not have a material effect on our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives and Hedging:</font><font style="font-family:inherit;font-size:10pt;"> In the first quarter of 2018, we adopted amended guidance for derivative instrument novations. The amendments clarify that a novation, a change in the counterparty, to a derivative instrument that has been designated as a hedging instrument does not, in and of itself, require dedesignation of that hedging relationship provided all other hedge accounting criteria continue to be met. The adoption of this amended guidance did not have an effect on our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Consolidation:</font><font style="font-family:inherit;font-size:10pt;">&#160;In the first quarter of 2018, we adopted amended guidance for VIEs. The amended guidance requires a single decision maker of a VIE to consider indirect economic interests in the entity held through related parties that are under common control on a proportionate basis when determining whether it is the primary beneficiary of that VIE.&#160; This amendment does not change the existing characteristics of a primary beneficiary. The adoption of this amended guidance did not have a material effect on our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inventory: </font><font style="font-family:inherit;font-size:10pt;">In the first quarter of 2018, we adopted amended guidance for the subsequent measurement of inventory. The amended guidance requires entities to measure inventory at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The requirement would replace the current lower of cost or market evaluation. Accounting guidance is unchanged for inventory measured using last-in, first-out (&#8220;LIFO&#8221;) or the retail method. The adoption of this amended guidance did not have a material effect on our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Issued Accounting Pronouncements Not Yet Adopted</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Share-Based Payments:</font><font style="font-family:inherit;font-size:10pt;">&#160;In May 2017, amended guidance was issued for employee share-based payment awards. This amendment provides guidance on which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. Under the amended guidance, we are required to account for the effects of a modification if the fair value, the vesting conditions or the classification (as an equity instrument or a liability instrument) of the modified award change from that of the original award immediately before the modification. The amended guidance is effective for us on a prospective basis commencing in the first quarter of 2019.&#160; Early adoption is permitted.&#160; We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Premium Amortization of Purchased Callable Debt Securities:</font><font style="font-family:inherit;font-size:10pt;">&#160;In March 2017, amended guidance was issued to shorten the amortization period for certain callable debt securities held at a premium.&#160; The amended guidance requires the premium of callable debt securities to be amortized to the earliest call date but does not require an accounting change for securities held at a discount as they would still be amortized to maturity.&#160; The amended guidance is effective for us on a modified retrospective basis commencing in the first quarter of 2020.&#160; Early adoption is permitted.&#160; We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Retirement Benefits:</font><font style="font-family:inherit;font-size:10pt;"> In March 2017, amended guidance was issued which requires us to report the service cost component of defined benefit pension plans and other postretirement plans in the same line item as other compensation costs arising from services rendered by the pertinent employees during the period. Other components of net benefit cost are required to be presented in the statements of operations separately from the service cost component. This amended guidance is effective for us in the first quarter of 2019 on a retrospective basis. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derecognition of Nonfinancial Assets:</font><font style="font-family:inherit;font-size:10pt;">&#160;In February 2017, amended guidance was issued that defines the term &#8220;in substance nonfinancial asset&#8221; as a financial asset promised to a counterparty in a contract if substantially all of the fair value of the asset that is promised is concentrated in nonfinancial assets. The scope of this amendment includes nonfinancial assets transferred within a legal entity including a parent entity&#8217;s transfer of nonfinancial assets by transferring ownership interests in consolidated subsidiaries. The amendment excludes all businesses and nonprofit activities from its scope and therefore all entities, with limited exceptions, are required to account for the derecognition of a business or nonprofit activity in accordance with the consolidation guidance once this amended guidance becomes effective. We are required to apply this amended guidance at the same time we apply the amended revenue guidance in the first quarter of 2019. It allows for either full retrospective adoption or modified retrospective adoption.&#160; Early adoption is permitted.&#160; We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill Impairment Testing:</font><font style="font-family:inherit;font-size:10pt;">&#160;In January 2017, amended guidance was issued to simplify goodwill impairment testing by eliminating the second step of the impairment test. Under the second step, the implied fair value of goodwill is calculated in a hypothetical analysis by subtracting the fair value of all assets and liabilities of the reporting unit, including any unrecognized intangible assets, from the fair value of the reporting unit calculated in the first step of the impairment test. If the carrying value of goodwill for the reporting unit exceeds the implied fair value of goodwill, an impairment charge is recorded for that excess. The amended guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value, if any. The amended guidance is effective for us on a prospective basis commencing in the first quarter of 2021. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Business Combinations:</font><font style="font-family:inherit;font-size:10pt;">&#160;In January 2017, amended guidance was issued to clarify the definition of a business to assist entities in evaluating whether transactions should be accounted for as acquisitions of assets or businesses. The amended guidance provides a practical screen to determine when an integrated set of assets and activities (collectively referred to as a &#8220;set&#8221;) is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. If the screen is not met, the amended guidance requires that to be considered a business, a set must include an input and a substantive process that together significantly contribute to the ability to create output. The amended guidance is effective for us commencing in the first quarter of 2019 on a prospective basis. Early adoption is permitted in certain circumstances.&#160; We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Cash:</font><font style="font-family:inherit;font-size:10pt;">&#160;In November 2016, amended guidance was issued that requires restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total cash amounts shown on the statement of cash flows. Transfers between cash and cash equivalents and restricted cash or restricted cash equivalents are not reported as cash flow activities in the statement of cash flows.&#160; The amended guidance is effective for us commencing in the first quarter of 2019 on a retrospective basis. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes - Intra-Entity Transfers of Assets Other Than Inventory:</font><font style="font-family:inherit;font-size:10pt;">&#160;In October 2016, amended guidance was issued to require entities to recognize income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The amended guidance is effective for us commencing in the first quarter of 2019 on a modified retrospective basis. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments:</font><font style="font-family:inherit;font-size:10pt;">&#160;In August 2016, amended guidance was issued to provide clarification on cash flow classification related to eight specific issues including contingent consideration payments made after a business combination and distributions received from equity method investees.&#160; The amended guidance&#160;is effective for us commencing in the first quarter of 2019 on a retrospective basis. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses:</font><font style="font-family:inherit;font-size:10pt;"> In June 2016, amended guidance was issued, which will change the impairment model for most financial assets and require additional disclosures. The amended guidance requires financial assets that are measured at amortized cost, be presented at the net amount&#160;expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of financial assets. The amended guidance also requires us to consider historical experience, current conditions, and reasonable and supportable forecasts that affect the collectibility of the reported amount in estimating credit losses. The amended guidance becomes effective for us commencing in the first quarter of 2021 and will be applied through a cumulative-effect adjustment to the beginning retained earnings in the year of adoption. Early adoption is permitted.&#160; We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases:</font><font style="font-family:inherit;font-size:10pt;"> In February 2016, amended guidance was issued for lease arrangements. The amended standard will require lessees to recognize assets and liabilities on the balance sheet for all leases with terms longer than 12 months and provide enhanced disclosures on key information of leasing arrangements.&#160; The amended guidance is effective for us commencing in the first quarter of 2020, on a modified retrospective basis.&#160; Early adoption is permitted.&#160; We plan to adopt the new standard on the effective date and are currently evaluating the impact of this amended guidance on our consolidated financial statements. We anticipate that the adoption of the amended lease guidance will materially affect our condensed consolidated balance sheet and will require certain changes to our systems and processes.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments: </font><font style="font-family:inherit;font-size:10pt;">In January 2016, amended guidance was issued that requires equity investments to be measured at fair value with changes in fair value recognized in net income and enhanced disclosures about those investments. This guidance also simplifies the impairment assessments of equity investments without readily determinable fair value. The investments that are accounted for under the equity method of accounting or result in consolidation of the investee are excluded from the scope of this amended guidance. The amended guidance will become effective for us commencing in the first quarter of 2019 and will be adopted through a cumulative-effect adjustment. Early adoption is not permitted except for certain provisions.&#160; We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition: </font><font style="font-family:inherit;font-size:10pt;">In May 2014, amended guidance was issued for recognizing revenue from contracts with customers.&#160; The amended guidance eliminates industry specific guidance and applies to all companies.&#160; Revenues will be recognized when an entity satisfies a performance obligation by transferring control of a promised good or service to a customer in an amount that reflects the consideration to which the entity expects to be entitled for that good or service.&#160; Revenue from a contract that contains multiple performance obligations is allocated to each performance obligation generally on a relative standalone selling price basis.&#160; The amended guidance also requires additional quantitative and qualitative disclosures.&#160; In March, April and May 2016, amended guidance was further issued including clarifying guidance on principal versus agent considerations, ability to choose an accounting policy election to account for shipping and handling activities that occur after the customer has obtained control of a good as an activity to fulfill the promise to transfer the good, and provided certain scope improvements and practical expedients.&#160; The amended standard is effective for us commencing in the first quarter of 2019 and allows for either full retrospective adoption or modified retrospective adoption.&#160; Early adoption is permitted.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While we continue to evaluate the effect of the amended standard, we have conducted a preliminary assessment for our Distribution Solutions segment and do not expect adoption of the amended standard to have a material impact on our consolidated financial statements.&#160; The majority of our Distribution Solutions segment&#8217;s revenue is generated from sales of pharmaceutical products, which will continue to be recognized when control of the goods is transferred to the customer. We generally anticipate having substantially similar performance obligations under the amended guidance as compared with deliverables and units of account currently being recognized. We intend to make policy elections within the amended standard that are consistent with our current accounting. Our preliminary assessment does not include certain businesses for which we are exploring strategic alternatives and we continue to evaluate the potential impact of the recent acquisitions. This preliminary assessment is subject to change prior to adoption. Additionally, we anticipate adopting this amended standard on a modified retrospective basis in our first quarter of 2019.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pension Benefits</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The net periodic expense for our defined pension benefit plans was </font><font style="font-family:inherit;font-size:10pt;">$6 million</font><font style="font-family:inherit;font-size:10pt;"> for the first quarters of 2018 and 2017.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash contributions to these plans were </font><font style="font-family:inherit;font-size:10pt;">$3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4 million</font><font style="font-family:inherit;font-size:10pt;"> for the first quarters of 2018 and 2017. The projected unit credit method is utilized in measuring net periodic pension expense over the employees&#8217; service life for the pension plans. Unrecognized actuarial losses exceeding </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> of the greater of the projected benefit obligation or the market value of assets are amortized straight-line over the average remaining future service periods and expected life expectancy.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the fourth quarter of 2016, we committed to a restructuring plan to lower our operating costs (the &#8220;Cost Alignment Plan&#8221;). The Cost Alignment Plan primarily consists of a reduction in workforce, and business process initiatives that will be substantially implemented prior to the end of 2019. Business process initiatives primarily include plans to reduce operating costs of our distribution and pharmacy operations, administrative support functions, and technology platforms, as well as the disposal and abandonment of certain non-core businesses. As a result of the Cost Alignment Plan, we expect to record total pre-tax charges of approximately </font><font style="font-family:inherit;font-size:10pt;">$250 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$270 million</font><font style="font-family:inherit;font-size:10pt;">, of which </font><font style="font-family:inherit;font-size:10pt;">$246 million</font><font style="font-family:inherit;font-size:10pt;"> of pre-tax charges were recorded to date. Estimated remaining charges primarily consist of exit-related costs and accelerated depreciation and amortization, which are largely attributed to our Distribution Solutions segment.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the first quarter of 2017, we recorded a pre-tax charge of </font><font style="font-family:inherit;font-size:10pt;">$9 million</font><font style="font-family:inherit;font-size:10pt;"> as part of the Cost Alignment Plan. There were no material restructuring charges recorded during the first quarter of 2018. During the first quarters of 2018 and 2017, we made </font><font style="font-family:inherit;font-size:10pt;">$14 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$45 million</font><font style="font-family:inherit;font-size:10pt;"> of cash payments, primarily related to severance. The reserve balances as of June 30, 2017 and March 31, 2017 include </font><font style="font-family:inherit;font-size:10pt;">$64 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$71 million</font><font style="font-family:inherit;font-size:10pt;"> recorded in other accrued liabilities, and </font><font style="font-family:inherit;font-size:10pt;">$35 million</font><font style="font-family:inherit;font-size:10pt;"> recorded in other noncurrent liabilities in our condensed consolidated balance sheet.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information regarding changes in our accumulated other comprehensive income (loss), net of tax, by component for the first quarter of 2018 is as follows:</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Foreign Currency Translation Adjustments, Net of Tax</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized Losses on Net Investment Hedges, </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net of Tax</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net of Tax</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized Net Gains (Losses) and Other Components of Benefit Plans, Net of Tax</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Accumulated Other Comprehensive Income (Loss)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,873</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(229</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss) before reclassifications </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">382</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">320</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts reclassified to earnings and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">382</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:30px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: amounts attributable to noncontrolling and redeemable noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss) attributable to McKesson</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">267</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(70</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">205</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,606</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(78</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(235</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,936</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information regarding other comprehensive income (loss) including redeemable noncontrolling interests, net of tax, by component is as follows:</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarter Ended June 30,</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;">&#160;(In millions)</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments arising during period, net of income tax benefit of nil and $12 </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2) (3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">382</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(275</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-left:36px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reclassified to income statement, net of income tax expense of nil and nil </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">382</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(255</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gains (losses) on net investment hedges </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(5)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gains (losses) on net investment hedges arising during period, net of income tax benefit of $44 and nil</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(70</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:36px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reclassified to income statement, net of income tax expense of nil and nil</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(70</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gains on cash flow hedges</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gains on cash flow hedges arising during period, net of income tax expense of nil and nil</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in retirement-related benefit plans </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(6)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net actuarial loss and prior service cost arising during the period, net of income tax benefit of nil and nil </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of actuarial loss and prior service costs, net of income tax expense of nil and $1 </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(7)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments and other, net of income tax expense of nil and nil</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss), net of tax</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">321</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(244</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Foreign currency translation adjustments primarily result from the conversion of non-U.S. dollar financial statements of our foreign subsidiary, Celesio, into the Company&#8217;s reporting currency, U.S. dollars, during the first quarters of 2018 and 2017.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The net foreign currency translation gains during the first quarter of 2018 were primarily due to the strengthening of the Euro and British pound sterling against the U.S. dollar from April 1, 2017 to June 30, 2017. During the first quarter of 2017, the currency translation losses were primarily due to the weakening of the Euro and British pound sterling against the U.S. dollar from April 1, 2016 to June 30, 2016.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The first quarter of 2018 includes net foreign currency translation gains of </font><font style="font-family:inherit;font-size:8pt;">$115 million</font><font style="font-family:inherit;font-size:8pt;"> and the first quarter of 2017 includes net foreign currency translation losses of </font><font style="font-family:inherit;font-size:8pt;">$67 million</font><font style="font-family:inherit;font-size:8pt;"> attributable to redeemable noncontrolling interests.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The first quarter of 2017 includes net foreign currency translation losses of </font><font style="font-family:inherit;font-size:8pt;">$20 million</font><font style="font-family:inherit;font-size:8pt;"> reclassified from accumulated other comprehensive income (loss) to loss from discontinued operations, net of tax, within our condensed consolidated statements of operations due to the sale of our Brazilian pharmaceutical distribution business. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(5)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The first quarter of 2018 includes foreign currency losses of&#160;</font><font style="font-family:inherit;font-size:8pt;">$114 million</font><font style="font-family:inherit;font-size:8pt;">&#160;on the net investment hedges from the&#160;</font><font style="font-family:inherit;font-size:8pt;">&#8364;1.2 billion</font><font style="font-family:inherit;font-size:8pt;">&#160;Euro-denominated notes and&#160;</font><font style="font-family:inherit;font-size:8pt;">&#163;450 million</font><font style="font-family:inherit;font-size:8pt;">&#160;British pound sterling-denominated notes.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(6)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The first quarters of 2018 and 2017 include net actuarial losses of </font><font style="font-family:inherit;font-size:8pt;">$1 million</font><font style="font-family:inherit;font-size:8pt;"> attributable to redeemable noncontrolling interests.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(7)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Pre-tax amount reclassified into cost of sales and operating expenses in our condensed consolidated statements of operations. The related tax expense was reclassified into income tax expense in our condensed consolidated statements of operations.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The computations for basic and diluted earnings per common share are as follows:</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarter Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(In millions, except per share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">363</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">673</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income attributable to noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(56</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income from continuing operations attributable to McKesson</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">307</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">655</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(113</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income attributable to McKesson</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">309</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">542</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">225</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options to purchase common stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">213</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Earnings (loss) per common share attributable to McKesson: </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.44</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.88</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.01</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.50</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.45</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.38</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.46</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.91</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.50</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.46</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.41</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Certain computations may reflect rounding adjustments.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information regarding intangible assets is as follows:</font></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26" rowspan="1"></td></tr><tr><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;">(Dollars in millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Period</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(years)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,411</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,392</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,893</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,295</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,598</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Service agreements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,023</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(332</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">691</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,009</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(316</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">693</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pharmacy licenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">741</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">591</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trademarks and trade names</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">870</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(136</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">734</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">845</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(124</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">721</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Technology</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(71</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">261</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(155</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(144</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,488</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,250</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,238</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,758</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,093</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,665</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in the carrying amount of goodwill were as follows:</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Distribution</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Solutions</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Technology</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Solutions</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance, March&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill acquired</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">940</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">940</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition accounting, transfers and other adjustments </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(330</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">230</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">230</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance, June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,626</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,750</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Effective April 1, 2017, our RHP business was transitioned from the Technology Solutions segment to the Distribution Solutions segment.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial information relating to our reportable operating segments and reconciliations to the condensed consolidated totals is as follows: </font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarter Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenues</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Distribution Solutions </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">North America pharmaceutical distribution and services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,211</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International pharmaceutical distribution and services</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,382</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,330</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical-Surgical distribution&#160;and services</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,533</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,468</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Distribution Solutions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,931</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,009</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Technology Solutions</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;</sup></font><font style="font-family:inherit;font-size:10pt;">- products and services </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">724</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:68px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,051</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,733</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating profit</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Distribution Solutions </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">713</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">928</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Technology Solutions </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(78</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">168</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">635</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,096</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate Expenses, Net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(109</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(105</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest Expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(68</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(79</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income from Continuing Operations Before Income Taxes</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">458</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">912</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Revenues derived from services represent less than </font><font style="font-family:inherit;font-size:8pt;">2%</font><font style="font-family:inherit;font-size:8pt;"> of this segment&#8217;s total revenues.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2018 revenues for the Technology Solutions segment include the results of our EIS business. Effective April 1, 2017, our RHP business was transitioned from the Technology Solutions segment to the Distribution Solutions segment. The first quarter of 2017 included the majority of our Core MTS Business which was contributed to Change Healthcare on March 1, 2017. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Distribution Solutions operating profit for the first quarters of 2018 and 2017 include </font><font style="font-family:inherit;font-size:8pt;">$26&#160;million</font><font style="font-family:inherit;font-size:8pt;"> and $</font><font style="font-family:inherit;font-size:8pt;">47 million</font><font style="font-family:inherit;font-size:8pt;"> in pre-tax charges related to our last-in, first-out (&#8220;LIFO&#8221;) method of accounting for inventories. LIFO expense was less in 2018 primarily due to the lower full year expectations for net price increases compared to the same period a year ago. Additionally, the first quarter of 2017 includes </font><font style="font-family:inherit;font-size:8pt;">$142 million</font><font style="font-family:inherit;font-size:8pt;"> of net cash proceeds representing our share of net settlements of antitrust class action lawsuits against drug manufacturers. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Operating profit for our Technology Solutions segment for the first quarter of 2018 includes our EIS business, our proportionate share of loss from Change Healthcare of </font><font style="font-family:inherit;font-size:8pt;">$120 million</font><font style="font-family:inherit;font-size:8pt;"> and a pre-tax gain of </font><font style="font-family:inherit;font-size:8pt;">$37 million</font><font style="font-family:inherit;font-size:8pt;"> from the Healthcare Technology Net Asset Exchange related to the final net working capital and other adjustments.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Segment Information</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We report our operations in </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> operating segments: McKesson Distribution Solutions and McKesson Technology Solutions. The factors for determining the reportable segments included the manner in which management evaluates the performance of the Company combined with the nature of the individual business activities. We evaluate the performance of our operating segments on a number of measures, including operating profit before interest expense, income taxes and results from discontinued operations.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial information relating to our reportable operating segments and reconciliations to the condensed consolidated totals is as follows: </font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarter Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenues</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Distribution Solutions </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">North America pharmaceutical distribution and services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,211</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International pharmaceutical distribution and services</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,382</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,330</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medical-Surgical distribution&#160;and services</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,533</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,468</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Distribution Solutions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,931</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,009</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Technology Solutions</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;</sup></font><font style="font-family:inherit;font-size:10pt;">- products and services </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">724</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:68px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,051</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,733</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating profit</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Distribution Solutions </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">713</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">928</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Technology Solutions </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(78</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">168</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">635</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,096</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate Expenses, Net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(109</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(105</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest Expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(68</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(79</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income from Continuing Operations Before Income Taxes</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">458</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">912</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Revenues derived from services represent less than </font><font style="font-family:inherit;font-size:8pt;">2%</font><font style="font-family:inherit;font-size:8pt;"> of this segment&#8217;s total revenues.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2018 revenues for the Technology Solutions segment include the results of our EIS business. Effective April 1, 2017, our RHP business was transitioned from the Technology Solutions segment to the Distribution Solutions segment. The first quarter of 2017 included the majority of our Core MTS Business which was contributed to Change Healthcare on March 1, 2017. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Distribution Solutions operating profit for the first quarters of 2018 and 2017 include </font><font style="font-family:inherit;font-size:8pt;">$26&#160;million</font><font style="font-family:inherit;font-size:8pt;"> and $</font><font style="font-family:inherit;font-size:8pt;">47 million</font><font style="font-family:inherit;font-size:8pt;"> in pre-tax charges related to our last-in, first-out (&#8220;LIFO&#8221;) method of accounting for inventories. LIFO expense was less in 2018 primarily due to the lower full year expectations for net price increases compared to the same period a year ago. Additionally, the first quarter of 2017 includes </font><font style="font-family:inherit;font-size:8pt;">$142 million</font><font style="font-family:inherit;font-size:8pt;"> of net cash proceeds representing our share of net settlements of antitrust class action lawsuits against drug manufacturers. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Operating profit for our Technology Solutions segment for the first quarter of 2018 includes our EIS business, our proportionate share of loss from Change Healthcare of </font><font style="font-family:inherit;font-size:8pt;">$120 million</font><font style="font-family:inherit;font-size:8pt;"> and a pre-tax gain of </font><font style="font-family:inherit;font-size:8pt;">$37 million</font><font style="font-family:inherit;font-size:8pt;"> from the Healthcare Technology Net Asset Exchange related to the final net working capital and other adjustments.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stockholders&#8217; Equity</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each share of the Company&#8217;s outstanding common stock is permitted </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> vote on proposals presented to stockholders and is entitled to share equally in any dividends declared by the Company&#8217;s Board of Directors (the &#8220;Board&#8221;). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company currently pays quarterly cash dividend of </font><font style="font-family:inherit;font-size:10pt;">$0.28</font><font style="font-family:inherit;font-size:10pt;"> per common share. On July 26, 2017, the Company&#8217;s quarterly dividend was raised from </font><font style="font-family:inherit;font-size:10pt;">$0.28</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$0.34</font><font style="font-family:inherit;font-size:10pt;"> per common share for dividends declared on or after such date by the Board. The Company anticipates that it will continue to pay quarterly cash dividends in the future.&#160; However, the payment and amount of future dividends remain within the discretion of the Board and will depend upon the Company's future earnings, financial condition, capital requirements and other factors.</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Share Repurchase Plans</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock repurchases may be made from time-to-time in open market transactions, privately negotiated transactions, through accelerated share repurchase (&#8220;ASR&#8221;) programs, or by any combination of such methods. The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including our stock price, corporate and regulatory requirements, restrictions under our debt obligations and other market and economic conditions.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2017, we entered into an ASR program with a third-party financial institution to repurchase </font><font style="font-family:inherit;font-size:10pt;">$250 million</font><font style="font-family:inherit;font-size:10pt;"> of the Company&#8217;s common stock. We received </font><font style="font-family:inherit;font-size:10pt;">1.4 million</font><font style="font-family:inherit;font-size:10pt;"> shares in March 2017 and </font><font style="font-family:inherit;font-size:10pt;">0.3 million</font><font style="font-family:inherit;font-size:10pt;"> additional shares in April 2017. In June 2017, we also entered into another ASR program with a third-party financial institution to repurchase </font><font style="font-family:inherit;font-size:10pt;">$250 million</font><font style="font-family:inherit;font-size:10pt;"> of the Company&#8217;s common stock. During the first quarter of 2018, we received </font><font style="font-family:inherit;font-size:10pt;">1.2 million</font><font style="font-family:inherit;font-size:10pt;"> shares as the initial share settlement under this 2018 ASR program and may receive additional shares at the termination of the ASR. The total authorization outstanding for repurchases of the Company&#8217;s common stock was </font><font style="font-family:inherit;font-size:10pt;">$2.5 billion</font><font style="font-family:inherit;font-size:10pt;"> at June 30, 2017. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information regarding other comprehensive income (loss) including redeemable noncontrolling interests, net of tax, by component is as follows:</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarter Ended June 30,</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:italic;">&#160;(In millions)</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments arising during period, net of income tax benefit of nil and $12 </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2) (3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">382</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(275</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-left:36px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reclassified to income statement, net of income tax expense of nil and nil </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">382</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(255</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gains (losses) on net investment hedges </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(5)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gains (losses) on net investment hedges arising during period, net of income tax benefit of $44 and nil</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(70</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:36px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reclassified to income statement, net of income tax expense of nil and nil</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(70</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gains on cash flow hedges</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gains on cash flow hedges arising during period, net of income tax expense of nil and nil</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in retirement-related benefit plans </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(6)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net actuarial loss and prior service cost arising during the period, net of income tax benefit of nil and nil </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of actuarial loss and prior service costs, net of income tax expense of nil and $1 </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(7)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments and other, net of income tax expense of nil and nil</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss), net of tax</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">321</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(244</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Foreign currency translation adjustments primarily result from the conversion of non-U.S. dollar financial statements of our foreign subsidiary, Celesio, into the Company&#8217;s reporting currency, U.S. dollars, during the first quarters of 2018 and 2017.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The net foreign currency translation gains during the first quarter of 2018 were primarily due to the strengthening of the Euro and British pound sterling against the U.S. dollar from April 1, 2017 to June 30, 2017. During the first quarter of 2017, the currency translation losses were primarily due to the weakening of the Euro and British pound sterling against the U.S. dollar from April 1, 2016 to June 30, 2016.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The first quarter of 2018 includes net foreign currency translation gains of </font><font style="font-family:inherit;font-size:8pt;">$115 million</font><font style="font-family:inherit;font-size:8pt;"> and the first quarter of 2017 includes net foreign currency translation losses of </font><font style="font-family:inherit;font-size:8pt;">$67 million</font><font style="font-family:inherit;font-size:8pt;"> attributable to redeemable noncontrolling interests.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(4)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The first quarter of 2017 includes net foreign currency translation losses of </font><font style="font-family:inherit;font-size:8pt;">$20 million</font><font style="font-family:inherit;font-size:8pt;"> reclassified from accumulated other comprehensive income (loss) to loss from discontinued operations, net of tax, within our condensed consolidated statements of operations due to the sale of our Brazilian pharmaceutical distribution business. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(5)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The first quarter of 2018 includes foreign currency losses of&#160;</font><font style="font-family:inherit;font-size:8pt;">$114 million</font><font style="font-family:inherit;font-size:8pt;">&#160;on the net investment hedges from the&#160;</font><font style="font-family:inherit;font-size:8pt;">&#8364;1.2 billion</font><font style="font-family:inherit;font-size:8pt;">&#160;Euro-denominated notes and&#160;</font><font style="font-family:inherit;font-size:8pt;">&#163;450 million</font><font style="font-family:inherit;font-size:8pt;">&#160;British pound sterling-denominated notes.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(6)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The first quarters of 2018 and 2017 include net actuarial losses of </font><font style="font-family:inherit;font-size:8pt;">$1 million</font><font style="font-family:inherit;font-size:8pt;"> attributable to redeemable noncontrolling interests.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><font style="font-family:inherit;font-size:8pt;">(7)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Pre-tax amount reclassified into cost of sales and operating expenses in our condensed consolidated statements of operations. The related tax expense was reclassified into income tax expense in our condensed consolidated statements of operations.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated Other Comprehensive Income (Loss)</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information regarding changes in our accumulated other comprehensive income (loss), net of tax, by component for the first quarter of 2018 is as follows:</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Foreign Currency Translation Adjustments, Net of Tax</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized Losses on Net Investment Hedges, </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net of Tax</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net of Tax</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized Net Gains (Losses) and Other Components of Benefit Plans, Net of Tax</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Accumulated Other Comprehensive Income (Loss)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,873</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(229</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss) before reclassifications </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">382</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">320</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts reclassified to earnings and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">382</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:30px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: amounts attributable to noncontrolling and redeemable noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss) attributable to McKesson</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">267</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(70</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">205</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,606</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(78</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(235</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,936</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To prepare the financial statements in conformity with GAAP, management must make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of these financial statements and income and expenses during the reporting period. Actual amounts may differ from these estimated amounts. In our opinion, the accompanying unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair presentation of our financial position, results of operations and cash flows for the interim periods presented. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of operations for the quarter ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results that may be expected for the entire year. These interim financial statements should be read in conjunction with the annual audited financial statements, accounting policies and financial notes included in our Annual Report on Form 10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> previously filed with the SEC on May 22, 2017 (&#8220;2017 Annual Report&#8221;).</font></div></div> EX-101.SCH 7 mck-20170630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2106100 - Disclosure - Business Combinations link:presentationLink link:calculationLink link:definitionLink 2406401 - Disclosure - Business Combinations (Details) link:presentationLink link:calculationLink link:definitionLink 2122100 - Disclosure - Commitments and Contingent Liabilities link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - Debt and Financing Activities link:presentationLink link:calculationLink link:definitionLink 2418403 - Disclosure - Debt and Financing Activities - Accounts Receivable Facilities (Details) link:presentationLink link:calculationLink link:definitionLink 2418404 - Disclosure - Debt and Financing Activities - Commercial Paper (Details) link:presentationLink link:calculationLink link:definitionLink 2418401 - Disclosure - Debt and Financing Activities - Long Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2418402 - Disclosure - Debt and Financing Activities - Revolving Credit Facilities (Details) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 2407401 - Disclosure - Discontinued Operations - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0002000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Earnings Per Common Share link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - Earnings Per Common Share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Earnings Per Common Share - Schedule of Computation for Basic and Diluted Earnings per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Earnings Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2121100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2421401 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Goodwill and Intangible Assets, Net link:presentationLink link:calculationLink link:definitionLink 2417404 - Disclosure - Goodwill and Intangible Assets, Net - Narrative - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2417402 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Changes in the Carrying Amount of Goodwill and Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2417403 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Information Regarding Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2317301 - Disclosure - Goodwill and Intangible Assets, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Healthcare Technology Net Asset Exchange link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Healthcare Technology Net Asset Exchange (Details) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Healthcare Technology Net Asset Exchange - Summarized Financial Information (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - Healthcare Technology Net Asset Exchange (Tables) link:presentationLink link:calculationLink link:definitionLink 2120100 - Disclosure - Hedging Activities link:presentationLink link:calculationLink link:definitionLink 2420403 - Disclosure - Hedging Activities - Derivative Instruments Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 2420402 - Disclosure - Hedging Activities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2320301 - Disclosure - Hedging Activities (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2413401 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Pension Benefits link:presentationLink link:calculationLink link:definitionLink 2419401 - Disclosure - Pension Benefits - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Redeemable Noncontrolling Interests and Noncontrolling Interests link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Redeemable Noncontrolling Interests and Noncontrolling Interests - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2414403 - Disclosure - Redeemable Noncontrolling Interests and Noncontrolling Interests - Schedule of Changes in Redeemable Noncontrolling Interests and Noncontrolling Interests (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Redeemable Noncontrolling Interests and Noncontrolling Interests (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Restructuring link:presentationLink link:calculationLink link:definitionLink 2408401 - Disclosure - Restructuring - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2124100 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 2424402 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 2324301 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2123100 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2423402 - Disclosure - Stockholders' Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2423404 - Disclosure - Stockholders' Equity - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) by Component (Details) link:presentationLink link:calculationLink link:definitionLink 2423403 - Disclosure - Stockholders' Equity - Schedule of Other Comprehensive Income (Loss), Net of Tax (Details) link:presentationLink link:calculationLink link:definitionLink 2323301 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 mck-20170630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 mck-20170630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 mck-20170630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Document And Entity Information [Abstract] Document And Entity Information. Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Common Stock, Shares Outstanding (Cover) Entity Common Stock, Shares Outstanding Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Business Segments [Axis] Segments [Axis] Segments [Domain] Segments [Domain] Distribution Solutions Distribution Solutions [Member] Distribution Solutions. Technology Solutions Technology Solutions [Member] Technology Solutions Member. Goodwill [Line Items] Goodwill [Line Items] Goodwill [Roll Forward] Goodwill [Roll Forward] Beginning balance Goodwill Goodwill acquired Goodwill, Acquired During Period Acquisition accounting, transfers and other adjustments Goodwill, Purchase Accounting Adjustments Foreign currency translation adjustments, net Goodwill, Foreign Currency Translation Gain (Loss) Ending balance Accumulated goodwill impairment losses Goodwill, Impaired, Accumulated Impairment Loss Derivative Instruments and Hedging Activities Disclosure [Abstract] Hedging Activities Derivative Instruments and Hedging Activities Disclosure [Text Block] Equity Method Investments and Joint Ventures [Abstract] Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Investment, Name [Axis] Investment, Name [Axis] Investment, Name [Domain] Investment, Name [Domain] Change Healthcare, LLC (“Change Healthcare”) Change Healthcare, LLC (“Change Healthcare”) [Member] Change Healthcare, LLC (“Change Healthcare”) [Member] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Joint Venture Corporate Joint Venture [Member] Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] Core MTS Businesses Core MTS Businesses [Member] Core MTS Businesses [Member] Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Operating Segments Operating Segments [Member] Segments [Axis] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Tax Receivable Agreement (“TRA”) Tax Receivable Agreement (“TRA”) [Member] Tax Receivable Agreement (“TRA”) [Member] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Related Party Transaction [Axis] Related Party Transaction [Axis] Related Party Transaction [Domain] Related Party Transaction [Domain] Transition Services Agreements (“TSA”) Transition Services Agreements (“TSA”) [Member] Transition Services Agreements (“TSA”) [Member] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Expected ownership interest in the joint venture (percent) Equity Method Investment, Ownership Percentage Gain on Healthcare Technology Net Asset Exchange Gain (Loss) on Disposition of Business Gain from sale of business, after tax Gain (Loss) on Disposition of Business After Tax Gain (Loss) on Disposition of Business After Tax Receivable from Change Healthcare Due from Joint Ventures Net losses from Change Healthcare Income (Loss) from Equity Method Investments Carrying value of investment Equity Method Investments Excess of carrying value of investment over proportional share of book value Equity Method Investment, Difference Between Carrying Amount and Underlying Equity Proportionate share of net loss reported by joint venture Equity Method Investment, Summarized Financial Information, Net Income (Loss) Noncurrent liability Liabilities, Noncurrent Reimbursements for transition services fees Related Party Transaction, Amounts of Transaction Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract] Pension Benefits Pension and Other Postretirement Benefits Disclosure [Text Block] Schedule of Summarized Equity Method Investment Financial Informations Equity Method Investments [Table Text Block] Equity [Abstract] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Accelerated Share Repurchases [Table] Accelerated Share Repurchases [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Share Repurchase Program [Axis] Share Repurchase Program [Axis] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Accelerated Share Repurchase Accelerated Share Repurchase [Member] Accelerated Share Repurchase [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Net Investment Hedging Net Investment Hedging [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Term Loan Loans Payable [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Euro Denominated Notes Euro Denominated Notes [Member] Euro Denominated Notes [Member] British Pound Sterling Denominated Notes British Pound Sterling Denominated Notes [Member] British Pound Sterling Denominated Notes [Member] Accelerated Share Repurchases [Line Items] Accelerated Share Repurchases [Line Items] Share of common stock outstanding, vote on proposals Common Stock, Voting Rights, Number of Votes Per Common Share Common Stock, Voting Rights, Number of Votes Per Common Share Dividends declared per common share (in dollars per share) Common Stock, Dividends, Per Share, Declared Common stock repurchased Treasury Stock, Value, Acquired, Cost Method Common stock repurchased (shares) Treasury Stock, Shares, Acquired Authorized amount available for future repurchases Stock Repurchase Program, Remaining Authorized Repurchase Amount Translation gain (loss) attributable to redeemable noncontrolling interest Other Comprehensive Income (Loss) Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Redeemable Noncontrolling Interest Other Comprehensive Income (Loss) Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Redeemable Noncontrolling Interest Reclassified to income statement, net of income tax expense of nil and nil Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax Losses from net investment hedges recorded in other comprehensive income Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net Long-term debt outstanding Long-term Debt Net actuarial losses attributable to redeemable noncontrolling interest Other Comprehensive Income (Loss) Defined Benefit Plans Net Unamortized Gain Loss Attributable to Redeemable Noncontrolling Interest Arising During Period Net Of Tax Other Comprehensive Income (Loss) Defined Benefit Plans Net Unamortized Gain Loss Attributable to Redeemable Noncontrolling Interest Arising During Period Net Of Tax Discontinued Operations and Disposal Groups [Abstract] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Brazil Distribution [Member] Brazil Distribution [Member] Brazil Distribution [Member] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] After-tax charge recognized upon settlement of indemnification matters Discontinued Operations, Gain (Loss) on Settlement, Net of Tax Discontinued Operations, Gain (Loss) on Settlement, Net of Tax Payment related to the sake of Brazilian pharmaceutical distribution business Payments for (Proceeds from) Businesses and Interest in Affiliates Noncontrolling Interest [Abstract] Changes in Redeemable Noncontrolling Interests and Noncontrolling Interests Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block] Net periodic pension expense Defined Benefit Plan, Net Periodic Benefit Cost Cash contributions to the plans Defined Benefit Plan, Contributions by Employer Percentage threshold of greater of projected benefit obligation or market value of assets (percent) Defined Benefit Plan, Funded Percentage Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Customer relationships Customer Relationships [Member] Service agreements Service Agreements [Member] Pharmacy licenses Pharmacy Licenses [Member] Pharmacy licenses [Member] Trademarks and trade names Trademarks and Trade Names [Member] Technology Technology-Based Intangible Assets [Member] Other Other Intangible Assets [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Weighted Average Remaining Amortization Period (years) Finite-Lived Intangible Assets, Remaining Amortization Period Gross Carrying Amount Finite-Lived Intangible Assets, Gross Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Net Carrying Amount Finite-Lived Intangible Assets, Net Schedule of information regarding other comprehensive income (loss) including noncontrolling and redeemable noncontrolling interests, net of tax, by component Comprehensive Income (Loss) [Table Text Block] Schedule of information regarding changes in accumulated other comprehensive income (loss), net of tax, by component Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Earnings Per Share [Abstract] Income from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Net income attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Income from continuing operations attributable to McKesson Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Income (loss) from discontinued operations, net of tax Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Net Income Attributable to McKesson Corporation Net Income (Loss) Attributable to Parent Weighted average common shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Effect of dilutive securities: Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract] Options to purchase common stock (in shares) Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Restricted stock units (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Earnings (loss) per common share attributable to McKesson: Earnings Per Share, Basic and Diluted [Abstract] Diluted Earnings Per Share, Diluted [Abstract] Continuing operations (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Discontinued operations (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Total (in dollars per share) Earnings Per Share, Diluted Basic Earnings Per Share, Basic [Abstract] Continuing operations (in dollars per share) Income (Loss) from Continuing Operations, Per Basic Share Discontinued operations (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Total (in dollars per share) Earnings Per Share, Basic Earnings Per Common Share Earnings Per Share [Text Block] Debt Disclosure [Abstract] Line of Credit Facility [Table] Line of Credit Facility [Table] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Revolving Credit Facility Revolving Credit Facility [Member] Line of Credit Line of Credit [Member] Senior Unsecured Revolving Credit Facility (Global Facility) Senior Unsecured Revolving Credit Facility (Global Facility) [Member] Senior Unsecured Revolving Credit Facility (Global Facility) [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Syndicated senior unsecured revolving credit facility Line of Credit Facility, Maximum Borrowing Capacity Syndicated senior unsecured revolving credit facility term Debt Instrument, Term Credit facility, aggregate sublimit Line of Credit Facility, Aggregate Sublimit Line of Credit Facility, Aggregate Sublimit Debt to capital covenant ratio (no greater than) Ratio of Indebtedness to Net Capital Amounts outstanding under facility Long-term Line of Credit Schedule of changes in the carrying amount of goodwill Schedule of Goodwill [Table Text Block] Schedule of information regarding intangible assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Commercial Paper Commercial Paper [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Outstanding notes (up to) Commercial paper Long-term Commercial Paper, Current Weighted average interest rate (percent) Debt, Weighted Average Interest Rate Income Statement [Abstract] Revenues Revenue, Net Cost of Sales Cost of Revenue Gross Profit Gross Profit Operating Expenses Operating Costs and Expenses Operating Expenses Operating Expenses Operating Income Operating Income (Loss) Other Income, Net Other Nonoperating Income Loss from Equity Method Investment in Change Healthcare Interest Expense Interest and Debt Expense Income from Continuing Operations Before Income Taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income Tax Expense Income Tax Expense (Benefit) Income from Continuing Operations Income (Loss) from Discontinued Operations, Net of Tax Net Income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net Income Attributable to Noncontrolling Interests Earnings (Loss) Per Common Share Attributable to McKesson Corporation Continuing operations (in dollars per share) Discontinued operations (in dollars per share) Continuing operations (in dollars per share) Discontinued operations (in dollars per share) Weighted Average Common Shares Diluted (in shares) Basic (in shares) Schedule of information regarding the fair value of derivatives on a gross basis Fair Value, by Balance Sheet Grouping [Table Text Block] Discontinued Operations Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair malue, measurements, recurring Fair Value, Measurements, Recurring [Member] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair value, inputs, level 2 Fair Value, Inputs, Level 2 [Member] Fair value, inputs, level 1 Fair Value, Inputs, Level 1 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Carrying amount of liabilities Estimated fair values of liabilities Debt Instrument, Fair Value Disclosure Investments in money market funds Cash and Cash Equivalents, Fair Value Disclosure Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Accounting Policies [Abstract] Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Fair Value Measurements Fair Value Disclosures [Text Block] Business Combinations [Abstract] Business Combinations Business Combination Disclosure [Text Block] Segment Reporting [Abstract] Schedule of financial information relating to reportable operating segments and reconciliations to the condensed consolidated totals Schedule of Segment Reporting Information, by Segment [Table Text Block] Statement of Comprehensive Income [Abstract] Net Income Other Comprehensive Income (Loss), Net of Tax Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Foreign currency translation adjustments arising during the period Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Unrealized losses on net investment hedges arising during the period Gain (Loss) on Derivative Used in Net Investment Hedge, Net of Tax Unrealized gains on cash flow hedges arising during the period Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax Retirement-related benefit plans Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax Other Comprehensive Income (Loss), Net of Tax Other Comprehensive Income (Loss), Net of Tax Comprehensive Income (Loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive Loss (Income) Attributable to Noncontrolling Interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Comprehensive Income (Loss) Attributable to McKesson Corporation Comprehensive Income (Loss), Net of Tax, Attributable to Parent Noncontrolling Interest [Table] Noncontrolling Interest [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Noncontrolling Interest Noncontrolling Interest [Member] Redeemable Noncontrolling Interest Redeemable Noncontrolling Interest [Member] Redeemable Noncontrolling Interest [Member] Noncontrolling Interest [Line Items] Noncontrolling Interest [Line Items] Beginning balance Stockholders' Equity Attributable to Noncontrolling Interest Net income attributable to noncontrolling interests Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest Payments to noncontrolling interests Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Purchase of noncontrolling interests Noncontrolling Interest, Increase from Subsidiary Equity Issuance Other Noncontrolling Interest, Increase (Decrease) Due to Other Noncontrolling Interest, Increase (Decrease) Due to Other Ending balance Redeemable Noncontrolling Interests Increase (Decrease) in Temporary Equity [Roll Forward] Beginning balance Redeemable Noncontrolling Interest, Equity, Common, Carrying Amount Net income attributable to noncontrolling interests Net Income (Loss) Attributable to Redeemable Noncontrolling Interest Reclassification of recurring compensation to other accrued liabilities Reclassification of Temporary Equity to Liability Reclassification of Temporary Equity to Liability Payments to noncontrolling interests Exercise of Put Right Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests Purchase of noncontrolling interests Other Ending balance Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Measurement Basis [Axis] Measurement Basis [Axis] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Estimate of Fair Value Estimate of Fair Value Measurement [Member] Trade Names Trade Names [Member] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Additional amount, Up to Scenario, Forecast [Member] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Discontinued Operations, Held-for-sale or Disposed of by Sale Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] CoverMyMeds, LLC (CMM) CoverMyMeds, LLC [Member] CoverMyMeds, LL ("CMM") [Member] Rexall Health Rexall Health [Member] Rexall Health [Member] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] CANADA CANADA Business Acquisition [Line Items] Business Acquisition [Line Items] Net purchase consideration Payments to Acquire Businesses, Net of Cash Acquired Contingent consideration Business Combination, Contingent Consideration, Liability Assets acquired as of the acquisition date, excluding goodwill and intangibles Business Combination, Recognized Identifiable Assets Acquired, Assets Excluding Goodwill and Intangibles Business Combination, Recognized Identifiable Assets Acquired, Assets Excluding Goodwill and Intangibles Liabilities assumed as of the acquisition date Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Goodwill Acquired identifiable intangibles Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Weighted average life of intangibles Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Number of retail pharmacies Number of Stores Measurement period adjustments to provisional fair value of intangibles Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles Assets of stores to be divested Disposal Group, Including Discontinued Operation, Assets Derivative [Table] Derivative, by Nature [Axis] Derivative Instrument [Axis] Derivative, Name [Domain] Derivative Contract [Domain] Foreign Exchange Contract Foreign Exchange Contract [Member] Cross Currency Swap Currency Swap [Member] Forward Contracts Forward Contracts [Member] Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Derivatives Designated for Hedge Accounting Designated as Hedging Instrument [Member] Derivatives not Designated for Hedge Accounting Not Designated as Hedging Instrument [Member] Derivative [Line Items] Notional values of financial instruments Derivative, Notional Amount Commitments and Contingencies Disclosure [Abstract] Commitments and Contingent Liabilities Commitments and Contingencies Disclosure [Text Block] Goodwill and Intangible Assets, Net Goodwill and Intangible Assets Disclosure [Text Block] Number of operating segments Number of Operating Segments Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Corporate Corporate, Non-Segment [Member] Segment Reconciling Items Segment Reconciling Items [Member] Total Distribution Solutions Subsegments Consolidation Items [Axis] Subsegments Consolidation Items [Axis] Subsegments Consolidation Items [Domain] Subsegments Consolidation Items [Domain] Reportable Subsegments Reportable Subsegments [Member] Subsegments [Axis] Subsegments [Axis] Subsegments [Domain] Subsegments [Domain] North America pharmaceutical distribution and services North America Distribution And Services [Member] North America Distribution And Services [Member] International pharmaceutical distribution and services International Distribution and Services [Member] International Distribution and Services [Member] Medical-Surgical distribution and services Distribution Solutions Medical Surgical Distribution And Services [Member] DistributionSolutionsMedicalSurgicalDistributionAndServicesMember Inventory [Axis] Inventory [Axis] Inventory [Domain] Inventory [Domain] LIFO Method of Accounting LIFO method of accounting [Member] LIFO method of accounting [Member] Unique Name [Axis] Unique Name [Axis] Noncash or Part Noncash Divestiture, Name [Domain] Noncash or Part Noncash Divestiture, Name [Domain] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Segment Reporting Information, Profit (Loss) [Abstract] Segment Reporting Information, Profit (Loss) [Abstract] Revenues Revenues [Abstract] Total Revenues Operating profit Operating Income (Loss) [Abstract] Total Corporate Expenses, Net Corporate Operating Expense and Other Income, Net Corporate Operating Expense and Other Income, Net Interest Expense Revenue derived from services, percentage (less than) Revenue Derived From Services, Percentage Revenue Derived From Services, Percentage Proceeds from legal settlements Proceeds from Legal Settlements Loss from equity method investment in Change Healthcare Gain from sale of business, pre-tax Segment Information Segment Reporting Disclosure [Text Block] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Foreign Currency Translation Adjustments, Net of Tax Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Unrealized Losses on Net Investment Hedges, Net of Tax Accumulated Net Investment Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member] Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member] Unrealized Net Gains (Losses) and Other Components of Benefit Plans, Net of Tax Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent [Member] Total Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Beginning balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Other comprehensive income (loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Amounts reclassified to earnings and other Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Less: amounts attributable to noncontrolling and redeemable noncontrolling interests Other comprehensive income (loss) attributable to McKesson Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Ending balance Healthcare Technology Net Asset Exchange Equity Method Investments and Joint Ventures Disclosure [Text Block] Statement of Financial Position [Abstract] ASSETS Assets [Abstract] Current Assets Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Receivables, net Receivables, Net, Current Inventories, net Inventory, Net Prepaid expenses and other Prepaid Expense and Other Assets, Current Total Current Assets Assets, Current Property, Plant and Equipment, Net Property, Plant and Equipment, Net Intangible Assets, Net Equity Method Investment in Change Healthcare Other Noncurrent Assets Other Assets, Noncurrent Total Assets Assets LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND EQUITY Liabilities and Equity [Abstract] Current Liabilities Liabilities, Current [Abstract] Drafts and accounts payable Accounts Payable, Current Short-term borrowings Short-term Debt Deferred revenue Deferred Revenue, Current Current portion of long-term debt Long-term Debt, Current Maturities Other accrued liabilities Accrued Liabilities, Current Total Current Liabilities Liabilities, Current Long-Term Debt Long-term Debt, Excluding Current Maturities Long-Term Deferred Tax Liabilities Deferred Tax Liabilities, Net Other Noncurrent Liabilities Other Liabilities, Noncurrent Redeemable Noncontrolling Interests McKesson Corporation Stockholders’ Equity Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, $0.01 par value, 100 shares authorized, no shares issued or outstanding Preferred Stock, Value, Issued Common stock, $0.01 par value, 800 shares authorized at June 30, 2017 and March 31, 2017, 274 and 273 shares issued at June 30, 2017 and March 31, 2017 Common Stock, Value, Issued Additional Paid-in Capital Additional Paid in Capital Retained Earnings Retained Earnings (Accumulated Deficit) Accumulated Other Comprehensive Loss Accumulated Other Comprehensive Income (Loss), Net of Tax Other Other Capital Other Capital Treasury Shares, at Cost, 64 and 62 at June 30, 2017 and March 31, 2017 Treasury Stock, Value Total McKesson Corporation Stockholders’ Equity Stockholders' Equity Attributable to Parent Noncontrolling Interests Total Equity Total Liabilities, Redeemable Noncontrolling Interests and Equity Liabilities and Equity Statement of Cash Flows [Abstract] Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Net income Adjustments to reconcile to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Deferred taxes Increase (Decrease) in Deferred Income Taxes Charges associated with last-in-first-out inventory method Inventory, LIFO Reserve, Period Charge Loss (gain) from sale of businesses Gain (Loss) on Disposition of Assets Other non-cash items Other Noncash Income (Expense) Changes in operating assets and liabilities, net of acquisitions: Increase (Decrease) in Operating Capital [Abstract] Receivables Increase (Decrease) in Receivables Inventories Increase (Decrease) in Inventories Drafts and accounts payable Increase (Decrease) in Accounts Payable Deferred revenue Increase (Decrease) in Deferred Revenue Taxes Increase (Decrease) in Accrued Taxes Payable Other Increase (Decrease) in Other Operating Assets and Liabilities, Net Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Payments for property, plant and equipment Payments to Acquire Property, Plant, and Equipment Capitalized software expenditures Payments to Acquire Software Acquisitions, net of cash and cash equivalents acquired Proceeds from/(payments for) sale of businesses, net Proceeds from Divestiture of Businesses, Net of Cash Divested Proceeds from/(payments for) sale of businesses, net Cash Divested from Deconsolidation Restricted cash for acquisitions Increase (Decrease) in Restricted Cash Other Payments for (Proceeds from) Other Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from short-term borrowings Proceeds from Short-term Debt Repayments of short-term borrowings Repayments of Short-term Debt Repayments of long-term debt Proceeds from (Repayments of) Debt Common stock transactions: Proceeds from (Repurchase of) Equity [Abstract] Issuances Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options Share repurchases, including shares surrendered for tax withholding Payments for Repurchase of Common Stock Dividends paid Payments of Ordinary Dividends, Common Stock Other Proceeds from (Payments for) Other Financing Activities Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents Net increase (decrease) in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Accumulated Defined Benefit Plans Adjustment, Net Prior Service and Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest Accumulated Defined Benefit Plans Adjustment, Net Prior Service and Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member] Accumulated Defined Benefit Plans Adjustment, Net Prior Service and Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member] Accumulated Defined Benefit Plans Adjustment, Amortization of Actuarial Loss, Prior Service Cost and Transition Obligation, Including Portion Attributable to Noncontrolling Interest Accumulated Defined Benefit Plans Adjustment, Amortization of Actuarial Loss, Prior Service Cost and Transition Obligation, Including Portion Attributable to Noncontrolling Interest [Member] Accumulated Defined Benefit Plans Adjustment, Amortization of Actuarial Loss, Prior Service Cost and Transition Obligation, Including Portion Attributable to Noncontrolling Interest [Member] Accumulated Defined Benefit Plans, Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest Accumulated Defined Benefit Plans, Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Accumulated Defined Benefit Plans, Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Reclassified to income statement, net of income tax expense Foreign currency translation adjustments arising during period, tax Other Comprehensive Income (Loss), Foreign Currency Translation Gain (Loss) Arising During Period, Tax Reclassified to income statement, tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Tax Unrealized gains (losses) on net investment hedges arising during period, tax Other Comprehensive Income (Loss) before Reclassifications, Tax Reclassified to income statement, tax Reclassification from AOCI, Current Period, Tax Unrealized gains on cash flow hedges arising during period, tax Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax Net actuarial loss and prior service cost arising during the period, tax Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Tax Amortization of actuarial loss and prior service costs, tax Other Comprehensive (Income) Loss, Amortization Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), Tax Foreign currency translation adjustments and other, tax Other Comprehensive Income Translation Impact On Pension Plans, Tax Other Comprehensive Income Translation Impact On Pension Plans, Tax Revenues Equity Method Investment, Summarized Financial Information, Revenue Loss from Continuing Operations Equity Method Investment, Summarized Financial Information, Income (Loss) from Continuing Operations Net Loss Borrowings and related securitized accounts receivable outstanding Income tax expense related to continuing operations Net discrete tax expense (benefit) Income Tax Expense (Benefit) Discrete Items Income Tax Expense (Benefit) Discrete Items Tax benefit recognized related to excess tax benefits arising from adoption of ASU 2016-09 Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Amount Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Amount Income tax rate (as a percent) Effective Income Tax Rate Reconciliation, Percent Unrecognized tax benefits Unrecognized Tax Benefits Unrecognized tax benefits that would reduce income tax expense and the effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Decrease in unrecognized tax benefits that could result from audit resolutions Decrease in Unrecognized Tax Benefits is Reasonably Possible Amortization expense of intangible assets Amortization of Intangible Assets Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract] Estimated annual amortization expense, remainder of 2018 Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year Estimated annual amortization expense, 2019 Finite-Lived Intangible Assets, Amortization Expense, Year Two Estimated annual amortization expense, 2020 Finite-Lived Intangible Assets, Amortization Expense, Year Three Estimated annual amortization expense, 2021 Finite-Lived Intangible Assets, Amortization Expense, Year Four Estimated annual amortization expense, 2022 Finite-Lived Intangible Assets, Amortization Expense, Year Five Estimated annual amortization expense, thereafter Finite-Lived Intangible Assets, Amortization Expense, after Year Five Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Current Portion of Long-term Debt Long-term Debt, Current Maturities [Member] Long-term Debt, Current Maturities [Member] Bonds Four Point Five Percent Bonds Due April Twenty Six Two Thousand Seventeen [Member] Four Point Five Percent Bonds Due April Twenty Six Two Thousand Seventeen [Member] Repayment of term loan Repayments of Long-term Debt Debt and Financing Activities Debt Disclosure [Text Block] Basis of Presentation Consolidation, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Fiscal Period Fiscal Period, Policy [Policy Text Block] Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Commitments and Contingencies Commitments and Contingencies, Policy [Policy Text Block] Schedule of computations for basic and diluted earnings per common share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Restructuring and Related Activities [Abstract] Restructuring Restructuring and Related Activities Disclosure [Text Block] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Common Stock, Shares, Issued Treasury stock, shares (in shares) Treasury Stock, Shares Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Derivatives Designated for Hedge Accounting Derivatives not Designated for Hedge Accounting Foreign Exchange Contract Prepaid Expenses and Other Prepaid Expenses and Other Current Assets [Member] Other Noncurrent Assets Other Noncurrent Assets [Member] Other Noncurrent Liabilities Other Noncurrent Liabilities [Member] Other Accrued Liabilities Other Current Liabilities [Member] Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Fair value of derivative, asset Derivative Asset, Fair Value, Gross Asset Fair value of derivative, liability Derivative Liability, Fair Value, Gross Liability U.S. Dollar notional amount, asset Derivative Asset, Notional Amount U.S. Dollar, notional amount, liability Derivative Liability, Notional Amount Redeemable Noncontrolling Interests and Noncontrolling Interests Noncontrolling Interest Disclosure [Text Block] Potentially dilutive securities excluded from computations of diluted net earnings per common share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Additional Paid-in Capital Additional Paid-in Capital [Member] Celesio Celesio [Member] Celesio [Member] Put right redemption price per share (in euros per share) Noncontrolling Interests, Put Right, Exercise Price Noncontrolling Interests, Put Right, Exercise Price Put right value, interest rate spread (as a percent) Put Right Value, Interest Rate Spread Put Right Value, Interest Rate Spread Payments to acquire shares of Celesio Payments for Repurchase of Redeemable Noncontrolling Interest Number of redeemable noncontrolling interest shares repurchased (shares) Repurchase of Redeemable Noncontrolling Interest, Shares Repurchased Repurchase of Redeemable Noncontrolling Interest, Shares Repurchased Decrease in redeemable noncontrolling interests Carrying value of redeemable noncontrolling interests Maximum redemption value of redeemable noncontrolling interest Redeemable Noncontrolling Interests, Maximum Redemption Value Redeemable Noncontrolling Interests, Maximum Redemption Value Ownership percentage (as a percent) Noncontrolling Interest, Ownership Percentage by Parent Common Stock, Dividends, Per Share, Cash Paid Common Stock, Dividends, Per Share, Cash Paid Net Income (Loss) Attributable to Redeemable Noncontrolling Interest Effect of changes in ownership interests with noncontrollling interests Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Changes, Net Net income attributable to McKesson and transfers from noncontrolling interests Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Change Due to Net Income Attributable to Parent and Effects of Changes, Net Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Restructuring Plan [Axis] Restructuring Plan [Axis] Restructuring Plan [Domain] Restructuring Plan [Domain] Cost Alignment Plan Cost Alignment Plan [Member] Cost Alignment Plan [Member] Restructuring Type [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] Severance Employee Severance [Member] Noncurrent Liabilities Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Expected total pre-tax charges Restructuring and Related Cost, Expected Cost Pre-tax restructuring charges incurred to-date Restructuring and Related Cost, Incurred Cost Pre-tax charges recorded during period Restructuring Charges Payments for severance Payments for Restructuring Restructuring liabilities Restructuring Reserve EX-101.PRE 11 mck-20170630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.7.0.1
Document and Entity Information
3 Months Ended
Jun. 30, 2017
shares
Document And Entity Information [Abstract]  
Entity Registrant Name MCKESSON CORP
Entity Central Index Key 0000927653
Current Fiscal Year End Date --03-31
Entity Filer Category Large Accelerated Filer
Document Type 10-Q
Document Period End Date Jun. 30, 2017
Document Fiscal Year Focus 2018
Document Fiscal Period Focus Q1
Amendment Flag false
Entity Common Stock, Shares Outstanding (Cover) 210,260,531
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Income Statement [Abstract]    
Revenues $ 51,051 $ 49,733
Cost of Sales (48,491) (46,826)
Gross Profit 2,560 2,907
Operating Expenses (1,964) (1,935)
Operating Expenses 1,927 1,935
Gain on Healthcare Technology Net Asset Exchange 37 0
Operating Income 633 972
Other Income, Net 13 19
Loss from Equity Method Investment in Change Healthcare (120) 0
Interest Expense (68) (79)
Income from Continuing Operations Before Income Taxes 458 912
Income Tax Expense (95) (239)
Income from Continuing Operations 363 673
Income (Loss) from Discontinued Operations, Net of Tax 2 (113)
Net Income 365 560
Net Income Attributable to Noncontrolling Interests (56) (18)
Net Income Attributable to McKesson Corporation $ 309 $ 542
Diluted    
Continuing operations (in dollars per share) $ 1.44 $ 2.88
Discontinued operations (in dollars per share) 0.01 (0.50)
Total (in dollars per share) 1.45 2.38
Basic    
Continuing operations (in dollars per share) 1.46 2.91
Discontinued operations (in dollars per share) 0.00 (0.50)
Total (in dollars per share) 1.46 2.41
Dividends declared per common share (in dollars per share) $ 0.28 $ 0.28
Weighted Average Common Shares    
Diluted (in shares) 213 228
Basic (in shares) 211 225
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
$ in Millions
3 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Statement of Comprehensive Income [Abstract]    
Net Income $ 365 $ 560
Other Comprehensive Income (Loss), Net of Tax    
Foreign currency translation adjustments arising during the period 382 (255)
Unrealized losses on net investment hedges arising during the period (70) 0
Unrealized gains on cash flow hedges arising during the period 14 0
Retirement-related benefit plans (5) 11
Other Comprehensive Income (Loss), Net of Tax 321 (244)
Comprehensive Income (Loss) 686 316
Comprehensive Loss (Income) Attributable to Noncontrolling Interests (172) 48
Comprehensive Income (Loss) Attributable to McKesson Corporation $ 514 $ 364
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Jun. 30, 2017
Mar. 31, 2017
Current Assets    
Cash and cash equivalents $ 2,339 $ 2,783
Receivables, net 19,132 18,215
Inventories, net 15,498 15,278
Prepaid expenses and other 728 672
Total Current Assets 37,697 36,948
Property, Plant and Equipment, Net 2,349 2,292
Goodwill 11,750 10,586
Intangible Assets, Net 4,238 3,665
Equity Method Investment in Change Healthcare 3,855 4,063
Other Noncurrent Assets 1,927 3,415
Total Assets 61,816 60,969
Current Liabilities    
Drafts and accounts payable 32,015 31,022
Short-term borrowings 3 183
Deferred revenue 279 346
Current portion of long-term debt 525 1,057
Other accrued liabilities 2,977 3,004
Total Current Liabilities 35,799 35,612
Long-Term Debt 7,424 7,305
Long-Term Deferred Tax Liabilities 3,752 3,678
Other Noncurrent Liabilities 1,938 1,774
Redeemable Noncontrolling Interests 1,390 1,327
McKesson Corporation Stockholders’ Equity    
Preferred stock, $0.01 par value, 100 shares authorized, no shares issued or outstanding 0 0
Common stock, $0.01 par value, 800 shares authorized at June 30, 2017 and March 31, 2017, 274 and 273 shares issued at June 30, 2017 and March 31, 2017 3 3
Additional Paid-in Capital 6,080 6,028
Retained Earnings 13,442 13,189
Accumulated Other Comprehensive Loss (1,936) (2,141)
Other (4) (2)
Treasury Shares, at Cost, 64 and 62 at June 30, 2017 and March 31, 2017 (6,282) (5,982)
Total McKesson Corporation Stockholders’ Equity 11,303 11,095
Noncontrolling Interests 210 178
Total Equity 11,513 11,273
Total Liabilities, Redeemable Noncontrolling Interests and Equity $ 61,816 $ 60,969
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares
Jun. 30, 2017
Mar. 31, 2017
McKesson Corporation Stockholders’ Equity    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 100,000,000 100,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 800,000,000 800,000,000
Common stock, shares issued (in shares) 274,000,000 273,000,000
Treasury stock, shares (in shares) 64,000,000 62,000,000
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Millions
3 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Operating Activities    
Net income $ 365 $ 560
Adjustments to reconcile to net cash provided by operating activities:    
Depreciation and amortization 227 242
Loss from equity method investment in Change Healthcare 120 0
Deferred taxes 85 31
Charges associated with last-in-first-out inventory method 26 47
Loss (gain) from sale of businesses (1) 113
Other non-cash items 8 29
Changes in operating assets and liabilities, net of acquisitions:    
Receivables (363) (300)
Inventories (59) (121)
Drafts and accounts payable 463 1,549
Deferred revenue (73) (113)
Taxes (18) 95
Other (39) (273)
Net cash provided by operating activities 741 1,859
Investing Activities    
Payments for property, plant and equipment (75) (76)
Capitalized software expenditures (43) (38)
Acquisitions, net of cash and cash equivalents acquired (1,485) (1,819)
Proceeds from/(payments for) sale of businesses, net 3  
Proceeds from/(payments for) sale of businesses, net   (101)
Restricted cash for acquisitions 1,469 935
Other 2 (55)
Net cash used in investing activities (129) (1,154)
Financing Activities    
Proceeds from short-term borrowings 2,282 7
Repayments of short-term borrowings (2,463) (14)
Repayments of long-term debt (541) (1)
Common stock transactions:    
Issuances 27 36
Share repurchases, including shares surrendered for tax withholding (300) (58)
Dividends paid (62) (66)
Other (74) 14
Net cash used in financing activities (1,131) (82)
Effect of exchange rate changes on cash and cash equivalents 75 (12)
Net increase (decrease) in cash and cash equivalents (444) 611
Cash and cash equivalents at beginning of period 2,783 4,048
Cash and cash equivalents at end of period $ 2,339 $ 4,659
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.7.0.1
Significant Accounting Policies
3 Months Ended
Jun. 30, 2017
Accounting Policies [Abstract]  
Significant Accounting Policies
Significant Accounting Policies
Basis of Presentation: The condensed consolidated financial statements of McKesson Corporation (“McKesson,” the “Company,” or “we” and other similar pronouns) include the financial statements of all wholly-owned subsidiaries and majority‑owned or controlled companies. For those consolidated subsidiaries where our ownership is less than 100%, the portion of the net income or loss allocable to the noncontrolling interests is reported as “Net Income Attributable to Noncontrolling Interests” on the condensed consolidated statements of operations. All significant intercompany balances and transactions have been eliminated in consolidation including the intercompany portion of transactions with equity method investees.
We consider ourselves to control an entity if we are the majority owner of and have voting control over such entity. We also assess control through means other than voting rights (“variable interest entities” or “VIEs”) and determine which business entity is the primary beneficiary of the VIE. We consolidate VIEs when it is determined that we are the primary beneficiary of the VIE. Investments in business entities in which we do not have control, but have the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method. Refer to Financial Note 2, “Healthcare Technology Net Asset Exchange” for further information on our equity method investment in Change Healthcare, LLC.
The condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) and, therefore, do not include all information and disclosures normally included in the annual consolidated financial statements.
To prepare the financial statements in conformity with GAAP, management must make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of these financial statements and income and expenses during the reporting period. Actual amounts may differ from these estimated amounts. In our opinion, the accompanying unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair presentation of our financial position, results of operations and cash flows for the interim periods presented.
The results of operations for the quarter ended June 30, 2017 are not necessarily indicative of the results that may be expected for the entire year. These interim financial statements should be read in conjunction with the annual audited financial statements, accounting policies and financial notes included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2017 previously filed with the SEC on May 22, 2017 (“2017 Annual Report”).
The Company’s fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year shall mean the Company’s fiscal year.
Recently Adopted Accounting Pronouncements
Investments: In the first quarter of 2018, we adopted amended guidance for the equity method of accounting. The amended guidance simplifies the transition to the equity method of accounting. This standard eliminates the requirement that when an existing cost method investment qualifies for use of the equity method, an investor must restate its historical financial statements, as if the equity method had been used during all previous periods. Additionally, at the point an investment qualifies for the equity method, any unrealized gain or loss in accumulated other comprehensive income (loss) will be recognized through earnings. The adoption of this amended guidance did not have a material effect on our condensed consolidated financial statements.
Derivatives and Hedging: In the first quarter of 2018, we adopted amended guidance for derivative instrument novations. The amendments clarify that a novation, a change in the counterparty, to a derivative instrument that has been designated as a hedging instrument does not, in and of itself, require dedesignation of that hedging relationship provided all other hedge accounting criteria continue to be met. The adoption of this amended guidance did not have an effect on our condensed consolidated financial statements.
Consolidation: In the first quarter of 2018, we adopted amended guidance for VIEs. The amended guidance requires a single decision maker of a VIE to consider indirect economic interests in the entity held through related parties that are under common control on a proportionate basis when determining whether it is the primary beneficiary of that VIE.  This amendment does not change the existing characteristics of a primary beneficiary. The adoption of this amended guidance did not have a material effect on our condensed consolidated financial statements.
Inventory: In the first quarter of 2018, we adopted amended guidance for the subsequent measurement of inventory. The amended guidance requires entities to measure inventory at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The requirement would replace the current lower of cost or market evaluation. Accounting guidance is unchanged for inventory measured using last-in, first-out (“LIFO”) or the retail method. The adoption of this amended guidance did not have a material effect on our condensed consolidated financial statements.
Recently Issued Accounting Pronouncements Not Yet Adopted
Share-Based Payments: In May 2017, amended guidance was issued for employee share-based payment awards. This amendment provides guidance on which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. Under the amended guidance, we are required to account for the effects of a modification if the fair value, the vesting conditions or the classification (as an equity instrument or a liability instrument) of the modified award change from that of the original award immediately before the modification. The amended guidance is effective for us on a prospective basis commencing in the first quarter of 2019.  Early adoption is permitted.  We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.
Premium Amortization of Purchased Callable Debt Securities: In March 2017, amended guidance was issued to shorten the amortization period for certain callable debt securities held at a premium.  The amended guidance requires the premium of callable debt securities to be amortized to the earliest call date but does not require an accounting change for securities held at a discount as they would still be amortized to maturity.  The amended guidance is effective for us on a modified retrospective basis commencing in the first quarter of 2020.  Early adoption is permitted.  We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.
Compensation - Retirement Benefits: In March 2017, amended guidance was issued which requires us to report the service cost component of defined benefit pension plans and other postretirement plans in the same line item as other compensation costs arising from services rendered by the pertinent employees during the period. Other components of net benefit cost are required to be presented in the statements of operations separately from the service cost component. This amended guidance is effective for us in the first quarter of 2019 on a retrospective basis. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.
Derecognition of Nonfinancial Assets: In February 2017, amended guidance was issued that defines the term “in substance nonfinancial asset” as a financial asset promised to a counterparty in a contract if substantially all of the fair value of the asset that is promised is concentrated in nonfinancial assets. The scope of this amendment includes nonfinancial assets transferred within a legal entity including a parent entity’s transfer of nonfinancial assets by transferring ownership interests in consolidated subsidiaries. The amendment excludes all businesses and nonprofit activities from its scope and therefore all entities, with limited exceptions, are required to account for the derecognition of a business or nonprofit activity in accordance with the consolidation guidance once this amended guidance becomes effective. We are required to apply this amended guidance at the same time we apply the amended revenue guidance in the first quarter of 2019. It allows for either full retrospective adoption or modified retrospective adoption.  Early adoption is permitted.  We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.
Goodwill Impairment Testing: In January 2017, amended guidance was issued to simplify goodwill impairment testing by eliminating the second step of the impairment test. Under the second step, the implied fair value of goodwill is calculated in a hypothetical analysis by subtracting the fair value of all assets and liabilities of the reporting unit, including any unrecognized intangible assets, from the fair value of the reporting unit calculated in the first step of the impairment test. If the carrying value of goodwill for the reporting unit exceeds the implied fair value of goodwill, an impairment charge is recorded for that excess. The amended guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, if any. The amended guidance is effective for us on a prospective basis commencing in the first quarter of 2021. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.
Business Combinations: In January 2017, amended guidance was issued to clarify the definition of a business to assist entities in evaluating whether transactions should be accounted for as acquisitions of assets or businesses. The amended guidance provides a practical screen to determine when an integrated set of assets and activities (collectively referred to as a “set”) is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. If the screen is not met, the amended guidance requires that to be considered a business, a set must include an input and a substantive process that together significantly contribute to the ability to create output. The amended guidance is effective for us commencing in the first quarter of 2019 on a prospective basis. Early adoption is permitted in certain circumstances.  We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.
Restricted Cash: In November 2016, amended guidance was issued that requires restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total cash amounts shown on the statement of cash flows. Transfers between cash and cash equivalents and restricted cash or restricted cash equivalents are not reported as cash flow activities in the statement of cash flows.  The amended guidance is effective for us commencing in the first quarter of 2019 on a retrospective basis. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.
Income Taxes - Intra-Entity Transfers of Assets Other Than Inventory: In October 2016, amended guidance was issued to require entities to recognize income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The amended guidance is effective for us commencing in the first quarter of 2019 on a modified retrospective basis. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.
Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments: In August 2016, amended guidance was issued to provide clarification on cash flow classification related to eight specific issues including contingent consideration payments made after a business combination and distributions received from equity method investees.  The amended guidance is effective for us commencing in the first quarter of 2019 on a retrospective basis. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.
Financial Instruments - Credit Losses: In June 2016, amended guidance was issued, which will change the impairment model for most financial assets and require additional disclosures. The amended guidance requires financial assets that are measured at amortized cost, be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of financial assets. The amended guidance also requires us to consider historical experience, current conditions, and reasonable and supportable forecasts that affect the collectibility of the reported amount in estimating credit losses. The amended guidance becomes effective for us commencing in the first quarter of 2021 and will be applied through a cumulative-effect adjustment to the beginning retained earnings in the year of adoption. Early adoption is permitted.  We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.
Leases: In February 2016, amended guidance was issued for lease arrangements. The amended standard will require lessees to recognize assets and liabilities on the balance sheet for all leases with terms longer than 12 months and provide enhanced disclosures on key information of leasing arrangements.  The amended guidance is effective for us commencing in the first quarter of 2020, on a modified retrospective basis.  Early adoption is permitted.  We plan to adopt the new standard on the effective date and are currently evaluating the impact of this amended guidance on our consolidated financial statements. We anticipate that the adoption of the amended lease guidance will materially affect our condensed consolidated balance sheet and will require certain changes to our systems and processes.
Financial Instruments: In January 2016, amended guidance was issued that requires equity investments to be measured at fair value with changes in fair value recognized in net income and enhanced disclosures about those investments. This guidance also simplifies the impairment assessments of equity investments without readily determinable fair value. The investments that are accounted for under the equity method of accounting or result in consolidation of the investee are excluded from the scope of this amended guidance. The amended guidance will become effective for us commencing in the first quarter of 2019 and will be adopted through a cumulative-effect adjustment. Early adoption is not permitted except for certain provisions.  We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.
Revenue Recognition: In May 2014, amended guidance was issued for recognizing revenue from contracts with customers.  The amended guidance eliminates industry specific guidance and applies to all companies.  Revenues will be recognized when an entity satisfies a performance obligation by transferring control of a promised good or service to a customer in an amount that reflects the consideration to which the entity expects to be entitled for that good or service.  Revenue from a contract that contains multiple performance obligations is allocated to each performance obligation generally on a relative standalone selling price basis.  The amended guidance also requires additional quantitative and qualitative disclosures.  In March, April and May 2016, amended guidance was further issued including clarifying guidance on principal versus agent considerations, ability to choose an accounting policy election to account for shipping and handling activities that occur after the customer has obtained control of a good as an activity to fulfill the promise to transfer the good, and provided certain scope improvements and practical expedients.  The amended standard is effective for us commencing in the first quarter of 2019 and allows for either full retrospective adoption or modified retrospective adoption.  Early adoption is permitted.
While we continue to evaluate the effect of the amended standard, we have conducted a preliminary assessment for our Distribution Solutions segment and do not expect adoption of the amended standard to have a material impact on our consolidated financial statements.  The majority of our Distribution Solutions segment’s revenue is generated from sales of pharmaceutical products, which will continue to be recognized when control of the goods is transferred to the customer. We generally anticipate having substantially similar performance obligations under the amended guidance as compared with deliverables and units of account currently being recognized. We intend to make policy elections within the amended standard that are consistent with our current accounting. Our preliminary assessment does not include certain businesses for which we are exploring strategic alternatives and we continue to evaluate the potential impact of the recent acquisitions. This preliminary assessment is subject to change prior to adoption. Additionally, we anticipate adopting this amended standard on a modified retrospective basis in our first quarter of 2019.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.7.0.1
Healthcare Technology Net Asset Exchange
3 Months Ended
Jun. 30, 2017
Equity Method Investments and Joint Ventures [Abstract]  
Healthcare Technology Net Asset Exchange
Healthcare Technology Net Asset Exchange
On June 28, 2016, we entered into a contribution agreement (“Contribution Agreement”) with Change Healthcare Holdings, Inc. (“Change”), a Delaware corporation, and others including shareholders of Change to form a joint venture, Change Healthcare, LLC (“Change Healthcare”), a Delaware limited liability company. On March 1, 2017, the transaction closed upon satisfaction of all closing conditions pursuant to the Contribution Agreement. Under the terms of the Contribution Agreement, we contributed the majority of our McKesson Technology Solutions businesses (“Core MTS Business”) to the newly formed joint venture, Change Healthcare. We retained our RelayHealth Pharmacy (“RHP”) and Enterprise Information Solutions (“EIS”) businesses. Change contributed substantially all of its businesses to the joint venture excluding its pharmacy switch and prescription routing business. In exchange for the contribution, we own 70% of the joint venture with the remaining equity ownership held by Change shareholders. The joint venture is jointly governed by us and Change shareholders. Change Healthcare is a healthcare technology company which provides software and analytics, network solutions and technology-enabled services that will deliver wide-ranging financial, operational and clinical benefits to payers, providers and consumers.
McKesson and Change shareholders have agreed to take steps to launch an initial public offering of an entity which holds equity in Change Healthcare, subject to market conditions. Sometime thereafter, we expect to exit our investment in Change Healthcare through a distribution to McKesson shareholders.

Gain from Healthcare Technology Net Asset Exchange
We accounted for this transaction as a sale of the Core MTS Business and a subsequent purchase of a 70% interest in the newly formed joint venture. Accordingly, in the fourth quarter of 2017, we deconsolidated the Core MTS Business and recorded a pre-tax gain of $3,947 million (after-tax gain of $3,018 million) within operating expenses in our consolidated statements of operations. This transaction did not meet the criteria to be reported as a discontinued operation since it did not constitute a significant strategic business shift for the Company. During the first quarter of 2018, we recorded a pre-tax gain of approximately $37 million (after-tax gain of $22 million) under the caption, “Gain on Healthcare Technology Net Asset Exchange,” upon the finalization of net working capital and other adjustments. At June 30, 2017, we had a receivable of $126 million from Change Healthcare representing the final settlement of the net working capital and other adjustments.
Equity Method Investment in Change Healthcare
Our investment in the joint venture is accounted for using the equity method of accounting. We disclose intervening events at the joint venture in the lag period that could materially affect our consolidated financial statements, if applicable. There were no material intervening events at the joint venture during June 2017. During the first quarter of 2018, we recorded our proportionate share of loss from Change Healthcare of $120 million, which included transaction and integration expenses incurred by the joint venture and amortization expenses associated with equity method intangible assets. This amount was recorded under the caption, “Loss from Equity Method Investment in Change Healthcare,” in our condensed consolidated statement of operations.
At June 30, 2017, the carrying value of our investment was $3,855 million, which exceeded our proportionate share of the joint venture’s book value of net assets by approximately $4,768 million, primarily reflecting equity method intangible assets and goodwill and other fair value adjustments.
Summarized financial information (unaudited) of Change Healthcare is as follows:
(In millions)
Quarter Ended June 30, 2017
Revenues
$
865

Loss from Continuing Operations
(84
)
Net Loss
(84
)

Our proportionate share of Change Healthcares net loss as reported was $59 million ($84 million at our 70% ownership).  Adjustments from their carrying value to our initial fair value basis of accounting resulted in a total reported net loss of $120 million for McKesson.  The amortization of fair value adjustments included incremental intangible amortization and removal of profit associated with the recognition of deferred revenue, as well as basis differences in long-term debt.
Agreements with Change Healthcare and Related Party Transactions
At the closing of the transaction, McKesson, Change Healthcare and certain Change shareholders also entered into various ancillary agreements, including transition services agreements (“TSA”), a transaction and advisory fee agreement (“Advisory Agreement”), a tax receivable agreement (“TRA”) and certain other commercial agreements.
Pursuant to the TRA, McKesson may be required to make certain payments or may be entitled to receive certain payments related to the cash tax savings attributable to the utilization of certain tax attributes, including certain amortizable tax basis in software contributed by McKesson to Change Healthcare. At June 30, 2017 and March 31, 2017, we had a $136 million noncurrent liability payable to Change Healthcare shareholders associated with the TRA. The amount is based on certain estimates and could become payable in periods after a disposition of our investment in Change Healthcare. No such payments were required to be made or received during the first quarter of 2018.
Pursuant to the TSA, McKesson provides various transitional services to the joint venture to support certain operations including information technology, accounting and other administrative services. The total fees charged by us for such transition services were $37 million for the first quarter of 2018. Transition services fees are included within operating expenses in our condensed consolidated statements of operations.
Pursuant to the Advisory Agreement, the joint venture pays McKesson and Change shareholders an agreed upon amount for each fiscal year on a quarterly basis. The foregoing advisory and transaction fees are non-refundable and allocated to McKesson and Change shareholders based on their respective equity ownership percentages. In the first quarter of 2018, we did not earn material advisory fees and transaction fees.
Revenues recorded and expenses incurred under commercial arrangements with Change Healthcare were not material during the first quarter of 2018. At June 30, 2017 and March 31, 2017, receivables from and payables to the joint venture were not material.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.7.0.1
Business Combinations
3 Months Ended
Jun. 30, 2017
Business Combinations [Abstract]  
Business Combinations
Business Combinations
CoverMyMeds LLC (“CMM”)
On April 3, 2017, we completed our acquisition of CMM, a privately-owned company headquartered in Columbus, Ohio. CMM provides electronic prior authorization solutions to pharmacies, providers, payers, and pharmaceutical manufacturers. The net purchase consideration of $1.3 billion was funded from cash on hand. The cash consideration was initially paid into an escrow account prior to our 2017 fiscal year end, and was included in “Other Noncurrent Assets” within our consolidated balance sheet at March 31, 2017. Pursuant to the agreement, McKesson may pay up to an additional $0.2 billion of contingent consideration based on CMM’s financial performance for 2018 and 2019. We recorded a liability for this remaining contingent consideration at its estimated fair value of $113 million as of the acquisition date on our condensed consolidated balance sheet.  The contingent consideration was estimated using a Monte Carlo simulation, which utilizes Level 3 inputs under the fair value measurement and disclosure guidance, including estimated financial forecasts. The contingent liability is re-measured at fair value at each reporting date until the liability is extinguished with changes in fair value being recorded to our statements of operations.  There was no material change in the contingent liability’s fair value during the first quarter of 2018. The initial fair value of this contingent consideration is a non-cash investing activity. The financial results of CMM are included in our North America pharmaceutical distribution and services business within our Distribution Solutions segment since the acquisition date.
The provisional fair value of assets acquired and liabilities assumed as of the acquisition date, excluding goodwill and intangibles, were $54 million and $8 million. Approximately $854 million of the preliminary purchase price allocation has been assigned to goodwill, which reflects the expected future benefits of certain synergies and intangible assets that do not qualify for separate recognition. The amount of goodwill is fully deductible for tax purposes. Included in the preliminary purchase price allocation are acquired identifiable intangibles of $502 million primarily representing customer relationships with a weighted average life of 17 years. Amounts recognized as of the acquisition date are provisional and subject to change within the measurement period as our fair value assessments are finalized.
Rexall Health
On December 28, 2016, we completed our acquisition of Rexall Health which operates approximately 470 retail pharmacies in Canada, particularly in Ontario and Western Canada. The net cash purchase consideration of $2.9 billion Canadian dollars (or, approximately $2.1 billion) was funded from cash on hand. As part of the transaction, McKesson agreed to divest 27 local stores that the Competition Bureau of Canada (the “Bureau”) identified during its review of the transaction. We expect to complete the sale of these local market divestitures during the first half of 2018. The financial results of Rexall Health are included in our North America pharmaceutical distribution and services business within our Distribution Solutions segment since the acquisition date.
During the first quarter of 2018, we recorded certain measurement period adjustments to the provisional fair value of assets acquired and liabilities assumed as of the acquisition date (primarily an increase of $17 million to intangibles). The amounts as of the acquisition date are provisional and subject to change within the measurement period as our fair value assessments are finalized.
Total adjusted provisional fair value of assets acquired and liabilities assumed as of the acquisition date, excluding goodwill and intangibles, were $674 million and $212 million. Approximately $950 million of the adjusted preliminary purchase price allocation has been assigned to goodwill, which primarily reflects the expected future benefits of certain synergies and intangible assets that do not qualify for separate recognition. Included in the adjusted preliminary purchase price allocation are acquired identifiable intangibles of $872 million, net of intangibles classified as held for sale, primarily representing trade names with a weighted average life of 19 years and customer relationships with a weighted average life of 19 years. At June 30, 2017, assets of those stores to be divested were approximately $193 million and were included under the captions, “Prepaid expenses and other” in the accompanying condensed consolidated balance sheet. There were no material liabilities associated with those stores at June 30, 2017.
The fair value of acquired intangibles from these acquisitions was primarily determined by applying the income approach, using several significant unobservable inputs for projected cash flows and a discount rate. These inputs are considered Level 3 inputs.
2017 Acquisitions

In the first quarter of 2017, we completed our acquisitions of Vantage Oncology Holdings, LLC (“Vantage”), Biologics, Inc., UDG Healthcare Plc (“UDG”) and other businesses for net cash payments of $1.8 billion.
Other Acquisitions

During the last two years, we also completed other acquisitions within both of our operating segments. Financial results for our business acquisitions have been included in our consolidated financial statements since their respective acquisition dates. Purchase prices for our business acquisitions have been allocated based on estimated fair values at the date of acquisition.
Goodwill recognized for our business acquisitions is generally not expected to be deductible for tax purposes. However, if we acquire the assets of a company, the goodwill may be deductible for tax purposes.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.7.0.1
Discontinued Operations
3 Months Ended
Jun. 30, 2017
Discontinued Operations and Disposal Groups [Abstract]  
Discontinued Operations
Discontinued Operations
In the fourth quarter of 2016, we entered into an agreement to sell our Brazilian pharmaceutical distribution business to a third party from our Distribution Solutions segment. In the first quarter of 2017, we completed the sale of this business and recognized an after-tax loss of $113 million within discontinued operations primarily for the settlement of certain indemnification matters as well as the release of the cumulative translation losses. We made a payment of approximately $100 million related to the sale of this business in the first quarter of 2017. The results of this business have been classified as discontinued operations since 2015.
The results of discontinued operations for the first quarters of 2018 and 2017 were not material except for the loss recognized upon the disposition of our Brazilian business in 2017. As of June 30, 2017 and March 31, 2017, the carrying amounts of total assets and liabilities of discontinued operations were not material.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.7.0.1
Restructuring
3 Months Ended
Jun. 30, 2017
Restructuring and Related Activities [Abstract]  
Restructuring
Restructuring
In the fourth quarter of 2016, we committed to a restructuring plan to lower our operating costs (the “Cost Alignment Plan”). The Cost Alignment Plan primarily consists of a reduction in workforce, and business process initiatives that will be substantially implemented prior to the end of 2019. Business process initiatives primarily include plans to reduce operating costs of our distribution and pharmacy operations, administrative support functions, and technology platforms, as well as the disposal and abandonment of certain non-core businesses. As a result of the Cost Alignment Plan, we expect to record total pre-tax charges of approximately $250 million to $270 million, of which $246 million of pre-tax charges were recorded to date. Estimated remaining charges primarily consist of exit-related costs and accelerated depreciation and amortization, which are largely attributed to our Distribution Solutions segment.

During the first quarter of 2017, we recorded a pre-tax charge of $9 million as part of the Cost Alignment Plan. There were no material restructuring charges recorded during the first quarter of 2018. During the first quarters of 2018 and 2017, we made $14 million and $45 million of cash payments, primarily related to severance. The reserve balances as of June 30, 2017 and March 31, 2017 include $64 million and $71 million recorded in other accrued liabilities, and $35 million recorded in other noncurrent liabilities in our condensed consolidated balance sheet.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.7.0.1
Income Taxes
3 Months Ended
Jun. 30, 2017
Income Tax Disclosure [Abstract]  
Income Taxes
Income Taxes
During the first quarters of 2018 and 2017, income tax expense related to continuing operations was $95 million and $239 million and included net discrete tax expense of $3 million and net discrete tax benefit of $35 million. Our discrete tax benefits for the first quarter of 2017 included $37 million related to the adoption of the amended accounting guidance on employee share-based compensation. Our reported income tax rates for the first quarters of 2018 and 2017 were 20.7% and 26.2%. Fluctuations in our reported income tax rates are primarily due to changes within our business mix, including varying proportions of income attributable to foreign countries that have lower income tax rates, discrete items and the impact of the intercompany sale of software.
As of June 30, 2017, we had $516 million of unrecognized tax benefits, of which $371 million would reduce income tax expense and the effective tax rate, if recognized. During the next twelve months, it is reasonably possible that audit resolutions could potentially reduce our unrecognized tax benefits by up to $60 million. However, this amount may change as we continue to have ongoing negotiations with various taxing authorities throughout the year.
We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. During the first quarter of 2017, we reached an agreement with the Internal Revenue Service (“IRS”) to settle all outstanding issues relating to the fiscal years 2007 through 2009. This settlement did not have a material impact on our provision for income taxes. We are subject to audit by the IRS for fiscal years 2010 through the current fiscal year. We are generally subject to audit by taxing authorities in various U.S. states and in foreign jurisdictions for fiscal years 2006 through the current fiscal year.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.7.0.1
Redeemable Noncontrolling Interests and Noncontrolling Interests
3 Months Ended
Jun. 30, 2017
Noncontrolling Interest [Abstract]  
Redeemable Noncontrolling Interests and Noncontrolling Interests
Redeemable Noncontrolling Interests and Noncontrolling Interests
Redeemable Noncontrolling Interests

Our redeemable noncontrolling interests relate to our consolidated subsidiary, Celesio AG (“Celesio”). The domination and profit and loss transfer agreement (the “Domination Agreement”) was entered into between McKesson and Celesio in connection with our 2014 acquisition of Celesio and became effective in December 2014. Under the Domination Agreement, the noncontrolling shareholders of Celesio have a right to put (“Put Right”) their Celesio shares at €22.99 per share increased annually for interest in the amount of 5 percentage points above a base rate published by the German Bundesbank semiannually, less any compensation amount or guaranteed dividend already paid by McKesson in respect of the relevant time period (“Put Amount”). The exercise of the Put Right will reduce the balance of redeemable noncontrolling interests. During the first quarter of 2018, we paid $50 million to purchase 1.9 million shares of Celesio through the exercises of the Put Right by the noncontrolling shareholders, which decreased the carrying value of redeemable noncontrolling interests by $53 million. The balance of redeemable noncontrolling interests is reported at the greater of its carrying value or its maximum redemption value at each reporting date. The redemption value is the Put Amount adjusted for exchange rate fluctuations each period. At June 30, 2017 and March 31, 2017, the carrying value of redeemable noncontrolling interests of $1.39 billion and $1.33 billion exceeded the maximum redemption value of $1.24 billion and $1.21 billion. At June 30, 2017 and March 31, 2017, we owned approximately 77% and 76% of Celesio’s outstanding common shares.

Under the Domination Agreement, the noncontrolling shareholders of Celesio received a one-time guaranteed dividend of €0.83 per Celesio share for the 2014 calendar year and are also entitled to receive an annual recurring compensation amount of €0.83 per Celesio share since January 2015. As a result, during the first quarters of 2018 and 2017, we recorded a total attribution of net income to the noncontrolling shareholders of Celesio of $9 million and $11 million. All amounts were recorded in our condensed consolidated statement of operations within the caption, “Net Income Attributable to Noncontrolling Interests,” and the corresponding liability balance was recorded within other accrued liabilities on our condensed consolidated balance sheet.
During fiscal 2014, subsequent to the effectiveness of the Domination Agreement, certain noncontrolling shareholders of Celesio initiated appraisal proceedings (“Appraisal Proceedings”) with the Stuttgart Regional Court to challenge the adequacy of the compensation amount, the guaranteed dividend and/or the Put Amount. As long as any Appraisal Proceedings are pending, the compensation amount, guaranteed dividend and/or Put Amount will be paid as specified currently in the Domination Agreement.
Noncontrolling Interests
Our noncontrolling interests represent third-party equity interests in our consolidated entities, primarily Vantage and ClarusONE Sourcing Services LLP, were $210 million and $178 million at June 30, 2017 and March 31, 2017. During the first quarters of 2018 and 2017, we allocated a total of $47 million and $7 million of net income to noncontrolling interests.

Changes in redeemable noncontrolling interests and noncontrolling interests for the first quarter of 2018 were as follows:
(In millions)
Noncontrolling Interests
Redeemable
Noncontrolling
Interests
Balance, March 31, 2017
$
178

$
1,327

Net income attributable to noncontrolling interests
47

9

Other comprehensive income

116

Reclassification of recurring compensation to other accrued liabilities

(9
)
Payments to noncontrolling interests
(18
)

Exercises of Put Right

(53
)
Other
3


Balance, June 30, 2017
$
210

$
1,390


Changes in redeemable noncontrolling interests and noncontrolling interests for the first quarter of 2017 were as follows:
(In millions)
Noncontrolling Interests
Redeemable
Noncontrolling
Interests
Balance, March 31, 2016
$
84

$
1,406

Net income attributable to noncontrolling interests
7

11

Other comprehensive loss

(66
)
Reclassification of recurring compensation to other accrued liabilities

(11
)
Purchase of noncontrolling interests
152


Other
(1
)

Balance, June 30, 2016
$
242

$
1,340



The effect of changes in our ownership interests with noncontrolling interests on our equity of $3 million was recorded as a net increase to McKesson’s stockholders’ paid-in capital during the first quarter of 2018. Net income attributable to McKesson and transfers from noncontrolling interests amounted to $312 million during the first quarter of 2018.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.7.0.1
Earnings Per Common Share
3 Months Ended
Jun. 30, 2017
Earnings Per Share [Abstract]  
Earnings Per Common Share
Earnings Per Common Share
Basic earnings per common share are computed by dividing net income by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share are computed similar to basic earnings per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.
The computations for basic and diluted earnings per common share are as follows:
  
Quarter Ended June 30,
(In millions, except per share amounts)
2017
 
2016
Income from continuing operations
$
363

 
$
673

Net income attributable to noncontrolling interests
(56
)
 
(18
)
Income from continuing operations attributable to McKesson
307

 
655

Income (loss) from discontinued operations, net of tax
2

 
(113
)
Net income attributable to McKesson
$
309

 
$
542

 
 
 
 
Weighted average common shares outstanding:
 
 
 
Basic
211

 
225

Effect of dilutive securities:
 
 
 
Options to purchase common stock
1

 
1

Restricted stock units
1

 
2

Diluted
213

 
228

 
 
 
 
Earnings (loss) per common share attributable to McKesson: (1)
 
 
 
Diluted
 
 
 
Continuing operations
$
1.44

 
$
2.88

Discontinued operations
0.01

 
(0.50
)
Total
$
1.45

 
$
2.38

Basic
 
 
 
Continuing operations
$
1.46

 
$
2.91

Discontinued operations

 
(0.50
)
Total
$
1.46

 
$
2.41


(1)
Certain computations may reflect rounding adjustments.
Potentially dilutive securities include outstanding stock options, restricted stock units, and performance-based and other restricted stock units. Approximately 2 million potentially dilutive securities were excluded from the computations of diluted net earnings per common share for each of the quarters ended June 30, 2017 and 2016, as they were anti-dilutive.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.7.0.1
Goodwill and Intangible Assets, Net
3 Months Ended
Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets, Net
Goodwill and Intangible Assets, Net
Changes in the carrying amount of goodwill were as follows:
(In millions)
Distribution
Solutions
 
Technology
Solutions
 
Total
Balance, March 31, 2017
$
10,132

 
$
454

 
$
10,586

Goodwill acquired
940

 

 
940

Acquisition accounting, transfers and other adjustments (1)
324

 
(330
)
 
(6
)
Foreign currency translation adjustments, net
230

 

 
230

Balance, June 30, 2017
$
11,626

 
$
124

 
$
11,750


(1)
Effective April 1, 2017, our RHP business was transitioned from the Technology Solutions segment to the Distribution Solutions segment.
As of June 30, 2017 and March 31, 2017, accumulated goodwill impairment losses were $290 million primarily in our Technology Solutions segment.
Information regarding intangible assets is as follows:
 
June 30, 2017
 
March 31, 2017
(Dollars in millions)
Weighted
Average
Remaining
Amortization
Period
(years)
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Carrying
Amount
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships
12
 
$
3,411

 
$
(1,392
)
 
$
2,019

 
$
2,893

 
$
(1,295
)
 
$
1,598

Service agreements
13
 
1,023

 
(332
)
 
691

 
1,009

 
(316
)
 
693

Pharmacy licenses
25
 
772

 
(164
)
 
608

 
741

 
(150
)
 
591

Trademarks and trade names
15
 
870

 
(136
)
 
734

 
845

 
(124
)
 
721

Technology
5
 
151

 
(71
)
 
80

 
69

 
(64
)
 
5

Other
5
 
261

 
(155
)
 
106

 
201

 
(144
)
 
57

Total
 
 
$
6,488


$
(2,250
)
 
$
4,238

 
$
5,758

 
$
(2,093
)
 
$
3,665


Amortization expense of intangible assets was $121 million and $115 million for the quarters ended June 30, 2017 and 2016. Estimated annual amortization expense of these assets is as follows: $328 million, $420 million, $405 million, $393 million and $361 million for the remainder of 2018 and each of the succeeding years through 2022 and $2,331 million thereafter. All intangible assets were subject to amortization as of June 30, 2017 and March 31, 2017.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.7.0.1
Debt and Financing Activities
3 Months Ended
Jun. 30, 2017
Debt Disclosure [Abstract]  
Debt and Financing Activities
Debt and Financing Activities
Long-Term Debt
Our long-term debt includes both U.S. dollar and foreign currency (primarily Euro and British pound sterling) denominated borrowings. At June 30, 2017 and March 31, 2017, $7,949 million and $8,362 million of total long-term debt were outstanding, of which $525 million and $1,057 million were included under the caption “Current portion of long-term debt” within the condensed consolidated balance sheets.
During the first quarter of 2018, we repaid our €500 million bond that matured on April 26, 2017.
Revolving Credit Facilities
We have a syndicated $3.5 billion five-year senior unsecured revolving credit facility (the “Global Facility”), which has a $3.15 billion aggregate sublimit of availability in Canadian dollars, British pound sterling and Euros. Borrowings under the Global Facility bear interest based upon the London Interbank Offered Rate, Canadian Dealer Offered Rate for credit extensions denominated in Canadian Dollars, a prime rate, or alternative overnight rates as applicable, plus agreed margins. The Global Facility contains a financial covenant which obligates the Company to maintain a debt to capital ratio of no greater than 65% and other customary investment grade covenants. If we do not comply with these covenants, our ability to use the Global Facility may be suspended and repayment of any outstanding balances under the Global Facility may be required. At June 30, 2017, we were in compliance with all covenants. There were no borrowings outstanding under this facility during the first quarter of 2018, and as of June 30, 2017.
We also maintain bilateral credit lines primarily denominated in Euros with a total committed and uncommitted balance of $244 million. Borrowings and repayments were not material during the first quarters of 2018 and 2017. As of June 30, 2017 and March 31, 2017, amounts outstanding under these credit lines were not material.
Commercial Paper
We maintain a commercial paper program to support our working capital requirements and for other general corporate purposes. Under the program, the Company can issue up to $3.5 billion in outstanding notes. As of June 30, 2017, there were no borrowings outstanding under the commercial paper program. As of March 31, 2017, we had $183 million commercial paper notes outstanding with a weighted average interest rate of 1.20%.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.7.0.1
Pension Benefits
3 Months Ended
Jun. 30, 2017
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]  
Pension Benefits
Pension Benefits
The net periodic expense for our defined pension benefit plans was $6 million for the first quarters of 2018 and 2017.

Cash contributions to these plans were $3 million and $4 million for the first quarters of 2018 and 2017. The projected unit credit method is utilized in measuring net periodic pension expense over the employees’ service life for the pension plans. Unrecognized actuarial losses exceeding 10% of the greater of the projected benefit obligation or the market value of assets are amortized straight-line over the average remaining future service periods and expected life expectancy.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.7.0.1
Hedging Activities
3 Months Ended
Jun. 30, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Hedging Activities
Hedging Activities
In the normal course of business, we are exposed to interest rate and foreign exchange rate fluctuations. At times, we limit these risks through the use of derivatives such as interest rate swaps, cross currency swaps and foreign currency forward contracts. In accordance with our policy, derivatives are only used for hedging purposes. We do not use derivatives for trading or speculative purposes.
Foreign currency exchange risk
We conduct our business worldwide in U.S. dollars and the functional currencies of our foreign subsidiaries, including Euro, British pound sterling and Canadian dollars. Changes in foreign currency exchange rates could have a material adverse impact on our financial results that are reported in U.S. dollars. We are also exposed to foreign currency exchange rate risk related to our foreign subsidiaries, including intercompany loans denominated in non-functional currencies. We have certain foreign currency exchange rate risk programs that use foreign currency forward contracts and cross currency swaps. These forward contracts and cross currency swaps are generally used to offset the potential income statement effects from intercompany loans denominated in non-functional currencies. These programs reduce but do not eliminate foreign exchange rate risk.
Net Investment Hedges and Derivatives Designated as Hedges
We have €1.2 billion Euro-denominated notes and £450 million British pound sterling-denominated notes which hedge portions of our net investments in non-U.S. subsidiaries against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar (“Net Investment Hedges”). For all notes that are designated as net investment hedges and meet effectiveness requirements, the changes in carrying value of the notes attributable to the change in spot rates are recorded in accumulated other comprehensive income (loss) within the condensed consolidated balance sheet where they offset foreign currency translation gains and losses recorded on our net investments.  To the extent foreign currency denominated notes designated as net investment hedges are ineffective, changes in value are recorded in earnings.  Losses from net investment hedges recorded in other comprehensive income were $114 million during the first quarter of 2018. We did not have any ineffective portion of the net investment hedges as of June 30, 2017 and March 31, 2017.
At June 30, 2017 and March 31, 2017, we had forward contracts to hedge the U.S. dollar against cash flows denominated in Canadian dollars with total gross notional values of $243 million, which were designated as cash flow hedges. These contracts will mature between March 2018 and March 2020.
From time to time, we enter into cross currency swaps to hedge intercompany loans denominated in non-functional currencies. For our cross currency swap transactions, we agree with another party to exchange, at specified intervals, one currency for another currency at a fixed exchange rate, generally set at inception, calculated by reference to agreed upon notional amounts. These cross currency swaps are designed to reduce the income statement effects arising from fluctuations in foreign exchange rates and have been designated as cash flow hedges.
At June 30, 2017 and March 31, 2017, we had cross currency swaps with total gross notional amounts of approximately $3,223 million and $2,663 million, which are designated as cash flow hedges. These swaps will mature between February 2018 and January 2024.
For forward contracts and cross currency swaps that are designated as cash flow hedges, the effective portion of changes in the fair value of the hedges is recorded into accumulated other comprehensive income (loss) and reclassified into earnings in the same period in which the hedged transaction affects earnings. Changes in fair values representing hedge ineffectiveness are recognized in current earnings. Gains or losses on these hedges recorded in other comprehensive income and earnings were not material in the first quarters of 2018 and 2017.
Derivatives Not Designated as Hedges
At June 30, 2017 and March 31, 2017, we had forward contracts to primarily hedge the U.S. dollar against cash flows denominated in Canadian dollars with total gross notional value of $177 million and $173 million. These contracts will mature through August 2017 and none of these contracts were designated for hedge accounting. Losses from these contracts were not material for the first quarters of 2018 and 2017.
We also have a number of forward contracts to hedge the Euro against cash flows denominated primarily in British pound sterling and other European currencies. At June 30, 2017 and March 31, 2017, the total gross notional amounts of these contracts were $167 million and $62 million.
These contracts will mature through December 2017 and none of these contracts were designated for hedge accounting. Changes in the fair values of contracts not designated as hedges are recorded directly into earnings. Gains from these contracts were recorded within operating expenses and were not material for the first quarters of 2018 and 2017. The gains or losses from these contracts are largely offset by changes in the value of the underlying intercompany foreign currency loans.
Information regarding the fair value of derivatives on a gross basis is as follows:
 
Balance Sheet
Caption
June 30, 2017
 
March 31, 2017
 
Fair Value of
Derivative
U.S. Dollar Notional
 
Fair Value of
Derivative
U.S. Dollar Notional
(In millions)
Asset
Liability
 
Asset
Liability
Derivatives designated for hedge accounting
 
 
 
 
 
 
 
 
Foreign exchange contracts (current)
Prepaid expenses and other
$
16

$

$
81

 
$
17

$

$
81

Foreign exchange contracts (non-current)
Other Noncurrent Assets
30


162

 
32


162

Cross currency swaps (current)
Prepaid expenses and other
11


174

 
17


174

Cross currency swaps (non-current)
Other Noncurrent Assets/Liabilities

26

3,049

 
90


2,489

Total
 
$
57

$
26

 
 
$
156

$

 
Derivatives not designated for hedge accounting
 
 
 
 
 
 
 
 
Foreign exchange contracts (current)
Prepaid expenses and other
$
1

$

$
139

 
$
1

$

$
198

Foreign exchange contracts (current)
Other accrued liabilities

4

205

 


37

Total
 
$
1

$
4

 
 
$
1

$

 

Refer to Financial Note 13, "Fair Value Measurements," for more information on these recurring fair value measurements.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.7.0.1
Fair Value Measurements
3 Months Ended
Jun. 30, 2017
Fair Value Disclosures [Abstract]  
Fair Value Measurements
Fair Value Measurements
At June 30, 2017 and March 31, 2017, the carrying amounts of cash, certain cash equivalents, restricted cash, marketable securities, receivables, drafts and accounts payable, short-term borrowings and other current liabilities approximated their estimated fair values because of the short maturity of these financial instruments.
The fair value of our commercial paper was determined using quoted prices in active markets for identical liabilities, which are considered to be Level 1 inputs.
Assets Measured at Fair Value on a Recurring Basis

Our long-term debt is carried at amortized cost. The carrying amounts and estimated fair values of these liabilities were $7.9 billion and $8.4 billion at June 30, 2017, and $8.4 billion and $8.7 billion at March 31, 2017. The estimated fair value of our long-term debt was determined using quoted market prices in a less active market and other observable inputs from available market information, which are considered to be Level 2 inputs, and may not be representative of actual values that could have been realized or that will be realized in the future.
Included in cash and cash equivalents at June 30, 2017 and March 31, 2017 were mainly investments in money market funds of $443 million and $478 million, which are reported at fair value. The fair value of the money market funds was determined by using quoted prices for identical investments in active markets, which are considered to be Level 1 inputs under the fair value measurements and disclosure guidance. The carrying value of all other cash equivalents approximates their fair value due to their relatively short-term nature.
Fair values of our forward foreign currency derivatives were determined using quoted market prices of similar instruments in an active market and other observable inputs from available market information.  Fair values of our foreign currency swaps were determined using the quoted foreign currency exchange rates and other observable inputs from available market information. These inputs are considered Level 2 under the fair value measurements and disclosure guidance, and may not be representative of actual values that could have been realized or that will be realized in the future. Refer to Financial Note 12, "Hedging Activities," for more information on our forward foreign currency derivatives including foreign currency forward contracts and swaps.
There were no transfers between Level 1, Level 2 or Level 3 of the fair value hierarchy during the quarters ended June 30, 2017 and 2016.
Liabilities Measured at Fair Value on a Nonrecurring Basis

At June 30, 2017, we measured the contingent consideration liability related to our acquisition of CMM at fair value on a nonrecurring basis. Refer to Financial Note 3, “Business Combinations”. There were no assets measured at fair value on a nonrecurring basis at June 30, 2017.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.7.0.1
Commitments and Contingent Liabilities
3 Months Ended
Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingent Liabilities
Commitments and Contingent Liabilities
In addition to commitments and obligations in the ordinary course of business, we are subject to various claims, including claims with customers and vendors, pending and potential legal actions for damages, investigations relating to governmental laws and regulations and other matters arising out of the normal conduct of our business. As described below, many of these proceedings are at preliminary stages and many seek an indeterminate amount of damages.
When a loss is considered probable and reasonably estimable, we record a liability in the amount of our best estimate for the ultimate loss. However, the likelihood of a loss with respect to a particular contingency is often difficult to predict and determining a meaningful estimate of the loss or a range of loss may not be practicable based on the information available and the potential effect of future events and decisions by third parties that will determine the ultimate resolution of the contingency. Moreover, it is not uncommon for such matters to be resolved over many years, during which time relevant developments and new information must be reevaluated at least quarterly to determine both the likelihood of potential loss and whether it is possible to reasonably estimate a range of possible loss. When a loss is probable but a reasonable estimate cannot be made, disclosure of the proceeding is provided.
Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. We review all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or range of loss can be made. As discussed above, development of a meaningful estimate of loss or a range of potential loss is complex when the outcome is directly dependent on negotiations with or decisions by third parties, such as regulatory agencies, the court system and other interested parties. Such factors bear directly on whether it is possible to reasonably estimate a range of potential loss and boundaries of high and low estimates.
Significant developments in previously reported proceedings and in other litigation and claims, since the filing of our 2017 Annual Report are set out below. We are party to the legal proceedings described below. Unless otherwise stated, we are currently unable to estimate a range of reasonably possible losses for the unresolved proceedings described below. Should any one or a combination of more than one of these proceedings be successful, or should we determine to settle any or a combination of these matters, we may be required to pay substantial sums, become subject to the entry of an injunction or be forced to change the manner in which we operate our business, which could have a material adverse impact on our financial position or results of operations.
Litigation, Government Subpoenas and Investigations
As previously disclosed, following removal of the action captioned State of West Virginia ex rel. Morrisey v. McKesson Corporation to the United States District Court for the Southern District of West Virginia, the court remanded the matter back to state court. On July 7, 2017, the Company again removed the matter to the United States District Court for the Southern District of West Virginia (Civil Action No. 2:16-cv-03555.)
Since May 24, 2017, the Company has been served with seven complaints filed in state courts in West Virginia alleging claims related to the distribution of controlled substances to pharmacies in West Virginia. These lawsuits are Mayor Reba Honaker, on behalf of the City of Welch v. West Virginia Board of Pharmacy, et al., Cabell County, West Virginia Circuit Court, Civil Action 17-C-18, removed to the United States District Court for the Southern District of West Virginia, Civil Action 1:17-cv-03364; County Commission of Lincoln County v. West Virginia Board of Pharmacy, et al., Lincoln County, West Virginia Circuit Court, Civil Action 17-C-46, removed to the United States District Court for the Southern District of West Virginia, Civil Action 2:17-cv-03366; Mayor Vivian Livinggood on behalf of the Town of Gilbert v. West Virginia Board of Pharmacy, et al., Mingo County, West Virginia Circuit Court, Civil Action 17-C-94, removed to the United States District Court for the Southern District of West Virginia, Civil Action 2:17-cv-03369; Mayor Charles Sparks on behalf of the Town of Kermit v. West Virginia Board of Pharmacy, et al., Mingo County, West Virginia Circuit Court, Civil Action 17-C-13, removed to the United States District Court for the Southern District of West Virginia, Civil Action 2:17-cv-03372; Mayor Robert Carlton on behalf of the City of Williamson v. West Virginia Board of Pharmacy, et al., Mingo County, West Virginia Circuit Court, Civil Action 17-C-99, removed to the United States District Court for the Southern District of West Virginia, Civil Action 2:17-cv-03532; The County Commission of Mercer County v. West Virginia Board of Pharmacy, et al., Mercer County, West Virginia Circuit Court, Civil Action 17-C-236; and Mayor Raaimie Barker on behalf of the Town of Chapmanville v. West Virginia Board of Pharmacy, et al., Logan County, West Virginia Circuit Court, Civil Action 17-C-168. The Company has filed motions to dismiss in all cases in which responses were due.
In response to the previously disclosed case captioned Cherokee Nation v. McKesson Corporation, et al., on June 8, 2017, the Company and the other defendants in this action filed suit in the United States District Court for the Northern District of Oklahoma, McKesson Corporation, et al. v. Todd Hembree, Attorney General of the Cherokee Nation, et al., No. 4:17-cv-00323, seeking a declaratory judgment that the Cherokee Nation District Court has no jurisdiction over the claims asserted by the Cherokee Nation. On that same day, the Company and the other plaintiffs in the federal action filed a motion for a preliminary injunction enjoining the defendants from taking any action in the case pending in the tribal court.
On May 25, 2017, a lawsuit was filed in Stockton County, California Superior Court against various pharmaceutical manufacturers and the Company by the County of San Joaquin, City of Stockton and Montezuma Fire Protection District. City of Stockton, et al. v. Purdue Pharma LP, et al., Case No. STK-CV-UBT-2017-5325.The suit seeks damages for the funds spent by plaintiffs on municipal services due to alleged excessive sales of opioids. The causes of action against the Company are unjust enrichment and parens patriaie claims. On July 17, 2017, this case was removed to the United States District Court for the Eastern District of California (Case No. 2:17-at-00719.)
Two municipalities in Ohio, the City of Dayton and the City of Lorain, have individually filed suit against various pharmaceutical manufacturers and three wholesalers, including the Company, as well as four individual physicians. City of Dayton v. Purdue Pharma LP, et al., Montgomery County, Ohio Court of Common Pleas, No. 2017 CV 02647, filed on June 5, 2017; and City of Lorain v. Purdue Pharma LP, et al., Lorain County, Ohio Court of Common Pleas, No. 17 CV 192705, filed on June 29, 2017. In each case, the plaintiff claims that all of the defendants engaged in unfair and deceptive acts or practices involving the marketing and sales of opioids, and created a public nuisance. Each plaintiff also contends that the distributor defendants failed to take any action to prevent or reduce the distribution of opioids. The suits contain causes of action for violation of the Ohio Consumer Sales Practices Act; deceptive trade practices; public nuisance; fraud, unjust enrichment; and negligence. On July 7, 2017, the City of Dayton case was removed to the United States District Court for the Southern District of Ohio (Case No. 3:17-cv-229).
On June 12, 2017, the County of Nassau, New York filed suit against various pharmaceutical manufacturers and three wholesalers, including the Company, as well as four individual physicians. The County of Nassau v. Purdue Pharma LP, et al., Supreme Court of the State of New York, County of Nassau, Index No. 605477/2017. The plaintiff claims that all of the defendants engaged in unfair and deceptive acts or practices involving the marketing and sales of opioids, and created a public nuisance. Each plaintiff also contends that the distributor defendants failed to take any action to prevent or reduce the distribution of opioids. The suit contains causes of action for deceptive acts and practices under New York General Business Law § 349; false advertising under New York General Business Law § 350; public nuisance; violation of New York Social Services Law § 145-B; fraud, unjust enrichment; and negligence.
On May 19, 2017, the plaintiff in the previously disclosed case captioned Silverman v. McKesson Corporation, filed a voluntary withdrawal of this action.
From time to time, the Company receives subpoenas or requests for information from various government agencies. The Company generally responds to such subpoenas and requests in a cooperative, thorough and timely manner. These responses sometimes require time and effort and can result in considerable costs being incurred by the Company. For example, the Company has received a request for information from the U.S. Attorney’s Office for the Eastern District of Pennsylvania relating to the use of a Company pharmacy management software system to process partially-filled prescriptions. The Company is currently responding to this request. Such subpoenas and requests also can lead to the assertion of claims or the commencement of civil or criminal legal proceedings against the Company and other members of the health care industry, as well as to settlements.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stockholders' Equity
3 Months Ended
Jun. 30, 2017
Equity [Abstract]  
Stockholders' Equity
Stockholders’ Equity
Each share of the Company’s outstanding common stock is permitted one vote on proposals presented to stockholders and is entitled to share equally in any dividends declared by the Company’s Board of Directors (the “Board”).
The Company currently pays quarterly cash dividend of $0.28 per common share. On July 26, 2017, the Company’s quarterly dividend was raised from $0.28 to $0.34 per common share for dividends declared on or after such date by the Board. The Company anticipates that it will continue to pay quarterly cash dividends in the future.  However, the payment and amount of future dividends remain within the discretion of the Board and will depend upon the Company's future earnings, financial condition, capital requirements and other factors.
Share Repurchase Plans

Stock repurchases may be made from time-to-time in open market transactions, privately negotiated transactions, through accelerated share repurchase (“ASR”) programs, or by any combination of such methods. The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including our stock price, corporate and regulatory requirements, restrictions under our debt obligations and other market and economic conditions.
In March 2017, we entered into an ASR program with a third-party financial institution to repurchase $250 million of the Company’s common stock. We received 1.4 million shares in March 2017 and 0.3 million additional shares in April 2017. In June 2017, we also entered into another ASR program with a third-party financial institution to repurchase $250 million of the Company’s common stock. During the first quarter of 2018, we received 1.2 million shares as the initial share settlement under this 2018 ASR program and may receive additional shares at the termination of the ASR. The total authorization outstanding for repurchases of the Company’s common stock was $2.5 billion at June 30, 2017.
Other Comprehensive Income (Loss)
Information regarding other comprehensive income (loss) including redeemable noncontrolling interests, net of tax, by component is as follows:
 
Quarter Ended June 30,
 (In millions)
2017
 
2016
Foreign currency translation adjustments (1)
 
 
 
Foreign currency translation adjustments arising during period, net of income tax benefit of nil and $12 (2) (3)
$
382

 
$
(275
)
Reclassified to income statement, net of income tax expense of nil and nil (4)

 
20

 
382

 
(255
)
Unrealized gains (losses) on net investment hedges (5)
 
 
 
Unrealized gains (losses) on net investment hedges arising during period, net of income tax benefit of $44 and nil
(70
)
 

Reclassified to income statement, net of income tax expense of nil and nil

 

 
(70
)
 

Unrealized gains on cash flow hedges
 
 
 
Unrealized gains on cash flow hedges arising during period, net of income tax expense of nil and nil
14

 

 
 
 
 
Changes in retirement-related benefit plans (6)
 
 
 
Net actuarial loss and prior service cost arising during the period, net of income tax benefit of nil and nil

 

Amortization of actuarial loss and prior service costs, net of income tax expense of nil and $1 (7)
1

 
3

Foreign currency translation adjustments and other, net of income tax expense of nil and nil
(6
)
 
8

 
(5
)
 
11

 
 
 
 
Other comprehensive income (loss), net of tax
$
321

 
$
(244
)
(1)
Foreign currency translation adjustments primarily result from the conversion of non-U.S. dollar financial statements of our foreign subsidiary, Celesio, into the Company’s reporting currency, U.S. dollars, during the first quarters of 2018 and 2017.
(2)
The net foreign currency translation gains during the first quarter of 2018 were primarily due to the strengthening of the Euro and British pound sterling against the U.S. dollar from April 1, 2017 to June 30, 2017. During the first quarter of 2017, the currency translation losses were primarily due to the weakening of the Euro and British pound sterling against the U.S. dollar from April 1, 2016 to June 30, 2016.
(3)
The first quarter of 2018 includes net foreign currency translation gains of $115 million and the first quarter of 2017 includes net foreign currency translation losses of $67 million attributable to redeemable noncontrolling interests.
(4)
The first quarter of 2017 includes net foreign currency translation losses of $20 million reclassified from accumulated other comprehensive income (loss) to loss from discontinued operations, net of tax, within our condensed consolidated statements of operations due to the sale of our Brazilian pharmaceutical distribution business.
(5)
The first quarter of 2018 includes foreign currency losses of $114 million on the net investment hedges from the €1.2 billion Euro-denominated notes and £450 million British pound sterling-denominated notes.
(6)
The first quarters of 2018 and 2017 include net actuarial losses of $1 million attributable to redeemable noncontrolling interests.
(7)
Pre-tax amount reclassified into cost of sales and operating expenses in our condensed consolidated statements of operations. The related tax expense was reclassified into income tax expense in our condensed consolidated statements of operations.
Accumulated Other Comprehensive Income (Loss)
Information regarding changes in our accumulated other comprehensive income (loss), net of tax, by component for the first quarter of 2018 is as follows:
(In millions)
Foreign Currency Translation Adjustments, Net of Tax
 
Unrealized Losses on Net Investment Hedges,
Net of Tax
 
Unrealized Gains (Losses) on Cash Flow Hedges,
Net of Tax
 
Unrealized Net Gains (Losses) and Other Components of Benefit Plans, Net of Tax
 
Total Accumulated Other Comprehensive Income (Loss)
Balance at March 31, 2017
$
(1,873
)
 
$
(8
)
 
$
(31
)
 
$
(229
)
 
$
(2,141
)
 
 
 
 
 
 
 
 
 
 
Other comprehensive income (loss) before reclassifications
382

 
(70
)
 
14

 
(6
)
 
320

Amounts reclassified to earnings and other

 

 

 
1

 
1

Other comprehensive income (loss)
382

 
(70
)
 
14

 
(5
)
 
321

Less: amounts attributable to noncontrolling and redeemable noncontrolling interests
115

 

 

 
1

 
116

Other comprehensive income (loss) attributable to McKesson
267

 
(70
)
 
14

 
(6
)
 
205

Balance at June 30, 2017
$
(1,606
)
 
$
(78
)
 
$
(17
)
 
$
(235
)
 
$
(1,936
)
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.7.0.1
Segment Information
3 Months Ended
Jun. 30, 2017
Segment Reporting [Abstract]  
Segment Information
Segment Information
We report our operations in two operating segments: McKesson Distribution Solutions and McKesson Technology Solutions. The factors for determining the reportable segments included the manner in which management evaluates the performance of the Company combined with the nature of the individual business activities. We evaluate the performance of our operating segments on a number of measures, including operating profit before interest expense, income taxes and results from discontinued operations.
Financial information relating to our reportable operating segments and reconciliations to the condensed consolidated totals is as follows:
 
Quarter Ended June 30,
(In millions)
2017
 
2016
Revenues
 
 
 
Distribution Solutions (1)
 
 
 
North America pharmaceutical distribution and services
$
43,016

 
$
41,211

International pharmaceutical distribution and services
6,382

 
6,330

Medical-Surgical distribution and services
1,533

 
1,468

Total Distribution Solutions
50,931

 
49,009

 
 
 
 
Technology Solutions - products and services (2) 
120

 
724

Total Revenues
$
51,051

 
$
49,733

 
 
 
 
Operating profit
 
 
 
Distribution Solutions (3)
$
713

 
$
928

Technology Solutions (4)
(78
)
 
168

Total
635

 
1,096

Corporate Expenses, Net
(109
)
 
(105
)
Interest Expense
(68
)
 
(79
)
Income from Continuing Operations Before Income Taxes
$
458

 
$
912

(1)
Revenues derived from services represent less than 2% of this segment’s total revenues.
(2)
2018 revenues for the Technology Solutions segment include the results of our EIS business. Effective April 1, 2017, our RHP business was transitioned from the Technology Solutions segment to the Distribution Solutions segment. The first quarter of 2017 included the majority of our Core MTS Business which was contributed to Change Healthcare on March 1, 2017.
(3)
Distribution Solutions operating profit for the first quarters of 2018 and 2017 include $26 million and $47 million in pre-tax charges related to our last-in, first-out (“LIFO”) method of accounting for inventories. LIFO expense was less in 2018 primarily due to the lower full year expectations for net price increases compared to the same period a year ago. Additionally, the first quarter of 2017 includes $142 million of net cash proceeds representing our share of net settlements of antitrust class action lawsuits against drug manufacturers.
(4)
Operating profit for our Technology Solutions segment for the first quarter of 2018 includes our EIS business, our proportionate share of loss from Change Healthcare of $120 million and a pre-tax gain of $37 million from the Healthcare Technology Net Asset Exchange related to the final net working capital and other adjustments.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.7.0.1
Significant Accounting Policies (Policies)
3 Months Ended
Jun. 30, 2017
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation: The condensed consolidated financial statements of McKesson Corporation (“McKesson,” the “Company,” or “we” and other similar pronouns) include the financial statements of all wholly-owned subsidiaries and majority‑owned or controlled companies. For those consolidated subsidiaries where our ownership is less than 100%, the portion of the net income or loss allocable to the noncontrolling interests is reported as “Net Income Attributable to Noncontrolling Interests” on the condensed consolidated statements of operations. All significant intercompany balances and transactions have been eliminated in consolidation including the intercompany portion of transactions with equity method investees.
We consider ourselves to control an entity if we are the majority owner of and have voting control over such entity. We also assess control through means other than voting rights (“variable interest entities” or “VIEs”) and determine which business entity is the primary beneficiary of the VIE. We consolidate VIEs when it is determined that we are the primary beneficiary of the VIE. Investments in business entities in which we do not have control, but have the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method. Refer to Financial Note 2, “Healthcare Technology Net Asset Exchange” for further information on our equity method investment in Change Healthcare, LLC.
The condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) and, therefore, do not include all information and disclosures normally included in the annual consolidated financial statements.
Use of Estimates
To prepare the financial statements in conformity with GAAP, management must make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of these financial statements and income and expenses during the reporting period. Actual amounts may differ from these estimated amounts. In our opinion, the accompanying unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair presentation of our financial position, results of operations and cash flows for the interim periods presented.
The results of operations for the quarter ended June 30, 2017 are not necessarily indicative of the results that may be expected for the entire year. These interim financial statements should be read in conjunction with the annual audited financial statements, accounting policies and financial notes included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2017 previously filed with the SEC on May 22, 2017 (“2017 Annual Report”).
Fiscal Period
The Company’s fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year shall mean the Company’s fiscal year.
Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Adopted
Recently Adopted Accounting Pronouncements
Investments: In the first quarter of 2018, we adopted amended guidance for the equity method of accounting. The amended guidance simplifies the transition to the equity method of accounting. This standard eliminates the requirement that when an existing cost method investment qualifies for use of the equity method, an investor must restate its historical financial statements, as if the equity method had been used during all previous periods. Additionally, at the point an investment qualifies for the equity method, any unrealized gain or loss in accumulated other comprehensive income (loss) will be recognized through earnings. The adoption of this amended guidance did not have a material effect on our condensed consolidated financial statements.
Derivatives and Hedging: In the first quarter of 2018, we adopted amended guidance for derivative instrument novations. The amendments clarify that a novation, a change in the counterparty, to a derivative instrument that has been designated as a hedging instrument does not, in and of itself, require dedesignation of that hedging relationship provided all other hedge accounting criteria continue to be met. The adoption of this amended guidance did not have an effect on our condensed consolidated financial statements.
Consolidation: In the first quarter of 2018, we adopted amended guidance for VIEs. The amended guidance requires a single decision maker of a VIE to consider indirect economic interests in the entity held through related parties that are under common control on a proportionate basis when determining whether it is the primary beneficiary of that VIE.  This amendment does not change the existing characteristics of a primary beneficiary. The adoption of this amended guidance did not have a material effect on our condensed consolidated financial statements.
Inventory: In the first quarter of 2018, we adopted amended guidance for the subsequent measurement of inventory. The amended guidance requires entities to measure inventory at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The requirement would replace the current lower of cost or market evaluation. Accounting guidance is unchanged for inventory measured using last-in, first-out (“LIFO”) or the retail method. The adoption of this amended guidance did not have a material effect on our condensed consolidated financial statements.
Recently Issued Accounting Pronouncements Not Yet Adopted
Share-Based Payments: In May 2017, amended guidance was issued for employee share-based payment awards. This amendment provides guidance on which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. Under the amended guidance, we are required to account for the effects of a modification if the fair value, the vesting conditions or the classification (as an equity instrument or a liability instrument) of the modified award change from that of the original award immediately before the modification. The amended guidance is effective for us on a prospective basis commencing in the first quarter of 2019.  Early adoption is permitted.  We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.
Premium Amortization of Purchased Callable Debt Securities: In March 2017, amended guidance was issued to shorten the amortization period for certain callable debt securities held at a premium.  The amended guidance requires the premium of callable debt securities to be amortized to the earliest call date but does not require an accounting change for securities held at a discount as they would still be amortized to maturity.  The amended guidance is effective for us on a modified retrospective basis commencing in the first quarter of 2020.  Early adoption is permitted.  We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.
Compensation - Retirement Benefits: In March 2017, amended guidance was issued which requires us to report the service cost component of defined benefit pension plans and other postretirement plans in the same line item as other compensation costs arising from services rendered by the pertinent employees during the period. Other components of net benefit cost are required to be presented in the statements of operations separately from the service cost component. This amended guidance is effective for us in the first quarter of 2019 on a retrospective basis. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.
Derecognition of Nonfinancial Assets: In February 2017, amended guidance was issued that defines the term “in substance nonfinancial asset” as a financial asset promised to a counterparty in a contract if substantially all of the fair value of the asset that is promised is concentrated in nonfinancial assets. The scope of this amendment includes nonfinancial assets transferred within a legal entity including a parent entity’s transfer of nonfinancial assets by transferring ownership interests in consolidated subsidiaries. The amendment excludes all businesses and nonprofit activities from its scope and therefore all entities, with limited exceptions, are required to account for the derecognition of a business or nonprofit activity in accordance with the consolidation guidance once this amended guidance becomes effective. We are required to apply this amended guidance at the same time we apply the amended revenue guidance in the first quarter of 2019. It allows for either full retrospective adoption or modified retrospective adoption.  Early adoption is permitted.  We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.
Goodwill Impairment Testing: In January 2017, amended guidance was issued to simplify goodwill impairment testing by eliminating the second step of the impairment test. Under the second step, the implied fair value of goodwill is calculated in a hypothetical analysis by subtracting the fair value of all assets and liabilities of the reporting unit, including any unrecognized intangible assets, from the fair value of the reporting unit calculated in the first step of the impairment test. If the carrying value of goodwill for the reporting unit exceeds the implied fair value of goodwill, an impairment charge is recorded for that excess. The amended guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, if any. The amended guidance is effective for us on a prospective basis commencing in the first quarter of 2021. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.
Business Combinations: In January 2017, amended guidance was issued to clarify the definition of a business to assist entities in evaluating whether transactions should be accounted for as acquisitions of assets or businesses. The amended guidance provides a practical screen to determine when an integrated set of assets and activities (collectively referred to as a “set”) is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. If the screen is not met, the amended guidance requires that to be considered a business, a set must include an input and a substantive process that together significantly contribute to the ability to create output. The amended guidance is effective for us commencing in the first quarter of 2019 on a prospective basis. Early adoption is permitted in certain circumstances.  We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.
Restricted Cash: In November 2016, amended guidance was issued that requires restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total cash amounts shown on the statement of cash flows. Transfers between cash and cash equivalents and restricted cash or restricted cash equivalents are not reported as cash flow activities in the statement of cash flows.  The amended guidance is effective for us commencing in the first quarter of 2019 on a retrospective basis. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.
Income Taxes - Intra-Entity Transfers of Assets Other Than Inventory: In October 2016, amended guidance was issued to require entities to recognize income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The amended guidance is effective for us commencing in the first quarter of 2019 on a modified retrospective basis. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.
Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments: In August 2016, amended guidance was issued to provide clarification on cash flow classification related to eight specific issues including contingent consideration payments made after a business combination and distributions received from equity method investees.  The amended guidance is effective for us commencing in the first quarter of 2019 on a retrospective basis. Early adoption is permitted. We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.
Financial Instruments - Credit Losses: In June 2016, amended guidance was issued, which will change the impairment model for most financial assets and require additional disclosures. The amended guidance requires financial assets that are measured at amortized cost, be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of financial assets. The amended guidance also requires us to consider historical experience, current conditions, and reasonable and supportable forecasts that affect the collectibility of the reported amount in estimating credit losses. The amended guidance becomes effective for us commencing in the first quarter of 2021 and will be applied through a cumulative-effect adjustment to the beginning retained earnings in the year of adoption. Early adoption is permitted.  We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.
Leases: In February 2016, amended guidance was issued for lease arrangements. The amended standard will require lessees to recognize assets and liabilities on the balance sheet for all leases with terms longer than 12 months and provide enhanced disclosures on key information of leasing arrangements.  The amended guidance is effective for us commencing in the first quarter of 2020, on a modified retrospective basis.  Early adoption is permitted.  We plan to adopt the new standard on the effective date and are currently evaluating the impact of this amended guidance on our consolidated financial statements. We anticipate that the adoption of the amended lease guidance will materially affect our condensed consolidated balance sheet and will require certain changes to our systems and processes.
Financial Instruments: In January 2016, amended guidance was issued that requires equity investments to be measured at fair value with changes in fair value recognized in net income and enhanced disclosures about those investments. This guidance also simplifies the impairment assessments of equity investments without readily determinable fair value. The investments that are accounted for under the equity method of accounting or result in consolidation of the investee are excluded from the scope of this amended guidance. The amended guidance will become effective for us commencing in the first quarter of 2019 and will be adopted through a cumulative-effect adjustment. Early adoption is not permitted except for certain provisions.  We are currently evaluating the impact of this amended guidance on our condensed consolidated financial statements.
Revenue Recognition: In May 2014, amended guidance was issued for recognizing revenue from contracts with customers.  The amended guidance eliminates industry specific guidance and applies to all companies.  Revenues will be recognized when an entity satisfies a performance obligation by transferring control of a promised good or service to a customer in an amount that reflects the consideration to which the entity expects to be entitled for that good or service.  Revenue from a contract that contains multiple performance obligations is allocated to each performance obligation generally on a relative standalone selling price basis.  The amended guidance also requires additional quantitative and qualitative disclosures.  In March, April and May 2016, amended guidance was further issued including clarifying guidance on principal versus agent considerations, ability to choose an accounting policy election to account for shipping and handling activities that occur after the customer has obtained control of a good as an activity to fulfill the promise to transfer the good, and provided certain scope improvements and practical expedients.  The amended standard is effective for us commencing in the first quarter of 2019 and allows for either full retrospective adoption or modified retrospective adoption.  Early adoption is permitted.
While we continue to evaluate the effect of the amended standard, we have conducted a preliminary assessment for our Distribution Solutions segment and do not expect adoption of the amended standard to have a material impact on our consolidated financial statements.  The majority of our Distribution Solutions segment’s revenue is generated from sales of pharmaceutical products, which will continue to be recognized when control of the goods is transferred to the customer. We generally anticipate having substantially similar performance obligations under the amended guidance as compared with deliverables and units of account currently being recognized. We intend to make policy elections within the amended standard that are consistent with our current accounting. Our preliminary assessment does not include certain businesses for which we are exploring strategic alternatives and we continue to evaluate the potential impact of the recent acquisitions. This preliminary assessment is subject to change prior to adoption. Additionally, we anticipate adopting this amended standard on a modified retrospective basis in our first quarter of 2019.
Commitments and Contingencies
When a loss is considered probable and reasonably estimable, we record a liability in the amount of our best estimate for the ultimate loss. However, the likelihood of a loss with respect to a particular contingency is often difficult to predict and determining a meaningful estimate of the loss or a range of loss may not be practicable based on the information available and the potential effect of future events and decisions by third parties that will determine the ultimate resolution of the contingency. Moreover, it is not uncommon for such matters to be resolved over many years, during which time relevant developments and new information must be reevaluated at least quarterly to determine both the likelihood of potential loss and whether it is possible to reasonably estimate a range of possible loss. When a loss is probable but a reasonable estimate cannot be made, disclosure of the proceeding is provided.
Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. We review all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or range of loss can be made. As discussed above, development of a meaningful estimate of loss or a range of potential loss is complex when the outcome is directly dependent on negotiations with or decisions by third parties, such as regulatory agencies, the court system and other interested parties. Such factors bear directly on whether it is possible to reasonably estimate a range of potential loss and boundaries of high and low estimates.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.7.0.1
Healthcare Technology Net Asset Exchange (Tables)
3 Months Ended
Jun. 30, 2017
Equity Method Investments and Joint Ventures [Abstract]  
Schedule of Summarized Equity Method Investment Financial Informations
ummarized financial information (unaudited) of Change Healthcare is as follows:
(In millions)
Quarter Ended June 30, 2017
Revenues
$
865

Loss from Continuing Operations
(84
)
Net Loss
(84
)
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.7.0.1
Redeemable Noncontrolling Interests and Noncontrolling Interests (Tables)
3 Months Ended
Jun. 30, 2016
Noncontrolling Interest [Abstract]  
Changes in Redeemable Noncontrolling Interests and Noncontrolling Interests
Changes in redeemable noncontrolling interests and noncontrolling interests for the first quarter of 2018 were as follows:
(In millions)
Noncontrolling Interests
Redeemable
Noncontrolling
Interests
Balance, March 31, 2017
$
178

$
1,327

Net income attributable to noncontrolling interests
47

9

Other comprehensive income

116

Reclassification of recurring compensation to other accrued liabilities

(9
)
Payments to noncontrolling interests
(18
)

Exercises of Put Right

(53
)
Other
3


Balance, June 30, 2017
$
210

$
1,390


Changes in redeemable noncontrolling interests and noncontrolling interests for the first quarter of 2017 were as follows:
(In millions)
Noncontrolling Interests
Redeemable
Noncontrolling
Interests
Balance, March 31, 2016
$
84

$
1,406

Net income attributable to noncontrolling interests
7

11

Other comprehensive loss

(66
)
Reclassification of recurring compensation to other accrued liabilities

(11
)
Purchase of noncontrolling interests
152


Other
(1
)

Balance, June 30, 2016
$
242

$
1,340

XML 37 R26.htm IDEA: XBRL DOCUMENT v3.7.0.1
Earnings Per Common Share (Tables)
3 Months Ended
Jun. 30, 2017
Earnings Per Share [Abstract]  
Schedule of computations for basic and diluted earnings per common share
The computations for basic and diluted earnings per common share are as follows:
  
Quarter Ended June 30,
(In millions, except per share amounts)
2017
 
2016
Income from continuing operations
$
363

 
$
673

Net income attributable to noncontrolling interests
(56
)
 
(18
)
Income from continuing operations attributable to McKesson
307

 
655

Income (loss) from discontinued operations, net of tax
2

 
(113
)
Net income attributable to McKesson
$
309

 
$
542

 
 
 
 
Weighted average common shares outstanding:
 
 
 
Basic
211

 
225

Effect of dilutive securities:
 
 
 
Options to purchase common stock
1

 
1

Restricted stock units
1

 
2

Diluted
213

 
228

 
 
 
 
Earnings (loss) per common share attributable to McKesson: (1)
 
 
 
Diluted
 
 
 
Continuing operations
$
1.44

 
$
2.88

Discontinued operations
0.01

 
(0.50
)
Total
$
1.45

 
$
2.38

Basic
 
 
 
Continuing operations
$
1.46

 
$
2.91

Discontinued operations

 
(0.50
)
Total
$
1.46

 
$
2.41


(1)
Certain computations may reflect rounding adjustments.
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.7.0.1
Goodwill and Intangible Assets, Net (Tables)
3 Months Ended
Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of changes in the carrying amount of goodwill
Changes in the carrying amount of goodwill were as follows:
(In millions)
Distribution
Solutions
 
Technology
Solutions
 
Total
Balance, March 31, 2017
$
10,132

 
$
454

 
$
10,586

Goodwill acquired
940

 

 
940

Acquisition accounting, transfers and other adjustments (1)
324

 
(330
)
 
(6
)
Foreign currency translation adjustments, net
230

 

 
230

Balance, June 30, 2017
$
11,626

 
$
124

 
$
11,750


(1)
Effective April 1, 2017, our RHP business was transitioned from the Technology Solutions segment to the Distribution Solutions segment.
Schedule of information regarding intangible assets
Information regarding intangible assets is as follows:
 
June 30, 2017
 
March 31, 2017
(Dollars in millions)
Weighted
Average
Remaining
Amortization
Period
(years)
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Carrying
Amount
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships
12
 
$
3,411

 
$
(1,392
)
 
$
2,019

 
$
2,893

 
$
(1,295
)
 
$
1,598

Service agreements
13
 
1,023

 
(332
)
 
691

 
1,009

 
(316
)
 
693

Pharmacy licenses
25
 
772

 
(164
)
 
608

 
741

 
(150
)
 
591

Trademarks and trade names
15
 
870

 
(136
)
 
734

 
845

 
(124
)
 
721

Technology
5
 
151

 
(71
)
 
80

 
69

 
(64
)
 
5

Other
5
 
261

 
(155
)
 
106

 
201

 
(144
)
 
57

Total
 
 
$
6,488


$
(2,250
)
 
$
4,238

 
$
5,758

 
$
(2,093
)
 
$
3,665

XML 39 R28.htm IDEA: XBRL DOCUMENT v3.7.0.1
Hedging Activities (Tables)
3 Months Ended
Jun. 30, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of information regarding the fair value of derivatives on a gross basis
Information regarding the fair value of derivatives on a gross basis is as follows:
 
Balance Sheet
Caption
June 30, 2017
 
March 31, 2017
 
Fair Value of
Derivative
U.S. Dollar Notional
 
Fair Value of
Derivative
U.S. Dollar Notional
(In millions)
Asset
Liability
 
Asset
Liability
Derivatives designated for hedge accounting
 
 
 
 
 
 
 
 
Foreign exchange contracts (current)
Prepaid expenses and other
$
16

$

$
81

 
$
17

$

$
81

Foreign exchange contracts (non-current)
Other Noncurrent Assets
30


162

 
32


162

Cross currency swaps (current)
Prepaid expenses and other
11


174

 
17


174

Cross currency swaps (non-current)
Other Noncurrent Assets/Liabilities

26

3,049

 
90


2,489

Total
 
$
57

$
26

 
 
$
156

$

 
Derivatives not designated for hedge accounting
 
 
 
 
 
 
 
 
Foreign exchange contracts (current)
Prepaid expenses and other
$
1

$

$
139

 
$
1

$

$
198

Foreign exchange contracts (current)
Other accrued liabilities

4

205

 


37

Total
 
$
1

$
4

 
 
$
1

$

 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stockholders' Equity (Tables)
3 Months Ended
Jun. 30, 2017
Equity [Abstract]  
Schedule of information regarding other comprehensive income (loss) including noncontrolling and redeemable noncontrolling interests, net of tax, by component
Information regarding other comprehensive income (loss) including redeemable noncontrolling interests, net of tax, by component is as follows:
 
Quarter Ended June 30,
 (In millions)
2017
 
2016
Foreign currency translation adjustments (1)
 
 
 
Foreign currency translation adjustments arising during period, net of income tax benefit of nil and $12 (2) (3)
$
382

 
$
(275
)
Reclassified to income statement, net of income tax expense of nil and nil (4)

 
20

 
382

 
(255
)
Unrealized gains (losses) on net investment hedges (5)
 
 
 
Unrealized gains (losses) on net investment hedges arising during period, net of income tax benefit of $44 and nil
(70
)
 

Reclassified to income statement, net of income tax expense of nil and nil

 

 
(70
)
 

Unrealized gains on cash flow hedges
 
 
 
Unrealized gains on cash flow hedges arising during period, net of income tax expense of nil and nil
14

 

 
 
 
 
Changes in retirement-related benefit plans (6)
 
 
 
Net actuarial loss and prior service cost arising during the period, net of income tax benefit of nil and nil

 

Amortization of actuarial loss and prior service costs, net of income tax expense of nil and $1 (7)
1

 
3

Foreign currency translation adjustments and other, net of income tax expense of nil and nil
(6
)
 
8

 
(5
)
 
11

 
 
 
 
Other comprehensive income (loss), net of tax
$
321

 
$
(244
)
(1)
Foreign currency translation adjustments primarily result from the conversion of non-U.S. dollar financial statements of our foreign subsidiary, Celesio, into the Company’s reporting currency, U.S. dollars, during the first quarters of 2018 and 2017.
(2)
The net foreign currency translation gains during the first quarter of 2018 were primarily due to the strengthening of the Euro and British pound sterling against the U.S. dollar from April 1, 2017 to June 30, 2017. During the first quarter of 2017, the currency translation losses were primarily due to the weakening of the Euro and British pound sterling against the U.S. dollar from April 1, 2016 to June 30, 2016.
(3)
The first quarter of 2018 includes net foreign currency translation gains of $115 million and the first quarter of 2017 includes net foreign currency translation losses of $67 million attributable to redeemable noncontrolling interests.
(4)
The first quarter of 2017 includes net foreign currency translation losses of $20 million reclassified from accumulated other comprehensive income (loss) to loss from discontinued operations, net of tax, within our condensed consolidated statements of operations due to the sale of our Brazilian pharmaceutical distribution business.
(5)
The first quarter of 2018 includes foreign currency losses of $114 million on the net investment hedges from the €1.2 billion Euro-denominated notes and £450 million British pound sterling-denominated notes.
(6)
The first quarters of 2018 and 2017 include net actuarial losses of $1 million attributable to redeemable noncontrolling interests.
(7)
Pre-tax amount reclassified into cost of sales and operating expenses in our condensed consolidated statements of operations. The related tax expense was reclassified into income tax expense in our condensed consolidated statements of operations.
Schedule of information regarding changes in accumulated other comprehensive income (loss), net of tax, by component
Information regarding changes in our accumulated other comprehensive income (loss), net of tax, by component for the first quarter of 2018 is as follows:
(In millions)
Foreign Currency Translation Adjustments, Net of Tax
 
Unrealized Losses on Net Investment Hedges,
Net of Tax
 
Unrealized Gains (Losses) on Cash Flow Hedges,
Net of Tax
 
Unrealized Net Gains (Losses) and Other Components of Benefit Plans, Net of Tax
 
Total Accumulated Other Comprehensive Income (Loss)
Balance at March 31, 2017
$
(1,873
)
 
$
(8
)
 
$
(31
)
 
$
(229
)
 
$
(2,141
)
 
 
 
 
 
 
 
 
 
 
Other comprehensive income (loss) before reclassifications
382

 
(70
)
 
14

 
(6
)
 
320

Amounts reclassified to earnings and other

 

 

 
1

 
1

Other comprehensive income (loss)
382

 
(70
)
 
14

 
(5
)
 
321

Less: amounts attributable to noncontrolling and redeemable noncontrolling interests
115

 

 

 
1

 
116

Other comprehensive income (loss) attributable to McKesson
267

 
(70
)
 
14

 
(6
)
 
205

Balance at June 30, 2017
$
(1,606
)
 
$
(78
)
 
$
(17
)
 
$
(235
)
 
$
(1,936
)
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.7.0.1
Segment Information (Tables)
3 Months Ended
Jun. 30, 2017
Segment Reporting [Abstract]  
Schedule of financial information relating to reportable operating segments and reconciliations to the condensed consolidated totals
Financial information relating to our reportable operating segments and reconciliations to the condensed consolidated totals is as follows:
 
Quarter Ended June 30,
(In millions)
2017
 
2016
Revenues
 
 
 
Distribution Solutions (1)
 
 
 
North America pharmaceutical distribution and services
$
43,016

 
$
41,211

International pharmaceutical distribution and services
6,382

 
6,330

Medical-Surgical distribution and services
1,533

 
1,468

Total Distribution Solutions
50,931

 
49,009

 
 
 
 
Technology Solutions - products and services (2) 
120

 
724

Total Revenues
$
51,051

 
$
49,733

 
 
 
 
Operating profit
 
 
 
Distribution Solutions (3)
$
713

 
$
928

Technology Solutions (4)
(78
)
 
168

Total
635

 
1,096

Corporate Expenses, Net
(109
)
 
(105
)
Interest Expense
(68
)
 
(79
)
Income from Continuing Operations Before Income Taxes
$
458

 
$
912

(1)
Revenues derived from services represent less than 2% of this segment’s total revenues.
(2)
2018 revenues for the Technology Solutions segment include the results of our EIS business. Effective April 1, 2017, our RHP business was transitioned from the Technology Solutions segment to the Distribution Solutions segment. The first quarter of 2017 included the majority of our Core MTS Business which was contributed to Change Healthcare on March 1, 2017.
(3)
Distribution Solutions operating profit for the first quarters of 2018 and 2017 include $26 million and $47 million in pre-tax charges related to our last-in, first-out (“LIFO”) method of accounting for inventories. LIFO expense was less in 2018 primarily due to the lower full year expectations for net price increases compared to the same period a year ago. Additionally, the first quarter of 2017 includes $142 million of net cash proceeds representing our share of net settlements of antitrust class action lawsuits against drug manufacturers.
(4)
Operating profit for our Technology Solutions segment for the first quarter of 2018 includes our EIS business, our proportionate share of loss from Change Healthcare of $120 million and a pre-tax gain of $37 million from the Healthcare Technology Net Asset Exchange related to the final net working capital and other adjustments.
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.7.0.1
Healthcare Technology Net Asset Exchange (Details) - USD ($)
$ in Millions
3 Months Ended
Jun. 30, 2017
Mar. 31, 2017
Jun. 30, 2016
Mar. 01, 2017
Schedule of Equity Method Investments [Line Items]        
Gain on Healthcare Technology Net Asset Exchange $ 37   $ 0  
Net losses from Change Healthcare 120   $ 0  
Carrying value of investment 3,855 $ 4,063    
Tax Receivable Agreement (“TRA”) | Change Healthcare, LLC (“Change Healthcare”)        
Schedule of Equity Method Investments [Line Items]        
Noncurrent liability 136 136    
Joint Venture | Transition Services Agreements (“TSA”)        
Schedule of Equity Method Investments [Line Items]        
Reimbursements for transition services fees 37      
Change Healthcare, LLC (“Change Healthcare”)        
Schedule of Equity Method Investments [Line Items]        
Proportionate share of net loss reported by joint venture 59      
Change Healthcare, LLC (“Change Healthcare”) | Core MTS Businesses | Operating Segments | Technology Solutions        
Schedule of Equity Method Investments [Line Items]        
Gain on Healthcare Technology Net Asset Exchange 37 3,947    
Gain from sale of business, after tax 22 $ 3,018    
Change Healthcare, LLC (“Change Healthcare”) | Joint Venture        
Schedule of Equity Method Investments [Line Items]        
Expected ownership interest in the joint venture (percent)       70.00%
Receivable from Change Healthcare 126      
Net losses from Change Healthcare 120      
Carrying value of investment 3,855      
Excess of carrying value of investment over proportional share of book value 4,768      
Proportionate share of net loss reported by joint venture $ 84      
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.7.0.1
Healthcare Technology Net Asset Exchange - Summarized Financial Information (Details) - Change Healthcare, LLC (“Change Healthcare”)
$ in Millions
3 Months Ended
Jun. 30, 2017
USD ($)
Schedule of Equity Method Investments [Line Items]  
Net Loss $ (59)
Joint Venture  
Schedule of Equity Method Investments [Line Items]  
Revenues 865
Loss from Continuing Operations (84)
Net Loss $ (84)
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.7.0.1
Business Combinations (Details)
$ in Millions, CAD in Billions
3 Months Ended
Apr. 03, 2017
USD ($)
Dec. 28, 2016
USD ($)
pharmacy
Dec. 28, 2016
CAD
Jun. 30, 2017
USD ($)
Jun. 30, 2016
USD ($)
Mar. 31, 2018
USD ($)
Mar. 31, 2017
USD ($)
Business Acquisition [Line Items]              
Net purchase consideration       $ 1,485 $ 1,819    
Goodwill       11,750     $ 10,586
CoverMyMeds, LLC (CMM)              
Business Acquisition [Line Items]              
Net purchase consideration $ 1,300            
Assets acquired as of the acquisition date, excluding goodwill and intangibles 54            
Liabilities assumed as of the acquisition date 8            
Goodwill 854            
Acquired identifiable intangibles $ 502            
Rexall Health | CANADA              
Business Acquisition [Line Items]              
Net purchase consideration   $ 2,100 CAD 2.9        
Assets acquired as of the acquisition date, excluding goodwill and intangibles   674          
Liabilities assumed as of the acquisition date   212          
Goodwill   950          
Acquired identifiable intangibles   $ 872          
Number of retail pharmacies | pharmacy   470          
Measurement period adjustments to provisional fair value of intangibles       17      
Discontinued Operations, Held-for-sale or Disposed of by Sale              
Business Acquisition [Line Items]              
Assets of stores to be divested       $ 193      
Discontinued Operations, Held-for-sale or Disposed of by Sale | Rexall Health | CANADA              
Business Acquisition [Line Items]              
Number of retail pharmacies | pharmacy   27          
Additional amount, Up to | CoverMyMeds, LLC (CMM)              
Business Acquisition [Line Items]              
Contingent consideration           $ 200  
Customer relationships | CoverMyMeds, LLC (CMM)              
Business Acquisition [Line Items]              
Weighted average life of intangibles 17 years            
Customer relationships | Rexall Health | CANADA              
Business Acquisition [Line Items]              
Weighted average life of intangibles   19 years 19 years        
Trade Names | Rexall Health | CANADA              
Business Acquisition [Line Items]              
Weighted average life of intangibles   19 years 19 years        
Estimate of Fair Value | CoverMyMeds, LLC (CMM)              
Business Acquisition [Line Items]              
Contingent consideration $ 113            
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.7.0.1
Discontinued Operations - Narrative (Details) - Brazil Distribution [Member]
$ in Millions
3 Months Ended
Jun. 30, 2016
USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
After-tax charge recognized upon settlement of indemnification matters $ 113
Payment related to the sake of Brazilian pharmaceutical distribution business $ 100
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.7.0.1
Restructuring - Narrative (Details) - Cost Alignment Plan - USD ($)
$ in Millions
3 Months Ended 16 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Mar. 31, 2017
Restructuring Cost and Reserve [Line Items]        
Pre-tax restructuring charges incurred to-date     $ 246  
Pre-tax charges recorded during period   $ 9    
Other Accrued Liabilities        
Restructuring Cost and Reserve [Line Items]        
Restructuring liabilities $ 64   64 $ 71
Noncurrent Liabilities        
Restructuring Cost and Reserve [Line Items]        
Restructuring liabilities 35   35 $ 35
Severance        
Restructuring Cost and Reserve [Line Items]        
Payments for severance 14 $ 45    
Minimum        
Restructuring Cost and Reserve [Line Items]        
Expected total pre-tax charges 250   250  
Maximum        
Restructuring Cost and Reserve [Line Items]        
Expected total pre-tax charges $ 270   $ 270  
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.7.0.1
Income Taxes (Details) - USD ($)
$ in Millions
3 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Income Tax Disclosure [Abstract]    
Income tax expense related to continuing operations $ 95 $ 239
Net discrete tax expense (benefit) $ 3 (35)
Tax benefit recognized related to excess tax benefits arising from adoption of ASU 2016-09   $ 37
Income tax rate (as a percent) 20.70% 26.20%
Unrecognized tax benefits $ 516  
Unrecognized tax benefits that would reduce income tax expense and the effective tax rate 371  
Decrease in unrecognized tax benefits that could result from audit resolutions $ 60  
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.7.0.1
Redeemable Noncontrolling Interests and Noncontrolling Interests - Narrative (Details)
shares in Millions, $ in Millions
3 Months Ended 12 Months Ended
Jun. 30, 2017
USD ($)
shares
Jun. 30, 2016
USD ($)
Dec. 31, 2014
€ / shares
Jun. 30, 2017
€ / shares
Jun. 30, 2017
USD ($)
Mar. 31, 2017
USD ($)
Mar. 31, 2016
USD ($)
Noncontrolling Interest [Line Items]              
Put right redemption price per share (in euros per share) | € / shares       € 22.99      
Put right value, interest rate spread (as a percent)         5.00%    
Payments to acquire shares of Celesio $ 50            
Number of redeemable noncontrolling interest shares repurchased (shares) | shares 1.9            
Carrying value of redeemable noncontrolling interests         $ 1,390 $ 1,327  
Maximum redemption value of redeemable noncontrolling interest         $ 1,240 $ 1,210  
Ownership percentage (as a percent)         77.00% 76.00%  
Noncontrolling Interests         $ 210 $ 178  
Net income attributable to noncontrolling interests $ 56 $ 18          
Net income attributable to McKesson and transfers from noncontrolling interests 312            
Celesio              
Noncontrolling Interest [Line Items]              
Common Stock, Dividends, Per Share, Cash Paid | € / shares     € 0.83        
Net Income (Loss) Attributable to Redeemable Noncontrolling Interest 9 11          
Noncontrolling Interest              
Noncontrolling Interest [Line Items]              
Decrease in redeemable noncontrolling interests 0            
Noncontrolling Interests   242     210 178 $ 84
Net income attributable to noncontrolling interests 47 7          
Redeemable Noncontrolling Interest              
Noncontrolling Interest [Line Items]              
Decrease in redeemable noncontrolling interests 53            
Carrying value of redeemable noncontrolling interests   1,340     $ 1,390 $ 1,327 $ 1,406
Net Income (Loss) Attributable to Redeemable Noncontrolling Interest 9 $ 11          
Additional Paid-in Capital              
Noncontrolling Interest [Line Items]              
Effect of changes in ownership interests with noncontrollling interests $ 3            
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.7.0.1
Redeemable Noncontrolling Interests and Noncontrolling Interests - Schedule of Changes in Redeemable Noncontrolling Interests and Noncontrolling Interests (Details) - USD ($)
$ in Millions
3 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Noncontrolling Interest [Line Items]    
Beginning balance $ 178  
Net income attributable to noncontrolling interests 56 $ 18
Other comprehensive income (loss) 116  
Ending balance 210  
Redeemable Noncontrolling Interests    
Beginning balance 1,327  
Other comprehensive income (loss) 116  
Ending balance 1,390  
Noncontrolling Interest    
Noncontrolling Interest [Line Items]    
Beginning balance 178 84
Net income attributable to noncontrolling interests 47 7
Other comprehensive income (loss) 0 0
Payments to noncontrolling interests (18)  
Purchase of noncontrolling interests   152
Other 3 (1)
Ending balance 210 242
Redeemable Noncontrolling Interests    
Other comprehensive income (loss) 0 0
Payments to noncontrolling interests (18)  
Exercise of Put Right 0  
Purchase of noncontrolling interests   152
Other 3 (1)
Redeemable Noncontrolling Interest    
Noncontrolling Interest [Line Items]    
Other comprehensive income (loss) 116 (66)
Payments to noncontrolling interests 0  
Purchase of noncontrolling interests   0
Other 0 0
Redeemable Noncontrolling Interests    
Beginning balance 1,327 1,406
Net income attributable to noncontrolling interests 9 11
Other comprehensive income (loss) 116 (66)
Reclassification of recurring compensation to other accrued liabilities (9) (11)
Payments to noncontrolling interests 0  
Exercise of Put Right (53)  
Purchase of noncontrolling interests   0
Other 0 0
Ending balance $ 1,390 $ 1,340
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.7.0.1
Earnings Per Common Share - Schedule of Computation for Basic and Diluted Earnings per Common Share (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
3 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Earnings Per Share [Abstract]    
Income from continuing operations $ 363 $ 673
Net income attributable to noncontrolling interests (56) (18)
Income from continuing operations attributable to McKesson 307 655
Income (loss) from discontinued operations, net of tax 2 (113)
Net Income Attributable to McKesson Corporation $ 309 $ 542
Weighted average common shares outstanding:    
Basic (in shares) 211 225
Effect of dilutive securities:    
Options to purchase common stock (in shares) 1 1
Restricted stock units (in shares) 1 2
Diluted (in shares) 213 228
Diluted    
Continuing operations (in dollars per share) $ 1.44 $ 2.88
Discontinued operations (in dollars per share) 0.01 (0.50)
Total (in dollars per share) 1.45 2.38
Basic    
Continuing operations (in dollars per share) 1.46 2.91
Discontinued operations (in dollars per share) 0.00 (0.50)
Total (in dollars per share) $ 1.46 $ 2.41
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.7.0.1
Earnings Per Common Share - Narrative (Details) - shares
shares in Millions
3 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Earnings Per Share [Abstract]    
Potentially dilutive securities excluded from computations of diluted net earnings per common share (in shares) 2 2
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.7.0.1
Goodwill and Intangible Assets, Net - Schedule of Changes in the Carrying Amount of Goodwill and Narrative (Details) - USD ($)
$ in Millions
3 Months Ended
Jun. 30, 2017
Mar. 31, 2017
Goodwill [Roll Forward]    
Beginning balance $ 10,586  
Goodwill acquired 940  
Acquisition accounting, transfers and other adjustments (6)  
Foreign currency translation adjustments, net 230  
Ending balance 11,750  
Accumulated goodwill impairment losses 290 $ 290
Distribution Solutions    
Goodwill [Roll Forward]    
Beginning balance 10,132  
Goodwill acquired 940  
Acquisition accounting, transfers and other adjustments 324  
Foreign currency translation adjustments, net 230  
Ending balance 11,626  
Technology Solutions    
Goodwill [Roll Forward]    
Beginning balance 454  
Goodwill acquired 0  
Acquisition accounting, transfers and other adjustments (330)  
Foreign currency translation adjustments, net 0  
Ending balance $ 124  
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.7.0.1
Goodwill and Intangible Assets, Net - Schedule of Information Regarding Intangible Assets (Details) - USD ($)
$ in Millions
3 Months Ended
Jun. 30, 2017
Mar. 31, 2017
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount $ 6,488 $ 5,758
Accumulated Amortization (2,250) (2,093)
Net Carrying Amount $ 4,238 3,665
Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Weighted Average Remaining Amortization Period (years) 12 years  
Gross Carrying Amount $ 3,411 2,893
Accumulated Amortization (1,392) (1,295)
Net Carrying Amount $ 2,019 1,598
Service agreements    
Finite-Lived Intangible Assets [Line Items]    
Weighted Average Remaining Amortization Period (years) 13 years  
Gross Carrying Amount $ 1,023 1,009
Accumulated Amortization (332) (316)
Net Carrying Amount $ 691 693
Pharmacy licenses    
Finite-Lived Intangible Assets [Line Items]    
Weighted Average Remaining Amortization Period (years) 25 years  
Gross Carrying Amount $ 772 741
Accumulated Amortization (164) (150)
Net Carrying Amount $ 608 591
Trademarks and trade names    
Finite-Lived Intangible Assets [Line Items]    
Weighted Average Remaining Amortization Period (years) 15 years  
Gross Carrying Amount $ 870 845
Accumulated Amortization (136) (124)
Net Carrying Amount $ 734 721
Technology    
Finite-Lived Intangible Assets [Line Items]    
Weighted Average Remaining Amortization Period (years) 5 years  
Gross Carrying Amount $ 151 69
Accumulated Amortization (71) (64)
Net Carrying Amount $ 80 5
Other    
Finite-Lived Intangible Assets [Line Items]    
Weighted Average Remaining Amortization Period (years) 5 years  
Gross Carrying Amount $ 261 201
Accumulated Amortization (155) (144)
Net Carrying Amount $ 106 $ 57
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.7.0.1
Goodwill and Intangible Assets, Net - Narrative - Intangible Assets (Details) - USD ($)
$ in Millions
3 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Mar. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]      
Accumulated goodwill impairment losses $ 290   $ 290
Amortization expense of intangible assets 121 $ 115  
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]      
Estimated annual amortization expense, remainder of 2018 328    
Estimated annual amortization expense, 2019 420    
Estimated annual amortization expense, 2020 405    
Estimated annual amortization expense, 2021 393    
Estimated annual amortization expense, 2022 361    
Estimated annual amortization expense, thereafter $ 2,331    
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.7.0.1
Debt and Financing Activities - Long Term Debt (Details)
$ in Millions
3 Months Ended
Jun. 30, 2017
EUR (€)
Jun. 30, 2017
USD ($)
Mar. 31, 2017
USD ($)
Debt Instrument [Line Items]      
Long-term debt outstanding   $ 7,949 $ 8,362
Term Loan | Bonds      
Debt Instrument [Line Items]      
Repayment of term loan | € € 500,000,000    
Current Portion of Long-term Debt      
Debt Instrument [Line Items]      
Long-term debt outstanding   $ 525 $ 1,057
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.7.0.1
Debt and Financing Activities - Revolving Credit Facilities (Details)
3 Months Ended
Jun. 30, 2017
USD ($)
Revolving Credit Facility | Senior Unsecured Revolving Credit Facility (Global Facility)  
Line of Credit Facility [Line Items]  
Syndicated senior unsecured revolving credit facility $ 3,500,000,000.0
Syndicated senior unsecured revolving credit facility term 5 years
Credit facility, aggregate sublimit $ 3,150,000,000
Debt to capital covenant ratio (no greater than) 0.65
Amounts outstanding under facility $ 0
Line of Credit  
Line of Credit Facility [Line Items]  
Syndicated senior unsecured revolving credit facility $ 244,000,000
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.7.0.1
Debt and Financing Activities - Commercial Paper (Details) - Commercial Paper - USD ($)
Jun. 30, 2017
Mar. 31, 2017
Debt Instrument [Line Items]    
Outstanding notes (up to) $ 3,500,000,000.0  
Commercial paper $ 0 $ 183,000,000
Weighted average interest rate (percent)   1.20%
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.7.0.1
Pension Benefits - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]    
Net periodic pension expense $ 6 $ 6
Cash contributions to the plans $ 3 $ 4
Percentage threshold of greater of projected benefit obligation or market value of assets (percent) 10.00%  
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.7.0.1
Hedging Activities - Narrative (Details)
£ in Millions, $ in Millions, € in Billions
3 Months Ended
Jun. 30, 2017
USD ($)
Jun. 30, 2017
EUR (€)
Jun. 30, 2017
GBP (£)
Jun. 30, 2017
USD ($)
Mar. 31, 2017
USD ($)
Derivative [Line Items]          
Long-term debt outstanding       $ 7,949 $ 8,362
Foreign Exchange Contract | Derivatives Designated for Hedge Accounting          
Derivative [Line Items]          
Notional values of financial instruments       243 243
Foreign Exchange Contract | Derivatives not Designated for Hedge Accounting          
Derivative [Line Items]          
Notional values of financial instruments       167 62
Cross Currency Swap | Derivatives Designated for Hedge Accounting          
Derivative [Line Items]          
Notional values of financial instruments       3,223 2,663
Forward Contracts | Derivatives not Designated for Hedge Accounting          
Derivative [Line Items]          
Notional values of financial instruments       $ 177 $ 173
Net Investment Hedging          
Derivative [Line Items]          
Losses from net investment hedges recorded in other comprehensive income $ 114        
Euro Denominated Notes | Term Loan          
Derivative [Line Items]          
Long-term debt outstanding | €   € 1.2      
British Pound Sterling Denominated Notes | Term Loan          
Derivative [Line Items]          
Long-term debt outstanding | £     £ 450    
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.7.0.1
Hedging Activities - Derivative Instruments Fair Value (Details) - USD ($)
$ in Millions
Jun. 30, 2017
Mar. 31, 2017
Derivatives Designated for Hedge Accounting    
Derivatives, Fair Value [Line Items]    
Fair value of derivative, asset $ 57 $ 156
Fair value of derivative, liability 26 0
Derivatives Designated for Hedge Accounting | Foreign Exchange Contract | Prepaid Expenses and Other    
Derivatives, Fair Value [Line Items]    
Fair value of derivative, asset 16 17
Fair value of derivative, liability 0 0
U.S. Dollar notional amount, asset 81 81
Derivatives Designated for Hedge Accounting | Foreign Exchange Contract | Other Noncurrent Assets    
Derivatives, Fair Value [Line Items]    
Fair value of derivative, asset 30 32
Fair value of derivative, liability 0 0
U.S. Dollar notional amount, asset 162 162
Derivatives Designated for Hedge Accounting | Cross Currency Swap | Prepaid Expenses and Other    
Derivatives, Fair Value [Line Items]    
Fair value of derivative, asset 11 17
Fair value of derivative, liability 0 0
U.S. Dollar notional amount, asset 174 174
Derivatives Designated for Hedge Accounting | Cross Currency Swap | Other Noncurrent Assets    
Derivatives, Fair Value [Line Items]    
Fair value of derivative, asset   90
Fair value of derivative, liability   0
U.S. Dollar notional amount, asset   2,489
Derivatives Designated for Hedge Accounting | Cross Currency Swap | Other Noncurrent Liabilities    
Derivatives, Fair Value [Line Items]    
Fair value of derivative, asset 0  
Fair value of derivative, liability 26  
U.S. Dollar notional amount, asset 3,049  
Derivatives not Designated for Hedge Accounting    
Derivatives, Fair Value [Line Items]    
Fair value of derivative, asset 1 1
Fair value of derivative, liability 4 0
Derivatives not Designated for Hedge Accounting | Foreign Exchange Contract | Prepaid Expenses and Other    
Derivatives, Fair Value [Line Items]    
Fair value of derivative, asset 1 1
Fair value of derivative, liability 0 0
U.S. Dollar notional amount, asset 139 198
Derivatives not Designated for Hedge Accounting | Foreign Exchange Contract | Other Accrued Liabilities    
Derivatives, Fair Value [Line Items]    
Fair value of derivative, asset 0 0
Fair value of derivative, liability 4 0
U.S. Dollar, notional amount, liability $ 205 $ 37
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.7.0.1
Fair Value Measurements (Details) - USD ($)
$ in Millions
Jun. 30, 2017
Mar. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Carrying amount of liabilities $ 7,949 $ 8,362
Fair malue, measurements, recurring | Fair value, inputs, level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Estimated fair values of liabilities 8,400 8,700
Fair malue, measurements, recurring | Fair value, inputs, level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments in money market funds $ 443 $ 478
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stockholders' Equity - Narrative (Details)
$ / shares in Units, £ in Millions, shares in Millions, $ in Millions, € in Billions
1 Months Ended 3 Months Ended
Jul. 26, 2017
$ / shares
Jun. 30, 2017
USD ($)
Apr. 30, 2017
shares
Mar. 31, 2017
USD ($)
shares
Jun. 30, 2017
USD ($)
$ / shares
shares
Jun. 30, 2016
USD ($)
$ / shares
Jun. 30, 2017
EUR (€)
vote
Jun. 30, 2017
GBP (£)
vote
Jun. 30, 2017
USD ($)
vote
Accelerated Share Repurchases [Line Items]                  
Share of common stock outstanding, vote on proposals | vote             1 1 1
Dividends declared per common share (in dollars per share) | $ / shares         $ 0.28 $ 0.28      
Authorized amount available for future repurchases                 $ 2,500
Translation gain (loss) attributable to redeemable noncontrolling interest         $ 115 $ (67)      
Reclassified to income statement, net of income tax expense of nil and nil         20        
Long-term debt outstanding       $ 8,362         $ 7,949
Net actuarial losses attributable to redeemable noncontrolling interest         1 $ 1      
Term Loan | Euro Denominated Notes                  
Accelerated Share Repurchases [Line Items]                  
Long-term debt outstanding | €             € 1.2    
Term Loan | British Pound Sterling Denominated Notes                  
Accelerated Share Repurchases [Line Items]                  
Long-term debt outstanding | £               £ 450  
Net Investment Hedging                  
Accelerated Share Repurchases [Line Items]                  
Losses from net investment hedges recorded in other comprehensive income         $ 114        
Accelerated Share Repurchase                  
Accelerated Share Repurchases [Line Items]                  
Common stock repurchased   $ 250   $ 250          
Common stock repurchased (shares) | shares     0.3 1.4 1.2        
Subsequent Event                  
Accelerated Share Repurchases [Line Items]                  
Dividends declared per common share (in dollars per share) | $ / shares $ 0.34                
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stockholders' Equity - Schedule of Other Comprehensive Income (Loss), Net of Tax (Details) - USD ($)
3 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Net actuarial losses attributable to redeemable noncontrolling interest $ 1,000,000 $ 1,000,000
Other comprehensive income (loss) before reclassifications 320,000,000  
Reclassified to income statement, net of income tax expense 1,000,000  
Other Comprehensive Income (Loss), Net of Tax 321,000,000 (244,000,000)
Foreign currency translation adjustments arising during period, tax 0 12,000,000
Reclassified to income statement, tax 0 0
Unrealized gains on cash flow hedges arising during period, tax 0 0
Net actuarial loss and prior service cost arising during the period, tax 0 0
Amortization of actuarial loss and prior service costs, tax 0 1,000,000
Foreign currency translation adjustments and other, tax 0 0
Foreign Currency Translation Adjustments, Net of Tax    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Other comprehensive income (loss) before reclassifications 382,000,000 (275,000,000)
Reclassified to income statement, net of income tax expense 0 20,000,000
Other Comprehensive Income (Loss), Net of Tax 382,000,000 (255,000,000)
Unrealized Losses on Net Investment Hedges, Net of Tax    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Other comprehensive income (loss) before reclassifications (70,000,000) 0
Reclassified to income statement, net of income tax expense 0 0
Other Comprehensive Income (Loss), Net of Tax (70,000,000) 0
Unrealized gains (losses) on net investment hedges arising during period, tax 44,000,000 0
Reclassified to income statement, tax 0 0
Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Other comprehensive income (loss) before reclassifications 14,000,000  
Reclassified to income statement, net of income tax expense 0  
Other Comprehensive Income (Loss), Net of Tax 14,000,000 0
Accumulated Defined Benefit Plans Adjustment, Net Prior Service and Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Other comprehensive income (loss) before reclassifications 0 0
Accumulated Defined Benefit Plans Adjustment, Amortization of Actuarial Loss, Prior Service Cost and Transition Obligation, Including Portion Attributable to Noncontrolling Interest    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Other comprehensive income (loss) before reclassifications 1,000,000 3,000,000
Accumulated Defined Benefit Plans, Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Other comprehensive income (loss) before reclassifications (6,000,000) 8,000,000
Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Other Comprehensive Income (Loss), Net of Tax $ (5,000,000) $ 11,000,000
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stockholders' Equity - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) by Component (Details) - USD ($)
$ in Millions
3 Months Ended
Jun. 30, 2017
Jun. 30, 2016
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance $ 11,273  
Other comprehensive income (loss) before reclassifications 320  
Amounts reclassified to earnings and other 1  
Other Comprehensive Income (Loss), Net of Tax 321 $ (244)
Less: amounts attributable to noncontrolling and redeemable noncontrolling interests 116  
Other comprehensive income (loss) attributable to McKesson 205  
Ending balance 11,513  
Foreign Currency Translation Adjustments, Net of Tax    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (1,873)  
Other comprehensive income (loss) before reclassifications 382 (275)
Amounts reclassified to earnings and other 0 20
Other Comprehensive Income (Loss), Net of Tax 382 (255)
Less: amounts attributable to noncontrolling and redeemable noncontrolling interests 115  
Other comprehensive income (loss) attributable to McKesson 267  
Ending balance (1,606)  
Unrealized Losses on Net Investment Hedges, Net of Tax    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (8)  
Other comprehensive income (loss) before reclassifications (70) 0
Amounts reclassified to earnings and other 0 0
Other Comprehensive Income (Loss), Net of Tax (70) 0
Less: amounts attributable to noncontrolling and redeemable noncontrolling interests 0  
Other comprehensive income (loss) attributable to McKesson (70)  
Ending balance (78)  
Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (31)  
Other comprehensive income (loss) before reclassifications 14  
Amounts reclassified to earnings and other 0  
Other Comprehensive Income (Loss), Net of Tax 14 $ 0
Less: amounts attributable to noncontrolling and redeemable noncontrolling interests 0  
Other comprehensive income (loss) attributable to McKesson 14  
Ending balance (17)  
Unrealized Net Gains (Losses) and Other Components of Benefit Plans, Net of Tax    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (229)  
Other comprehensive income (loss) before reclassifications (6)  
Amounts reclassified to earnings and other 1  
Other Comprehensive Income (Loss), Net of Tax (5)  
Less: amounts attributable to noncontrolling and redeemable noncontrolling interests 1  
Other comprehensive income (loss) attributable to McKesson (6)  
Ending balance (235)  
Total Accumulated Other Comprehensive Income (Loss)    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (2,141)  
Ending balance $ (1,936)  
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.7.0.1
Segment Information (Details)
$ in Millions
3 Months Ended
Jun. 30, 2017
USD ($)
segment
Mar. 31, 2017
USD ($)
Jun. 30, 2016
USD ($)
Segment Reporting [Abstract]      
Number of operating segments | segment 2    
Revenues      
Total Revenues $ 51,051   $ 49,733
Operating profit      
Total 633   972
Interest Expense (68)   (79)
Income from Continuing Operations Before Income Taxes 458   912
Loss from equity method investment in Change Healthcare 120   0
Gain from sale of business, pre-tax 37   0
Operating Segments      
Revenues      
Total Revenues 51,051   49,733
Operating profit      
Total 635   1,096
Operating Segments | Total Distribution Solutions      
Revenues      
Total Revenues 50,931   49,009
Operating profit      
Total $ 713   $ 928
Revenue derived from services, percentage (less than) 2.00%   2.00%
Proceeds from legal settlements     $ 142
Operating Segments | Total Distribution Solutions | LIFO Method of Accounting      
Operating profit      
Total $ 26   47
Operating Segments | Total Distribution Solutions | Reportable Subsegments | North America pharmaceutical distribution and services      
Revenues      
Total Revenues 43,016   41,211
Operating Segments | Total Distribution Solutions | Reportable Subsegments | International pharmaceutical distribution and services      
Revenues      
Total Revenues 6,382   6,330
Operating Segments | Total Distribution Solutions | Reportable Subsegments | Medical-Surgical distribution and services      
Revenues      
Total Revenues 1,533   1,468
Operating Segments | Technology Solutions      
Revenues      
Total Revenues 120   724
Operating profit      
Total (78)   168
Corporate      
Operating profit      
Corporate Expenses, Net (109)   (105)
Segment Reconciling Items      
Operating profit      
Interest Expense (68)   $ (79)
Joint Venture | Change Healthcare, LLC (“Change Healthcare”)      
Operating profit      
Loss from equity method investment in Change Healthcare 120    
Core MTS Businesses | Change Healthcare, LLC (“Change Healthcare”) | Operating Segments | Technology Solutions      
Operating profit      
Gain from sale of business, pre-tax $ 37 $ 3,947  
EXCEL 66 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 67 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 68 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 70 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 165 250 1 false 71 0 false 11 false false R1.htm 0002000 - Document - Document and Entity Information Sheet http://mckesson123.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://mckesson123.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 2 false false R3.htm 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Sheet http://mckesson123.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Statements 3 false false R4.htm 1003000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://mckesson123.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 4 false false R5.htm 1003501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) Sheet http://mckesson123.com/role/CondensedConsolidatedBalanceSheetsParentheticals CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) Statements 5 false false R6.htm 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://mckesson123.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 2101100 - Disclosure - Significant Accounting Policies Sheet http://mckesson123.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 7 false false R8.htm 2102100 - Disclosure - Healthcare Technology Net Asset Exchange Sheet http://mckesson123.com/role/HealthcareTechnologyNetAssetExchange Healthcare Technology Net Asset Exchange Notes 8 false false R9.htm 2106100 - Disclosure - Business Combinations Sheet http://mckesson123.com/role/BusinessCombinations Business Combinations Notes 9 false false R10.htm 2107100 - Disclosure - Discontinued Operations Sheet http://mckesson123.com/role/DiscontinuedOperations Discontinued Operations Notes 10 false false R11.htm 2108100 - Disclosure - Restructuring Sheet http://mckesson123.com/role/Restructuring Restructuring Notes 11 false false R12.htm 2113100 - Disclosure - Income Taxes Sheet http://mckesson123.com/role/IncomeTaxes Income Taxes Notes 12 false false R13.htm 2114100 - Disclosure - Redeemable Noncontrolling Interests and Noncontrolling Interests Sheet http://mckesson123.com/role/RedeemableNoncontrollingInterestsAndNoncontrollingInterests Redeemable Noncontrolling Interests and Noncontrolling Interests Notes 13 false false R14.htm 2115100 - Disclosure - Earnings Per Common Share Sheet http://mckesson123.com/role/EarningsPerCommonShare Earnings Per Common Share Notes 14 false false R15.htm 2117100 - Disclosure - Goodwill and Intangible Assets, Net Sheet http://mckesson123.com/role/GoodwillAndIntangibleAssetsNet Goodwill and Intangible Assets, Net Notes 15 false false R16.htm 2118100 - Disclosure - Debt and Financing Activities Sheet http://mckesson123.com/role/DebtAndFinancingActivities Debt and Financing Activities Notes 16 false false R17.htm 2119100 - Disclosure - Pension Benefits Sheet http://mckesson123.com/role/PensionBenefits Pension Benefits Notes 17 false false R18.htm 2120100 - Disclosure - Hedging Activities Sheet http://mckesson123.com/role/HedgingActivities Hedging Activities Notes 18 false false R19.htm 2121100 - Disclosure - Fair Value Measurements Sheet http://mckesson123.com/role/FairValueMeasurements Fair Value Measurements Notes 19 false false R20.htm 2122100 - Disclosure - Commitments and Contingent Liabilities Sheet http://mckesson123.com/role/CommitmentsAndContingentLiabilities Commitments and Contingent Liabilities Notes 20 false false R21.htm 2123100 - Disclosure - Stockholders' Equity Sheet http://mckesson123.com/role/StockholdersEquity Stockholders' Equity Notes 21 false false R22.htm 2124100 - Disclosure - Segment Information Sheet http://mckesson123.com/role/SegmentInformation Segment Information Notes 22 false false R23.htm 2201201 - Disclosure - Significant Accounting Policies (Policies) Sheet http://mckesson123.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://mckesson123.com/role/SignificantAccountingPolicies 23 false false R24.htm 2302301 - Disclosure - Healthcare Technology Net Asset Exchange (Tables) Sheet http://mckesson123.com/role/HealthcareTechnologyNetAssetExchangeTables Healthcare Technology Net Asset Exchange (Tables) Tables http://mckesson123.com/role/HealthcareTechnologyNetAssetExchange 24 false false R25.htm 2314301 - Disclosure - Redeemable Noncontrolling Interests and Noncontrolling Interests (Tables) Sheet http://mckesson123.com/role/RedeemableNoncontrollingInterestsAndNoncontrollingInterestsTables Redeemable Noncontrolling Interests and Noncontrolling Interests (Tables) Tables http://mckesson123.com/role/RedeemableNoncontrollingInterestsAndNoncontrollingInterests 25 false false R26.htm 2315301 - Disclosure - Earnings Per Common Share (Tables) Sheet http://mckesson123.com/role/EarningsPerCommonShareTables Earnings Per Common Share (Tables) Tables http://mckesson123.com/role/EarningsPerCommonShare 26 false false R27.htm 2317301 - Disclosure - Goodwill and Intangible Assets, Net (Tables) Sheet http://mckesson123.com/role/GoodwillAndIntangibleAssetsNetTables Goodwill and Intangible Assets, Net (Tables) Tables http://mckesson123.com/role/GoodwillAndIntangibleAssetsNet 27 false false R28.htm 2320301 - Disclosure - Hedging Activities (Tables) Sheet http://mckesson123.com/role/HedgingActivitiesTables Hedging Activities (Tables) Tables http://mckesson123.com/role/HedgingActivities 28 false false R29.htm 2323301 - Disclosure - Stockholders' Equity (Tables) Sheet http://mckesson123.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://mckesson123.com/role/StockholdersEquity 29 false false R30.htm 2324301 - Disclosure - Segment Information (Tables) Sheet http://mckesson123.com/role/SegmentInformationTables Segment Information (Tables) Tables http://mckesson123.com/role/SegmentInformation 30 false false R31.htm 2402402 - Disclosure - Healthcare Technology Net Asset Exchange (Details) Sheet http://mckesson123.com/role/HealthcareTechnologyNetAssetExchangeDetails Healthcare Technology Net Asset Exchange (Details) Details http://mckesson123.com/role/HealthcareTechnologyNetAssetExchangeTables 31 false false R32.htm 2402403 - Disclosure - Healthcare Technology Net Asset Exchange - Summarized Financial Information (Details) Sheet http://mckesson123.com/role/HealthcareTechnologyNetAssetExchangeSummarizedFinancialInformationDetails Healthcare Technology Net Asset Exchange - Summarized Financial Information (Details) Details 32 false false R33.htm 2406401 - Disclosure - Business Combinations (Details) Sheet http://mckesson123.com/role/BusinessCombinationsDetails Business Combinations (Details) Details http://mckesson123.com/role/BusinessCombinations 33 false false R34.htm 2407401 - Disclosure - Discontinued Operations - Narrative (Details) Sheet http://mckesson123.com/role/DiscontinuedOperationsNarrativeDetails Discontinued Operations - Narrative (Details) Details 34 false false R35.htm 2408401 - Disclosure - Restructuring - Narrative (Details) Sheet http://mckesson123.com/role/RestructuringNarrativeDetails Restructuring - Narrative (Details) Details 35 false false R36.htm 2413401 - Disclosure - Income Taxes (Details) Sheet http://mckesson123.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://mckesson123.com/role/IncomeTaxes 36 false false R37.htm 2414402 - Disclosure - Redeemable Noncontrolling Interests and Noncontrolling Interests - Narrative (Details) Sheet http://mckesson123.com/role/RedeemableNoncontrollingInterestsAndNoncontrollingInterestsNarrativeDetails Redeemable Noncontrolling Interests and Noncontrolling Interests - Narrative (Details) Details http://mckesson123.com/role/RedeemableNoncontrollingInterestsAndNoncontrollingInterestsTables 37 false false R38.htm 2414403 - Disclosure - Redeemable Noncontrolling Interests and Noncontrolling Interests - Schedule of Changes in Redeemable Noncontrolling Interests and Noncontrolling Interests (Details) Sheet http://mckesson123.com/role/RedeemableNoncontrollingInterestsAndNoncontrollingInterestsScheduleOfChangesInRedeemableNoncontrollingInterestsAndNoncontrollingInterestsDetails Redeemable Noncontrolling Interests and Noncontrolling Interests - Schedule of Changes in Redeemable Noncontrolling Interests and Noncontrolling Interests (Details) Details 38 false false R39.htm 2415402 - Disclosure - Earnings Per Common Share - Schedule of Computation for Basic and Diluted Earnings per Common Share (Details) Sheet http://mckesson123.com/role/EarningsPerCommonShareScheduleOfComputationForBasicAndDilutedEarningsPerCommonShareDetails Earnings Per Common Share - Schedule of Computation for Basic and Diluted Earnings per Common Share (Details) Details 39 false false R40.htm 2415403 - Disclosure - Earnings Per Common Share - Narrative (Details) Sheet http://mckesson123.com/role/EarningsPerCommonShareNarrativeDetails Earnings Per Common Share - Narrative (Details) Details 40 false false R41.htm 2417402 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Changes in the Carrying Amount of Goodwill and Narrative (Details) Sheet http://mckesson123.com/role/GoodwillAndIntangibleAssetsNetScheduleOfChangesInCarryingAmountOfGoodwillAndNarrativeDetails Goodwill and Intangible Assets, Net - Schedule of Changes in the Carrying Amount of Goodwill and Narrative (Details) Details 41 false false R42.htm 2417403 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Information Regarding Intangible Assets (Details) Sheet http://mckesson123.com/role/GoodwillAndIntangibleAssetsNetScheduleOfInformationRegardingIntangibleAssetsDetails Goodwill and Intangible Assets, Net - Schedule of Information Regarding Intangible Assets (Details) Details 42 false false R43.htm 2417404 - Disclosure - Goodwill and Intangible Assets, Net - Narrative - Intangible Assets (Details) Sheet http://mckesson123.com/role/GoodwillAndIntangibleAssetsNetNarrativeIntangibleAssetsDetails Goodwill and Intangible Assets, Net - Narrative - Intangible Assets (Details) Details 43 false false R44.htm 2418401 - Disclosure - Debt and Financing Activities - Long Term Debt (Details) Sheet http://mckesson123.com/role/DebtAndFinancingActivitiesLongTermDebtDetails Debt and Financing Activities - Long Term Debt (Details) Details 44 false false R45.htm 2418402 - Disclosure - Debt and Financing Activities - Revolving Credit Facilities (Details) Sheet http://mckesson123.com/role/DebtAndFinancingActivitiesRevolvingCreditFacilitiesDetails Debt and Financing Activities - Revolving Credit Facilities (Details) Details 45 false false R46.htm 2418404 - Disclosure - Debt and Financing Activities - Commercial Paper (Details) Sheet http://mckesson123.com/role/DebtAndFinancingActivitiesCommercialPaperDetails Debt and Financing Activities - Commercial Paper (Details) Details 46 false false R47.htm 2419401 - Disclosure - Pension Benefits - Narrative (Details) Sheet http://mckesson123.com/role/PensionBenefitsNarrativeDetails Pension Benefits - Narrative (Details) Details 47 false false R48.htm 2420402 - Disclosure - Hedging Activities - Narrative (Details) Sheet http://mckesson123.com/role/HedgingActivitiesNarrativeDetails Hedging Activities - Narrative (Details) Details 48 false false R49.htm 2420403 - Disclosure - Hedging Activities - Derivative Instruments Fair Value (Details) Sheet http://mckesson123.com/role/HedgingActivitiesDerivativeInstrumentsFairValueDetails Hedging Activities - Derivative Instruments Fair Value (Details) Details 49 false false R50.htm 2421401 - Disclosure - Fair Value Measurements (Details) Sheet http://mckesson123.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://mckesson123.com/role/FairValueMeasurements 50 false false R51.htm 2423402 - Disclosure - Stockholders' Equity - Narrative (Details) Sheet http://mckesson123.com/role/StockholdersEquityNarrativeDetails Stockholders' Equity - Narrative (Details) Details 51 false false R52.htm 2423403 - Disclosure - Stockholders' Equity - Schedule of Other Comprehensive Income (Loss), Net of Tax (Details) Sheet http://mckesson123.com/role/StockholdersEquityScheduleOfOtherComprehensiveIncomeLossNetOfTaxDetails Stockholders' Equity - Schedule of Other Comprehensive Income (Loss), Net of Tax (Details) Details 52 false false R53.htm 2423404 - Disclosure - Stockholders' Equity - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) by Component (Details) Sheet http://mckesson123.com/role/StockholdersEquityScheduleOfChangesInAccumulatedOtherComprehensiveIncomeLossByComponentDetails Stockholders' Equity - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) by Component (Details) Details 53 false false R54.htm 2424402 - Disclosure - Segment Information (Details) Sheet http://mckesson123.com/role/SegmentInformationDetails Segment Information (Details) Details http://mckesson123.com/role/SegmentInformationTables 54 false false All Reports Book All Reports mck-20170630.xml mck-20170630.xsd mck-20170630_cal.xml mck-20170630_def.xml mck-20170630_lab.xml mck-20170630_pre.xml true true ZIP 72 0000927653-17-000011-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000927653-17-000011-xbrl.zip M4$L#!!0 ( ,R ^TI.-W";>#L! )67$ 0 ;6-K+3(P,3R9)%N>?V4Q\(*)*8!@$V%EF< M7W\C 50!8!96 B! PJ?;EE!;;!E;1D;\Y?]\O^O\\*WH#]J][G^\P3^B-S\4 MW6:OU>[>_,>;/Z[>FBOW[MV;__/+__[+__?V[?^UG]__X'O-T5W1'?[@^D5C M6+1^^+,]O/WAOUK%X%\_7/=[=S_\5Z__K_:WQMNWDX?N?R:BT$HUFOI:*R;5 M5]W40LA"(ZZ$O*;X___^,T("?U42LV:#,HJ5+II";V^'P_N>??DJ7?AP4S1]O>M]^FE[\B2 LWB+\ MEN(WY6.C?A^07/;<]&K-@ZVB7?\,7$BWL\7;B^_-V_K[TY6:][>[WXK!L/Z1 MR;7T$'WTT*#'");54W_^^>>/XR=[_1NX'=&?IG>4#W3:W7^MN#M=_MH8%.7M M=\W9W?#G8C#H=3&A/S9[=PD:B01%Y;W=1KLYJ(=_?"D]@!?![_:ZW=%=/3RM M8?^GX<-]\1/<]!;N*OKM9O7<^H<6'^@7UTNQ%C_!U?+&0;M9CP)E"Z]&"J.@YN;APZ[#V5CZY=3A_:WN5,'<'PT:W68GG M]TR<_Z3CN['6^J?QU>K60:ON1G@M_NG_?GA_U;PM[AJSF]OK;WY;0?/+__Y? M?TG?^GDPOO"YN/YA_.V?;\=R!POG;;E8?@0XWDRO)C;\QYM!^^Z^ QC]E-XR MT7+-7G=8?!_^T :0HX='U>_X'U]\^DYY"^C@]O A_5#^TFZEWZ[;1?^',1C% M @:E6+IW__GF%P3_:"(%IW_YZ?'#XV_\]/@CTV_:_"A3H#SV8@E\2 MAF]1TH+EX[-K(M1;.OMI MWDVDZA3I-%E6PQH)*:\\#6WY.SM]M"FHY7VC?>K<%H?@MCAY;HM]]#L] :C?C&P#_"7 M^]Z@T?FUWQO=#^ 5G5&*+-(] &V[.RI:T^\"<&-PP% "I/WBPYH4'Z_#OT= Y0_%\+;7>C=VD!-L^:]%\5OCKIA]X+;1O2G^6C0Z MP]MFHU^\?^\>__3XDQ7>4Z!**E7O_%(T;[N]3N_FX:K7&8T1FKSC:*)7&9D) M:..?)K^UX,O?[SOM9GLX@>F'5AMNF<1\4Q1_KI>/-[^4UY<(R%]^JOW"ME\_ MCGB]^058]?,2^=H3)D^1SBE\FXKGOB!>)=P3D)9*]RH0*L]F)I!/<"OQ=F[E MO#[=CUL)OM*\/OU<=%+ZXQ- \O"EW^@.&LU$EYE"2+^-I?:JZ']K-XN!N>D7 M8SH/OER91PIFR=M R.>O+&AL$./['@AW\;=>NSO\.[QW5 K&N>B<%32$E(+P$A.<:$)Z:VWMQ02XNR/,O\Y>SQJ8;-1\:_8N; M?UEC+V>-/=[E0WO>Y9L/B]W8[;D!J)(W!Q(R\7WLPY>'^YGT?FE\_UPTB_:W MQM=.4278OGQ^G*1TJ:2JZ-\GUK]L\5]+MZD7M)IP>Y+Z.K*?J#0?9*O^(LT7 M:7XFW;S'/?G)ECSU19.H2@;+ ,LTP7)--CHJ,?Q=$OG*"[DFDMV#'S%MZS(]]Q^Z/N?GFERD[?W;F M2 &$>(O)6Z(VKW!;N/T@0?J."^ZR1EZ27)Y 8#OOI*^22=?[5O0_0$C3&H Y M/"^W8Z6@U2%V++L.S*=[L^OO]FC7+VKFS-7,0DWG@C4[*?_Q(F=G+F>GY&;M M4P$N;."-G680DV:C>GSNOIH=O;\6G5;L]:\:G>)C?_(JN'QM'](OER6PYR6P MAE>S2&=G9KV,M7I@F_ 43_))"04W&@Q[=T5_O"&0.'K;OC^S$H>]>JB'3ABL MH/=1XR:ZJ:%Y=/N3#:YC,MMPW1SS)?,-VC94^7X\JO MN6H6W0; L""]Y8_@8Q7-QF!XD=.M?,5YFLZDLYZH1Y%#=8@3P?/Z]."QU[G( MWO,&-B>['?_<&Y@K_-]+5'^6HYS,;VL>\3"&[3?^IYU>-.RW MOXXKO\]+NQ_S8,$R6AU-4)^UP\PT7D\%O.Q+[V^C+D5SA;Q DU%S..H#&3\! M"^9XE6+6.FVUF)V/&&@;S%[KDWOK)AO?N&][]7XF1^' MMT7?C;OQ#=^W&U_;'5B96?72BQ6D9?29.X"UBD![LKNG),Z';(\TZQM6+UEC M9+LM^*WH?RL6TT1W]YW>0U%<%1"5)I:]%@E=0Z"YG$X]A5Z@B)Z2^H%"?>@2_X4^#JG>>T$H/T! >C>Z>RT26!%@)G(+%+C( MU[[EJ_']ME)AP*Q[^"6TO82V M^Y'IYVZ_LELR\1+:7D+;XW95>B/[REW^MT M@#SOTE'IXMR*=U9B.I.W5:B>K[_UR-2NYOJD3*)5%'?IS/TKX/VD=F$3A%^I M);O(R\G)R^D8B0O[GYW]A^UP<_$13M!'V/].\U8^PH7KK]Y]; M55./%N6>)M^QW]K=&%^&WOFA2?.'QWGG,MILFRM(!S@-,$]T^4IN=3OS4:+?> M=5WCOCUL=,Y#!+;TR5;B^DHT_>/M@5V.S4\'I\[FIIZ7M.QT'GT)SN>Y8; / M(1@W&[]K]/\U,-W6X\[C+UH45F+^>@5B7.OU^.Y7( XK\#Y?89@O(-A).U3# M_&QCD#_W"L1B(PJ<;XG!K@*2PHQ/MXW^7:/Y\!X,:G?PHFU&BD?JT3U/UM?$ M&1?U<(;JX>1BDJ<:G$M,",7ZW/6OL=>MLTNF:]3 M2HR?E'-ZL1?/9"].RN/8DQ!=(M[GG6EV]@)TR:@?(:-^ZH(S&VHP'1UR-4%S MYL_.S/E5KS,>2'!F@K(2Q8D3NQ3'5R(82UM*7*3BN%+Q7)V&EO)Y?A#)R^7T M"BPO&N B&<>6C&=I'W-A]',S^K#)K(M-/PF;?E@FNW[1:@]CHYFZ<#XLY@MZ M=Q U-]OI< Q\Y;PXF^,UEQ"H0^Q\V3EOA2_L/#([#UOEM(*=GXMOO+[^>$GYB3W2E_GA(]C2'GIP,LDU]N>Z-!H]M*+='A:T7WD=R_[W5OAD7_+GWK MR\/]8L?Y][U&=_"I\9#:,IR75"^3JGW0;D^"7T?YV=++2?]*P^45FOT]>*(? MKRWTB>MSI;.QDAR/&\2ID.7/C32:(;9 MV(=S$=CE RZ2V&R Z'DJO8U'H5S8_3SL/FQ687^3;SP \@V>_U;,U.[G]N!? MCPI5TEN:#U=_-NX?/?_7HG4#>M@7@_9--X>C_+UHF<'TUMEW7HKH+91B'WZ4 MSBJ6S1?9/.;9GCY?S_'9AS=@^0O7N4L6X7SQY';K+_;Z!= T?&_>ID&>+K4M M;#2'EZ6XZ5+=>WX(\[-;)V@7YJ5_<-]JM\/U^7.ANNJWYN:.[ MK\^+?=QH46Y._HNE//N%N96[>JB%>3&<+V2-7NSH*3FV)[U

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end